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Abstract 
Introduction: There is a need to study the level of percutaneous coronary intervention 
(PCI) care in the UK to promote improvements in care for all patients with 
cardiovascular disease. The aim of this thesis was to utilise contemporary population-
based data to perform a number of investigations and answer several important 
questions regarding the level of care provided to patients who have undergone PCI in 
the UK on the basis of outcomes including survival. 
Methods: A linked population-based study using the prospectively collected British 
Cardiovascular Intervention Society (BCIS) registry of patients who have undergone 
PCI in the UK since January 2005. Three main analyses were performed and for each 
part; a literature review, analysis (descriptive statistics, comparisons, adjusted 
associations and survival), multi-level modelling and fit for purpose imputation were 
conducted. 
Results: In the first analysis, 5,065 patients with unprotected left main stem disease 
(UPLMS) were studied. More than half of patients treated with PCI to the UPLMS 
presented acutely, their early and late mortality were significantly worse than that for 
elective patients. Cardiogenic shock was common in ST elevation myocardial infarction 
(STEMI) and associated with a 1 in 2 risk of early mortality. In acute patients, radial 
access was associated with improved early outcomes. In the second analysis, 10,827 
patients with UPLMS were studied. The number of acute patients with UPLMS PCI 
increased over the years with stable early and late mortality rates. In the third analysis, 
98,637 patients with STEMI were studied. The survival of primary PCI patients was 
worse than that of facilitated and rescue mainly because majority of the procedures 
were performed after more than two hours from the onset of symptoms. Old age, 
cardiogenic shock, more than two hours delay before intervention, inter-hospital 
transfer and being already in a cardiac centre were independent predictors of worse 
survival in primary interventions. 
Conclusions: The novel prospective data used in this thesis have provided the 
opportunity to gain more knowledge and understanding of the quality of care provided 
to patients following PCI which represents a step forward in the assessment and 
improvement of cardiovascular health services in the UK. 
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1 Chapter 1 Introduction 
 
 
 
 
1.1 Structure of Thesis 
The research aim and objectives form the bases on which this thesis is structured. 
However, they are presented later in Chapter 2 (section 2.6) as they are more effectively 
reflected and understood by the proceeding backgrounds and literature reviews. 
The thesis starts with an expansion of the narrative backgrounds conducted in this 
chapter. In order to provide more understanding on the topics which the thesis is aiming 
to research, this chapter describes coronary artery disease (section 1.2), percutaneous 
coronary intervention (section 1.3) and the data sources used within the thesis, including 
the British Cardiovascular Intervention Society database, a preliminary description of 
the data (section 1.4), and the Office for National Statistics (section 1.5) which provides 
the long-term data on patient mortality. 
Chapter 2 explores the available literature which is focused around the research 
aim and objectives. The review aimed to identify key components of both contextual 
and compositional influences on patients with coronary artery disease who underwent 
PCI. This current knowledge base was then used to build the rationale for the proposed 
research and develop the research questions used to achieve the research aim. 
Chapter 3 introduces the practical and conceptual bases of the used 
methodological approaches, using the knowledge base presented in the same chapter to 
describe the construction of the BCIS dataset, the data management and the statistical 
methods used in the thesis. 
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The main results of the research are presented in three chapters focusing on the 
clinical determinants of outcomes in patients with UPLMS who received PCI in 
England and Wales (Chapter 4), the temporal trends of mortality among UK patients 
with UPLMS who underwent PCI (Chapter 5) and the clinical determinants of primary 
PCI survival among patients with STEMI in the UK (Chapter 6). Each chapter included: 
detailed objectives, more specific methods, interpretation of the descriptive, analytical 
and sensitivity analysis, as well as discussion of the findings. 
Chapter 7 discusses the findings of all three analyses as a whole and highlights the 
key contributions of this work in the context of previous research and policy. The 
strengths and limitations of the research on which these are based are also discussed. 
This included the research design, chosen methodologies, their strengths and 
weaknesses, and the analytical framework used to achieve the research questions. The 
final part of the chapter discusses recommendations for the enhancement of the BCIS 
data collection, suggestions for improving the care provided to PCI patients, 
considerations for future research and the conclusions drawn throughout the thesis. 
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1.2 Coronary artery disease 
 
1.2.1 Background and pathophysiology 
Coronary artery disease (CAD), or what is also known as coronary heart disease 
or ischemic heart disease, is the commonest type of cardiovascular disease globally [1, 
2]. CAD is a series of diseases that arise from the narrowing or obstruction of coronary 
vessels, which subsequently leads to restriction of the blood flow to the heart [3]. 
Basically, the term CAD represents a spectrum of diseases that consist of acute coronary 
syndromes (ACS) and chronic stable angina. ACS include more severe and acute 
conditions, such as ST elevation myocardial infarction (STEMI), non-ST elevation 
myocardial infarction (NSTEMI) and unstable angina [4]. 
 
1.2.1.1 Chronic stable angina 
Chronic stable angina is defined as the presence of chest discomfort or tightness 
and other concomitant symptoms over a period ranging between at least two months to 
years. These symptoms, on one hand, are frequently triggered by some precipitants 
factors, including physical exertion and emotional or psychological stress. On the other 
hand, these symptoms can be relieved by rest or the use of short acting nitrates [3, 4]. 
Chronic stable angina is a result of myocardial ischemia, which is the consequence of 
the mismatching between the oxygen demand and supply in the myocardial muscles. 
This mismatching is due to steady narrowing of the lining of the affected coronary 
artery or arteries over a number of years [4]. 
 
1.2.1.2 Unstable angina 
Unstable angina is differentiated from chronic stable angina by the occurrence of 
symptoms at rest or on minimal physical effort, and over a shorter period ranging from 
four to six weeks [4]. The pathophysiology of unstable angina is best explained by an 
acute myocardial ischemia that occurs in an unpredicted way, caused by vessel spasms 
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or thrombus formation. Sequentially, this leads to severe restriction or complete abrupt 
occlusion of the affected coronary artery or arteries [4]. 
 
1.2.1.3 Acute myocardial infarction  
Arterial occlusion is usually occurs at the site of atherosclerosis in the affected 
coronary artery or arteries. Atherosclerotic plaque is a derivative of the deposition of 
lipids on the wall of medium to large arteries, which subsequently decreases the luminal 
diameter and the blood flow of the affected artery or arteries [5]. Occasionally the 
plaque may rupture, and that leads to the formation of thrombus, which is the main 
cause of unexpected complete or incomplete occlusion of the affected artery [5]. 
Persistent unreserved acute myocardial ischemia of a period more than 15 to 20 minutes 
often results in necrosis of the myocardium which when, at presentation, associated 
with electrocardiography (ECG) changes and/or elevated cardiac enzymes, is known as 
acute myocardial infarction (AMI) [3, 4].  
The existence or absence of ST elevation in ECG differentiates between STEMI 
and NSTEMI, while cardiac enzymes (troponins) have a major role in differentiating 
NSTEMI from unstable angina (Figure 1.1) [4, 6, 7]. The typical presenting symptom of 
AMI is persistent or sporadic retro sternal chest pain or discomfort that radiates to the 
left arm, neck or jaw, lasting over 20 minutes. Such pain usually takes place at rest or 
on minimal effort with a previous history of similar complaint over the last few days or 
weeks [3, 4]. Other atypical symptoms of AMI can be either dyspnoea, abdominal pain, 
nausea or diaphoresis [4].  
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Figure 1.1: The spectrum of coronary artery disease. 
 
 
 
 
1.2.2 Coronary artery disease and mortality epidemiology 
Over the last decade, cardiovascular diseases continue to be the leading cause of 
morbidity and mortality across the world [2, 8]. In 2008, 36 million deaths (63.0% of all 
deaths) were due to non-communicable diseases (NCDs), of which 17.3 million (30.0%) 
were due to cardiovascular diseases (27.0% of male deaths and 32.0% of female deaths) 
[2, 9]. In 2010, cardiovascular diseases related deaths decreased to 15.6 million (29.6%) 
[10]. In the same year, more than 147,000 deaths in England (around 33.0% of all 
deaths) were due to cardiovascular diseases [11]. In 2012, deaths due to cardiovascular 
diseases declined to 28.0% of all deaths in the UK [12]. 
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Ranging from 4.0% of all premature deaths (deaths at less than 60 years of age) 
in developed countries to 42.0% in developing countries, cardiovascular diseases related 
mortality rates have been declining over the years in developed countries. On the 
contrary, mortality rates due to cardiovascular diseases have been rising tremendously 
in developing countries, leading to significant economic burdens worldwide [2]. In the 
same way, deaths due to cardiovascular diseases in the UK have been decreasing from 
more than 50.0% of all deaths in 1961 to 32.0% in 2009 [13]. Even with the reduction 
in mortality rates in many European countries, cardiovascular diseases remain 
responsible for causing more than four million deaths (46.0%) annually (42.0% of male 
deaths and 51.0% of female deaths) [1]. In the UK, nearly 191,000 deaths are caused by 
cardiovascular diseases every year [14]. 
Over time, the prognosis of CAD has changed distinctly along with the changes 
in certain risk factors at both individual and population levels [13]. These risk factors 
can be either behavioural (like type of diet, physical activity, smoking or alcohol 
consumption) or medical (such as obesity, diabetes, hypertension or 
hypercholesterolemia) [11]. In 2008, 7.3 million cardiovascular deaths worldwide 
(42.0% of all cardiovascular deaths) were due to CAD; 80.0% of them were in low- to 
middle-income countries, predominantly in Asian and middle eastern countries [2, 9]. 
By the year 2013, CAD was still the leading cause of death worldwide, causing more 
than 8.1 million deaths (16.8%) [15].  
In European countries, CAD accounts for about 1.8 million deaths (20.0%) 
every year [1]. In 2008, 88,236 deaths (46.0% of all cardiovascular deaths) in the UK 
were caused by CAD [14]. In 2010,  more than 65,000 deaths (37,873 males and 27,370 
females) occurred because of CAD in England alone [11]. In 2012, CAD accounted for 
nearly 37,500 deaths (46.0% of all cardiovascular diseases related deaths) in the UK 
(16.0% of male deaths and 10.0% of female deaths) [12]. Despite the great decline in 
the number of deaths caused by CAD in the UK, from 166,000 deaths in 1961 to 80,000 
deaths in 2009, the number of CAD patients is increasing over the years because of the 
increase in survival rates and an aging population [13].  
In the UK, 28,258 deaths in 2008 caused by CAD were at age less than 75 years, 
out of which 20,850 deaths (18.0%) were in males and 7,408 deaths (9.0%) were in 
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females. Among UK countries these premature deaths were mainly in England (22,549 
deaths), followed by Scotland (3,333 deaths), then Wales (1,588 deaths) and Northern 
Ireland (788 deaths) [14]. Furthermore, in 2010, out of the total deaths in CAD patients 
in the UK, 706,184 deaths (18.0%) were at age less than 75 years and 330,598 deaths 
(14.0%) were at age less than 65 years [1]. Likewise in the same year, it was estimated 
that more than 21,000 deaths in England at age less than 75 years were caused by CAD 
[11]. In 2012, almost 42,000 deaths from cardiovascular diseases in the UK were at age 
less than 75 years, out of which  15.0% of male deaths and 8.0% of female deaths was a 
result of CAD [12].  
 
1.2.3 Burden of coronary artery disease in the UK 
In the medical literature, it is well known that CAD is a major burden to the UK 
National Health Service (NHS). In England, the prevalence of CAD in 2006 was 
estimated to be more than 2.2 million patients (1.3 million males and 860,000 females) 
[11]. In 2010, about 2.0% (more than 263,000 males and 142,000 females) of all 
inpatient admissions in England were because of CAD [11]. Between 2012 and 2013, 
nearly 2.3 million patients in the UK were diagnosed with  CAD, with a prevalence of 
3.4% in England, 3.9% in Wales, 4.3% in Scotland and 3.9% in Northern Ireland [12]. 
During the same period in all UK countries, CAD was responsible for 323,776 (3.5%) 
of all male inpatient admissions and 169,545 (1.5%) of all female inpatient admissions 
[12].  
Furthermore, the costs of disease related outcomes of CAD in 2006 were £3.2 
billion and the estimated costs in 2012 were around £7.1 billion [11, 16]. In England 
alone, between 2012 and 2013, the costs of cardiovascular diseases treatment in the 
NHS were over £6.8 billion. These expenses were mainly spent on the secondary 
management of emergency cases (63.4%), followed by primary care (20.9%) [12]. In 
2013, the cost of medication prescriptions for cardiovascular diseases were over 300 
million in England alone, which is six fold higher than the expenditure on medication 
prescriptions in 1981 (£1,387.5 million) [12]. In 2012, over 90,000 percutaneous 
coronary intervention (PCI) procedures were carried out in the UK, which is twice the 
number of procedures that was performed 10 years ago. Similarly for all UK countries 
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in 2012, nearly 17,000 coronary artery bypass graft (CABG) surgeries were performed. 
Although CABG is less prevalent nowadays, the frequency of the surgery remains high 
[12]. 
 
1.2.4 Unprotected left main stem disease  
The left main coronary artery or left main stem (LMS) originates from the aorta, 
and is classically placed above and in front of the left side of the heart exterior wall. The 
LMS is basically divided into three parts: an ostium, a shaft and a distal part that ends 
by bifurcating into the left anterior descending and circumflex artery [17]. Significant 
stenosis of more than 50% of the LMS is a rare, however an important, cause of 
symptomatic CAD [18, 19]. The LMS stenosis’ commonest position is the shaft or at 
the bifurcation, and usually is associated with significant stenosis of other coronary 
arteries [17]. In about 5% of all patients with CAD, unprotected LMS disease (UPLMS) 
takes place, and this can be life threatening when it is occluded [18, 19]. UPLMS is 
known as a LMS disease that does not have a patent graft to any left-sided coronary 
artery [20].  
CABG remains the standard treatment of choice for all types of LMS disease, 
nevertheless in contemporary practice, PCI is considered a reasonable line of 
management since it reduces the in-hospital mortality rate and increases the survival at 
one year when compared to reported CABG outcomes [21-24]. Furthermore, with the 
expansions in stent technology (drug eluted stents, equipment and techniques), PCI 
procedures are yielding higher rates of success with encouraging outcomes in the 
management of UPLMS [25].  
Given the fact that the success of any PCI procedure for UPLMS (in terms of 
short- and long-term outcomes including survival) is influenced by various risk factors, 
such as age, cardiogenic shock and diabetes, it is believed that these factors are less 
common among the elective cases compared to the unstable emergency cases [25-27]. 
Besides, unless it is not contraindicated, CABG is the recommended line of 
management for UPLMS, and PCIs would be preserved for more complicated cases, 
such as the multi-morbid, thus affecting its success further [19, 26, 28]. 
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1.2.5 Why study cohort data about PCI in UPLMS? 
There is conflicting evidence regarding what the main independent clinical 
predictors of PCI outcomes in UPLMS are. However, these predictors can be elucidated 
through the fact that most UPLMS cases treated by PCI are actually a high-risk group of 
patients who have previously been rejected from surgical treatment [26]. Besides, 
regardless of the degree and location of stenosis, the argument continues about these 
risk factors and their short- and long-term effect on the outcomes and survival of PCI 
procedures in UPLMS patients [25, 26].  
Moreover, there is a gap in the knowledge base regarding the relative merits of 
PCI to an UPLMS culprit lesion in patients who present with STEMI or NSTEACS 
[29]. For patients with cardiogenic shock, there are limited data available in the 
literature, with early outcomes reported in only small ‘hypothesis-generating’ cohort 
studies. Ben Dor et al. [30] and Schrale et al. [31] demonstrated that increased mortality 
rate was significantly associated with cardiogenic shock. At the present time, the radial 
approach is considered to be safer and cost-effective than the femoral in patients with 
STEMI [32-34]. However, although recent international guidelines recommend the 
radial approach to PCI over that of the femoral approach [35], the wider implications of 
this have not been studied in patients who receive PCI to disease of the UPLMS.  
In addition, details from the existing literature to date regarding the temporal 
trends in incidence, care and clinical outcomes of UPLMS PCI across the full spectrum 
of acute and chronic stable patients have been limited. These studies from the literature 
were small, regional and non-consecutive series of patients or inferred from randomised 
controlled trials that tend to recruit less high-risk patients [36-42]. Few recent studies, 
such as Park et al. [43] and Conrotto et al. [44] have reported the temporal trends of 
UPLMS outcomes. However, the size of the cohort of these studies were small and less 
representatives since they were performed outside the UK. Notably, in the UK, there are 
no whole-country studies of the temporal trends in UPLMS PCI and the associated 
procedural and longer-term outcomes. 
The British Cardiovascular Intervention Society (BCIS) registry is a prospective 
whole-country registry of all adult PCIs that has collected patient-level data for from all 
centres in the UK since 2005. It provides data that cannot be collected within an RCT, 
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and few cohort studies have comparable population coverage, long-term follow-up and 
depth of data detail in relation to clinical risk.  
There is, therefore, value in using the BCIS data to address UPLMS knowledge 
gaps as well as to report contemporary and representative outcomes data for PCI to the 
UPLMS in order to inform patients, healthcare professionals and regulators of both the 
benefits and inherent risks of such therapy, and also to highlight areas where novel 
interventions aimed at improving outcomes may be targeted [31, 42, 45-48].  
 
 
1.3 Percutaneous coronary intervention 
 
1.3.1 Background 
Percutaneous coronary intervention is a non-surgical procedure performed by 
interventional cardiologists. The procedure is basically the insertion of a catheter, 
guided by X-ray, into an access vessel (usually femoral or radial arteries). On that 
catheter a deflated balloon, stent or other devices are carried up through the circulatory 
system to the occluded vessel in the heart and treat the obstruction [4].  
Cardiac catheterisation was introduced in the late 1920s, then later in the 1950s, 
coronary angiography was technologically established. In the 1960s, balloon 
angioplasty was first initiated, and was modified to allow the revascularisation  of 
coronary arteries in the late 1970s [49]. In the 1980s, stents were introduced to 
revascularisation and, over time, the technology and pharmacology around percutaneous 
revascularisation progressed tremendously (84.2% of all  PCIs in 1999) [50].  
To treat an occluded coronary artery, CABG and PCI may be used [23]. In spite 
of the unvarying utilisation of CABG over recent years, the use of PCI for CAD in the 
UK and globally has increased tremendously, especially after the introduction of the 
drug eluting stent in 2002 [50]. In 2004, drug eluting stents were used in 53% of UK 
PCI procedures and the ratio of PCI to CABG had increased to 2.5:1 [51-53]. 
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Furthermore in 2010, more than 87,000 PCI procedures were performed in the UK, 
which was over seven times more than those performed in 1992 [11]. In 2012, the 
prevalence of PCI in the UK increased to more than 90,000 procedures, while 
approximately 17,000 CABGs were performed in the same year [12]. By 2013, the total 
number of PCIs undertaken in all of the UK was 92,589 procedures: 76,712 (82.9%) in 
England, 8,515 (9.2%) in Scotland, 3,563 (3.8%) in Northern Ireland and 3,799 (4.1%) 
in Wales [54]. 
Lately, PCI has progressed significantly with the combination of experienced 
practitioners, modern drug therapy and contemporary equipment [55].  At first, PCI was 
used for the management of patients with stable angina or individual lesions in a single 
coronary artery. At the present time, though, PCI has numerous indications, including 
unstable angina, STEMI, multi vessel and complex CAD [55].  
 
1.3.2 Percutaneous coronary intervention and outcomes 
In addition to patient stability, the risks at hand, operator experience and the 
facilities available, the success of any PCI procedure depends on the visualisation of the 
stenosed or occluded artery and the nearby arterial branches [56, 57]. On the other hand, 
unfavourable outcomes of PCI procedures can be observed more in the presence of 
different risk factors such as old age, diabetes, renal failure, cardiogenic shock, unstable 
angina, previous myocardial infarction, a large area of myocardium at risk and multi 
vessel disease [52, 53].  
Major complications of PCI procedures are rare. However, there was much 
variation in the reporting of complication rates in the literature. Grech et al. [56] 
reported that 0.2% of PCI procedures developed major complications, including death. 
However, they concluded that this may be higher in cases with additional risks: 
myocardial infarction in 1%, stroke in 0.5%, cardiac tamponade in 0.5% and systemic 
bleeding in 0.5%.  
Naik et al. [58] concluded that mortality rates at three years and major adverse 
cardiac and cerebrovascular events (MACCE) were the same in both CABG and PCI, 
while target vessel revascularisation (TVR) was higher with PCI. A meta-analysis by 
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Capodanno et al. [59] stated that “left main coronary artery (LMCA) disease patients 
treated with PCI have non-significantly different 1-year rates of MACCE, death, and 
myocardial infarction, a lower risk of stroke, and a higher risk of TVR compared with 
CABG”. 
Over the last 30 years, many studies in the medical literature looked into the 
impact of provider yearly volume, either at hospital or at operator level, on PCI short-
term unfavourable outcomes such as mortality. Most of these studies reported a 
significant inverse impact of volume on the incidence of short-term outcomes after PCIs 
[60-67]. A meta-analysis by Post et al. [68] carried out on ten PCI studies, including 
1,322,342 patients in 1,746 hospitals, concluded that high volume hospitals 
demonstrated significantly lower short-term mortality compared to low volume 
hospitals. 
Enormous increments in the success rate of PCI procedures with obvious decline 
in post procedure complications were mainly linked to the current advances in 
implementing guidelines for management, catheter techniques, development of new 
guide wires, drug eluting stents, atherectomy devices and contemporary medications 
which have occurred along with the increased understanding of cardiovascular 
physiology and atherosclerosis pathogenesis [69]. 
 
1.3.3 Primary percutaneous coronary intervention 
For the treatment of STEMI, the urgency of the intervention procedure and the 
use of medical treatment such as fibrinolytic therapy is critical. Therefore, PCI can be 
primary (when it is performed unaided by fibrinolytic therapy in less than two hours 
after onset), facilitated (when associated with fibrinolytic therapy) or rescue (when it is 
undertaken after a failed fibrinolytic therapy) (Figure 1.2) [4, 7].   
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Figure 1.2: The spectrum of STEMI treatment strategy. 
 
 
 
 
 
 
Primary PCI is the first line of management for STEMI patients worldwide and in 
the UK [4, 70]. Between 2004 and 2007 in England and Wales, primary PCI procedures 
increased from 5.0% to 20.0% [71]. It is well known that the preferred time period for 
primary PCI is less than two hours after symptoms onset [4]. With delays to the 
procedure, the outcomes of primary PCI generally worsen [71-73]. For STEMI with 
cardiogenic shock, primary PCI remains the favoured line of treatment over fibrinolytic 
therapy [4, 74]. 
Performing primary PCI for acute myocardial infarction cases has always been an 
immense challenge for all interventional cardiology centres, and in order to attain such 
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an approach, interventional cardiology centres within hospitals should always have 
experienced, well-trained interventional cardiologists and fully equipped operation, high 
dependency and emergency departments with all needed supporting staff [60]. At 
present, experienced interventionists in high volume cardiac centres are noted to have 
better outcomes of primary PCI [4, 71].  
Patients with STEMI have a wide range of risk factors, such as old age, 
cardiogenic shock, hypertension and diabetes, which have impact on the outcomes of 
primary PCI. Despite this and the increasing burden of STEMI requiring primary PCI, 
survival rates have improved (up to 97% 3 years survival) [71, 75, 76]. It is believed 
that primary PCI is cost-effective in treating STEMI, mainly due to the reduced 
mortality outcomes associated with the procedure [77]. Consequently, a plan by the 
NHS in England and Wales was initiated to provide a national primary PCI service for 
all STEMI by 2012; such strategies have significant organisational and financial impact 
on the NHS [71]. 
 
1.3.4 Why investigate survival following primary PCI? 
Evidence from the medical literature supports the fact that primary PCI produces 
better outcomes for STEMI patients [70]. Delays in treatment frequently lead to 
undesirable complications and outcomes [71-73]. At the same time, the practice of 
primary PCI is increasing globally and, particularly, in the UK [70]. However, there is a 
gap of knowledge regarding the clinical determinants of primary PCI survival in 
particular. In addition, there is a lack of data about the impact of the timing of the 
procedure in relation to the routes of admission as well as the effect of hospital level 
factors such as patient volume. 
The majority of the literature about primary PCI has arisen from randomised 
controlled trials, and typically conducted outside the UK; thus it may not be 
generalisable to the UK. In the UK, there are few population-based studies on survival 
in patients with STEMI after primary PCI. Likewise, less studies have been conducted 
about the impact of clinical predictors on survival, including the admission routes and 
hospital variations [78, 79]. 
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In an observational national-based dataset such as the BCIS database, the 
availability of contemporary data on primary PCI allow to infer primary patients’ 
survival for the UK population. Consequently, significant results will be important to 
patients, cardiology professionals and healthcare managers in the UK to quantify the 
benefits of existing interventional care of patients as well as to highlight to stakeholders 
all areas where care and/or organisational changes and improvements are required. 
 
 
1.4 The British Cardiovascular Intervention Society registry 
 
1.4.1 Background 
Currently, in the UK, PCI is the most common procedure used in the invasive 
treatment of CAD. In order to establish organised healthcare services related to PCI 
procedures within the UK, proposals were made to collect significant reliable data about 
PCI procedures, operators, survival and outcomes [51, 52, 69]. One of the major 
organisations which established such data was the British Cardiovascular Intervention 
Society (BCIS).  
In 1988, BCIS was initiated and along with that the collection of data, aiming  to 
describe the national development and practice of PCI in England and Wales [80]. BCIS 
began as a voluntary group of physicians who gathered to discuss cases and matters 
relating to PCI and, as the practice expanded and developed, so did the society [80]. The 
society represents all concerned groups, including physicians, technicians, nurses and 
regulatory authorities [80]. One of the main aims of BCIS was to create a 
comprehensive and accurate registry of all PCI procedures performed in England and 
Wales. This was to review and assess the quality of care, improve and determine the 
standards of patients care, and provide data for research [80, 81].  
Between 1988 and 1991, yearly descriptive surveys of PCI procedures were 
published in the British Heart Journal. However, since 1992, annual information and 
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reports have been made available on the society’s website [81]. The BCIS data were 
mainly related to procedure quantities, centre numbers, as well as basic clinical 
characteristics. Over the years, efforts were made to determine clinical outcomes after 
PCIs, but it was clear that there were many errors in the data collected. Eventually, the 
system had a significant improvement with electronic techniques for data collection. 
This was funded by the Department of Health and developed by the Central Cardiac 
Audit Database (CCAD) group [80, 81]. In 1996, these techniques were tested as a pilot 
in some hospitals, and by 2005, full nationwide coverage was attained by using 
electronic data collection [52, 80, 81]. 
The society has an important role in teaching and education. For example, in 1996 
and in 2000, a joint working group between BCIS and the British Cardiac Society set 
out guidelines for training and continuing competence in PCI. At the same time, BCIS 
entered into a joint project with other specialised groups in cardiovascular medicine like 
the Heart Valve Registry, the Society of Cardiothoracic Surgeons, and the Association 
of Cardiothoracic Anaesthetists. Since April 2011, BCIS and five other UK cardiac 
audits have been brought together in one organisation called the National Institute for 
Clinical Outcomes Research (NICOR) [51, 80, 81]. 
The BCIS database is an electronic registry of all attempts of PCI procedures that 
have been carried out in all UK hospitals since 1994 [81]. For each PCI attempt, when 
any coronary device is used to probe or cross one or more coronary lesions with the 
intention of performing a coronary intervention, a total of 113 variables are regularly 
collected, which include patient demographics (e.g. age, sex and ethnicity), pre-
procedural clinical status (e.g. history of MI, renal disease, diabetes and cardiogenic 
shock), admission routes, procedures indications, related dates and times, operators’ 
details, procedures technical aspects and outcomes, together with all patient 
complications up to hospital discharge [81]. Changes to the BCIS database are 
performed to meet the requirements of care providers and patients’ needs; in the last 
updated version (2005 – 2014) of the BCIS database, the number of variables to be 
collected increased to 124 [54]. 
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1.4.2 How are the data entered? 
As of March 2010, about 460,000 records were in the BCIS registry. Around 
80,000 new records are added each year, reaching more than 747,000 by the end of 
March 2014 [20, 54, 81]. Data entry is usually done by healthcare professionals and 
data entry clerks. The data are uploaded into local software systems, followed by 
subsequent electronic encryption to ensure data security, then the data are transferred by 
internet to CCAD central data servers. As feedback to all PCI centres and others who 
are concerned (e.g. participating PCI centres and operators), monthly, quarterly and 
annual reports of PCI activities and outcomes across the UK are regularly distributed 
[20, 52, 81] (Figure 1.3). 
 
 
 
Figure ‎1.3: British Cardiovascular Intervention Society (BCIS) data flow. 
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1.4.3 Patient identification, follow-up and mortality 
Part of the BCIS-CCAD project is to track subsequent patient’s vital status and 
mortality dates after discharge from hospital. Tracking is carried out by CCAD using 
the National Health Service (NHS) central register number, which provides a unique 
identifier for any person registered with the NHS in the UK. The NHS number is 
pseudo-anonymised within the database; however, other identifiers are available in the 
database like hospital numbers, dates of birth and postcodes. These kinds of data as well 
as the hospital identity are protected and researchers do not have access to such data 
[39, 53] (Figure 1.3). 
Analysis of all-cause mortality is executed by the Medical Research Information 
System (MRIS) by linkage with the Office for National Statistics (ONS) using each 
patient’s unique NHS number. Using each patient’s geographical residence, their index 
of multiple deprivation (IMD) score was linked to their corresponding BCIS record, a 
linkage that was made by the CCAD as all patients’ identifiers such as names, hospital 
numbers, dates of birth and postcodes, as well as interventionists and hospitals 
identifiers were secondary anonymised in BCIS data. In this thesis, two versions of 
BCIS data have been utilised, and the censoring date for the 2010 BCIS database was 
10th August 2011 while for the 2014 database it was 1st July 2014 [20, 54].  
 
1.4.4 Data structure 
The BCIS data is structured into six themes, each containing specific 
information. All are described in Table 1.1. Within this thesis, data from two time 
periods are used:  
• The 2010 BCIS dataset: the initially received version, from 1st of January 2005 
to 31st of December 2010. The overall description is demonstrated in this chapter 
(section 1.4.5). This version was used for analysis in Chapter 4.  
• The 2014 BCIS dataset: an updated version which was available more recently, 
from 1st of January 2005 to 31st of March 2014. The overall description is 
demonstrated in this chapter (section 1.4.6). This version was used for analyses 
in Chapters 5 and 6.  
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Table 1.1: BCIS database fields, information and contents. 
Theme Type of information Examples of contents 
Patient Demographic and 
identification information of 
patients. 
Patient name, gender, date of birth, ethnicity, 
post code, NHS number and hospital 
identifier.  
Clinical Clinical presentation, 
investigation, medical history, 
and pre-procedure 
information. 
Clinical syndrome, intervention indications, 
presence of cardiogenic shock, admission 
route, presenting ECG, history of previous 
acute myocardial infarction, previous PCI, 
Diabetes, pre-procedural LVEF and pre-
procedural flow in infarct related artery. 
Procedural Operator, procedural 
techniques, devices and 
medications and post-
procedural investigation 
Information. 
Operators identifier, number and type of 
stents used, diagnostic and procedural devices 
used such as intravascular ultrasound, 
circulatory support, arterial management and 
post-procedural flow in infarct related artery. 
Outcomes In-hospital outcomes, post-
procedural enzymes and 
discharge information. 
In-hospital outcomes such as acute 
myocardial infarction, cerebrovascular 
accident, bleeding or death; troponin 
biomarker level, status at discharge (dead or 
alive) and date of discharge. 
Miscellanies  Clinical, investigation, 
procedural and post-
procedural information. 
Cholesterol level, smoking status, history of 
renal disease, indication for stenting, arterial 
access, procedural complications and left 
main stem protection. 
Therapy * Therapeutic tests and scores; 
and some specific treatments. 
Use of ventilation, hypothermia treatment, 
arterial blood gas results and Glasgow coma 
scaling. 
* This part was added in the 2014 updated version of BCIS database. 
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1.4.5 BCIS database (the 2010 version after data cleaning) 
The 2010 BCIS database is a linked prospective national registry of all adult 
percutaneous coronary interventions that holds pseudo-anonymised patient-level data 
from all centres in the UK registered with the BCIS audit program, in the period 
between 1st January 2005 and 31st December 2010. 
 
1.4.5.1 Who is in the database? 
A total of 114 interventional cardiology centres and hospitals in the UK provide 
data to the BCIS, including all adult PCIs performed within these centres: 99 (86.8%) in  
England, eight (7.1%) in Scotland, four (3.5%) in Northern Ireland and three (2.6%) in 
Wales [20]. Although all four countries in the UK contribute to the BCIS data, robust 
mortality tracking was only available for patients who live in England and Wales; this 
represents approximately 89% of the whole adult UK population (based on the Office 
for National Statistics UK population estimates for 2013) [82] (Figure 1.4).  
 
1.4.5.2 Data description 
A comprehensive description of the overall 2010 version of the BCIS data is 
presented in Appendix I including demographic, clinical, procedural, and outcomes 
characteristics. 
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Figure 1.4: Distribution of all PCI patients by country in England and Wales from 
2005 to 2010. 
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1.4.6 BCIS database (the 2014 version after data cleaning) 
Similar to the 2010 BCIS database, the updated 2014 database is a linked 
prospective population-based registry of all adult percutaneous coronary interventions, 
and holds pseudo-anonymised patient-level data from all centres in the UK that were 
registered with the BCIS audit program in the period between 1st January 2005 and 31st 
March 2014. 
 
1.4.6.1 Who is in the database? 
Other than the data about the extra years from 2011 to 2014, the main difference 
between the 2014 updated BCIS database and the previous 2010 version was the linkage 
to mortality tracking which is available for all patients living in the UK. In the 2010 
database, mortality tracking was restricted to the patients from England and Wales. All 
PCI procedures from 117 registered interventional cardiology centres and hospitals in 
UK provide data to the BCIS, 101 (86.4%) being in  England, eight (6.8%) in Scotland, 
four (3.4%) in Northern Ireland and four (3.4%) in Wales [54]. Figure 1.5 shows the 
distribution of PCI procedures in all four countries of the UK. 
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Figure 1.5: Distribution of all PCI patients by country in the UK from 2005 to 
2014. 
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1.4.6.2 Data description 
1.4.6.2.1 Demographic characteristics 
Table 1.2 illustrates the distribution of baseline demographic characteristics of 
PCIs in the 2014 BCIS database. A total of 699,248 PCIs were recorded in the 2014 
BCIS database. By means of continuance of what had been demonstrated in the 
previous 2010 version, the number of PCI procedures undertaken per year rose 
gradually (from 41,031 procedures in 2005 to 96,655 in 2013) (Figure1.6).  
The mean age (SD) for all patients increased to 64.6 (11.7) years. Male patients 
remained dominant (73.5%) out of all patients; the mean age (SD) was 63.4 (11.5) years 
for male patients and 68.1 (11.5) years for females. Figure 1.7 demonstrates the 
difference in the frequency and age distribution between males and females. NHS 
hospitals/centres continued leading in performing the majority of procedures (85.0%), 
while private hospitals/centres were (3.8%) only. Direct admission to cardiac centre 
became the main route of admission at 43.9% compared to 33.5% in the 2010 database. 
 
 
 
Table 1.2: Baseline demographic characteristics of all PCI patients in the UK from 
2005 to 2014. 
Variable Total    n= 699,248 Missing values (%) 
Mean (SD) age, years   64.6 (11.7) 
690 (0.1) Age 
Less than 65 years (%) 347,131 (49.6) 
65 – 80 years (%) 288,670 (41.3) 
Greater than 80 years (%) 62,757 (9.0) 
Gender Female (%) 181,854 (26.0) 3,407 (0.5) Male (%) 513,987 (73.5) 
Ethnic groups 
Caucasian (%) 442,584 (63.3) 
187,946 (26.9) Black (%) 3,904 (0.6) Asian (%) 33,283 (4.7) 
Other (%) 31,531 (4.5) 
Patient type NHS (%) 594,554 (85.0) 78,064 (11.2) Private (%) 26,630 (3.8) 
Admission route 
(ACS only) * 
Direct to cardiac centre (%) 173,884 (43.9) 
55,335 (13.9) Inter-hospital transfer (%) 140,351 (35.4) 
Already in cardiac centre (%) 26,979 (6.8) 
Index of multiple deprivation score, mean (SD) 19.5 (16.5) 65,313 (9.3) 
* ACS n= 396,549. 
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Figure 1.6: Number of PCIs performed per year, from 2005 to 2014. 
 
 
 
Figure 1.7: Age distribution by gender of all PCI patients in the UK from 2005 to 
2014. 
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1.4.6.2.2 Clinical characteristics 
The total number of patients with chronic stable angina decreased remarkably 
compared to stable patients in the 2010 database (50.3% vs. 39.6%). Though, the 
number of patients with STEMI and NSTEACS increased (20.0% and 36.8%, 
respectively). Between 2011 and 2014, the drop in the frequency of chronic stable 
angina patients continued, however, in slower rates (from 36.5% in 2011 to 35.1% in 
2014); similarly, the frequency of STEMI patients increased slowly compared to 
previous years (25.9% in 2011 to 26.9% in 2014) (Figure 1.8). Compared to data from 
the 2010 database, the prevalence of primary PCI procedures increased from 67.8% to 
87.2% in the 2014 database. Patients with pre-procedural cardiogenic shock were 
13,376 (1.9%), and those with severe LVSD (ejection fraction less than 30%) were 
34,750 (5.0%) patients. More details on the clinical characteristics of PCI between 2005 
and 2014 are listed in Table 1.3. 
 
 
 
Figure 1.8: Distribution of all PCI patients in the UK from 2005 to 2014, by clinical 
syndrome. 
 
55.0
9.8
35.2
51.4
10.8
37.8
46.1
13.0
40.9
45.5
16.1
38.4
41.6
19.9
38.5
38.1
23.7
38.2
36.5
25.9
37.6
35.9
26.8
37.3
34.9
26.8
38.3
35.1
26.9
38.0
0
20
40
60
80
10
0
Pe
rc
en
ta
ge
s 
(%
)
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Years
CSA STEMI NSTEACS
 
 
27 
 
Table 1.3: Baseline clinical characteristics of all PCI patients in the UK from 2005 
to 2014. 
Variable Total    n= 699,248 Missing values (%) 
Clinical 
syndrome  
CSA (%) 276,897 (39.6) 
25,802 (3.7) STEMI (%) 139,607 (20.0) 
NSTEACS (%) 256,942 (36.8) 
PCI type  
(STEMI only) * 
Primary (%) 121,764 (87.2) 
4,619 (3.3) Facilitated (%) 3,171 (2.3) 
Rescue (%) 10,053 (7.2) 
Previous acute myocardial infarction (%) 178,696 (25.6) 77,216 (11.0) 
Previous PCI (%) 145,192 (20.8) 39,801 (5.7) 
Family history of coronary artery disease (%) 269,736 (38.6) 115,669 (16.5) 
Diabetes mellitus (%) 123,658 (17.7) 45,610 (6.5) 
History of renal disease (%) 16,836 (2.4) 10,127 (1.5) 
Smoking status 
Never smoked (%) 217,961 (31.2) 
96,622 (13.8) Ex-smoker (%) 235,465 (33.7) 
Current smoker (%) 149,200 (21.3) 
Recent thrombolysis (%) 28,611 (4.1) 298,006 (42.6) 
Cardiogenic shock (%) 13,376 (1.9) 56,488 (8.1) 
LVEF (%) 
Good, LVEF ≥ 50%  250,890 (35.8) 
328,460 (47.0) Fair, LVEF = 30 – 49% 85,148 (12.2) 
Poor (sever) LVEF < 30%  34,750 (5.0) 
* STEMI n= 139,607.  
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1.4.6.2.3 Procedural characteristics 
As a whole, the use of femoral artery as an access route was to some extent 
higher than the use of radial artery (50.5% compared to 45.8%). However, compared to 
earlier years, femoral artery access became less frequently used (84.7% in 2005 vs. 
27.0% in 2014). In contrast, the use of radial artery access became more prevalent 
(15.3% in 2005 vs. 73.0 in 2014) (Figure 1.9). Pre-procedural TIMI 3 was in 64,267 
(16.2%) acute patients and afterward post-procedure increased to be in 207,048 (52.1%) 
acute patients. Drug eluted stents were used alone in 60.2% of procedures and 4.3% 
with one or more bare metal stents, while bare metal stents were used alone in 23.2% of 
procedures. More details on procedural characteristics are presented in Table 1.4. 
 
 
 
Figure 1.9: Proportion of femoral and radial access in patients who received PCI 
in the UK from 2005 to 2014. 
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Table 1.4: Baseline procedural characteristics of all PCI patients in the UK from 
2005 to 2014. 
Variable Total    n= 699,248 Missing values (%) 
Pre-procedural flow in 
infarct related artery 
(ACS only) * 
TIMI 0 (%) 84,375 (21.3) 
189,957 (47.9) 
TIMI 1 (%) 15,607 (3.9) 
TIMI 2 (%) 23,180 (5.9) 
TIMI 3 (%) 64,267 (16.2) 
Unknown (%) 19,163 (4.8) 
Arterial access 
Femoral artery (%) 353,017 (50.5) 
24,371 (3.5) Radial artery (%) 320,095 (45.8) 
Other arteries (%) 1,765 (0.2) 
Total number stents 
used 
1 stent (%) 348,708 (49.9) 
88,326 (12.6) 2 stents (%) 167,381 (23.9) 
≥ 3 stents (%) 94,833 (13.6) 
Longest stented/treated segment, mean (SD) mm 24.2 (13.6) 155,428 (22.2) 
Largest balloon/stent used, mean (SD) mm 3.4 (3.5) 168,268 (24.1) 
Type of stent used 
Bare metal stent (%) 161,940 (23.2) 
86,076 (12.3) Drug eluting stent (%) 421,526 (60.2) 
Both together (%) 29,706 (4.3) 
Type of 
drug 
eluting 
stent used  
Taxus liberte (Boston Scientific) (%) 59,373 (8.5) 
69,506 (9.9) 
Cypher (Cordis) (%) 36,098 (5.2) 
Endeavor (Medtronic) (%) 37,613 (5.4) 
Xience V (Abbott) (%) 57,703 (8.3) 
Promus (Boston Scientific) (%) 74,561 (10.7) 
BioMatrix (%) 20,414 (2.9) 
Promus Element (%) 37,440 (5.4) 
Xience Prime (%) 27,902 (4.0) 
Resolute Integrity (%) 25,353 (3.6) 
Drugs used 
None (%) 470,191 (67.2) 
66,921 (9.6) Abciximab (%) 
114,110 (16.3) 
Eptifibitide (%) 17,895 (2.6) 
Tirofiban (%) 30,131 (4.3) 
Use of intravascular ultra sound (%) 29,825 (4.2) 89,825 (12.9) 
Use of intravascular pressure wire (%) 48,428 (6.9) 89,825 (12.9) 
Use of Intra-aortic balloon pump (%) 10,692 (1.5) 66,193 (9.5) 
Post-procedural flow in 
infarct related artery 
(ACS only) * 
TIMI 0 (%) 12,094 (3.1) 
143,042 (36.1) 
TIMI 1 (%) 2,429 (0.6) 
TIMI 2 (%) 8,358 (2.1) 
TIMI 3 (%) 207,048 (52.1) 
Unknown (%) 23,578 (6.0) 
* ACS n= 396,549. 
  
 
 
30 
 
1.4.6.2.4 Clinical outcomes  
Clinical outcomes and mortality rates are listed in Table 1.5. In general, 
compared to data from the 2010 database, there were no major changes in the 
prevalence of all procedural complications or in-hospital outcomes, including acute 
myocardial infarction, MACCE and revascularisation. Likewise, mortality rates 
increased from 1.4% in-hospital to 1.8% at 30 days post the procedure and to 4.2% at 
one year post the procedure.  
 
 
 
 
Table 1.5: Outcomes of all PCI patients in the UK from 2005 to 2014. 
Variable Total           n= 699,248 
Missing 
values (%) 
Procedural 
complications 
Side branch occlusion (%) 4,321 (0.6) 
85,451 (12.2) 
Coronary dissection (%) 10,984 (1.6) 
Coronary perforation (%) 2,000 (0.3) 
Direct current cardioversion (%) 2,410 (0.3) 
No flow/slow flow (%) 6,523 (0.9) 
Ventilated (%) 1,152 (0.2) 
Cardiogenic shock induced by procedure (%) 1,356 (0.2) 
In-hospital 
outcomes 
Acute myocardial infarction (%) 3,414 (0.5) 
29,459 (4.2) 
Stroke (%) 783 (0.1) 
Renal failure/dialysis (%) 685 (0.1) 
Blood transfusion (%) 1,427 (0.2) 
Revascularisation 
PCI (%) 2,082 (0.3) 
Coronary artery bypass 
graft (%) 1,869 (0.3) 
Unadjusted MACCE rate (%) 14,128 (2.0) 
Unadjusted in-hospital mortality rate (%) 9,411 (1.4) 22,054 (3.2) 
Unadjusted mortality rate at 30 days  (%) 12,568 (1.8) 77,96 (11.2) 
Unadjusted mortality rate at 1 year *  (%) 27,312 (4.2) 71,596 (12.0) 
* Censored at 31/7/2014, therefore all PCI procedures performed after 31/7/2013 were not included in 
describing this rate. 
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1.4.6.3 Data completeness  
A total of 124 variables are in the 2014 BCIS database. Out of them, only two 
(1.6%) variables were 100% complete, which were the month of operation and the year 
of operation. The remaining 122 variables had missing information that ranged between 
0.1% (clinical syndrome type) and 99.9% (pH level on the arterial blood gas on arrival 
to catheterisation lab). Tables 1.2 to 1.5 list the missing values of most of the 2014 
BCIS database.  
Altogether, between 2011 and 2014, there was a slight decrease in the 
proportion of missing data; for example, missing values in pre-procedural cardiogenic 
shock declined from 5.2% in 2011 to 4.6% in 2014, missing values for left ventricular 
ejection fraction dropped from 47.9% to 45.9%, and missing values for arterial access 
decreased from 2.1% in 2011 to 1.9% in 2014 (Figure 1.10). 
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Figure 1.10: Proportions of complete and missing values for pre-procedural 
cardiogenic shock, left ventricular ejection fraction and arterial access in the UK 
stratified by years from 2005 to 2014. 
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1.4.7 BCIS audit and data quality 
A national comparative audit is the best description for the BCIS data. Such data 
offers the opportunity to compare PCI services, techniques and outcomes across the UK 
[55, 83]. BCIS provides regular recommendations, comprehensive guidelines and 
technical advices for PCI operators and data entry personnel in order to ensure the 
continuity of data collection and to maintain data quality to high standards. In order to 
attain that, a partnership was built between the BCIS audit and the National Institute for 
Cardiovascular Outcomes Research (NICOR) [55].  
Hosted by NICOR, the BCIS data entry spreadsheet is available on the BCIS 
website, which also includes the definitions of all variables. BCIS-NICOR data entry, 
cleaning, analysis and consistency checks are designed to minimise common data entry 
errors and to improve its accuracy [55]. In addition, to keep the BCIS database always 
relevant and up to date, occasional alterations to data structure are often made whilst 
aiming to diminish any interference to data entry, management and quality [55].  
Although the precision and completeness of any recorded information in the 
BCIS database is primarily the responsibility of the procedure operator, registered PCI 
hospitals and centres are mandated to nominate an audit leader who is principally 
accountable for securing and organising the progression of data collection [55]. Also, it 
is the responsibility of the local audit to organise the linkage of all post-discharge events 
of their patients and validate record ascertainment and the completeness of such data 
[55].  
Furthermore, there is no independent validation of the BCIS data and each local 
audit is accountable for performing consistent data validation and maintains data 
accuracy and completeness. For example, validation of the data quality for patients who 
underwent primary PCIs is typically performed for the date/time variables. [55]. Using 
the patient’s NHS number as a unique identifier, the BCIS database has been linked to 
other databases and national registries within the CCAD group such as the Myocardial 
Ischaemia National Audit Project (MINAP). The linkage between BCIS and other 
databases offers a unique opportunity to estimate records ascertainment and to some 
extent the quality of data especially for acute cases [81]. 
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1.4.8 Publications  
In order to expand and promote the interventional research potentials of the 
BCIS database, anonymised or pseudo-anonymised versions of the data are distributed 
to researchers through the BCIS research and development group. Currently, 25 
research projects are being conducted after approval from the research and development 
group [84]. Some examples of the publications in peer-reviewed journals include: 
‘Long-term follow-up of elective chronic total occlusion angioplasty’ by Sudhakar et al. 
[85], ‘Outcomes after Emergency PCI in patients with Unprotected Left Main stem 
Occlusion’ by Patel et al. [86], and ‘Arterial access site utilisation in cardiogenic shock 
in the United Kingdom: is radial access feasible?’ by Mamas et al [54, 87]. 
 
1.4.9 Strengths 
As a research source, there are five key strengths of the BCIS database: 
1. Size and population coverage: BCIS database is a national data source that 
provides data in a large and unselected consecutive cohort of patients. Currently, 
there are more than 747,000 records of PCIs in the database [54]. 
2. Representativeness: conducted studies on the BCIS database can be generalised 
to the UK population as the data collected from all participating hospitals and 
centres represent all four countries of the UK [54]. 
3. The depth of detail of the data: a wide range of up-to-date PCI related 
information are recorded in 124 variables in BCIS database that describes 
patient demographics, pre-procedural clinical features, procedural 
characteristics, complications, in-hospital outcomes, providers’ information and 
dates and times [54]. 
4. Mortality tracking and linkage: by using the NHS number as an identifier and 
linking to ONS mortality data. 
5. Less recall bias: as data collection is executed prospectively. 
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1.4.10 Weaknesses  
Although BCIS database is considered as a unique and valuable source for 
research, there are three main limitations that need to be pointed out: 
1. Missing data: out of the 124 variables in the data, 122 variables had missing 
information that ranged from 0.1% to 99.9%. 
2. Incomplete patient ascertainment: the variation in reporting all PCIs 
performed between participating hospitals and centres as some may report acute 
cases only and the others report stable alone or both stable and acute, which 
consequently leads to underreporting of one type or more of the clinical 
presentations. 
3. Funds for data entry: this is always the responsibility of local hospitals or 
centres, thus it is subjected to variability in funds as well as the clinical 
background of the appointed data entry personnel, which will subsequently 
affect the quality and accuracy of the entered data. 
 
 
1.5 Office for National Statistics (ONS) 
Since the induction of the UK Births and Deaths registration in 1837, death 
registration became a legal obligation. Four years afterward, in 1841, the cause of death 
was added to the registry [88]. The database of ONS on mortality statistics is a complete 
source of mortality data and the underlying causes, which use patient’s NHS number as 
a unique identifier. The coding of ONS mortality data is based on the codes of the 10th 
revision of the International Classification of Disease (ICD-10), a classification for fatal 
and non-fatal disease developed by the World Health Organisation (WHO) [88]. 
All ONS data are entered online by registrars at local registration services. 
Around 75% of records are referred to the Medical Certificate of Cause of Death 
(MCCD), which is mostly completed by the treating physician of the deceased patient. 
The remaining 25% of records, such as unclear cause of death in the MCCD, are 
managed by a coroner who confirms the cause of death from the MCCD, treating 
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physician or post-mortem data [89]. To confirm the accuracy and consistency of the 
entered data, validation checks are initially performed by the online data entry system, 
and regular diagnostic tests are then implemented by ONS [89].  
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2 Chapter 2   Literature reviews and rationale for study 
 
 
 
 
2.1 Summary 
The previous chapter outlined an overview to the clinical backgrounds as well as 
the BCIS data (framework and description). Two motivating questions were explored 
previously: why study cohort data about PCI in UPLMS? (section 1.2.5) and why investigate 
survival following primary PCI? (section 1.3.4). This chapter describes and evaluates two 
literature reviews about these two questions, which are “clinical determinants and 
temporal trends of outcomes for PCI in UPLMS disease” (section 2.4) and “clinical 
determinants of survival for primary PCI” (section 2.5). From which the rational, aims 
and objectives of this thesis are developed (section 2.6). 
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2.2 Preview  
In order to define the best methodological and analytical approaches, different 
search strategies were built and initial comprehensive literature reviews were performed 
to answer three research questions: “What are the clinical determinants of outcomes for 
PCI in UPLMS in the UK and what is the impact of the existence of cardiogenic shock 
and the type of arterial access on the outcomes?”, “What are the temporal trends of the 
outcomes for PCI in UPLMS in the UK?”, and “What are the survival and outcomes of 
primary PCI in the UK and what is the impact of clinical determinants such as the 
admission route and hospital dissimilarities on survival?”. Answers to the first two 
questions about UPLMS patients were reviewed together as a whole, while answers to 
the question on primary PCI were reviewed separately.  
 
2.3 General search strategy 
For each of the three research questions, a literature search strategy was built to be 
restricted to relevant studies on humans only, and to English publications using Ovid 
Medline and PubMed databases to increase the specificity of the search. Pending 
unpublished articles, abstract only articles, case reports and case series articles were 
excluded. A similar strategy was performed in Google and Google Scholar database to 
identify publications from institutions and governmental departments that would not 
have been identified on Medline and PubMed. References of the relevant publications 
were screened and citation trees were followed to identify further articles. In addition, 
the websites of several institutions, such as BCIS and ONS, were reviewed for relevant 
information. All identified articles were downloaded into Endnote software and 
duplicates were removed. Then the articles were screened by titles and abstracts and the 
relevant ones were fully reviewed. 
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2.4 Literature review on ‘clinical determinants and temporal trends 
of outcomes for PCI in UPLMS disease’ 
 
2.4.1 Introduction 
 CABG remains the standard treatment of choice for all types of LMS disease, 
and with the advances in surgical procedures, CABG has demonstrated that it has better 
survival benefits compared to other surgical and medical treatments [21-23, 90, 91]. 
However, in contemporary practice, PCI has been evolving tremendously, particularly 
in treating LMS disease [2-4]. Percutaneous coronary intervention is now considered a 
reasonable line of management since it reduces the in-hospital mortality rate and 
increases the survival at one year when compared to reported CABG outcomes [24]. 
Furthermore, with the expansions in stent technology (drug eluting stents, equipment 
and techniques) PCIs are yielding higher rates of success with encouraging outcomes in 
the management of unprotected LMS (UPLMS), not only for stable elective cases but 
also for emergency cases when CABG is contraindicated [25, 90, 92].  
Given the fact that the success of any PCI procedure for UPLMS (in terms of 
survival, short- and long-term outcomes) is influenced by different risk factors, for 
example, increasing age, cardiogenic shock, diabetes, renal failure, and previously 
derived cardiac risk scores such as EuroSCORE, SYNTAX score and Parsonett score, it 
is believed that these factors are less common among the elective cases compared to the 
unstable emergency cases [25-27]. Besides, unless it is not contraindicated, CABG is 
the recommended line of management for UPLMS, and PCIs would be preserved for 
contra-indicated cases, thus affecting its success further [19, 26, 28]. It is what this 
section of the chapter is aiming to review, the clinical determinants of PCI procedural 
survival and clinical outcomes among patients with UPLMS, as well as to review the 
temporal trends of such cases. 
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2.4.2 Search methods 
A literature search was conducted using Ovid Medline, PubMed and Google 
Scholar between January 1996 and September 2015. An initial search of “unprotected 
left main coronary artery disease” and “unprotected left main stem disease” obtained 
over 31,000 results, requiring a more tightly focused search strategy. Using Ovid 
Medline database, two main topics related to UPLMS were therefore targeted: 
percutaneous coronary interventions and outcomes in UPLMS patients. In terms of 
percutaneous coronary intervention, keyword searches included “percutaneous coronary 
intervention”, “PCI” and “stenting”. Keyword searches for outcomes included 
“outcomes”, “mortality”, and “survival” in conjunction with percutaneous coronary 
intervention and UPLMS related words.  
In addition, articles that did not comprise percutaneous coronary intervention in 
the management of UPLMS and/or any clinical determinant were also excluded. At the 
end of the focused literature search, 101 relevant publications were picked up and 
scanned by titles and abstracts at first, and then only applicable articles were completely 
reviewed. References of the articles were screened and other related publications and 
resources from citation trees concerning percutaneous coronary intervention and 
UPLMS outcomes were correspondingly followed and cited using PubMed and Google 
Scholar databases. A total of 23 journal papers were included and reviewed.  
 
2.4.3 Statistical analysis 
In all reviewed articles, different statistical methods were used in order to 
describe the relationship between intended clinical predictors and percutaneous 
coronary intervention survival and outcomes in UPLMS. At the level of multivariate 
analysis, logistic regression, Kaplan-Meier method and Cox’s proportional hazards 
regression were the most commonly used statistical methods. Logistic regression was 
employed in six studies, while Cox’s proportional hazards regression was used in 17 
studies. Only three studies employed stepwise Cox’s proportional hazards strategies, 
and one used a backward stepwise logistic regression model, where the idea behind both 
methods was that the measured predictors were selected based on a specific significant 
P value. A detailed list of reviewed studies describing the clinical determinants 
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associated with PCI survival and outcomes in UPLMS patients are summarised in Table 
2.1. Extra papers that did not have sufficient information were mentioned in the review 
but were not presented in the table. 
 
2.4.4 Age as a determinant of survival and outcomes 
Universally, the elderly population is evidently rising especially in developed 
countries. At the same time, cardiovascular diseases and related risk factors are higher 
among this age group compared to younger individuals [93]. Previously, due to the 
increase in post-procedural unfavourable outcomes, PCIs were less commonly 
performed on elderly patients with LMS disease. However, the number of PCI 
procedures among this age group has been increasing with time. Currently, more than 
20% of all patients treated by PCI are age 75 years or older [93, 94]. 
Despite the methodological disparities, evidence from medical literature showed 
that old age is one of the important determinants of poorer prognosis in any PCI 
procedure [86, 92, 93]. A recent publication by Lee et al. [95] showed that age of more 
than 70 years, among other factors, was a significant predictor of 30-day mortality. 
Another contemporary publication by Sim et al. [96] reported that age 65 years and over 
was a risk factor of higher 1-year mortality rate (aHR 3.0, 95% CI 1.5 to 6.0, P=0.002). 
A review by Marco and Fajadet stated several clinical risk factors that influence 
the success of PCI procedures and one of the findings was that the higher the age (75 
years and over), the higher the risk of developing in-hospital outcomes after PCI for 
patients with UPLMS [26]. Also, a study by Schrale et al. [31] revealed that the age of 
more than 75 years was among other predictors of mortality (P=0.032).  
Maluenda et al. [97] concluded that old age (70 years and over) was among 
eight risk factors that were significantly associated with a high one year mortality rate 
after PCIs and, as age increased further (80 years and over), the risk became higher. A 
study by Parma et al. [48] showed that one of the predictor risk factors of high early 30-
day mortality and midterm three year survival after PCI for UPLMS was the age of 75 
years or more. In addition, a study by Min et al. [47] on 1102 UPLMS cases treated 
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with PCI showed that target vessel revascularisation (TVR) was significantly reduced in 
those with age 75 years and over (aHR 0.5, 95% CI 0.3 to 0.9). 
In an observational study by De Luca et al. [45], it was concluded that 
increasing age was a significant independent predictor of major adverse cardiac or 
cerebrovascular events (MACCE) and overall mortality (aHR 2.1, 95% CI 2.0 to 3.3 
and aHR 4.6, 95% CI 2.8 to 12.7) respectively. Similarly, Onuma et al. [94] reported 
that for all UPLMS cases treated by PCIs, age at both univariate and multivariate levels 
of analysis was a significant predictor of mortality. In the same way, Meliga et al. [98] 
demonstrated that age was a predictor of cardiac mortality (aHR 1.06, 95% CI 1.01 to 
1.11).  
Moreover, Buszman et al. [99] also stated that being over 60 years of age was a 
risk factor of higher short- and long-term mortality rates (aOR 2.5, 95% CI 1.0 to 5.9). 
A paper by Kang et al. [100] demonstrated that the association between age (65 years 
and over) and a composite of mortality, myocardial infarction and stroke was 
significant. Lee et al.’s study [101] on 164 UPLMS cases showed that age (per 10 
years) was significantly associated with worse 30-day survival. 
 
2.4.5 Clinical determinants of survival and outcomes 
There is conflicting evidence regarding what the main independent clinical 
predictors of PCI outcomes in UPLMS are; however these predictors can be elucidated 
through the fact that most UPLMS cases treated by PCI are actually a high risk group of 
patients who have previously been rejected from surgical treatment [26]. What’s more, 
the argument continues on which are the most important risk factors and their short- and 
long-term effect on the outcomes and survival of PCI procedures for such patients. In 
the available literature, most studies showed a similar pattern of clinical predictors; 
however, some of the studies used different modes of scoring mechanisms in order to 
overcome any interactions between these predictors.  
In a meta-analysis study by Vis et al. [34] in which 977 patients from 13 
observational studies were reviewed, 30-day mortality was 55.0% in cardiogenic shock 
patients (RR 3.7, 95% CI 2.9 to 4.8, P <0.001). Patel et al. [86] demonstrated in their 
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results that peri-procedural cardiogenic shock as well as age, female gender, acute 
LVEF, presence of an occlusive lesion, glycoprotein (GP) IIb/IIIa inhibitor use and the 
presence of post-procedural no-reflow were all significant predictors of 30-day 
mortality; however, in terms of the predictors at three year mortality, all except acute 
LVEF were significant predictors. 
Likewise, Beak et al. [102] stated that the presence of cardiogenic shock at 
presentation or a heart rate of more than 100 beats per minute were associated with 
higher cardiac mortality. In the same way, Sim et al. [96] concluded that the presence of 
cardiogenic shock,  LVEF of less than 40% and the use of mechanical ventilation were 
significant determinants of high 1-year mortality rate. Dores et al. [36] demonstrated the 
significant predictors of MACCE at five years for 95 PCI UPLMS cases. These were 
myocardial infarction (aHR 2.9, 95% CI 1.2 to 6.9, P=0.015), hypertension (aHR 5.7, 
95% CI 1.9 to 17.5, P =0.002) and the EuroSCORE I (aHR 1.1, 95% CI 1.0 to 1.1, P 
=0.001). 
In a previously mentioned paper by Parma et al. [48], in addition to age, 
cardiogenic shock at presentation and post PCI TIMI flow grade <3 were also identified 
as risk factors of higher 30 day and three year mortality. Correspondingly, in Kang et 
al.’s study [100], significant risk factors for a composite of mortality, myocardial 
infarction, and stroke were cardiogenic shock at presentation and a history of peripheral 
artery disease as well as old age, and for TVR the risk was significantly higher with 
emergency procedures.  
An observational study by Ben Dor et al. [30] found that increased mortality at 
six months and one year was significantly correlated with cardiogenic shock, emergency 
procedures, LVEF <35% and renal failure. However, MACCE were correlated with 
cardiogenic shock, emergency procedures, renal failure and diabetes mellitus. 
Furthermore, besides age, Schrale et al. [31] reported cardiogenic shock (aHR 7.9, 95% 
CI 1.7 to 3.6) as a predictor of mortality. A paper by Wu et al. [103] identified 
hyperlipidaemia as a significant independent predictor for MACCE after PCI in 55 
UPLMS cases.  
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In an earlier study by Khattab et al. [104], where the outcomes of PCI treatment 
in 82 UPLMS cases were compared to the outcomes in 118 cases with protected LMS 
disease, significant determinants of increased mortality, higher risk of myocardial 
infarction and increased TVR were female gender, diabetes mellitus, renal 
insufficiency, STEMI, cardiogenic shock and LVEF (40% or less). A further earlier 
study by Lee et al. [105] stated that significant univariate predictors of higher MACCE 
were myocardial infarction, diabetes and Parsonnet score, while the significant 
independent determinants of the hazard of MACCE were diabetes and Parsonnet score.  
Above and beyond the Parsonnet score, the EuroSCORE was extensively 
studied in medical literature particularly as a determinant for post-PCI outcomes in 
UPLMS, and the majority of the studies agreed on the fact that the risk of post-PCI 
unfavourable outcomes increases as EuroSCORE increases. In De Luca et al.’s study 
[45], EuroSCORE was identified as a significant independent determinant of both 
MACCE and mortality, whereas diabetes was a significant determinant of MACCE and 
TVR. In addition, a paper by Fernandez et al. [46] comparing the risks of PCI treatment 
in diabetics vs non-diabetics with UPLMS revealed that cardiac mortality and  
EuroSCORE were significantly higher in diabetic patients.  
Likewise, Min et al. [47] reported that in UPLMS cases treated by PCI, 
EuroSCORE ≥6, chronic renal failure and previous congestive heart failure were 
independent predictors of mortality. An observational study by Brennan et al. [42] 
demonstrated that high logistic EuroSCORE scores (≥33.5%) and high clinical urgency 
(primary PCI, rescue or facilitated PCI for STEMI, pre-procedural cardiogenic shock, or 
emergent or salvage status) were significantly associated with higher 30 day MACCE.  
Buszman et al. [99] also identified LVEF <50% and EuroSCORE on admission 
>9 as risk factors for higher mortality. Another study on 849 UPLMS cases by 
Tamburino et al. [106] reported that chronic renal disease, LVEF and EuroSCORE were 
significant predictors of PCI outcomes. In an observational study on 358 UPLMS cases, 
Meliga et al. [98] revealed age, cardiogenic shock, EuroSCORE and LVEF <50% as 
significant independent predictors of cardiac mortality. At the same time, diabetes and 
EuroSCORE were significant determinants of MACCE; and diabetes and LVEF <50% 
were significant determinants for TVR.  
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Earlier studies on PCI and UPLMS were more focused on individual clinical 
features and EuroSCORE as the main clinical determinants of procedural outcomes. 
However, recently, a score quantifying particular patient and operator predictors, the 
SYNTAX score, has been developed to determine the most appropriate choice of 
therapy on individual basis [107]. Contemporary studies are more attracted toward the 
SYNTAX score as the main predictor of interest; for example, Onuma et al. [94] 
reported that at both univariate and multivariate levels of analysis, cardiogenic shock at 
presentation, 10 points increase in SYNTAX scores and EuroSCORE were significant 
determinants of 1-year and four year mortality.  
Another example is an observational study by Capodanno et al. [108] on 255 
UPLMS cases treated by PCI demonstrated that SYNTAX scores significantly predicted 
the rate of both cardiac mortality and MACCE. The authors also found that cardiac 
mortality was higher among cases with high SYNTAX scores (>34) compared to those 
with a low score (≤34) (aHR 15.8, 95% CI 3.4 to 73.4). Similarly, a comparison study 
between 903 cases of LMS treated by PCI and 879 treated by CABG by Serruys et al. 
[109] reported that, in PCI treatment cases, MACCE were significantly higher among 
those with high SYNTAX scores (23.4%) as compared with those with intermediate 
scores (16.7%) (P =0.040) and low scores (13.6%) (P =0.002).  
A randomised controlled trial by Jolly et al. [32] comparing radial and femoral 
approaches stated that the use of radial access for PCIs have lower vascular 
complications (such as haematoma) compared to the use of femoral access (aHR 0.4, 
95% CI 0.3 to 0.6, P <0.001), although both still considered being equally effective. 
Another randomised clinical trial by Romagnoli et al. [33] supported the results of the 
former trial, reporting that cardiac mortality and bleeding rates were lower in patients 
approached through the radial artery compared to those approached through the femoral 
artery (P =0.020 and P =0.026, respectively). Similarly, a recently published study by 
Mamas et al. [87] demonstrated that the use of radial access in patients with cardiogenic 
shock was associated with lower 30-day mortality (aHR 0.6, 95% CI 0.5 to 0.7, P 
<0.001), MACCE (aHR 0.6, 95% CI 0.5 to 0.8, P <0.001) and bleeding aHR 0.4, 95% 
CI 0.2 to 0.7, P =0.004). 
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2.4.6 Temporal trends 
Up-to-date details regarding the temporal trends in incidence, care and outcomes 
of UPLMS PCI across the full spectrum of acute and elective patients have been limited 
by small, regional and non-consecutive series of cases or inferred from randomised 
controlled trials in highly select groups of patients [36-44].  
Several studies have reported the temporal trends of UPLMS PCI, one of the 
major studies ever performed was by Park et al. [43], which included 1,124 UPLMS 
patients treated by PCI compared to 1,494 UPLMS patients treated by CABG over a 
period of 12 years (wave one 1995 – 1998, wave two 2003 – 2006 and wave three 2007 
– 2010). Their results demonstrated that the use of PCI for the management of UPLMS 
increased by 17%, MACCE declined significantly (aHR 0.6, 95% CI 0.5 to 0.7, P 
<0.001), all-cause mortality decreased by 40% (aHR 0.6, 95% CI 0.4 to 0.9, P=0.008), 
the composite of mortality, myocardial infarction and stroke decreased by 35% (aHR 
0.7, 95% CI 0.5 to 0.9, P <0.001) and repeat revascularisation similarly decreased by 
46% (aHR: 0.5, 95% CI 0.4 to 0.7, P <0.001). 
A multinational study by Conrotto et al. [44] compared four year trends of 218 
UPLMS patients treated by PCI and 86 UPLMS patients treated by CABG, and 
concluded that mortality was higher in PCI cases (7.3%) compared to (3.5%) in CABG 
cases. In the same way, target vessel revascularisation was higher in PCI cases (10.0% 
vs 4.2%). Another multi-centre study, which was carried out by Naganuma et al. [39] 
on 262 PCI UPLMS patients over four years, showed a trend toward higher target lesion 
revascularisation (aHR 2.0, 95% CI 0.9 to 4.5, P=0.090); however, there was no 
significant differences in the trends of MACCE, all-cause mortality, and composite 
endpoint of all-cause mortality, myocardial infarction and stroke.  
 
2.4.7 Conclusions 
In this literature review, several clinical determinants have been identified as 
predictors of post-PCI outcomes mainly in UPLMS. For instance, older age was found 
to increase the probability of in-hospital mortality, MACCE and TVR. On the contrary, 
literature regarding the effect of being elderly on outcomes beyond hospital stay was 
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inadequate. Cardiogenic shock at presentation, however, was one of the most frequently 
found significant predictors of PCI short and long-term outcomes (overall mortality, 
cardiac mortality, myocardial infarction, stroke, MACCE and TVR).  
Other significant risk factors revealed from the results of this review were 
emergency procedures, STEMI, diabetes mellitus and renal failure, which again were 
associated with mortality, MACCE and TVR. Incongruity was noted in the relationship 
between LVEF and mortality rate after PCI, where not all the findings were concordant 
to the evidence from literature [26]. Scoring mechanisms (EuroSCORE and SYNTAX 
score) were all significant determinants of PCI short- and long-term outcomes. 
However, the paucity of evidence to support SYNTAX score as a reliable predictor 
suggests the need for further studies.  
Recently, there is an evolution in the use of radial artery as an access point as a 
replacement for femoral artery [87, 110]. Therefore, further evaluating the associations 
between the type of arterial access and outcomes in UPLMS PCIs is essential. With the 
increasingly growing proportion of high-risk UPLMS patients, the need for alternative 
lines of management, other than CBAG, is rising. Lately, PCI started to be a promising 
choice of management for such patients. However, risk benefit analysis is always 
needed to be reviewed and assessed in order to predict favorable and unfavorable 
procedural outcomes. In addition, there is deficiency in whole-country studies of the 
temporal trends in UPLMS PCI and the associated procedural and longer-term 
outcomes [39, 43] therefore, additional investigation in such issue is necessary. 
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Table 2.1:  Summary of clinical predictors associated with percutaneous coronary intervention outcomes in UPLMS from a 
number of reviewed studies. 
Study Design 
Country 
& data 
years 
Population Statistical analysis Regression model Predictors and Outcomes 
Patel et al. 
2014 [86] 
Observational 
(population 
based) 
England and 
Wales 
2007 - 2012 
2125 
UPLMS 
Cox  hazard 
regression 
Age, sex, cardiovascular risk factors, renal 
dysfunction, history of previous (MI, PCI, or 
CABG), symptom to balloon time, recent 
lysis, Acute LVEF, peri-procedural 
cardiogenic shock, occlusive LMS disease, 
multivessel disease, intra-aortic balloon pump 
support, glycoprotein (GP) IIb/IIIa inhibitor 
use, thrombus aspiration use and the presence 
of post-procedural no-reflow 
 30-day mortality  3-year mortality 
Occlusive UPLMS   HR: 1.6 [1.1, 2.4] P 0.020 
HR: 1.5 [1.1, 2.2] P 
0.020 
Peri-procedural 
cardiogenic shock  
HR: 5.4 [3.2, 9.1] P < 
0.001 
HR: 3.0 [2.0, 4.5] P < 
0.001 
Age HR: 1.02 [1.01, 1.03] P 0.040 
HR: 1.02 [1.01, 1.03] P 
0.030 
Female sex  HR: 0.4 [0.3, 0.7] P 0.001 
HR: 0.6 [0.4, 0.9] P 
0.020 
Acute  LVEF HR: 2.4 [1.2, 4.8] P 0.010 
HR: 1.3 [0.8, 2.2] P 
0.260 
GP IIb/IIIa inhibitor  HR: 0.6 [0.4, 0.9] P 0.030 
HR: 0.6 [0.4, 0.9] P 
0.004 
Post-procedural no-reflow HR:4.2 [2.2, 7.8] P<0.001 
HR: 2.7 [1.6, 4.8] 
P<0.001 
Lee et al. 
2014 [95] 
Observational 
(hospital 
based) 
Kaohsiung, 
Taiwan 
2010 - 2012 
309 UPLMS logistic regression 
30-day mortality with  age, female gender, 
acute kidney injury, body mass index, WBC 
count, AC sugar and acute ischemic stroke 
Age > 70 OR: 4.5 [1.2,  16.3] P 0.024 
Female sex OR: 3.7 [1.2,  10.9] P 0.018 
WBC count OR: 1.2 [1.0,  1.3] P 0.003 
acute kidney injury      OR: 16.0 [3.7,  70.2] P < 0.001 
BMI OR: 1.2 [1.1,  1.4] P 0.003 
Beak et 
al. 2014 
[102] 
Observational 
(population 
based) 
Seoul, 
Korea 
2005 - 2009 
61 UPLMS Cox  hazard regression 
Cardiac mortality with the presence of shock 
and the heart rate of more than 100 beat / 
minute 
Presenting in cardiogenic shock    HR, 4.3 [1.0, 18.0] P 0.049 
Heart rate >100 beat / minute HR, 5.0 [1.2, 21.0; P  0.029 
Sim et al. 
2013 [96] 
Observational 
(population 
based) 
Gwangju, 
Korea 
2005 - 2008 
587 UPLMS 
Stepwise 
Cox 
hazards 
regression 
1-year mortality with age ≥ 65,  cardiogenic 
shock,  LVEF < 40% and ventilation 
Age ≥ 65 HR: 3.0 [1.5, 6.0] P 0.002 
Cardiogenic shock HR: 4.8 [2.7, 8.5] P < 0.001 
LVEF < 40% HR: 1.9 [1.1, 3.1] P 0.020 
Ventilation  HR: 7.1 [4.2, 12.1] P < 0.001 
Dores et 
al. (2013) 
[36] 
Observational 
(hospital 
based) 
Lisbon, 
Portugal 
1999 - 2006 
95 UPLMS 
Cox  
hazard 
regression 
MACCE with  EuroSCORE I, hypertension 
and a previous history of  myocardial 
infarction 
Myocardial infarction  HR: 2.9 [1.2, 6.9] P 0.015 
Hypertension HR: 5.7 [1.9, 17.5] P 0.002 
EuroSCORE I HR: 1.1 [1.0, 1.1] P 0.001 
Parma et 
al. 2012 
[48] 
Observational 
(hospital 
based) 
Rome, Italy 
2000 - 2010 
58 STEMI 
due to 
UPLMS 
Backward 
logistic 
regression 
and Cox  
hazard 
regression 
30 day mortality with cardiogenic shock, age, 
baseline & post PCI TIMI flow grade in LMS, 
left ventricular ejection fraction, and logistic 
EuroSCORE (58patients) 
3 year follow up survival with cardiogenic 
shock, age, post PCI TIMI flow grade in LMC 
(35 patients) 
 30 day mortality 3 year survival 
Age ≥ 75 OR: 5.9 [1.3, 26.5] P 0.019 
HR: 3.9 [1.8 , 8.7] P < 
0.001 
Cardiogenic shock 
at presentation 
OR: 12.6 [3.0, 53.6] 
P <0.001 
HR: 5.2 [1.8 , 14.3] 
P 0.002 
Post-PCI TIMI 
flow grade <3 
OR: 3.9 [1.8 , 5.7] 
P 0.020 
HR: 4.9 [1.6 , 14.6] 
P 0.005 
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Continued Table 2.1:  Summary of clinical predictors associated with percutaneous coronary intervention outcomes in UPLMS 
from a number of reviewed studies. 
Study Design 
Country 
& data 
years 
Population Statistical analysis 
Regression model 
 Predictors and Outcomes 
Brennan 
et al. 2012 
[42] 
Observational 
(population 
based) 
United 
States 
2004 - 2008 
5627 
UPLMS 
Cox  
hazard 
regression 
Logistic EuroSCORE values were calculated and 
classified as high (≥33.5%) or low (<33.5%). High 
urgency revascularisation  procedures included 
primary, rescue or facilitated PCI for STEMI, those 
involving pre-procedural cardiogenic shock, or 
emergent or salvage status 
High vs. low logistic EuroSCORE and MACCEs by 
30 days 
76.6% 
vs.53.9% 
P < 0.001 
High vs. low  urgency and  MACCEs by 30 days 
74.2% vs. 
52.8% 
P < 0.001 
Mortality by 30 months (DES vs. 
BMS) 
HR: 0.84, 95% CI: 0.73 to 0.96 P 
< 0.001 
MACCE (DES vs. BMS) HR: 0.95, 95% CI: 0.84 to 1.06 P < 0.001 
Fernandez 
et al. 2011 
[46] 
Observational 
(hospital 
based) 
Huelva, 
Spain 
2002 - 2008 
334 UPLMS  Logistic regression  
EuroSCORE &  
MACCE RR: 2.4 [1.2 , 4.9] P 0.016 
De Luca 
et al. 2011 
[45] 
Observational 
(hospital 
based)  
Rome, Italy 
2006 - 2009 107 UPLMS 
Kaplan-
Meier and 
Cox  
hazard 
regression 
 
Age, gender, EuroSCORE, hypercholesterolemia, 
diabetes, cardiogenic shock,  LVEF < 50%  and stent 
per patient  
Age &  MACCE HR: 2.1 [2.0, 3.3]   P 0.030 
Age & Overall mortality HR: 4.6 [2.8, 12.7] P 0.004 
EuroSCORE &  MACCE HR: 1.2 [1.0, 1.3]   P < 0.001 
EuroSCORE & Overall mortality HR: 3.2 [1.6, 7.8]   P 0.008 
Diabetes &  MACCE HR: 3.5 [1.1, 6.9]   P 0.010 
Diabetes & TVR HR: 2.9 [1.9, 5.8]   P < 0.001 
Onuma et 
al. 2010 
[94] 
Observational 
(hospital 
based) 
Rotterdam, 
Netherlands 
& Ferrara, 
Italy 
2002 - 2005 
227 UPLMS 
Kaplan-
Meier and 
Cox  
hazard 
regression 
Mortality with age, shock at entry, hypertension, 
hypercholesterolemia, bifurcation angle. the 
SYNTAX score and  EuroSCORE 
 
 
 At 1 year At 4 years 
Age HR: 1.1 [1.0, 1.1] P 0.030 
HR: 1.0 [1.0, 1.1] P 
0.009 
Cardiogenic shock 
at presentation  
HR: 4.2 [1.5, 1.8] P 
0.006 
HR: 5.5 [2.4, 12.7] 
P < 0.001 
EuroSCORE HR: 1.2 [1.1, 1.4]  P <0.001 
HR: 1.1 [1.0, 1.2]   P 
0.009 
SYNTAX score HR: 1.2 [1.1, 1.4] P 0.006 
HR: 1.2 [1.0, 1.3] P 
0.030 
Min et al. 
2010 [47] 
Observational 
(population 
based) 
Seoul, 
Korea 
2000 - 2006 
2240 
UPLMS 
 
Cox  
hazard 
regression 
Mortality with age  ≥ 75, chronic renal failure, 
previous congestive heart failure, atrial fibrillation, 
right coronary artery disease,  EuroSCORE  and LMS 
distal bifurcation disease 
 
TVR with age ≥ 75, ACS, previous PCI, and LM 
distal bifurcation disease 
 PCI (n=1102) CABG (n=1138) 
Age ≥ 75 & Mortality HR: 1.4 [0.8, 2.6] P 0.269 
HR: 1.9 [1.2, 
3.2] P 0.010 
Age ≥ 75 & TVR HR: 0.50 [0.3, 0.9] P 0.048 
HR: 0.8 [0.2, 
3.5] P  0.785 
Chronic renal failure & 
Mortality  
HR: 4.28 [2.1, 
8.7] P < 0.001 
HR: 1.7 [0.2, 
0.7] P 0.216 
Previous congestive heart 
failure & Mortality  
HR: 3.0 [1.4, 
6.3] P 0.004 
HR: 1.5 [0.7, 
3.2] P 0.354 
EuroSCORE ≥ 6 & Mortality HR: 2.6 [1.4, 4.6] P 0.001 
HR: 2.3 [1.5, 
3.6] P < 0.001 
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Continued Table 2.1:  Summary of clinical predictors associated with percutaneous coronary intervention outcomes in UPLMS 
from a number of reviewed studies. 
Study Design 
Country 
& data 
years 
Population Statistical analysis 
Regression model 
 Predictors and Outcomes 
Wu et al. 
2010 [103] 
Observational 
(hospital 
based)  
Taipei, 
Taiwan 
2003 - 2007 
55 UPLMS 
Cox  
hazard 
regression 
 
Hyperlipidemia and  MACCE HR: 6.2 [1.3, 30.0] P 0.024 
Bifurcation involvement  and  
MACCE HR: 4.4 [1.1, 17.0] P 0.008 
Kang et al. 
2010 [100] 
 
Observational 
(hospital 
based) 
Seoul, 
Korea 
2003 - 2006 
462 UPLMS 
Cox  
hazard 
regression 
Predictors for  composite of mortality, MI, and CVA in 
CABG group were: older age ≥ 65 years, history of 
stroke, low ejection fraction < 50%, high EuroSCORE 
≥ 6, and use of angiotensin-converting enzyme 
inhibitors 
Predictors in PCI group were: older age ≥ 65, shock 
present at admission, and a history of peripheral artery 
disease 
Predictors for TVR in PCI group were: need for an 
emergency procedure and true bifurcation 
 PCI (n=205) CABG (n=257) 
Age ≥ 65 & composite of 
mortality, MI, and CVA 
HR: 2.3 [1.1, 
4.6] P 0.022 
HR: 2.6 [1.2, 5.5] 
P 0.010 
Cardiogenic shock at 
presentation & composite of 
mortality 
HR: 3.7 [1.1, 12.5] 
P 0.035 --- 
Peripheral artery disease & 
Composite of mortality 
HR: 4.8 [2.3, 10.0] 
P < 0.001 --- 
Emergency procedure & 
TVR 
HR: 2.3 [1.0, 5.5]  
P 0.048 --- 
Serruys et 
al. 2009 
[109] 
RCT 
(multicentre) 
United 
States 
2005 - 2007 
1782 
UPLMS 
Kaplan-
Meier 
SYNTAX scores:  low score ≤22, intermediate score 
as 23 - 32 and high score ≥33 
High SYNTAX scores in PCI compared to 
Intermediate scores P 0.040 
High SYNTAX scores in PCI compared to Low 
scores P 0.002 
Mortality 30 days after PCI procedure RR:  1.2 [0.8–1.7] 
Mortality 12 months after randomization 
(PCI) RR:  1.4 [1.2–1.8] 
Buszman et 
al. 2009 
[99] 
Observational 
(population 
based) 
Poland 
1997 - 2008 
252 UPLMS 
 
Logistic 
regression 
Age > 60 years,  diabetes, hypertension, 
hypercholesterolemia, Smoking, Distal LM 
involvement, Stent diameter (mm), LVEF < 50%  and  
EuroSCORE on admission > 9 
Age > 60 & Mortality rate OR: 2.5 [1.0, 5.9] P 0.030 
LVEF < 50%& Mortality 
rate OR: 3.3 [1.5, 7.3] P 0.010 
EuroSCORE > 9 & 
Mortality rate OR: 2.5 [1.1, 4.6] P 0.040 
Ben-Dor et 
al. 2009 
[30] 
Observational 
(hospital 
based)  
Ramat, 
Israel 
2003 - 2007 
71 UPLMS Logistic regression 
Cardiogenic shock, emergency  procedures, LVEF < 
35%, renal failure and diabetes 
Emergency  procedures with Mortality & 
MACCE OR: 2.8 P 0.020 
Tamburino 
et al. 2009 
[106] 
Observational 
(population 
based)  
Legnano, 
Italy 
2002 - 2006 
849 UPLMS 
Kaplan-
Meier and 
Cox  
hazard 
regression 
Age, gender, diabetes, increase of cardiac biomarkers, 
chronic renal disease, multivessel disease, bifurcation, 
LVEF,  EuroSCORE, and Propensity score 
Chronic renal disease & 
Mortality HR: 1.86 [1.23, 2.81] P  0.003 
Chronic renal disease & MI HR: 3.81 [1.81, 8.03] P < 0.001 
LVEF& Mortality HR: 0.97 [0.95, 0.98] P < 0.001 
LVEF & TLR HR: 0.98 [0.95, 1.00] P 0.03 
EuroSCORE & Mortality HR: 1.16 [1.06, 1.26] P 0.001 
EuroSCORE & TLR HR: 0.85 [0.73, 0.99] P 0.04 
Propensity score & Mortality HR: 0.96 [0.95, 0.97] P < 0.001 
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Continued Table 2.1:  Summary of clinical predictors associated with percutaneous coronary intervention outcomes in UPLMS 
from a number of reviewed studies. 
Study Design 
Country 
& data 
years 
Population Statistical analysis Regression model Predictors and Outcomes 
Capodanno 
et al. 2009 
[108] 
Observational 
(hospital 
based) 
Catania, 
Italy 
2003 – 2008 
255 UPLMS Cox hazard regression 
Age, gender, smoking, diabetes, acute coronary 
syndrome, renal dysfunction, LVEF, EuroSCORE, 
reference vessel diameter, lesion length, bifurcation 
lesion, emergent setting, complete revascularisation  
as independent control variables, and the SYNTAX 
score as the independent study variable of interest. 
low SYNTAX score ≤34 and high SYNTAX score 
>34 
SYNTAX score & cardiac 
mortality 
HR: 1.2 [1.0, 1.3] 
P 0.003 
SYNTAX score & MACCE HR: 1.1 [1.0, 1.1] P 0.005 
 
Lee et al. 
2008 [101] 
 
Observational 
(population 
based) 
 
Los 
Angeles, 
United 
States 
1993 - 1998 
 
164 UPLMS 
 
Kaplan-
Meier and 
Cox  
hazard 
regression 
 
Age, sex, prior MI, hypertension, diabetes, congestive 
heart failure, renal failure, smoking, prior CABG, 
prior PCI, multivessel disease, CABG vs PCI, cardiac 
index, cardiac power index, systolic BP, and heart rate 
Cardiac mortality in high 
SYNTAX score cases vs. low 
score cases 
HR: 15.8 [3.4, 73.4] 
P < 0.001 
Age (per 10 years) & 30 days 
survival rate 
HR: 1.0 [1.0, 1.1] 
P 0.020 
Diabetes mellitus  and TVR HR: 2.9 [1.6, 5.3] P < 0.001 
Cardiogenic shock and cardiac 
mortality HR: 11.0 [1.9, 63.9] P 0.008 
EuroSCORE &  cardiac mortality HR: 1.2 [1.0, 1.3] P 0.046 
EuroSCORE &  MACCE HR: 1.1 [1.0, 1.2] P 0.014 
LVEF < 50% & TVR HR1.0 [1.0, 1.1] P 0.050 
Schrale et 
al. 2008 
[31] 
Observational 
(hospital 
based) 
Oxford, 
United 
Kingdom 
2001 - 2005 
100 UPLMS 
 
Stepwise 
Cox 
hazards 
regression 
 
BMS & mortality HR: 4.4 [1.1, 17.0] P 0.034 
Failed thrombolysis & mortality HR: 8.5 [1.7, 41.7] P 0.008 
Cardiogenic shock & mortality HR: 7.9 [1.7, 3.6] P 0.008 
Khattab et 
al. 2007 
[104] 
Observational 
(population 
based) 
Segeberg, 
Germany 
2002 - 2004 
118  
Protected 
LMS 
82  UPLMS 
Kaplan-
Meier and  
logistic 
regression 
Mortality, MI and TVR with gender,  diabetes 
mellitus,  renal insufficiency,  STEMI,  cardiogenic 
shock and  LVEF 
 
  
Female gender OR: 2.4 [1.0,  5.9] P 0.044 
Diabetes mellitus OR: 2.4 [1.0, 5.8] P 0.046 
Renal insufficiency OR: 3.6 [1.4, 9.5] P 0.006 
STEMI OR: 6.4 [1.8, 21.9]P 0.001 
Cardiogenic shock OR: 15.9 [1.4, 182.7] P 0.003 
LVEF ≤ 40% OR: 3.3 [1.0, 11.1] P 0.038 
Lee et al. 
2006 [105] Observational  
Los 
Angeles, 
United 
States 
2003 - 2006 
173 UPLMS 
Stepwise 
Cox hazard 
regression 
MACCE free survival with age, gender, diabetes 
mellitus, Parsonnet score, ejection fraction, chronic 
renal insufficiency, myocardial infarction, and CABG 
Parsonnet score  & MACCE free 
survival HR: 1.1 [1.0, 1.1] P < 0.010 
Diabetes mellitus & MACCE free 
survival HR: 2.2 [1.1, 4.6] P 0.030 
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2.5 Literature review on ‘clinical determinants of survival for 
primary PCI’ 
 
2.5.1 Introduction  
The survival of acute myocardial infarction patients, particularly that of STEMI 
patients, is profoundly affected by the timing (i.e. urgency) of the medical or 
interventional treatment provided [4, 7]. Globally, the first line of management for 
STEMI patients with or without cardiogenic shock is primary PCI [4, 74, 76, 111]. In 
general, any delays to primary PCI procedures of more than two hours after onset of 
symptoms can lead to unfavourable complications and outcomes [71-73]. Lately, the 
practice of primary PCI is growing internationally and in the UK in particular; in 
England and Wales, the frequency of primary PCIs increased by 15.0% from 2004 to 
2007 [70, 71].  
In contemporary practice, primary PCI survival rates are clearly rising; yet, in 
STEMI patients there is a wide range of discrepancy related to the presence of certain 
predictors (such as old age, cardiogenic shock, heart failure, previous myocardial 
infarction and diabetes mellitus) that subsequently have influence on the outcomes and 
survival of primary PCIs [71, 75, 76]. Furthermore, the influence of admission route and 
hospital differences on primary PCI survival rates is not well defined [78, 79]. It is what 
this section of the chapter is aiming to review: the clinical determinants of primary PCI 
procedural survival among STEMI patients. 
 
2.5.2 Search strategy 
A preliminary literature search of “primary percutaneous coronary intervention” 
and “primary PCI” acquired 3,589 results. The search was performed using Ovid 
Medline between January 1996 and October 2015. A more focused search strategy was 
required; therefore, the term “survival” was added in combination with the search words 
“primary percutaneous coronary intervention” and “primary PCI” by using Ovid 
Medline database.  
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The final result of the search showed 39 relevant articles that have been browsed 
by titles and abstracts initially. Publications that did not contain information on primary 
PCI survival were excluded; only applicable articles were completely reviewed. 
References of the articles were screened and other related publications and resources 
from citation trees relating to primary PCI survival were correspondingly followed and 
cited using PubMed and Google Scholar databases. A total of nine journal papers were 
included and reviewed. 
 
2.5.3 Statistical analysis 
Different statistical methods were used in all fully reviewed articles to outline 
the relationship between the clinical risk factors and primary PCI survival. At the level 
of multivariate analysis; logistic regression, Cox’s proportional hazards regression and 
Kaplan-Meier method were the most commonly used statistical methods. Cox’s 
proportional hazards regression was used in eight studies, whereas logistic regression 
was used in two studies. Kaplan-Meier curves were performed in all nine studies. A 
detailed list of the reviewed studies describing the clinical determinants associated with 
primary PCI survival and outcomes in STEMI patients are summarised in Table 2.2. 
More papers that did not have sufficient information were described in the review but 
were not in the table. 
 
2.5.4 Results 
Currently, the available medical literature continued to support the fact that 
primary PCI produces better outcomes for patients with STEMI [70]. Most of the 
studies in literature were not on population-based cohorts and/or conducted outside the 
UK. Therefore, they may not be generalisable to the UK. At the same time, important or 
key predictors of primary PCI survival rate have been acknowledged in literature. 
However, there is a gap of knowledge regarding the impact of the routes of admission 
as well as the effect of hospital level factors such as patient volume [78, 79]. 
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In a recently published paper by McCormick et al. [112]; direct stenting, when 
compared to pre-dilation followed by stenting, was found to be an independent 
predictive factor of better survival at one year after  primary PCI (96.7% vs 91.2%, P 
<0.001). In addition, McCormick et al. demonstrated that the significant clinical 
predictors of 1-year mortality were age, number of diseased vessels, cardiogenic shock, 
left main stem intervention, proximal left anterior descending artery intervention and 
pre-dilation followed by stenting. However, the procedure time from the onset of 
symptoms was not significantly associated with 1-year mortality (aOR 1.0, 95% CI 0.9 
to 1.0, P =0.730). 
Taniguchi et al. [113] studied the clinical predictors of five-year survival after 
primary PCI in 3,476 STEMI patients with and without pre-infarction angina pectoris, 
and found that the significant predictors with better five-year survival with the presence 
of pre-infarction angina pectoris were total ischemic time of three to six hours, 
thrombolysis in myocardial infarction flow grade zero, absence of cardiogenic shock, 
absence of heart failure and anterior myocardial infarction. In a non-randomised trial 
study by Bergh et al. [114] on 139 STEMI patients with cardiogenic shock, the use of 
intra-aortic balloon pump was not found to be a significant predictor of better survival 
at 30 days (P =0.720). 
Mamas et al. [87] concluded that radial approach was significantly associated 
with lower 30-day mortality (aHR 0.6, 95% CI 0.5 to 0.7, P <0.001). However, they 
found that age, renal disease, poor left ventricular ejection fraction, the use of intra-
aortic balloon pump and the number of diseased vessels were determinants of worse 
early mortality. They also demonstrated that primary PCI was associated significantly 
with worse survival at 30 days (aHR 1.5, 95% CI 1.3 to 1.8, P <0.001).  
In the same way, De Luca et al. [115] demonstrated that age of more than 75 
years, diabetes, previous myocardial infarction, anterior myocardial infarction, post-
procedural thrombolysis in myocardial infarction flow grade three, myocardial blush 
grade three, as well as the number of diseased vessels were all significant predictors of 
survival at 30 days. They also found that the patients’ survival at one year was 
associated significantly with the number of diseased vessels (aHR 1.8, 95% CI 1.3 to 
2.3, P =0.002). 
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The availability of experienced personnel, facilities and suitable timing have an 
admirable impact on the outcomes of any primary PCI [4, 7, 116]. An ecological study 
by Laut et al. [117], using aggregated data from 12 European countries between 2003 
and 2008 to describe the associated country level dissimilarities in primary PCI use, 
indicated that higher utilisation was associated significantly with the  numbers of 
physicians, nurses and acute care beds available per 100,000 population (P <0.001).  
Gale et al. [78] used the MINAP database (a population-based database of acute 
coronary syndrome in England and Wales) and concluded that the differences at 
hospital level (high volume vs. low volume hospitals and/or centres) have a significant 
effect on the survival at six months for STEMI patients who undergo primary PCI (P 
<0.001). One of the findings by Danchin et al. [118] demonstrated that fibrinolysis for 
patients with STEMI had better five-year survival compared to primary PCI after 90 
minutes from call (in patients called three hours or less from onset aHR 0.6, 95% CI 0.4 
to 0.9, P =0.039). 
In 240 STEMI patients, Kritikou et al. [119] compared the difference in the 
survival to discharge between primary PCI capable and non-capable hospitals and 
stated: “Although there was a statistically significant correlation between the type of the 
hospital and the delay from the onset of symptoms to PPCI (P =0.001), such correlation 
was not found between the delay PPCI and the outcome of the patients (P >0.05)”. In 
another ward, this study concluded that even for STEMI patients who presented to a 
non-capable hospital, better outcomes from primary PCI were noticed once there was 
rapid transfer to a capable hospital.  
In another set of patients with acute myocardial infarction complicated by 
cardiogenic shock, Guo et al. [120] found a significant association between the time 
from symptoms onset and in-hospital mortality (P =0.036) as well as mid-term survival 
(P =0.015). Brodie et al. [121] showed that in 2,496 STEMI patients with cardiogenic 
shock, better late cardiac survival was independently predicted by the age of 70 years or 
less, cardiogenic shock caused by right ventricular infarction and the time of two hours 
or less from door to balloon. 
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In a study by Chan et al. [79] which compared between directly transferred (by 
the ambulance) STEMI patients’ survival and inter-hospital emergency transferred 
STEMI patients’ survival, and showed that the existence of a pre-hospital ECG triage in 
an ambulance has a significant impact on 30-day mortality (aOR 0.3, 95% CI 0.1 to 0.7] 
P =0.007) and 1-year survival (aHR 0.4, 95% CI 0.2 to 0.8] P=0.006); therefore, direct 
admission had better outcomes.  
Similarly, Ortolani et al. [122] demonstrated that more than 80% of STEMI 
patients who were exposed to pre-hospital ECG triage were re-vascularised within 90 
minutes from the first call. Although they found that the overall impact of pre-hospital 
ECG triage on long-term survival was not statistically significant (P=0.160), the 
survival of certain high-risk patients (such as patients with diabetes, cardiogenic shock 
and TIMI risk score >30) was significantly influenced by the direct transfer using pre-
hospital ECG triage. 
On the other hand, Wöhrle et al. [123] illustrated that transfer status (inter-
hospital transfer vs. direct admission) was not a significant predictor of 30-day and 1-
year survival rate with and without adjusting for treatment times (time from symptoms 
onset). However, their results showed that Killip class 2-4, creatinine clearance and 
history of diabetes were significant predictors of 30-day survival with and without 
adjusting for treatment times. Likewise, their results concluded that 1-year survival with 
and without adjusting for treatment times was significantly predicted by Bivalirudin, 
study site in the United States, anterior myocardial infarction, Killip class 2-4, 
creatinine clearance and history of congestive heart failure. Time from symptom onset 
to first hospital was a significant predictor of 1-year survival only (aHR 1.1, 95% CI 1.0 
to 1.2] P =0.005). 
 
2.5.5 Conclusions 
A number of significant predictive factors in this review have been identified as 
determinants of survival after primary PCI procedures in STEMI patients. Older age, 
cardiogenic shock, history of diabetes mellitus, previous acute myocardial infarction, 
heart failure and thrombolysis in myocardial infarction flow were the commonest 
significant predictors of short-term survival after primary PCI. In addition to the above, 
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the number of diseased vessels and anterior myocardial infarction were as well 
associated with worse short- and long-term survival primary PCI. 
The procedure time from the symptoms onset was found in one study to be a 
non-significant determinant of primary PCI survival in STEMI patients; however, many 
other studies contradicted this finding and concluded that the shorter the time of 
procedure from onset of symptoms, the better the short- and long-term survival of such 
patients. The utilisation of pre-hospital ECG triage, leading to more direct admissions of 
STEMI patients, was also found to have a significant influence on post-procedure 
survival compared to inter-hospital emergency transfer. Likewise, hospital volume load 
and capability (in terms of the availability of facilities and trained personnel) were also 
found as significant predictors of primary PCI survival.  
The results of most of the reviewed studies were not representative of the 
general population as the majority of these studies were implemented at hospital-based 
level, and only three researches were performed using population-based datasets; thus, 
further representative studies using national registries are essential. Currently, primary 
PCI is the first choice of management for STEMI patients and is widely practiced 
worldwide and on a national scale with encouraging better post-procedure survival rates 
[4, 70, 71]; though, the predictors of survival have a variety of incongruity that need 
additional exploration and analysis. 
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Table 2.2:  Summary of clinical predictors associated with survival for primary percutaneous coronary intervention in STEMI 
patients from a number of reviewed studies. 
Study Design Country & data years Population 
Statistical 
analysis Regression model Predictors and Outcomes 
Mamas et 
al. 2014 
[87]  
Observational  
(multicentre  
population 
based) 
Manchester, 
United 
Kingdom 
2006 - 2012 
7231 
STEMI 
Kaplan-
Meier and   
Cox hazards 
regression 
30-day mortality with age, sex, diabetes, 
hypertension, hypercholesterolemia, peripheral 
vascular disease, previous stroke (cerebrovascular 
accident, renal failure, previous AMI, previous PCI, 
previous coronary artery bypass graft,  intra-aortic 
balloon pump , and ventilation. 
Radial vs femoral HR: 0.6 [0.5, 0.7] P < 0.001 
Age  HR: 1.03 [1.02, 1.04] P < 0.001 
Renal failure HR: 1.4 [1.1, 1.8] P  0.008 
Primary PCI HR: 1.5 [1.3, 1.8] P < 0.001 
Poor  left ventricular ejection 
fraction HR: 2.6 [2.0, 3.3] P < 0.001 
Intra-aortic balloon pump HR: 1.2 [1.0, 1.4] P  0.031 
Number of diseased vessels HR: 1.1 [1.0, 1.1] P  0.053 
McCormick 
et al. 2014 
[112] 
Observational  
(multicentre 
hospital 
based) 
Cambridge, 
United 
Kingdom 
2008 - 2010 
1562 
STEMI 
Kaplan-
Meier and  
logistic 
regression 
1-year mortality with age, sex, previous  MI, current 
smoker,  left main PCI proximal  left anterior 
descending artery PCI, number of diseased vessels, 
cardiogenic shock,  number of stents,  multi-vessel 
PCI, procedure time (min) and  pre-dilatation 
(followed by stenting) 
Age  OR: 1.1 [1.0, 1.1] P < 0.001 
Number of diseased vessels OR: 1.6 [1.1, 2.4] P 0.009 
Cardiogenic shock  OR: 4.6 [1.7, 12.4] P 0.003 
Left main PCI OR: 19.8 [4.5, 86.7] P < 0.001 
Proximal  left anterior descending 
PCI OR: 2.1 [1.2, 3.7] P 0.012 
Procedure time (min) OR: 1.0 [0.9, 1.0] P 0.730 
Pre-dilatation (followed by stenting) OR: 2.4 [1.1, 5.5] P 0.032 
Taniguchi 
et al. 2014 
[113] 
Observational 
(population 
based) 
Japan. 
2005 - 2007 
3476 
STEMI 
 
Kaplan-
Meier and  
Cox hazards 
regression 
5-year survival with age, gender, BMI, medications 
at discharge, infarct location, hypertension, 
hemodynamic, presence of multi-vessel disease, 
current smoker, anemia, TIMI flow grade 0,  liver 
cirrhosis, diabetes, previous MI, total stent length 
>28 mm,  Thrombocytopenia, COPD,  minimum 
stent size <3.0 mm,  prior stroke, hours from onset to 
presentation, hours from onset to balloon and 
cardiogenic shock 
Total ischemic time of 3 - 6 
hours HR: 0.6 [0.4, 0.9] P 0.009 
TIMI flow grad 0 HR: 0.6 [0.4, 0.9] P 0.003 
No cardiogenic shock, HR: 0.7 [0.5, 0.9] P 0.020 
No  heart failure HR: 0.7 [0.5, 0.9] P 0.030 
Anterior myocardial infarction HR: 0.6 [0.4, 0.8] P 0.001 
Danchin et 
al. 2014 
[118] 
Observational 
(population 
based) 
France 
October 
2005 
1492 
STEMI 
Kaplan-
Meier and  
Cox hazards 
regression 
5-year survival with age, sex, type and region of 
institution; time to first call; history of heart failure, 
history of diabetes, hypertension, current smoking, 
prior AMI, stroke, peripheral artery disease, 
comorbidity; anemia on admission; early use of 
aspirin, clopidogrel, low molecular weight heparin, 
or glycoprotein IIB-IIIa inhibitors, and presence of 
triple-vessel coronary artery disease 
Fibrinolysis  vs. primary PCI after  
90 minutes of call in patients called 
three hours or less from onset 
HR: 0.6 [0.4, 0.9] P 0.039 
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Continued Table 2.2:  Summary of clinical predictors associated with survival for primary percutaneous coronary intervention in 
STEMI patients from a number of reviewed studies. 
Study Design Country & data years Population 
Statistical 
analysis Regression model Predictors and Outcomes 
De Luca et al. 
2013 [115] 
Observational 
(population 
based) 
Italy 1494 STEMI 
Kaplan-Meier and  
Cox hazards 
regression 
30-day mortality with age, diabetes, 
smoking, previous myocardial infarction, 
previous revascularisation , anterior 
myocardial infarction, abciximab 
administration, post procedural TIMI 3 
flow and myocardial blush grade 3 
Number of diseased vessel HR: 1.5 [1.1, 2.2] P 0.022 
Age > 75 years HR: 7.5 [3.7, 15.1] P < 0.001 
Diabetes HR: 2.0 [1.1, 3.9] P 0.033 
Previous myocardial infarction HR: 3.0 [1.1, 8.6] P 0.039 
Anterior myocardial infarction HR: 2.9 [1.4, 6.0] P 0.003 
Myocardial blush grade3 HR: 0.5 [0.2, 0.9] P 0.043 
Post procedural TIMI 3 flow HR: 0.5 [0.2, 0.9] P 0.038 
Chan et al. 
2012 [79] 
Observational 
(multicentre 
hospital based) 
Canada  
 594 STEMI 
Kaplan-Meier,  
logistic and  Cox 
hazards regression 
30-day & 1-year mortality with age, 
cardiogenic shock, cardiac arrest 
requiring ventilation, left ventricular 
ejection fraction <40%,  prior history of 
myocardial infarction  and pre-hospital 
ECG triage strategy 
Pre-hospital ECG triage & 
30-day mortality  OR: 0.3 [0.1,  0.7] P 0.007 
Pre-hospital ECG triage & 
1-year survival HR: 0.4 [0.2,  0.8] P 0.006 
Ortolani et al. 
2011 [122] 
Observational 
(hospital based) 
Seoul, Korea 
2003 - 2007 1619 STEMI 
Cox  hazard 
regression 
Survival with cardiogenic shock, TIMI 
risk score >30, diabetes mellitus and pre-
hospital ECG triage strategy 
Pre-hospital ECG triage & 
survival     HR: 0.8 [0.6, 1.1] P 0.160 
Wöhrle et al. 
2010 [123] 
RCT 
(multicentre 
hospital based ) 
United States  3602  STEMI 
Kaplan-Meier and  
Cox hazards 
regression 
30-day & 1-year mortality with treatment 
times, randomization to bivalirudin, age, 
gender, race,  study site in or out US, 
BMI, Killip class, anterior MI, anemia; 
platelet counts, creatinine clearance, 
history of (hypertension, hyperlipidemia, 
smoking, diabetes, MI, PCI, CABG, 
CAD, angina, congestive heart failure or 
peripheral vascular) and medications 5 
days before enrolment 
 30-day mortality 1-year mortality 
Transfer vs. no 
transfer, not including 
treatment times 
HR: 1.0 
[0.6, 1.7]  
P 0.870 
HR: 0.9 [0.6, 1.4]  
P 0.060 
Transfer vs. no 
transfer, including 
treatment times 
HR: 1.0 
[0.6, 1.7]  
P 0.980 
HR: 0.9 [0.6, 1.5]  
P 0.890 
Time from symptom 
onset to first hospital ----- 
HR: 1.1 [1.0, 1.2] P 
0.005 
Brodie et al. 
2007 [121] 
Observational 
(hospital based) 
United States 
1984 - 2004 2496  STEMI 
Kaplan-Meier and  
Cox hazards 
regression 
Late cardiac survival (3.5 years) with age, 
gender, diabetes, previous infarction, 
previous bypass surgery, hypertension, 
multivessel coronary disease, door-to-
balloon time, and right ventricle 
infarction versus left ventricle pump 
failure 
Shock due to  right 
ventricle infarction HR: 0.3 [0.1, 0.6] P 0.002 
Door to balloon time 
of 2 hours or less HR: 0.5 [0.3, 0.9] P 0.020 
Age ≤ 70 years HR: 0.6 [0.4, 0.9] P 0.020 
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2.6 Development of research aims and objectives  
2.6.1 Rationale 
Cardiovascular diseases are the leading cause of morbidity and mortality in the 
UK and worldwide [2, 8, 10, 11]. In addition, it has always been a major burden to the 
UK NHS [12]. At the same time, the majority of contemporary studies in literature were 
conducted outside the UK and were not based on real-world observational data. 
Therefore, it was not possible to measure the level of care provided to cardiovascular 
diseases patients in the UK, based on such evidence. However, with the enhancements 
in NHS treatment strategies and the availability of sufficient clinical data about certain 
procedures, such as that of BCIS, the care of most cardiovascular diseases in the UK 
can be monitored and assessed [80, 81]. Nonetheless, there are clinical and statistical 
concerns about the use of routine clinical data for the purposes of research, which create 
biases when the datasets have missing and/or implausible values [124]. All that 
stimulates the need to study percutaneous coronary intervention quality of care, so that a 
framework for excellence may be defined that will promote improvements in care for all 
CAD patients admitted to hospital (specifically UPLMS and STEMI patients) regardless 
of where they live in the UK. 
 
2.6.2 Aims 
In this thesis, a variety of statistical techniques are considered to evaluate the 
effect of missing data on research outcomes and offer the potential to enhance the 
research strengths of the BCIS database. Full description of the used methods with 
justification review are in Chapter 3 (sections 3.4.7 and 3.4.8). Subsequently, the main 
aim of this research is to utilise contemporary population-based data from the BCIS 
database to perform a number of comparative investigations and answer several 
important questions regarding the level of care provided to patients who have 
undergone percutaneous coronary intervention in the UK, on the bases of survival and 
outcomes. Answering these questions using such type of analyses might be one of the 
few times they will be tested on a population-based data and on UK data. 
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2.6.3 Objectives 
1. To use BCIS data to evaluate the level of care provided to patients who have 
undergone PCI in the UK. 
2. To evaluate the outcomes and survival of PCI outcomes in UPLMS patients 
stratified by clinical presentation. 
3. To identify the clinical determinants of PCI outcomes in UPLMS and to 
measure their level of association including the impact of cardiogenic shock and 
arterial access approach. 
4. To quantify the temporal trends in the complications, in-hospital outcomes and 
mortality of UPLMS patients after PCI. 
5. To evaluate the outcomes and survival of primary PCI for STEMI patients 
compared to facilitated and rescue PCI. 
6. To identify the clinical determinants of primary PCI survival in STEMI patients 
and to measure their level of association including the impact of admission route 
and procedure time from symptoms onset. 
7. To identify potentially modifiable gaps in the care provided to patients who have 
undergone percutaneous coronary intervention in the UK which may be 
addressed in subsequent research or specialist societies. 
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3 Chapter 3   Data assessment and methodology 
 
 
 
 
3.1 Summary 
Further insight about the types of datasets and the statistical methods used in the 
thesis is described in more detail in this chapter. First, the study design is summarised 
(section 3.2), then data provision procedures including application, ethics and security is 
discussed (section 3.3), followed by details on the performed data management 
activities such as collection, transformation, cleaning and recoding (section 3.4), and 
lastly, the analyses methodology including a summary of the statistical methods used, 
model selection methods, imputation methods, how to handle missing values and 
justification of the multiple imputation method applied (section 3.5). 
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3.2 Study setting and design   
The overall aim of the thesis is to evaluate the level of care provided to patients 
who have undergone percutaneous coronary intervention in the UK and since the 1st of 
January 2005. The study design is a linked prospective multi-centre population-based 
observational study using the BCIS national registry of patients who have undergone 
percutaneous coronary intervention in the UK. The dataset included all registered 
interventional cardiology centres and hospitals which have been increasing with time. 
Presently, 117 registered interventional cardiology centres and hospitals in UK provide 
data to the BCIS (based on BCIS Audit Returns, Adult Interventional Procedures, 
January 2013 to December 2013) [54].  
This thesis consists of three analyses of data from the BCIS registry on different 
cohorts of patients who have undergone percutaneous coronary intervention. The time 
period of the studies varied, from January 2005 to December 2010 in one study and 
from January 2005 to March 2014 in two studies. After performing a complete analysis 
using the 2010 versions of the BCIS database in Chapter 4, a new version of the 
database became available in 2014. The 2014 version was used in the analyses of 
Chapters 5 and 6 of the thesis. Based on the cohort of intention, more details on each 
study settings and designs can be found in Table 3.1. 
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Table 3.1: Summary of settings and designs for the three studies (result chapters) of this thesis. 
Results chapters BCIS database Time period Area Patients’ cohort 
Participating cardiac 
centres and hospitals 
Chapter 4: Determinants of outcomes after 
percutaneous coronary intervention for 
UPLMS disease 
2010 version 1
st of January 2005 to 31st 
of December 2010 
England and 
Wales 
5,065 patients with UPLMS 
disease 89 
Chapter 5: Mortality trends after 
percutaneous coronary intervention for 
UPLMS disease 
2014 version 1
st of January 2005 to 31st 
of March 2014 The UK 
10,827 patients with 
UPLMS disease 113 
Chapter 6: Determinants of survival after 
primary percutaneous coronary intervention 2014 version 
1st of January 2005 to 31st 
of March 2014 The UK 
98,637 patients with STEMI 
who received primary, 
rescue and facilitated PCI 
111 
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3.3 Data provision 
3.3.1 Preview 
The BCIS national database is a secondary anonymised data relating to patients 
who have undergone percutaneous coronary intervention in the UK, which has been 
collected locally and entered by all registered interventional centres and hospitals into 
the BCIS national audit database via the CCAD [20, 54, 81]. More details on BCIS 
audit database, data entry, structure and quality are described in Chapter 1 (section 1.4).  
 
3.3.2 Application and eligibility 
As mentioned previously in Chapter 1, two versions of the BCIS database are 
used in this thesis. The first is the 2010 version of the BCIS database that was received 
in December 2011, which was requested by Dr Gale earlier in the same year. After a 
successful application, permission for the use of BCIS national audit data to undertake 
this research has been granted from the BCIS Academic Committee. A full extract of 
the secondary, anonymised BCIS dataset was received in a zipped, encrypted file on a 
special CCAD secure web drop box and a username and two passwords were given to 
me separately (one by e-mail and the other by phone) for additional protection.  
In 2014, another application for a more updated BCIS audit data was made in 
December 2013 and successfully accepted by the BCIS Academic Committee. 
Likewise, an encrypted file on a CCAD secure web drop box comprising a secondary 
anonymised BCIS dataset was received in November 2014 with a username. Later on, 
two passwords were provided separately in the same way as the previous version. The 
application form is shown in Appendix II. 
 
3.3.3 Ethical considerations 
With the intention to undertake statistical and epidemiological research work 
using secondary anonymised BCIS data, where the identification of patients and 
providers (either physicians or hospitals) can only be made by BCIS and NICOR, an 
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enquiry in regard to the need for ethical approval or audit/service evaluation was 
requested from University of Leeds, the faculty of medicine and health research ethics 
committee (FREC) on November 2011. In February 2012, a response was received from 
FREC stating that studies undertaking secondary analysis of anonymised patient data no 
longer require the National Research Ethics Service (NRES) review or approval. Please 
see Appendix III for a copy of the form about requirements for review of queries that 
have been sent to FREC and a copy of the reply e-mail received from FREC. 
Furthermore, the National Institute for Cardiovascular Outcomes Research 
(NICOR), which includes the BCIS database (Ref: NIGB: ECC 1-06 (d)/2011), has 
support under section 251 of the National Health Service (NHS) Act 2006. Therefore, 
ethical approval was not required under NHS research governance arrangements for the 
research. 
 
3.3.4 Data security 
For both versions (2010 and 2014), once the dataset was received and 
downloaded, it was placed on the University of Leeds servers, where it is securely 
stored and regular back-ups are automatically made frequently. The BCIS data was 
saved in a special account in the N-drive (the Division of Epidemiology and 
Biostatistics server). Accessibility to the data was restricted to the research team only. 
For additional security, the team agreed that the data should not be accessed from 
networks other than the university network and/or server. At the same time, and since 
the size of data file was too big to be handled by the available Stata software in the 
university student account, a single user Stata version 12 perpetual licence (updated 
later on to Stata version 13 and then to version 14) was purchased and installed on the 
university desktop C-drive. 
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3.4 Data management  
3.4.1 Preview 
Data management is an important part of any research. It ensures a robust 
statistical analysis by removing duplicates as well as improving the accuracy, 
completeness and reliability of the data, consequently, enhances the producibility and 
impact of findings [125]. The data management part was a vital step in establishing 
good quality modified data for this thesis and for other related research. In fact, both 
modified versions (2010 and 2014) of the BCIS dataset have been used by other 
researchers [81, 87, 126-129]. As part of this thesis and with the support of the research 
team, all the steps of data management for both versions of the BCIS database were 
performed. The data management included data transformation, cleaning and recoding, 
followed by the intended analyses.  
 
3.4.2 Using a Delphi group to develop optimal clinical definitions 
The Delphi group or method was best defined by Linstone et al. [130] as “a 
method for structuring a group communication process so that the process is effective in 
allowing a group of individuals, as a whole, to deal with a complex problem”. In order 
to achieve the best outcomes from the data management and the afterward analyses in 
this thesis; a Delphi group was formed. In addition to the primary investigator, the 
group included, Dr Chris Gale, Dr Paul Baxter, Dr Sarah Fleming, Dr Peter Ludman, Dr 
Mark de Belder and Dr Nick Curzen. 
This Delphi group was simply a combination of the individual knowledge as well 
as the group decisions and revisions. Using the available BCIS data, the Delphi group 
was structured to communicate and agree on the best means to define clinical and 
statistical diagnostic groupings. For example, the group agreed on the methods used in 
defining the study cohort (the UPLMS cohort, the clinical presentation type and the 
primary PCI cohort). Another example was during data cleaning and recoding such as 
cleaning the route of admission variable and incorrect entries particularly in numeric 
variables.  
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3.4.3 Data collection and entry 
The data are collected and entered locally by data clerks and/or interventional 
cardiologist into local software systems. Subsequently, electronic encryption takes place 
by NICOR to ensure data security, and then transfer the data to CCAD central servers. 
More details on BCIS data collection, entry and quality are mentioned in Chapter 1 
(section 1.4).  
Following data linkage, encryption, cleaning and consistency checks performed 
by NICOR to improve data accuracy, more than 411,000 records of raw data in the 2010 
version and more than 747,000 records in the 2014 version of the BCIS dataset were 
available for research in 2014 [20, 54, 81]. However, the raw data in both versions were 
not in an appropriate form and required extensive management and processing to be 
converted into a suitable research-ready format for further analysis.  
  
3.4.4 Data transformation and statistical software 
At first, for both versions (2010 and 2014), the initially received files were in the 
form of Microsoft Office Excel comma separated values files that have been 
transformed later into Stata dataset files. In order to be handled easily by the available 
software, the huge sizes of both datasets files (411,324 and 699,248 records, 
respectively) required splitting initially, transforming to Stata files then merging later 
on. Afterward, all the variables in the raw data were extracted and coded into a Stata 
suitable format to be ready for cleaning and recoding if required. Stata 12 and Stata 13 
software were utilised to transform, clean and recode the 2010 and 2014 BCIS datasets 
respectively.  
 
3.4.5 Data cleaning and recoding 
In spite of the importance of data collection and analysis, data quality remains a 
persistent problem in most databases, particularly in clinical datasets such as this, which 
have been collected over a long period [125].  The main disadvantages of routine 
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clinical data, such as the BCIS include: large datasets with a lot of errors, mismatches 
and incomplete information [125, 131].  
From January to May 2012, the 2010 version required five months of data 
cleaning and recoding, while the 2014 version required only one month (December 
2014) of data management as most of the cleaning codes were available from the 
previous version of data management. The majority of data cleaning and recoding codes 
were according to clinical opinion of the Delphi group. 
As mentioned previously, recoding of most of the variables in the BCIS data 
was essential in order to transform the whole dataset. This was achieved by recoding all 
string format variables to numeric format, then all categorical variables were re-labelled 
(categorised). All continuous variables in the raw data file were in string format and 
required cleaning and recoding to numeric format so they can be recognised and 
analysed by the Stata software. For analytical reasons, some continuous variables 
required recoding to categorical format.  
During the recoding process, each variable was assessed for data mismatches 
and/or errors, and all entries that were considered as such were cleaned by recoding 
them as missing in most situations, or by recoding them to another entry when 
applicable. Entries like “Unknown” and “Unlisted” were also recoded as missing in 
most of the variables however, this value was kept in some entries as they were 
meaningful. For continuous variables (such as the number of stents used, attempted 
vessels and creatinine level), numbers that were clinically implausible were excluded 
and recoded as missing.  
 
3.4.5.1 2010 BCIS data 
Out of 127 variables a total of 98 variables were transformed and/or recoded. 
Most required recoding and cleaning like gender, indication for intervention and 
procedure urgency variables. Others required transformation from string format to 
numeric using “destring” command in Stata like height, weight and creatinine level 
variables. Moreover, variables that contain dates and times were recorded as Stata data 
string format using “date (variable, "DMY")” and “format variable %td” commands. To 
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be exact, nine new dummy variables were also created from one or more existing 
variables, for example clinical presentation variable which was drawn from three 
different variables.  
At the same time, some variables (for example PCI hospital outcome, procedural 
complications and history of renal disease) contained multiple entries for each case 
record, and most of these entries were integrated with each other. Therefore, in order to 
overcome this problem and for easier future analysis, new binary variables were created 
in a way that each new generated variable is an entry from the original variable (Figure 
3.1). In addition, a few other variables were generated from the variables containing 
dates for the necessity in future analysis (such as number of hospital stay days, help 
days and number of days between procedure and death or census dates). 
 
Figure 3.1: Graphic illustration of recoding a variable with multiple entries. 
 
A, B, C and D are categories in the original variable.  
The original 
variable in raw 
data (A, B, C 
,D)
New 
variable 
A (Yes or 
No)
New 
variable 
D (Yes or 
No)
New 
variable 
C (Yes or 
No)
New 
variable 
B (Yes or 
No)
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3.4.5.2 2014 BCIS data 
The overall number of variables in the received 2014 version was 151, out of 
which 143 variables were transformed and/or recoded. As in the previous version, most 
of the variables required recoding from string to numeric format, with or without 
cleaning, such as ethnic groups, history of previous myocardial infarction and life status 
at discharge variables.  
Variables containing dates were not entirely provided in this version; however, 
durations or time intervals based on dates were provided separately and were recoded 
and cleaned accordingly. Most of the numeric variables (continuous and discrete) 
required cleaning, yet few needed recoding to categorical format as required in the 
analysis. An example for such variables is age at procedure as it was cleaned from all 
ages less than 18 years and more than 100, then recoded into categories. 
Similarly, to the previous BCIS version, seven new variables were created from 
the existing variables. These variables were clinical presentation, procedure date, 
biennial years, type of stents used, censoring date, survival time, and life status at 
censoring. In the same way, multiple entry variables were recoded as in the 2010 
version. A few examples of how some variables have been recoded and cleaned are 
shown in table 3.1. 
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Table 3.2: Examples of some recoded variables in 2014 version of the BCIS 
database. 
Variable name Row data format Recoded data format 
Examples for recoded variables from string to numeric with data cleaning  
Gender 
1. Male 1 = Male 
2. Female 0 = Female 
"."  
. = Missing 
0. Not known 
1.07.Gender 
9. Not specified 
X1.07.Gender 
Admission route 
1. Direct to cardiac centre (from the 
community) 1 = Direct to Cardiac Centre 
2. Inter-hospital transfer 2 = Inter-hospital transfer 
3. Already in cardiac centre 3 = Already in cardiac centre 
"." . = Missing Unlisted 
An example for recoded date variables 
Date of procedure 
Month of procedure (1 – 12) 
01jan2005  
01feb2005  
01mar2005 
… … …. 
01mar2014 
Year of procedure (2005 – 2014) 
An example for recoded multiple entry variables  
Diagnostic devices 
used during 
procedure 
0. None 63,398 
None 
0 = No 
0. None; 2. Pressure wire 1 = Yes 
0. None; 3. Flow wire . = Missing 
0. None; 99. Unlisted 
IVUS 
0 = No 
1. IVUS 1 = Yes 
1. IVUS; 2. Pressure wire . = Missing 
1. IVUS; 2. Pressure wire; 3. Flow wire 
Pressure wire 
0 = No 
1. IVUS; 2. Pressure wire; 99. Unlisted  1 = Yes 
2. Pressure wire; 3. Flow wire . = Missing 
… … …. … … …. … … …. … … …. 
An example for numeric variables date cleaning and recoding to categorical format  
Age (years) 
Row (numeric) Cleaned (18 - 100) Recoded (categorical) 
Minimum (8) Minimum (19.6) 1 = <65 years 
Maximum (1062.8) Maximum (99.5) 2 = 65 – 80 years 
Median (65) Median (72) 3 = >80 years 
Mean (64.9) Mean (70.5) . = Missing 
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3.5 Data analysis 
3.5.1 Statistical analyses  
3.5.1.1 Summary of descriptive methods 
All analyses were conducted using Stata IC version 12 for the 2010 BCIS 
database and Stata IC version 13 for the 2014 BCIS database (Stata Corp LP, Texas, 
USA). Data in both versions were described throughout this thesis using crude 
unadjusted numerical data. Results for categorical variables were expressed as 
frequencies and percentages (%). Continuous variables were described by mean and 
standard deviation (SD) or if the values weren’t normally distributed median and 
interquartile range [132, 133]. Missing data were excluded from all measured 
proportions. The linear-by-linear Chi square test was used to compare distributions of 
observed and expected proportions for categorical variables. However, for continuous 
variables, groups were compared using Student’s t-test and ANOVA whenever normal 
distribution is plausible. If not normally distributed, Mann-Whitney U test was used 
[132, 133]. 
 
3.5.1.2 Summary of analytical methods 
Cumulative event rates were estimated using the Kaplan-Meier survival curves, 
and differences were compared using the log-rank method. Using multivariate logistic 
regression and/or Cox regression models, the associations between an outcome and 
predictors were measured by adjusted odds ratios (aOR) and adjusted hazard ratios 
(aHR) with 95% confidence interval (CI) respectively. For all tests, a P value < 0.05 
was considered a cut-off point for statistical significance [132, 133]. 
 
3.5.1.3 Logistic regression 
Binary categorical outcome variables for instance mortality rate are the kind of 
outcomes (dependent variables) used in logistic regression. The application of logistic 
regression is relatively common. Le [133] described it as the method that is used to 
measure the association between an outcome variable and one or more predictor 
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(independent) variables. In a way, logistic regression is comparable to linear regression; 
however, the hypothesis of normality does not stand for binary outcomes [133].  
The probability in the regression model undergoes repeated estimated logistic 
transformations (the maximum likelihood) ensuing variables coefficients of the model. 
A coefficient exponential gives the estimated odds ratio (OR) which is simply for a 
binary outcome, the ratio between the probability of one category against the probability 
of the other category [133]. When the model has more than one predictor to adjust for 
the confounding effect of the predictors, then the ratio is termed adjusted odds ratio 
(aOR) and the model is termed multivariate logistic model.  
Multivariate logistic regression modelling was employed in the analysis of Chapter 
4 “predictors of outcomes in UPLMS patients who underwent percutaneous coronary 
intervention” and in Chapter 5 “mortality trends after UPLMS percutaneous coronary 
intervention”. This method fulfils the aims and objectives of both analysis, and the 
choice was supported by the conclusions from the literature review provided in Chapter 
2 (section 2.4). 
 
3.5.1.4 Survival analysis 
Modelling the duration or time period for an event to occur is known as survival 
analysis. It was termed “survival” as death is the typically measured event. Estimation 
of the direct risk of an event at a period of time is termed as the hazard function. 
Quantifying the association between an event survival (dependent variable) and a 
predictor or more (independent variables) is known as survival modelling. The most 
common method of survival modelling is Cox proportional hazards regression 
modelling [134].  
Cox proportional hazards model is similar to a linear regression model; 
however, it requires the hazard function or the log hazard measurement in the model 
[134]. In the same way like logistic regression, the exponential of a coefficient is termed 
the estimated hazard ratio (HR), and when there is more than one predictor in the 
model, then the ratio is called adjusted hazard ratio (aHR). 
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Multivariate Cox regression modelling was implemented in the analysis of 
Chapter 6 “predictors of survival for primary percutaneous coronary intervention in 
STEMI patients”. Cox regression modelling accomplishes the aims and objectives of 
the analysis, and the choice was supported by the conclusions from the literature review 
provided in Chapter 2 (section 2.5). The same method was used in the majority of the 
reviewed studies.  
 
3.5.1.5 Multi-level regression 
In a fixed effects model, either a logistic regression or a Cox regression model, 
the observations at the patients’ level are assumed to be independent. However, this 
may not always be true as patients sometimes come from different groups or clusters 
(e.g. from different hospitals). Multi-level regression or mixed effects modelling help to 
overcome this dilemma. The effect of each cluster is measured using shared collective 
information, not only from the cluster but also from the other clusters. Simply, a mixed 
effects model accounts for the variance in the predictor (independent) variables as well 
as the variance in the higher level (e.g. hospitals) [133]. 
Multi-level regression modelling measures the association between a dependent 
variable and a predictor or more (independent variables) at level of each cluster. This 
method was used as a sensitivity analysis in Chapters 4, 5 and 6 to adjust for hospital 
clustering of patient’s observations and outcomes. 
 
3.5.1.6 Model selection summary 
Logistic and Cox regression models in this thesis were selected by identifying a 
set of independent variables as potential predictors of the intended dependent variable. 
The predictors’ identification was based on the clinical and statistical input from the 
Delphi group as well as the literature review provided in Chapter 2 (sections 2.4 and 
2.5).  
Afterward, each predictor was fitted individually in a univariable model with the 
dependent variable. Odds ratios (OR) or hazard ratios (HR), 95% confidence intervals 
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and P values were computed to assess the statistical association of each predictor with 
the dependent variable. All variables with significant predictive value of a P value < 
0.05 were then added to the multivariate model. In addition, variables of specific 
clinical importance and interest to the analysis were also added to the model. 
The likelihood ratio test was used to assess any interactions between the 
predictors and the dependent variable. After estimation, the same test was used to 
evaluate the goodness of fit of the logistic and Cox regression models. The test 
compares the fit of one model with the fit of the second model by simply likening the 
two models log likelihoods. A statistically significant Chi square statistic indicates that 
the second model prediction fits the data significantly better than the first and vice 
versa.  
 
 
3.5.2 Handling missing values and multiple imputation method justification 
3.5.2.1 Introduction  
In most of medical research, missing values can occur in any variable collected, 
whether it is an explanatory or an outcome variable. Any missing value can arise from 
not being collected at all, being lost after collection or deleted intentionally after 
collection due to inaccuracy [124, 135]. Missing data in any database can lead to biased 
results as well as decrease in the power, inference and validity of the analysis 
undertaken. Together and due to the paucity of understanding such statistical 
phenomena, medical researchers frequently fail to appreciate the importance of the 
influence of missing data on the analysis of their research [124, 136]. 
Relevant literature concerning missing data and multiple imputation was 
identified using Ovid Medline, PubMed and Google Scholar between January 1996 and 
October 2015. The search terms used include “missing data”, “missing values”, 
“missingness” as well as “multiple imputation”. Also, the focused literature search 
entailed only reviewing relevant publications. Bibliographies of the publications were 
screened and other related publications and resources from citation trees concerning 
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missing data and multiple imputation were correspondingly followed, reviewed and 
cited using PubMed, Google and Google Scholar databases.  
 
3.5.2.2 Types and implications of missing data 
As it is well known to all statisticians and most researchers, missing data can be 
one of three different types based on the reasons these data where missing for; this was 
clearly described in several occasions in the statistics literature [135, 137-140]. Rubin 
(1976) [135] was the first to describe these three types. The first type is when the data 
have no systematic differences between the missing and non-missing values; in another 
words, missingness does not depend on the non-missing observed values or the 
unobserved values. This type is called Missing Completely At Random (MCAR) and 
the best example for it is when a laboratory blood sample is accidently dropped and 
spoiled. A complete case analysis of a dataset containing such type of missing data 
usually leads to loss in precision but does not cause bias [135, 137-141]. 
Second is when there are systematic differences between the missing and non-
missing values which can be fully explained by the observed non-missing values in the 
dataset, this type is called Missing At Random (MAR). The presence of other covariates 
that can help in predicting the missing values in one variable increases the likelihood 
that the missingness in this variable is MAR. A good example for MAR values is when 
there are missing readings in blood pressure data for elderly patients who tend to have 
their blood pressure recorded; therefore, the missing values are conditioned to the 
observed patients’ age and these values can be predicted by other variables in their 
database such as age and/or previous readings [135, 137-140, 142].  
The third type is when there are again systematic differences between the 
missing and non-missing values but at the same time the missingness is dependent on 
unobserved values or events. This one is called Missing Not At Random (MNAR) or 
non-ignorable missingness. For example, when there are missing readings in blood 
pressure data for patients who were commonly assumed to have normal blood pressure 
by health professionals and, therefore, do not get their blood pressure measured and/or 
recorded at most occasions and the missing values here cannot be explained by any 
other variables in the database [135, 137-140]. 
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For any research analysis, it is crucial to know the type of missing values in the 
dataset in order to treat it properly [140, 143]. Dealing with missing data, as illustrated 
by Graham and Donaldson (1993) [144], can be either accessible or inaccessible. 
Referring to that treating missing data can be accessible when accounting for the cause 
of missingness is possible; these include MCAR and most MAR values. Conversely, it 
is inaccessible when the missingness mechanism itself cannot be measured and these 
include any MNAR values as well as MAR values with known but unmeasured cause of 
missing data. 
As mentioned previously, ignoring missing data in any analysis can lead to lack 
of power, loss of precision, as well as the likelihood to generate inaccurate or biased 
estimates. Moreover, a confounder variable with missing data cannot be excluded from 
any analysis as such action can cause bias and as a consequence lead to misleading 
results. Likewise, excluding an outcome variable with missing values from the analysis 
is not a practical option [124]. The inefficiency of most estimates generated after the 
analysis of such variables stimulates the need for dealing with missing data. 
 
3.5.2.3 Handling missing data 
Over the last ten years, determining the best statistical and analytical approach a 
statistician or a researcher could utilise to deal with missing value problems was a 
perplexing question. Including only complete records in the analysis while ignoring 
those with missing values (complete case analysis) is what most researchers usually do 
with this problem [138, 140, 143]. This method of exclusion is the simplest technique of 
handling missing data as no further data manipulation is necessary before any analysis. 
For that reason, it is the default method of analysis in most statistical packages. 
Complete case analysis mostly will cause a biased sample that will then have an effect 
on the precision and power of such research (see Figure 3.2) [137, 138, 140, 143].  
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Figure 3.2: Graphic illustration of complete case analysis. 
 
 
 
 
 
 
 
 
 
Other examples of statistical methods that can be used to treat missing values are 
available case analysis, ad hoc replacement and mean substitution [137, 138, 140]. 
Generally, these methods can cause biased inefficient estimates and none of them is 
statistically valid. Single imputation is another way of treating missing data by imputing 
single alternative value for each missing value and, at that point, analyse the completed 
data as if it is true data. Unfortunately, this technique usually fails to account for 
missing data uncertainty and thus leads to small standard errors. Consequently, to 
overcome this uncertainty dilemma, most data analysts and statisticians use multiple 
imputation to deal with missing values [137, 138, 140]. 
 
3.5.2.4 Multiple imputation 
In multiple imputation, existing non-missing values from an observed variable 
or variables are used to predict the missing values for another variable. When these 
predicted values (imputes) are used to replace the missing values, a new full dataset 
(imputed dataset) is created. Furthermore, multiple imputed datasets can be created by 
carrying out this method several times and that is why it is called multiple imputation. 
Ultimately, each imputed dataset can be statistically analysed using standard statistical 
ID Age Gender Ethnicity Heart 
rate 
1 44 Female Caucasian 75 
2 37 Male . 80 
3 60 . Black . 
4 52 Female Caucasian 80 
5 59 Female . 85 
6 38 Male Asian 77 
ID Age Gender Ethnicity Heart 
rate 
1 44 Female Caucasian 75 
2 37 Male . 80 
3 60 . Black . 
4 52 Female Caucasian 80 
5 59 Female . 85 
6 38 Male Asian 77 
Complete case 
analysis 
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techniques (such as regression modelling) creating multiple results which are then 
combined and pooled together to generate one overall result or estimate (Figure 3.3) 
[144-146]. 
Imputing missing data using the other variables in the dataset means that these 
variables and the causes of missing data are correlated, and through this the natural 
variability of missing data is maintained. Moreover, pooling of the analysis of imputed 
datasets using Rubin’s rules (represented by the equation below) will always take 
account of the variability between the imputed datasets by creating unbiased parameter 
estimates which reflect the missing data uncertainty. In addition to that, multiple 
imputation offers efficient estimates when treating datasets with small sample size 
and/or high rates of missingness giving major advantages over complete case analysis 
[138, 143, 146]. 
 
 
 
Equation A : Rubin's rule [146]. 
 𝑇𝑇 =  1
𝑘𝑘
  �  𝑘𝑘
𝑖𝑖=1 � + 𝑘𝑘 + 1𝑘𝑘𝑖𝑖   [ 1𝑘𝑘 − 1 �  𝑘𝑘𝑖𝑖=1  (𝑄𝑄𝑖𝑖 −  𝑄𝑄)−2] 
𝑄𝑄� = 𝑉𝑉𝑉𝑉𝑉𝑉𝑖𝑖𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 
𝑇𝑇 = 𝑇𝑇𝑇𝑇𝑇𝑇𝑉𝑉𝑇𝑇 𝑉𝑉𝑒𝑒𝑇𝑇𝑖𝑖𝑒𝑒𝑉𝑉𝑇𝑇𝑉𝑉𝑒𝑒 𝑣𝑣𝑉𝑉𝑉𝑉𝑖𝑖𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑉𝑉𝑒𝑒𝑒𝑒𝑇𝑇𝑉𝑉𝑖𝑖𝑉𝑉𝑇𝑇𝑉𝑉𝑒𝑒 𝑤𝑤𝑖𝑖𝑇𝑇ℎ 𝑄𝑄� 
𝑘𝑘 = 𝑁𝑁𝑁𝑁𝑒𝑒𝑁𝑁𝑉𝑉𝑉𝑉 𝑇𝑇𝑜𝑜 𝑖𝑖𝑒𝑒𝑖𝑖𝑁𝑁𝑇𝑇𝑉𝑉𝑒𝑒 𝑒𝑒𝑉𝑉𝑇𝑇𝑉𝑉𝑒𝑒𝑉𝑉𝑇𝑇𝑒𝑒 
𝑖𝑖 = 𝑇𝑇ℎ𝑉𝑉 𝑉𝑉𝑉𝑉𝑉𝑉𝑇𝑇𝑎𝑎𝑒𝑒𝑉𝑉𝑒𝑒 𝑔𝑔𝑉𝑉𝑇𝑇𝑁𝑁𝑖𝑖 (1,2,3, … … … ,𝑘𝑘) 
𝑄𝑄𝑖𝑖 = 𝐸𝐸𝑒𝑒𝑇𝑇𝑖𝑖𝑒𝑒𝑉𝑉𝑇𝑇𝑖𝑖𝑇𝑇𝑉𝑉 𝑇𝑇𝑜𝑜 𝑇𝑇ℎ𝑉𝑉 𝑖𝑖𝑇𝑇ℎ  𝑔𝑔𝑉𝑉𝑇𝑇𝑁𝑁𝑖𝑖 
∐ = 𝒊𝒊 𝑽𝑽𝑽𝑽𝑽𝑽𝒊𝒊𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽 𝒇𝒇𝒇𝒇𝑽𝑽 𝒕𝒕𝒕𝒕𝑽𝑽 𝒊𝒊𝒕𝒕𝒕𝒕 𝒈𝒈𝑽𝑽𝒇𝒇𝒈𝒈𝒈𝒈  
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Figure 3.3: Graphic illustration of multiple imputation application and the analysis 
afterward. 
 
 
k = number of imputed datasets 
 
  
Dataset 
with 
missing 
data
Dataset 1 Dataset kDataset 2
Pooled 
estimates
Estimate & 
Standard 
Erorr 1
Estimate & 
Standard 
Erorr k
Estimate & 
Standard 
Erorr 2
…
 
…
 
Imputed 
datasets 
Analysis 
 
 
83 
 
3.5.2.5 Multiple imputation for multivariate missing data 
Multiple imputation was first introduced in 1977 by Rubin, and then was 
described in more detail in 1987 and 1996 again by Rubin, and also in 1997 by Schafer. 
In 1996, Rubin described multiple imputation in three distinctive steps: firstly the 
creation of multiply imputed datasets in which unsystematic draws from correlated 
complete variables replace the missing values in a variable, secondly complete 
statistical analysis of each imputed dataset, and finally pooling or combining the results 
of each dataset analysis into one valid estimate [145, 147-149].  
However, Rubin’s original rule in 1987 failed to elucidate the application of 
multiple imputation when there are missing values in more than one variable in the 
dataset, i.e. multivariate missing data. Since then, various methods have been proposed 
to deal with the complexity of imputing multivariate missing data which can be 
summarised into two broad methods: joint modelling and fully conditional specification 
[150-154].  
Joint modelling is simply one model for all multivariate missing data that 
include a set of correlated complete variables (predictors) as well as the incomplete 
variables (to be imputed); the same model is for both imputation and analysis afterward 
[150, 151]. This method has some pitfalls in the created imputation, particularly in the 
presence of differences between the variables in terms of type (binary, categorical or 
continuous), which consequently lead to bias by generating unrealistic assumptions 
and/or incorrect combinations in the imputed variables (e.g. pregnant male) [153, 155]. 
Fully conditional specification imputation method, first introduced by Buuren et 
al. in 1999, is a more flexible alternative of joint modelling method in which separate 
individual conditional models for each incomplete variable are specified for the 
imputation alone. Afterward, separate analysis models are applied to the imputed 
datasets and then pooled together in one estimate. Multiple imputation by chained 
equation (MICE) is another name for conditional specification method which have been 
applied in various statistical software such as R, S-Plus and SPSS [154, 155]. A similar 
software package in Stata called (ice) was introduced be Royston in 2004 [156].  
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The flexibility of the fully conditional specification method is more recognisable 
in the way that different conditional models are specific for each variable type (binary, 
categorical or continuous); more details can be seen in table 3.2. Another advantage of 
this method is the option to comprise constraints to make certain that the imputed values 
do not have incorrect combinations [155] 
 
 
Table 3.3: Imputation methods based on the type of the variable with missing data. 
Type of variable Imputation method 
Binary Logistic regression [145] 
Categorical Polytomous logistic regression [157, 158] 
Continuous 
Linear regression [145, 159] 
Predictive mean matching [159, 160] 
Semi-continuous 
(mixed discrete and continues) 
Two step (logistic + linear regression) [145] 
 
 
 
 
3.5.2.6 The number of imputations 
Rubin in 1987 demonstrated statistically that the number of imputations depends 
on the fraction of missing data [145]. Imputations between five and ten were the number 
suggested by early publications [154, 161]; however, more recent researches suggested 
that increasing the number of imputation datasets would be more beneficial, since they 
concluded that the lower the number of imputations the lower the loss of statistical 
power for detecting small effect sizes, and the more the variability between important 
statistics are, such as standard errors, P value and 95% confidence interval. The final 
number of imputation datasets suggested more recently was 20 [162-164].  
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3.5.2.7 Multiple imputation model specification 
Faultily specified imputation models will always lead to inaccurate imputation 
and consequently wrong estimates, and in order to avoid this some approaches have 
been proposed in literature: 
• Including all the variables in the dataset into the imputation model minimises 
bias [154]. However, in several medical datasets where the number of variables 
are too high, this kind of model is not achievable as it tends to produce 
multicollinearity between the variables. Thus, it was recommended in the 
literature that in such datasets, the number of variables to be included in the 
imputation model should be between 15 and 25 variables [154]. 
• MAR assumption is more plausible if as many predictors as possible are 
included in the model [142, 150, 165]. 
• The congenial imputation model is a model that comprises all the variables to be 
applied in the analysis (including the outcome variable). The absence of 
congeniality in an imputation model will lead to inaccurate underestimation of 
the predictive associations [166]. At the same time, additional auxiliary 
variables that are not important to the analysis but contribute to the prediction of 
missing values should be included [167]. The inclusion of auxiliary variables to 
an imputation model reduces the bias produced from the pooled analyses 
estimates later on [138, 142]. 
• Non-linear transformations as well as interactions should always be included in 
the imputation model as they also lead to underestimation of the predictive 
associations [164]. 
• The assumption of normality for the included continuous variables should be 
confirmed before running any imputation model; non-normality creates a lack of 
face validity (i.e. the imputation sets produced will be closer to normal 
distribution rather than the original distribution) [164]. To avoid such an issue, 
any non-normally distributed variable should be transformed to an approximate 
normal distribution before the imputation. Then, the imputed data should be 
transformed back to the original scale before any analysis [164]. 
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3.5.2.8 Multiple imputation application in the medical literature 
Lately, deliberations were raised either toward or against the use of multiple 
imputation, in particular, and the other statistical methods in general in order to deal 
with missingness in datasets. Twenty years ago, Greenland and Finkle [139] pointed out 
that the use of missing data treatment methods in epidemiological researches was not so 
common, and this was due to their complexity as well as the lack of accessibility, 
mainly owing to the paucity of statistical software packages that implement multiple 
imputation at that time. Similarly, Rubin [168] concluded that statistical software 
packages are important for implement multiple imputation to be the standard method to 
deal with missing data. 
Further, Klebanoff and Cole [136] demonstrated that less than 2% of 
epidemiological published papers has used missing data treatment methods, and 
multiple imputation was one of these methods. However, several researchers used 
multiple imputation in analysing their datasets, which showed promising performance. 
Good examples of such researchers are Graham et al., Wayman as well as Schafer and 
Graham [136, 169]. 
However, after the introduction of some statistical software packages that 
implement multiple imputation such as MICE packages by Buuren et al. in 1999 [154]  
and the ice software package by Royston in 2004 [156], there was an increase in the use 
of multiple imputation in the recent years, particularly in the medical researches. As a 
matter of fact, the use of multiple imputation in the medical literature has been rising 
slowly but gradually over the last ten years. 
Barzi and Woodward [170] used multiple imputation of serum cholesterol level 
to compare the results of 28 studies in the Asia pacific cohort studies collaboration. In 
this study, eight different imputation methods were used for each study. Cholesterol 
level values of <10% were missing in 22 studies, and the pooled analysis showed 
comparable results between the methods. Four studies, however, with 10 to 60% 
missing values showed differences between the methods and proposed that multiple 
imputation is the method of choice. Cholesterol level values of > 60% missing values 
were present in two studies, and none of the imputation methods were effective.  
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Schiattino et al. [146] used multiple imputation to evaluate differences in serum 
tumour necrosis factor (TNF) concentrations increment in rheumatoid arthritis patients 
receiving anti-TNF therapy. The results of this study showed that multiple imputation is 
> 98% efficient, and this association was statistically significant (P <0.001). Another 
published study by Eisemann et al. [171] used different models for multiple imputation 
to analyse stage specific numbers of cases of malignant melanoma and female breast 
cancer in a population-based cancer registry. They concluded that with reasonable levels 
(< 20%) of cases of missingness in tumour stages, multiple imputation is a suitable 
approach to handle missing values in such population-based registries.  
Heron et al. [172] used full information maximum likelihood and multiple 
imputation to compare their estimators in a UK-based birth cohort to analyse smoking 
frequency in young adolescents. The complete case analysis showed that smoking 
prevalence was lower than that estimated by the pooled 100 imputed datasets and the 
full information maximum likelihood method. It also showed that the relationship 
between smoking patterns and covariates was also varying between the methods used.  
In another study, undertaken by Cattle et al. [141], they utilised multiple 
imputation to complete the missingness in the database of a national register of heart 
attacks (Myocardial Ischemia National Audit Project or MINAP). In this study, the 
authors concluded that multiple imputation improved the quality and value of the 
MINAP database by giving it better precision of estimates of odds ratios, which was 
achieved by using the measured variables from the incomplete records.  
Montealgre et al. [173] used multiple imputation of the birth place variable to 
describe and compare the survival between the United States born vs. foreign born 
patients with cervical, prostate or colorectal cancer. The results of this study indicated 
that multiple imputation of the birth place status disclosed different associations 
between birth place and cancer survival when compared to complete case analyses of 
the same cohort. 
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3.5.2.9 Conclusions and justifications 
Although the influence of missing data on any kind of analysis is well 
established and well understood in the statistical society, most of the applied medical 
studies failed to appreciate the importance of using statistical methods to deal with 
missing data. Ignoring the missing values in any analysis can create biased estimates, 
loss of the statistical power and loss of precision, which mean results may not be valid 
to clinical practice. Even though multiple imputation is not a perfect method to treat 
missing values, it is clear that other alternative statistical methods produce less precision 
and power in any analysis results compared to multiple imputation.  
In published medical research since the introduction of statistical software 
packages that implement multiple imputation, there was a slow, steady increase in the 
use of multiple imputation. Accordingly, and since the BCIS databases (both 2010 and 
2014 versions) have a large number of missing values in most of the variables (as 
described earlier in Chapter 1 (sections 1.3.4.3 and 1.3.53)), multiple imputation was 
selected to be the statistical method of choice, together with the complete case analysis, 
to treat the missing data in the analysis of all the studies included in this thesis.  
Furthermore, multiple imputation in the recent literature has been the most 
common method used to deal with missing data. However, it was clear that multiple 
imputation was not widely used in the cardiovascular literature, and employing the 
method in the analysis of this thesis will make it better known. Details of the specific 
methodology used in the thesis as well as a full description of the imputation models 
specifications are provided in the next section. However, thorough descriptions of the 
missing data patterns as well as the imputed data specification and analysis are provided 
separately in Chapters 4, 5 and 6.  
 
 
3.5.3 Multiple imputation method 
To enhance the research potential of the BCIS database, multiple imputation was 
performed ‘fit for purpose’. Imputation models were specified twice for UPLMS 
patients who underwent percutaneous coronary intervention as well as STEMI patients 
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treated by primary percutaneous coronary intervention. The models included all the 
variables of interest in the main regression or survival analyses. At the same time, 
auxiliary variables were included to the imputation models in order to improve the 
prediction of missing data in the regression/survival selected variables.  
The outcome variables (30-day and 1-year mortality), survival estimates and 
censoring indicators were retained in the imputation models. The inclusion of the 
outcome variables to imputation models decreases the bias from the pooled estimates 
[166]. Imputation variables (predictors and auxiliaries) were selected based on 
comprehensive literature reviews and the Delphi group clinical agreements on the 
clinical plausibility of some variables. 
Based on the cohort of intention, the datasets were inspected for the percentages 
of missing values. Assuming that they were missing at random, the missing values in all 
selected variables (predictors and auxiliaries) in the imputation models were imputed 
except for those with more than 40% missingness, as it is not recommended [174]. This 
assumption simply vindicates the certainty that the missingness can be predicted by the 
available observed information. MAR assumption is more plausible if as many 
predictors as possible are included in the model [142, 150, 165]. 
In order to test for collinearity, disease specific statistical predictor matrices 
were designed based on clinical judgement as well as using thresholded P values of less 
than 5% as related and ≥ 0.05 as unrelated. For continuous-continuous and continuous-
categorical associations (continuous variables were modelled as the response) linear 
regression was used. While for categorical-categorical (including binary and ordinal 
variables), Chi-squared test was used. 
All imputations were conducted using Stata IC versions 12.0 and 13.0 (Stata 
Corp LP, Texas, USA). The recommended number of imputations datasets was 20 [162-
164]. Therefore, for each of the selected variables with missing values, 20 datasets were 
imputed using the chained equation method. Fully conditional specification imputation 
method was used in all imputations; a detailed explanation of the method was 
mentioned earlier (section 3.4.3.5). Continuous variables were imputed using predictive 
mean matching and the categorical data imputed using either logistic regression or 
polytomous regression (Table 3.2).  
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In predictive mean matching, the predicted model is estimated from the 
observed data, which ensures that the extra uncertainty about the unknown true model is 
reflected [175]. The normality assumption of all continuous variable used in imputation 
were verified graphically using histograms. However, in both 2010 and 2014 versions 
of the BCIS database, one variable (IMD score) was not normally distributed. The 
variable needed logarithmic transformation before multiple imputation and then 
reversed back later for the intended analysis.  
Interaction terms were considered during the imputation process as well as in the 
analyses later on. Imputation diagnostics were evaluated and did not give any cause for 
concern. To be more precise, the likelihood ratio was the test used to assess any 
interactions between the predictors and to evaluate the goodness of fit of the imputation 
models. Furthermore, and in order to test for any implausible values in the imputations, 
descriptive statistics of the imputed datasets were inspected and compared to those of 
the complete case datasets. In all the imputations performed in this thesis, the 
distributions of the imputed and complete case datasets were comparable. This 
comparability added more reliability to the MAR assumption as well as signifying that 
the imputation models were acceptable. Finally, imputed datasets for each predictor 
were pooled together using Rubin's rule and followed by the intended regression or 
survival analyses. 
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4 Chapter 4   Determinants of outcomes after PCI for UPLMS 
 
 
 
 
4.1 Summary 
In the previous three chapters, clinical background, literature reviews, data 
discerption and overall methodologies were illustrated (Chapters 1, 2 and 3). This 
chapter concerns an analysis using the 2010 BCIS data to answer one of the questions 
regarding the care provided to the patients who received PCI in the UK; the clinical 
determinants of outcomes in patients with UPLMS. Brief definitions of the types of 
clinical presentation of patients with coronary artery disease as well as a full 
introduction to UPLMS PCI were described in Chapter 1 (sections 1.2.1, 1.2.4 and 
1.2.5). A literature review regarding ‘the clinical determinants and temporal trends of 
outcomes for PCI in UPLMS disease’ was provided in Chapter 2 (section 2.4). This 
chapter is split into five sections covering: the background, rationale and aims (section 
4.2), methodology including study design, population, stratification, definitions, follow-
up as well as statistical and sensitivity analyses (section 4.3), results including 
completeness, descriptive statistics, survival time, multivariate modelling results and 
sensitivity results (section 4.4) and discussion and conclusion (section 4.5). 
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4.2 Introduction 
 
4.2.1  Background and rationale 
In contemporary practice, PCI has become an alternative strategy to CABG in 
patients who have UPLMS, particularly in those deemed at high risk for surgery [176], 
even though, repeat revascularisation procedures are increased with LMS disease PCI 
compared to CABG [23].  Notably, higher rates of success are not confined to chronic 
stable angina patients, and favourable outcomes have been reported in emergency cases 
when CABG is often contraindicated [24, 25, 28].  Yet, for patients who receive PCI for 
disease of the UPLMS, there is a paucity of data that measures outcomes in unselected 
patients on a large scale, and in a consecutive series.  
For UPLMS, a variety of clinical risk factors or determinants (such as old age, 
cardiogenic shock, diabetes and renal failure) have an impact on the outcomes of most 
PCI procedures. These determinants are believed to be less common among elective 
patients compared to those with acute onset [25-27]. Furthermore, unless it is not 
contraindicated; CABG is the recommended line of management and PCI procedures 
for UPLMS are usually the choice of treatment in patients with contra-indications; 
therefore, affecting its success further [19, 26, 28]. Additionally, there is a gap in the 
knowledge base regarding the relative merits of PCI to an UPLMS culprit lesion in 
patients who present with ST-elevation myocardial infarction (STEMI) or non ST-
elevation acute coronary syndrome (NSTEACS) [29]. 
In the literature, data relating to UPLMS patients with cardiogenic shock are 
very limited and early outcomes reported in only small cohort studies. Likewise, current 
international guidelines recommend the radial access to PCI over that of the femoral 
[35, 87, 110]. However, additional evaluation of the wider implications of radial access 
on the outcomes in UPLMS after PCIs is necessary.  
There is, therefore, value in reporting contemporary and representative outcome 
data for PCI to the UPLMS  in order  to inform patients, healthcare professionals and 
regulators of both the benefits and inherent risks of such therapy, and also to highlight 
areas where novel interventions aimed at improving outcomes may be targeted [25, 31, 
42, 45-48]. 
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4.2.2 Aims  
The overall rationale and aims of the thesis were outlined in Chapter 2 (section 
2.6). The primary aim of this chapter was to perform a population-based comparative 
investigation into the clinical outcomes of patients who received PCI to UPLMS 
according to clinical syndrome at presentation over a period of six years (from January 
1, 2005 to December 31, 2010): 
 
1. To report the overall completeness of the 2010 BCIS data for all patients with 
UPLMS. 
2. To describe demographic and clinical characteristics of patients by clinical 
presentation. 
3. To describe the procedural characteristics of patients by clinical presentation. 
4. To describe the outcomes and survival for patients with UPLMS after PCI by 
clinical presentation. 
5. To identify the clinical determinants of PCI outcomes in patients with UPLMS 
and to measure their level of association by clinical presentation. 
6. To quantify the impact of cardiogenic shock on the clinical outcomes of patients 
by clinical presentation. 
7. To report the impact of the radial versus femoral access approach on the clinical 
outcomes of patients by clinical presentation. 
 
 
4.3 Methodology 
4.3.1 Study setting and design 
The study design was a prospective population based linked cohort study using 
data of patients having PCI to an UPLMS from 89 interventional cardiology centres and 
hospitals in England and Wales registered with the BCIS audit program between 2005 
and 2010 (based on BCIS Audit Returns, Adult Interventional Procedures, January 2010 
to December 2010) [20]. 
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4.3.2 Patients, procedures and treatments (study population) 
Although BCIS collects data from all countries in the UK, robust mortality 
tracking was only available for patients who live in England and Wales; this represents 
approximately 89% of the whole adult UK population (based on the Office for National 
Statistics UK population estimates for 2013) [82]. Thus, the sampling frame comprised 
all patients in England and Wales.  
In the 2010 BCIS dataset, the total number of consecutive patients who attended 
for PCI in England and Wales between the 1st of January, 2005 and the 31st of 
December, 2010 was 411,324 patients. Out of these, eligible patients for the UPLMS 
analyses were; patients aged 18 years or more who had received PCI to a diseased 
UPLMS over the six year period (from 2005 to 2010). For those with multiple 
admissions, the earliest intervention record was used.  
Furthermore, in order to specifically select the appropriate analytical cohort 
population, an inclusion and exclusion criteria was identified (based on the Delphi 
group clinical agreement): 
• Firstly, patients who had no vessels attempted or missing information about that 
were excluded. In the same way, those who had no lesions attempted or missing 
information about that were also excluded. The remaining number of PCI 
patients was 382,017.   
• Secondly, 10,410 patients were included as they were drawn from those who 
had the left main stem as the treated vessel. Simultaneously, 371,607 patients 
who received PCI for disease of other vessels were excluded.  
• Thirdly, patients with a history of previous CABG, missing information on that 
or who had any number of grafts present pre-procedure were excluded. At the 
same time, patients with an UPLMS were defined as those who did not have a 
patent graft to any left sided coronary artery [20]. Therefore, 5,223 patients were 
included as they received PCI for UPLMS.  
•Finally, 153 patients with missing records for their clinical presentation and 
another 5 patients with mismatched date records for procedure and census were 
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excluded. Thus, the final population included was 5,065 patients. A detailed flow 
chart of the selected cohort population is shown in Figure 4.1.  
Figure 4.1: Flow chart of the selected cohort population. 
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4.3.3 Stratification of cohort population  
According to the mode of clinical presentation of UPLMS patients who were 
treated by PCI, the whole analysis of this chapter was divided into three main strata: 
• ST-elevation myocardial infarction (STEMI). 
• Non ST-elevation acute coronary syndrome (NSTEACS). 
• Chronic stable angina (CSA). 
This stratification was selected and agreed by the Delphi group based on the 
results from the literature review in order to compare and understand the difference 
between these three groups of patients. The clinical definition of each stratum was 
described previously in Chapter 1 (section 1.2). The definitions from the BCIS database 
spreadsheet version 5.6.x are shown in Table 4.1.  
 
 
 
 
 
Table 4.1: Clinical presentation strata definitions from on the BCIS database 
spread sheet version 5.6.x. 
CSA 
Stable - angina Stable patients off waiting list with symptomatic or silent ischaemia. 
Stable - coronary/LV anatomy Stable patients off waiting list without angina because PCI 
believed to offer prognostic benefit or would improve ventricular function to include PCI for 
arrhythmia. 
NSTEACS ACS - PCI for NSTEMI Acute coronary syndrome with or without enzyme release and a history typical of acute myocardial infarction. 
STEMI 
ACS - Primary PCI for STEMI (no lysis) Emergency PCI for acute STEMI, no thrombolysis 
given. Includes patients presenting with a clear history of AMI and LBBB. 
ACS - Facilitated PCI for STEMI (lysis + PCI) Emergency PCI performed in the acute setting 
as soon as possible after thrombolysis for acute STEMI (or new LBBB) with a clear history of 
AMI, provided as a routine treatment in addition to thrombolysis. 
ACS - Rescue PCI for STEMI (failed lysis) Emergency PCI for acute STEMI for failed 
thrombolysis - defined as failure of the ST segment to fall by 50% or more in the ECG lead 
showing the greatest ST elevation prior to thrombolysis, 1-3 hours after starting thrombolysis. 
ACS - PCI for reinfarction (no lysis) Emergency PCI for acute STEMI for reinfarction in the 
same territory as the admission infarct, but no thrombolysis given for the new event. 
ACS - Rescue PCI for reinfarction (failed lysis) Emergency PCI for acute STEMI for 
reinfarction in the same territory as admission infarct, when thrombolysis for the new event has 
failed. 
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4.3.4 Definitions  
The consensus document of the Joint European Society of Cardiology / 
American College of Cardiology was used as the diagnostic standard for acute 
myocardial infarction (AMI) and provided the basis for categorisation by the local 
supervising cardiologist into STEMI and NSTEACS, according to the clinical 
presentation, electrocardiogram and troponin level where appropriate [177, 178].  
The STEMI group included patients receiving primary PCI, rescue PCI, PCI for 
re-infarction and facilitated PCI for STEMI. Percutaneous coronary intervention was 
defined as a procedure that has been performed using any coronary device approaches, 
probes or crosses one or more coronary lesions, with the intention of carrying out a 
coronary intervention [81]. 
Cardiogenic shock was defined as a systolic blood pressure less than 100 mmHg 
and pulse greater than 100 bpm in a patient who was peripherally shut down and/or who 
required inotropes, an intra-aortic balloon pump or cardiopulmonary support for 
circulation [81]. Major Adverse Cardiac and Cerebrovascular Events (MACCE) were 
defined as a group of complications or events that occurred in-hospital after an 
intervention. MACCE included stroke, heart attack, need for emergency coronary 
bypass surgery or death. 
 
4.3.5 Follow-up and mortality  
Detailed information regarding patients’ follow up and morality can be found in 
Chapter 1 (section 1.4.3 and Figure 1.3). However in short, the analysis of all-cause 
mortality was performed by the MRIS by linkage with the ONS using each patient’s 
unique NHS number. Subsequently, using each patient’s geographical residence and 
IMD score; a linkage that was made by the CCAD to their corresponding BCIS record.  
Patients, interventionists or hospitals identifiers were secondary anonymised in 
the 2010 versions of the BCIS database that we received. Due to the date of linkage for 
censored data (10th August 2011), mortality data at 1-year were not available for 519 
(10.2%) patients. Therefore, patients with a follow-up period of less than 12 months 
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were excluded from the analysis of 1-year mortality rate; however those patients were 
included in all other parts of the analysis. 
 
4.3.6 Statistical analysis 
4.3.6.1 Descriptive data analysis 
Initially, a descriptive analysis for the overall cohort was performed to gain a 
better understanding of patients’ characteristics followed by a detailed description of the 
extent of missing data in the cohort. The exploration of data that was missing included 
all the variables in the 2010 BCIS database. Later, missing data patterns were measured 
and assessed based on the percentage of missing data. 
As mentioned previously, the whole analysis was stratified by the mode of clinical 
presentation of UPLMS patients (CSA, STEMI and NSTEACS). The aim of this 
stratification was to compare the differences between stable and acute patients. It is 
believed that acute patients are liable to more clinical risk factors, such as cardiogenic 
shock, that have an obvious impact on PCI outcomes [48, 51, 52]. Types of tests and 
methods used for data description have been outline previously in detail in Chapter 3 
(section 3.5). 
The described characteristics included baseline demographics, clinical features, 
pre-procedural, procedural and post-procedural characteristics as well as clinical 
outcomes. The clinical outcomes of intention included: 
• Procedural complications such as side branch occlusion, coronary dissection, 
the need for ventilation and cardiogenic shock. 
• In-hospital outcomes such as acute myocardial infarction, renal failure, blood 
transfusion, revascularisation and MACCE. 
• Mortality rate at 30 days and at one year. 
 
 
4.3.6.2 Survival curves 
Cumulative unadjusted survival estimates of patients with UPLMS disease who 
received PCI were depicted using the Kaplan-Meier method from the time of the 
procedure to 6.6 years. The differences across strata were compared using the Mantel-
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Cox log-rank test. The same analysis was repeated to compare the differences between 
patients with and without cardiogenic shock in STEMI and NSTEACS groups.  
 
4.3.6.3 Adjusted in-hospital MACCE  
Adjustment for in-hospital MACCE (predicted MACCE) was undertaken using 
the factors age, female sex, procedure urgency, procedure emergency cardiogenic 
shock, left main stem PCI, graft PCI, history of a stroke and the corresponding 
published coefficients from the North West Quality Improvement Project (NWQIP) risk 
model [179]. The adjustment was simply performed by generating a new variable using 
the following Stata commands: 
• gen Predicted_MACCE = (-5.4959 + [age 71 to 79 years * 0.7048] + [age 80 
years and more * 1.0106] + [female sex * 0.4586] + [procedure urgency * 
0.4788] + [procedure emergency * 1.3625] + [cardiogenic shock * 
3.2636001]+ [left main stem PCI * 1.6502] + [graft PCI * 0.9101] + 
[history of a stroke * 0.8618]) 
• replace  Predicted_MACCE = Predicted_MACCE^2 
 
 
4.3.6.4 Multivariate regression modelling 
All clinical outcomes were analysed without adjustment apart from the predicted 
in-hospital MACCE, 30-day mortality and 1-year mortality which was analysed with 
adjustment (multivariate logistic regression). The associations between the clinical 
determinants and the predicted MACCE, 30-day and 1-year mortality were quantified 
using fixed effects multivariate logistic models and estimates were expressed as 
adjusted odds ratios (aOR) with 95% confidence intervals (CI).  
The first regression model aimed to measure the association between the clinical 
outcomes (predicted in-hospital MACCE, 30-day mortality and 1-year mortality) and 
the mode of clinical presentation. The adjusted estimate of each of the three models 
were standardised for age groups, sex, history of diabetes mellitus, history of renal 
disease, post-procedural complications (side branch occlusion, coronary dissection and 
shock induced by procedure) and the mode of clinical presentation.  
For 30-day and 1-year mortality rates, each model estimate was adjusted using 
covariates selected after a literature review on ‘the clinical determinants and temporal 
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trends of outcomes for PCI in UPLMS disease’, see Chapter 2 (section 2.4). 
Furthermore, based on the clinical significance recommended by the Delphi group for 
each clinical determinant (predictor), the estimates of the multivariate logistic 
regression model were adjusted by different covariates. The selected predictors are 
listed by clinical presentation and mortality outcomes in Table 4.2. Multivariate model 
selection process, interaction assessment and the evaluation of goodness of fit were 
outlined in detail in Chapter 3 (section 3.4.6.5). 
 
 
 
 
Table 4.2: Summary of the multivariate logistic models used including the selected 
predictor variables and covariates, by clinical presentation and mortality 
outcomes. 
Clinical presentation, 
outcome and method Predictors Covariates 
30-day mortality and 1-
year mortality using 
fixed effects 
multivariate logistic 
regression model in 
patients with UPLMS 
who underwent PCI 
(CSA patients) 
Age groups 
Age groups, sex, 
history of diabetes 
mellitus, history of 
renal disease and post-
procedural 
complications (side 
branch occlusion, 
coronary dissection 
and shock induced by 
procedure) 
Sex 
History of diabetes mellitus 
History of renal disease 
Procedural complications 
History of acute myocardial infarction 
History of percutaneous coronary intervention 
Left ventricular ejection fraction 
Vessels attempted 
Number of stents used 
Drugs used during procedure 
Intravascular ultrasound use during procedure 
Use of intra-aortic balloon pump 
Arterial access 
Longest stented/treated segment 
In-hospital acute myocardial infarction & stroke 
30-day mortality and 1-
year mortality using 
fixed effects 
multivariate logistic 
regression model in 
patients with UPLMS 
who underwent PCI 
(STEMI and NSTEACS 
patients) 
Age groups 
Age groups, sex, pre-
procedural cardiogenic 
shock, history of 
diabetes mellitus, 
history of renal disease 
and post-procedural 
complications (side 
branch occlusion, 
coronary dissection 
and shock induced by 
procedure) 
Sex 
Pre-procedural cardiogenic shock 
History of diabetes mellitus 
History of renal disease 
Procedural complications 
History of acute myocardial infarction 
History of percutaneous coronary intervention 
Left ventricular ejection fraction 
Vessels attempted 
Number of stents used 
Drugs used during procedure 
Intravascular ultrasound use during procedure 
Use of intra-aortic balloon pump 
Arterial access 
Longest stented/treated segment 
In-hospital acute myocardial infarction & stroke 
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4.3.7 Sensitivity analyses  
A series of sensitivity analyses were performed in order to assess potential bias 
from the fixed effect regression methods used. First, the impact of mixed effects models 
(multi-level logistic regression models) was evaluated. Second, multivariate logistic 
regression analyses were considered after multiple imputation.  
 
4.3.7.1 Multi-level regression modelling 
Models were fitted with a hierarchy of patients clustered in each hospital using 
random intercepts for hospitals thus allowing for correlations between patient outcomes. 
Therefore, the mixed effects models accounted for the variance in the predictor 
variables as well as the variance in the hospitals level [133].  More explanation on the 
methods of multi-level regression modelling can be found in Chapter 3 (section 3.5.1.5). 
Similar to the fixed effect multivariate logistic regression models, the same 
outcomes (predicted in-hospital MACCE, 30-day mortality and 1-year mortality), 
predictor variables and adjustment covariates (Table 4.2) were fitted in the mixed effect 
models. Subsequently, estimates were compared with those from equivalent fixed 
effects models.  
 
4.3.7.2 Multiple imputation method 
In total 24 imputation predictors were selected based on clinical consensus and a 
literature review, Chapter 2 (section 2.4) [26, 30, 31, 45, 48, 94, 97, 104]. More details 
on general methods of multiple imputation were presented in Chapter 3 (sections 3.5.2 
and 3.5.3). Table 4.3 displays the list of imputation predictor variables of the outcomes 
of patients with UPLMS who had PCI with a summary of missing data and the methods 
used for imputation. 
The frequency of missing values ranged from 0.06% to 35.50% and all missing 
values were assumed to be missing at random. No data were missing for five of these 
variables ‘clinical presentation’, ‘cardiogenic shock’, ‘year of operation’, ’30-day 
mortality’ and ‘1-year mortality’. Yet, these variables were still used as auxiliary 
variables in the imputation for the remaining 19 variables.  Two other variables, ‘largest 
balloon/stent’ and ‘longest stented segment’, were not imputed or even included in the 
predictor matrix due to collinearity.  
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A predictor matrix was designed based on clinical judgement as well as using 
thresholded P values of less than 0.05 as related and greater than or equal to 0.05 as 
unrelated. The predictor matrix is shown in Table 4.4. For continuous-continuous and 
continuous-categorical associations, linear regression was used. While for categorical-
categorical, Chi-squared test was used. For each of the 19 predictors with missing 
values, 20 datasets were imputed using the chained equation method and the fully 
conditional specification imputation method [141, 153, 180].  
All 19 variables were categorical and were all imputed using either logistic 
regression (if binary) or polytomous regression (if ordinal). For each of STEMI, 
NSTEACS and CSA, 20 separate imputation datasets were created for 30-day mortality 
and then 20 others for 1-year mortality. Finally, imputed datasets for each predictor 
were pooled together using Rubin's rule and followed by the intended regressions. The 
adjusted estimates from both complete case and multiple imputation data were 
compared in order to test for the sensitivity of this analyses. 
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Table 4.3: Imputation predictor variables of the outcomes of patients with UPLMS who PCI with a summary of missing data and 
the methods used for imputation. 
Variables Variable type Missing % Imputation method 
1 Age groups Ordinal 0.06 Polytomous regression 
2 Sex Binary 1.09 logistic regression 
3 Clinical presentation Ordinal 0.00 Auxiliary (not imputed) 
4 Pre-procedural cardiogenic shock Binary 0.00 Auxiliary (not imputed) 
5 History of acute myocardial infarction Binary 13.58 logistic regression 
6 History of percutaneous coronary intervention Binary 1.40 logistic regression 
7 History of diabetes mellitus Binary 5.19 logistic regression 
8 Left ventricular ejection fraction Ordinal 35.50 Polytomous regression 
9 Year of operation Continuous 0.00 Auxiliary (not imputed) 
10 Major adverse cardiac and cerebrovascular event Binary 5.77 logistic regression 
11 History of renal disease Binary 7.82 logistic regression 
12 Vessels attempted Binary 0.59 logistic regression 
13 Procedural complication: Side branch occlusion Binary 10.11 logistic regression 
14 Procedural complication:  Coronary dissection Binary 10.11 logistic regression 
15 Procedural complication: No flow / slow flow  Binary 10.11 logistic regression 
16 Procedural complication: Shock induced by procedure Binary 10.11 logistic regression 
17 Number stents used Ordinal 0.43 Polytomous regression 
18 Stent type Ordinal 3.51 Polytomous regression 
19 Drugs used during procedure Ordinal 5.88 Polytomous regression 
20 Intravascular ultrasound use during procedure Binary 13.35 logistic regression 
21 Use of intra-aortic balloon pump Binary 6.36 logistic regression 
22 Arterial access Ordinal 1.68 Polytomous regression 
23 30-day mortality Binary 0.00 Auxiliary (not imputed) 
24 1-year mortality Binary 0.00 Auxiliary (not imputed) 
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Table 4.4: Predictor matrix of the outcomes of patients with UPLMS who received PCI using the 2010 BCIS database. 
Variables 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
1 Age                                                 
2 Sex 1                                               
3 Clinical presentation 1 1                                             
4 Pre-procedural cardiogenic shock 1 0 1                                           
5 History of Acute myocardial infarction 1 0 1 1                                         
6 History of Percutaneous coronary intervention 1 0 1 1 1                                       
7 History of Diabetes mellitus 1 0 1 1 1 1                                     
8 Left ventricular ejection fraction 1 0 1 1 1 1 1                                   
9 Year of operation 1 0 0 1 0 1 0 0                                 
10 Major adverse cardiac and cerebrovascular event 1 1 1 1 0 1 0 1 0                               
11 History of Renal disease 1 1 1 1 1 0 1 1 1 1                             
12 Vessels attempted 1 1 1 0 1 0 1 1 0 1 1                           
13 P-complication: side branch occlusion 1 0 0 0 0 0 0 0 0 1 0 0                         
14 P-complication: coronary dissection 0 1 0 0 1 0 0 0 0 1 0 1 1                       
15 P-complication: no / slow flow phenomenon 0 1 1 1 1 0 0 1 0 1 0 0 1 1                     
16 P-complication: shock induced by procedure 0 0 1 1 0 0 0 1 0 1 0 1 1 1 1                   
17 Number of stents used 1 0 1 1 1 1 0 1 1 1 1 1 1 1 0 0                 
18 Stent Type 1 0 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1               
19 Drugs used during procedure 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1             
20 Intravascular ultrasound use during procedure 1 0 1 1 0 1 0 1 1 1 0 0 0 1 1 1 1 1 1           
21 Use of intra-aortic balloon pump 1 0 1 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1         
22 Arterial access 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 1 1       
23 30-day mortality 1 0 1 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1     
24 1-year mortality 1 1 1 1 1 0 1 1 1 1 1 1 0 0 1 1 1 1 0 1 1 0 1   
0: not related, 1: related, P-complication: procedural complication. 
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4.4 Results 
Across 89 (78.1%) hospitals in England and Wales, a total of 10,410 patients 
received PCI to a left main stem from 2005 to 2010. Of these 5,065 (48.7%) had PCI to 
UPLMS met all eligibility criteria (Figure 4.1). There were 784 (15.5%) patients with 
STEMI, 2,381 (47.0%) with NSTEACS and 1,900 (37.5%) with CSA (Figure 4.2). 
 
 
Figure 4.2: Frequency of patients with UPLMS who received PCI by clinical 
presentation. 
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4.4.1 Data completeness 
A total of 103 variables were used in this analysis, 13 (12.6%) variables were 
100% complete. These variables were ‘clinical presentation type’, ‘indication for 
intervention’, ‘pre-procedure cardiogenic shock’, ‘previous CABG’, ‘number of grafts 
present pre-PCI’, ‘number of grafts patent pre-PCI’, ‘date of operation’, ‘number of 
vessels attempted not Epicardial’, ‘7-day mortality’ ‘30-day mortality’, ‘180-day 
mortality’, ‘1-year mortality’ and ‘predicted MACCE NQWIP risks’.  
Conversely, the remaining 90 variables had missing information that ranged 
between 0.02% and 96.84%. The one with the least missing values was ‘number of 
lesions attempted’ (0.02%) followed by ‘age at procedure’ (0.04%). The highest 
missingness was in ‘date of electrocardiography triggering (primary PCI)’ (96.84%). In 
total, 31 (30.1%) variables had less than 10% missing values, 50 (48.5%) had missing 
values from 10 to 50%, five (4.9%) had missing values from more than 50 to 90% and 
four (3.9%) had missing values of more than 90%. The variable with the greatest 
missingness was ‘date of electrocardiography triggering’, (96.84%), ‘patient location at 
time of STEMI onset (94.39%), ‘creatinine level’ (95.76%) and ‘third operator status’ 
(94.47%). 
The mean (SD) level of values missing was 19.05% (23.98%) and the median 
percentage of missing values was 11.96%.The frequency and percentages of values 
missing in the variables of UPLMS cohort from the 2010 BCIS data are shown in Table 
4.5.  
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Table 4.5: Recoded variables and summary of missing data in the variables of 
UPLMS cohort from the 2010 BCIS data. 
Variable Name Missing Frequency Missing % 
Age At Procedure 3 0.06 
Sex 55 1.09 
Ethnic Group 1,760 34.75 
Patient Status 345 6.81 
Clinical presentation type 0 0.00 
Indication for Intervention 0 0.00 
Procedure Urgency 4 0.08 
Cardiogenic Shock Pre-PCI 0 0.00 
Angina Status Pre-Surgery 1,815 35.83 
Dyspnoea Status Pre-PCI (Stable Only) 301 15.84 
Date Symptom Onset PCI (ACS Only) 874 27.61 
Date Arrival At Hospital (ACS Only) 945 29.86 
Admission Route (ACS Only) 355 11.22 
Presenting electrocardiography (ACS Only) 632 19.97 
Recent Lysis (ACS Only) 408 12.89 
Cardiac Enzymes/Markers Raised (ACS Only) 945 29.86 
Previous acute myocardial infarction 688 13.58 
Previous coronary artery bypass graft (CABG) 0 0.00 
Previous percutaneous coronary intervention (PCI) 71 1.40 
Diabetes 263 5.19 
Height 2,327 45.94 
Weight 2,058 40.63 
Left Ventricular Ejection Fraction Category 1,798 35.50 
Left Ventricular Ejection Fraction 3,859 76.19 
Number of Grafts Present Pre-PCI, CABG Only 0 0.00 
Number of Grafts Patent Pre- PCI, CABG Only 0 0.00 
Left Main Stem Stenosis Pre-PCI 548 10.82 
Left anterior descending Proximal Stenosis Pre-PCI 823 16.25 
Left anterior descending Other Stenosis Pre-PCI 949 18.74 
Right coronary artery Stenosis Pre-PCI 954 18.84 
Circumflex coronary artery Stenosis Pre-PCI 882 17.41 
Flow In infarct related artery Pre-PCI (ACS Only) 3,257 64.30 
Pseudonymised First Operator Status 165 3.26 
Primary Operator 202 3.99 
Second Operator Status 1,722 34.00 
Third Operator Status 4,785 94.47 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data) 
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(Continued) Table 4.5: Recoded variables and summary of missing data in the 
variables of UPLMS cohort from the 2010 BCIS data. 
Variable Name Missing Frequency Missing % 
Date of Operation 0 0.00 
Vessels Attempted 30 0.59 
Number of vessels attempted not Epicardial 
T it i  
0 0.00 
Number Of Lesions Attempted 1 0.02 
Number Of Chronic Occlusions Attempted 306 6.04 
Number Restenosis Attempted 290 5.73 
Number Instant Stenosis Attempted 793 15.66 
Number Stents Used 22 0.43 
Number Drug-Eluting Stents Used 173 3.42 
Type of stent used 178 3.51 
Drugs Eluted By Stents 558 11.02 
Drugs Used During Procedure 298 5.88 
Intravascular ultrasound use during procedure 676 13.35 
pressure wire use during procedure 676 13.35 
Use of intra-aortic balloon pump 322 6.36 
Left Main Stem Stenosis Post-PCI 606 11.96 
Left anterior descending Proximal Stenosis Post-PCI 915 18.07 
Left anterior descending Other Stenosis Post-PCI 1,046 20.65 
Right coronary artery Stenosis PCI 1,076 21.24 
Circumflex coronary artery Stenosis PCI 970 19.15 
Number Lesions Successful 119 2.35 
Number Coronary Grafts Patent PostOp 1,993 39.35 
Flow In infarct related artery PostOp (ACS only) 1,378 43.54 
Device Failure 687 13.56 
PCI Hospital Outcome: No Complications 777 15.34 
PCI Hospital Outcome: AMI or CVA 711 14.04 
PCI Hospital Outcome: Renal disease 742 14.65 
PCI Hospital Outcome: MACCEs 292 5.77 
PCI Hospital Outcome: Revascularisation 292 5.77 
Enzymes Post-PCI 3,863 76.27 
Status At Discharge 156 3.08 
Discharge Date 435 8.59 
Cholesterol 3,833 75.68 
Smoking Status 769 15.18 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data) 
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(Continued) Table 4.5: Recoded variables and summary of missing data in the 
variables of UPLMS cohort from the 2010 BCIS data. 
Variable Name Missing Frequency Missing % 
Family History Of coronary artery disease 996 19.66 
Date of 1st Balloon Inflation PCI (ACS) Only) 1,448 45.75 
History Of Renal Disease 396 7.82 
Ventilated Pre-PCI 731 14.43 
Q Wave On electrocardiography 983 19.41 
Electrocardiography Ischaemia 817 16.13 
Drug Therapy Pre-PCI 250 4.94 
Follow On AdHoc Procedure 286 5.65 
Why No IIb/IIIA During Procedure 1,412 27.88 
Indication For Stent 579 11.43 
Surgical Cover 751 14.83 
Left Main Stem Protected 0 0.00 
Date of electrocardiography Triggering (primary PCI) 613 96.84 
Patient Location at Time of STEMI Onset (STEMI) 740 94.39 
Creatinine 4,850 95.76 
Training Procedure 474 9.36 
Research Procedure 513 10.13 
Arterial Access 85 1.68 
Largest Balloon/Stent Used 819 16.17 
Longest Stented/Treated Segment 811 16.01 
Procedural Complication 512 10.11 
Patient Status During Transfer To Theatre 1,310 25.86 
Call For Help Date 4,194 82.80 
Pseudonymised Hospital Code 5 0.10 
Life Status 300 5.92 
Date Of Death Or Census Date 300 5.92 
Days between operation & census 300 5.92 
7-day mortality 0 0.00 
30-day mortality 0 0.00 
180-day mortality  0 0.00 
1-year mortality 0 0.00 
Index of Multiple Deprivation Score  2,029 40.06 
Predicted MACCE NQWIP Risks 0 0.00 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data)
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4.4.2 Baseline demographic characteristics 
The mean (SD) age of the UPLMS who received PCI in England and Wales was 
70.2 (12.3) years; which was 67.3 (13.7) years for STEMI patients, 72.2 (12.1) years for 
NSTEACS and 68.9 (11.3) years for those with CSA (P <0.001). There were 3,483 
(69.5%) males and 1,527 (30.5%) females. In all three groups, there was a 
preponderance of male gender (STEMI: 568 (72.8%), NSTEACS: 1,368 (87.9%) and 
CSA: 1,036 (86.2%) (P <0.001)), and Caucasian ethnicity (STEMI: 484 (88.5%), 
NSTEACS: 1,565 (66.3%) and 1,350 (72.2%) (P =0.770)).  
Private patients were more frequent in CSA patients, whereas NHS patients 
were the majority in all three groups; NHS (STEMI: 712 (99.0%), NSTEACS: 2,191 
(98.5%) and CSA: 1,611 (90.8%)) and private (STEMI: 7 (1.0%), NSTEACS: 32 
(1.5%) and CSA: 163 (9.2%)) (P <0.001). Most of the STEMI patients were admitted 
directly to the cardiac centre or hospital, 448 (60.0%). Then again, 1,067 (51.7%) 
NSTEACS patients were treated after being transferred from another hospital (P 
<0.001). The overall mean (SD) of index of multiple deprivation score was 21.4 (13.9). 
Table 4.6 shows the distribution of baseline demographic characteristics of patients with 
UPLMS disease who received PCI, by clinical presentation.  
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Table 4.6: Baseline demographic characteristics of patients with UPLMS disease who received PCI, by clinical presentation. 
Variable 
CSA  
n=1900 
STEMI  
n=784 
NSTEACS  
n=2381 
P value * 
Mean (SD) age, years  68.9 (11.3) 67.3 (13.7) 72.2 (12.1) <0.001 
Age 
Less than 65 years (%) 676/1,900 (35.6) 331/782 (42.3) 626/2,380 (26.3) 
<0.001 65 - 80 years (%) 890/1,900 (46.8) 294/782 (37.6) 1,014/2,380 (42.6) 
More than 80 years (%) 334/1,900 (17.6) 157/782 (20.1) 740/2,380 (31.1) 
Gender 
Female (%) 519/1,869 (27.8) 212/780 (27.2) 796/2,361 (33.7) 
<0.001 
Male (%) 1,350/1,869 (72.2) 568/780 (72.8) 1,565/2,361 (66.3) 
Ethnic groups 
Caucasian (%) 1,036/1,202 (86.2) 484/547 (88.5) 1,368/1,556 (87.9) 
0.770 
Black (%) 11/1,202 (0.9) 4/547 (0.7) 9/1,556 (0.6) 
Asian (%) 66/1,202 (5.5) 28/547 (5.1) 82/1,556 (5.3) 
Other (%) 89/1,202 (7.4) 31/547 (5.7) 97/1,556 (6.2) 
Patient type 
NHS hospital or centre (%) 1,611/1774 (90.8) 713/720 (99.0) 2,191/2,223 (98.5) 
<0.001 
Private hospital or centre (%) 163/1774 (9.2) 7/720 (1.0) 32/2,223 (1.5) 
Admission route  
(ACS only) (%) 
Direct to cardiac centre --- 448/747 (60.0) 629/2,063 (30.5) 
<0.001 Inter-hospital transfer --- 231/747 (30.9) 1,067/2,063 (51.7) 
Already in cardiac centre --- 68/747 (9.1) 367/2,063 (17.8) 
Index of multiple deprivation score, mean (SD) 20.1 (13.2) 23.9 (14.8) 21.8 (14.0) <0.001 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
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4.4.3 Clinical characteristics 
Diabetes mellitus, a family history of coronary artery disease, previous PCI and 
previous acute myocardial infarction were less frequent in STEMI (all P <0.001). A 
history of chronic renal failure was more frequent in patients with NSTEACS (STEMI: 
30 (4.4%), NSTEACS: 216 (9.8%) and CSA: 80 (4.5%) (P <0.001)). Current smokers 
were more common in STEMI patients (STEMI: 221 (34.0%), NSTEACS: 358 (17.8%) 
and CSA: 162 (9.9%) (P <0.001)).  
In total, 323 (41.2%) STEMI and 222 (9.3%) NSTEACS presented with 
cardiogenic shock (P <0.001).  The proportion of missing data for severe left ventricular 
systolic dysfunction was 35.5%, reflecting the lack of a left ventricular angiogram or 
urgent echocardiogram in the acute setting at the time when the procedural part of the 
database was completed. 
Recent thrombolysis was more frequent in patients with STEMI (STEMI: 105 
(14.3%) and NSTEACS: 123 (6.1%) (P <0.001)).  Overall, the frequency of severe left 
ventricular systolic dysfunction, defined as a left ventricular ejection fraction less than 
30%, was 584 (17.9%), and was present in 148 (44.3%) cases of STEMI. The 
distribution of the clinical characteristics of patients with UPLMS who received PCI 
stratified by clinical presentation can be seen in more detail in Table 4.7. 
 
  
 
113 
 
Table 4.7: Baseline clinical characteristics of patients with UPLMS disease who received PCI, by clinical presentation. 
Variable 
CSA 
n=1900 
STEMI 
n=784 
NSTEACS 
n=2381 
P value * 
Previous acute myocardial infarction (%) 482/1,637 (29.4) 130/694 (18.7) 823/2,046 (40.2) <0.001 
Previous percutaneous coronary intervention (%) 539/1,892 (28.5) 73/764 (9.6) 429/2,338 (18.4) <0.001 
Family history of coronary artery disease (%) 803/1,560 (51.5) 220/594 (37.1) 845/1,915 (44.1) <0.001 
Diabetes mellitus (%) 359/1,805 (19.9) 111/736 (15.1) 519/2,261 (23.0) <0.001 
History of renal disease (%) 80/1,774 (4.5) 30/690 (4.4) 216/2,205 (9.8) <0.001 
Smoking status 
Never smoked (%) 622/1,637 (38.0) 231/650 (35.5) 670/2,009 (33.6) 
<0.001 Ex-smoker (%) 853/1,637 (52.1) 198/650 (30.5) 981/2,009 (48.8) 
Current smoker (%) 162/1,637 (9.9) 221/650 (34.0) 358/2,009 (17.8) 
Recent thrombolysis (ACS only) (%) --- 105/733 (14.3) 123/2,024 (6.1) <0.001 
Cardiogenic shock (%) --- 323/784 (41.2) 222/2,381 (9.3) <0.001 
Severe left ventricular systolic dysfunction (%) 118/1,298 (9.1) 148/334 (44.3) 318/1,635 (19.5) <0.001 
Raised cardiac enzymes (%) --- 297/378 (78.6) 1,434/1,842 (77.9) <0.001 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
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4.4.4 Procedural characteristics 
Tables 4.8 shows the distribution of baseline pre-procedural, procedural and 
post-procedural characteristics by strata of clinical presentation. Pre-procedural TIMI 3 
was more common in NSTEACS patients (STEMI: 117 (17.6%) and NSTEACS: 451 
(70.9%) (P <0.001)). Left main stem stenosis of more than or equal to 50% and the use 
of ventilation prior to PCI procedures were more frequent in STEMI (all P <0.001).  
The femoral approach was more frequent than the radial (STEMI: 526 (68.5%) 
vs. 231 (30.1%), NSTEACS: 1,497 (63.7%) vs. 791 (33.7%) (P =0.057)), the former 
occurring more frequently in STEMI and NSTEACS complicated by cardiogenic shock 
(255 (80.7%) and 167 (75.6%), respectively). Multi-vessel PCI was frequent in each 
stratum (STEMI: 595 (76.2%), NSTEACS: 1,722 (72.6%) and CSA: 1,314 (69.8%) (P 
=0.003)).  
Drug eluting stents were deployed in 450 (59.4%) STEMI, 1,644 (71.1%) 
NSTEACS and 1,414 (77.8%) CSA. When bare metal stents were used, they were 
deployed more frequently in STEMI (STEMI: 271 (35.8%), NSTEACS: 576 (24.9%), 
CSA: 249 (13.7%) (P <0.001). Of all stents, Taxus liberte were used most often, in 925 
(18.3%) patients (STEMI: 82 (11.3%), NSTEACS: 447 (21.4%) and CSA: 396 (21.8%) 
(P <0.001). The second most common type of stent was Xience V in 464 (9.2%) 
patients.  
An intravascular ultrasound (IVUS) was used more frequently in elective than 
emergency cases (STEMI: 97 (14.6%), NSTEACS: 617 (30.1%) and CSA: 602 (35.9%) 
(P <0.001)). Pressure wire assessment was performed in 4 (0.6%) of STEMI, 100 
(4.9%) of NSTEACS and 202 (12.0%) of CSA (P <0.001). An intra-aortic balloon 
pump was inserted in 284 (39.1%) of STEMI and 371 (16.7%) of NSTEACS (P 
<0.001). Rotational atherectomy was undertaken in 3 (0.4%) STEMI, 160 (6.7%) 
NSTEACS and 115 (6.1%) CSA and the glycoprotein IIb IIIa inhibitor, Abciximab used 
in 456 (59.9%) STEMI, 660 (29.4%) NSTEACS and 415 (23.6%) CSA (both P <0.001).  
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Table 4.8: Baseline pre-procedural, procedural and post-procedural characteristics of patients with UPLMS disease who received 
PCI, by clinical presentation. 
Variable CSA  n=1900 
STEMI  
n=784 
NSTEACS  
n=2381 
P value * 
Left main stem stenosis (%) 
0% 209/1,674 (12.5) 71/729 (9.7) 211/2,114 (10.0) 
<0.001 1-49% 296/1,674 (17.7) 75/729 (10.3) 258/2,114 (12.2) 
≥ 50% 1,169/1,674 (69.8) 583/729 (80.0) 1,645/2,114 (77.8) 
Flow in infarct related artery  
TIMI 0 (%) ---  343/666 (51.5) 58/636 (9.1) 
<0.001 
TIMI 1 (%) --- 89/666 (13.3) 40/636  (6.3) 
TIMI 2 (%) --- 117/666 (17.6)      87/636  (13.7) 
TIMI 3 (%) --- 117/666 (17.6)      451/636  (70.9) 
Drug therapy  
Aspirin (%) 1,542/1,805 (85.4) 606/743 (81.6)      1,949 /2,267 (86.0) 0.012 
Thienopyridines (%) 1,484/1,805 (82.2) 561/743 (75.5)      1,946 /2,267 (85.8) <0.001 
Use of ventilation (%) 6/1,545 (0.4) 117/706 (16.6) 84/2,083 (4.0) <0.001 
Consultant as the primary operator (%) 1,460/1,827 (79.9) 661/751 (88.0) 1,831/2,285 (80.1) <0.001 
Vessels attempted (%) Left main stem only (%) 
569/1.883 (30.2) 186/781 (23.8) 649/2,371 (27.4) 
0.003 Multi-vessels (%) 1,314/1,883 (69.8) 595/781 (76.2) 1,722/2,371 (72.6) 
Number of lesions attempted 
(%) 
1 (%) 696/1,899 (36.7) 267/784 (34.1) 791/2,381 (33.2) 
0.070 2 (%) 622/1,899 (32.7) 287/784 (36.6) 814/2,381 (34.2) 
3 or more (%) 581/1,899 (30.6) 230/784 (29.3) 776/2,381 (32.6) 
Total number stents used 
0 (%) 196/1,893 (10.4)    45/781 (5.8) 118/2,369 (5.0) 
<0.001 1 (%) 
548/1,893 (28.9)    249/781 (31.9) 738/2,369 (31.1) 
2 (%) 522/1,893 (27.6)    252/781 (32.2) 681/2,369 (28.8) 
3 or more (%) 627/1,893 (33.1)    235/781 (30.1) 832/2,369 (35.1) 
Type of stents used (%) Bare metal stents 249/1,663 (13.7) 271/721 (35.8) 576/2,220 (24.9) <0.001 Drug eluted stents 1,414/1,663 (77.8) 450/721 (59.4) 1,644/2,220 (71.1) 
Arterial access 
Femoral (%) 1,243/1,864 (66.7) 526/768 (68.5) 1,497/2,348 (63.7) 
0.057 Radial (%) 580/1,864  (31.1) 231/768 (30.1) 791/2,348 (33.7) 
Others (%) 41/1,864  (2.2) 11/768 (1.4) 60/2,348 (2.6) 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables. 
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(Continued) Table 4.8: Baseline pre-procedural, procedural and post-procedural characteristics of patients with UPLMS disease 
who received PCI, by clinical presentation. 
Variable CSA  n=1900 
STEMI  
n=784 
NSTEACS  
n=2381 
P value * 
Type of DES used 
Taxus liberte (Boston Scientific) (%) 396/1,692 (21.8) 82/726 (11.3) 447 /2,089 (21.4) <0.001 
Cypher (Cordis) (%) 159/1,692 (9.4) 45/726 (6.2) 169/2,089 (8.1) 0.048 
Endeavor (Medtronic) (%) 111/1,692 (6.6) 58/726 (8.0) 146/2,089 (7.0) 0.307 
Xience V (Abbott) (%) 171/1,692 (10.1) 79/726 (10.9) 214/2,089 (10.2) 0.627 
Promus (Boston Scientific) (%) 91/1,692 (5.4) 44/726 (6.1) 144/2,089 (6.9) 0.198 
Largest balloon/stent used in millimetres, mean (SD) 3.9 (0.6) 3.7 (0.6) 3.9 (0.6) <0.001 
Longest stented/treated segment in millimetres, mean (SD) 25.7 (15.3) 25.9 (14.0) 26.1 (15.6) 0.734 
Drugs used 
None (%) 1273/1758 (72.4) 236/761 (31.0) 1361/2,248 (60.5) 
<0.001 Abciximab (%)  415/1758 (23.6) 456/761 (59.9) 660/2,248 (29.4) Eptifibitide (%) 40/1758 (2.3) 31/761 (4.1) 63/2,248 (2.8) 
Tirofiban (%) 30/1758 (1.7) 38/761 (5.0) 164/2,248 (7.3) 
Use of intravascular ultra sound (%) 602/1,679 (35.9) 97/663 (14.6) 617/2,047 (30.1) <0.001 
Use of intravascular pressure wire (%) 202/1,679 (12.0) 4/663 (0.6) 100/2,047 (4.9) <0.001 
Use of Intra-aortic balloon pump (%) 74/1,792 (4.1) 284/727 (39.1) 371/2,224 (16.7) <0.001 
Number of lesions successful  
1 (%) 687/1,793 (38.3) 259/722 (35.9) 809/2,285 (35.4) 
0.072 2 (%) 579/1,793 (32.3) 270/722 (37.4) 792/2,285 (34.7) 
3 or more (%) 527/1,793 (29.4) 193/722 (26.7) 684/2,285 (29.9) 
Left main stem stenosis (%) 
0% 1,281/1,665 (76.9) 510/720 (70.9) 1,613/2,074 (77.8) 
<0.001 1-49% 298/1,665 (17.9) 158/720 (21.9) 385/2,074 (18.6) 
≥ 50% 86/1,665 (5.2) 52/720 (7.2) 76/2,074 (3.6) 
Flow in infarct related artery  
TIMI 0 (%) 8/567 (1.4)  46/680 (6.8) 23/1,107 (2.0) 
<0.001 
TIMI 1 (%) 2/567 (0.4)  26/680 (3.8) 3/1,107 (0.3) 
TIMI 2 (%) 7/567 (1.2)  72/680 (10.6) 22/1,107 (2.0) 
TIMI 3 (%) 550/567 (97.0)  536/680 (78.8) 1,059/1,107 (95.7) 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
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4.4.5 Procedural complications and in-hospital outcomes 
Direct current cardioversion, no flow/slow flow, ventilated patients and 
cardiogenic shock induced by procedure were more frequent in STEMI (all P <0.001). 
Table 4.9 illustrates the clinical outcomes of patients with UPLMS disease who 
received PCI stratified by clinical presentation. In-hospital outcomes were infrequent 
and comparable in all three strata. Table 4.10 demonstrates the in-hospital outcomes and 
mortality rates of patients with UPLMS disease who received PCI stratified by clinical 
presentation. 
 
4.4.6 In-hospital MACCE  
Crude in-hospital MACCE rates were highest in STEMI (STEMI: 193 (27.0%), 
NSTEACS: 147 (6.5%), CSA: 60 (3.4%) (P <0.001)). For acute cases with cardiogenic 
shock, in-hospital MACCE rates were significantly higher, occurring in 50.2% cases of 
STEMI and 21.7% NSTEACS compared with 10.8% and 5.0%, respectively, for 
patients without shock (P <0.001). Likewise, in ventilated patients, in-hospital MACCE 
occurred in 53.6% of STEMI and 24.7% of NSTEACS (P <0.001). 
Using the corresponding published coefficients from the NWQIP risk model, see 
(section 4.3.6.3), the highest mean (SD) of the predicted in-hospital MACCE rate was in 
STEMI (STEMI: 39.2 (32.1), NSTEACS: 14.0 (19.2) and CSA: 4.1 (3.2) (P <0.001)). 
After adjustment using multivariate regression, the risk of in-hospital MACCE was 
eleven-fold higher for STEMI and two-fold higher for NSTEACS than for CSA 
(STEMI: aOR 10.91, 95% CI 7.81 to 15.24, NSTEACS: aOR 1.85, 95% CI 1.33 to 
2.59).  
 
4.4.7 Crude mortality and survival time 
The median follow-up period of the cohort was 910 days (range: 1 day to 2,406 
days). Overall there were 1,280 (25.3%) deaths over a total follow-up period of 
4,052,783 patient years. The length of follow-up was not imbalanced (STEMI: 311 
(39.7%) deaths over 388,339 patient years, NSTEACS: 696 (29.2%) deaths over 
1,871,624 patient years and CSA: 273 (14.4%) deaths over 1,792,820 patient years).  
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Across the strata of clinical presentation, crude 30-day and 1-year mortality rates 
were:  STEMI 28.3% and 37.6%, NSTEACS 8.9% and 19.5%, CSA 1.4% and 7.0%, 
respectively. Figure 4.3 shows the Kaplan–Meier curves for unadjusted survival time 
(from time of procedure to 6 years) to all-cause mortality in UPLMS patients who 
received PCI.  After adjustment, acute cases remained at a significantly elevated risk of 
death (30-day mortality; STEMI: aOR 29.45, 95% CI 19.37 to 44.80, NSTEACS: aOR 
6.45, 95% CI 4.27 to 9.76, 1-year mortality; STEMI: aOR 4.95, 95% CI 4.07 to 6.02, 
NSTEACS: aOR 2.07, 95% CI 1.76 to 2.43).  
Mortality rates in patients with STEMI who had cardiogenic shock were higher 
than in STEMI patients without shock (30-days: 52.0% vs. 11.7%, 1-year: 61.1% vs. 
20.9%). The Kaplan–Meier curves for unadjusted survival time (from time of procedure 
to 6 years) to all-cause mortality in UPLMS patients with and without cardiogenic 
shock who received PCI is shown in Figure 4.4. For STEMI and NSTEACS, the 
presence of cardiogenic shock was associated with significantly worse outcomes. In 
acute cases without cardiogenic shock, compared with the femoral approach, the radial 
approach was associated with lower crude rates of mortality – but only at 30-days 
(STEMI: 30-days: 14.8% vs. 6.2%, 1-year: 20.8% vs. 19.4%; NSTEACS: 30-days: 
7.4% vs. 5.7%, 1-year 17.0% vs. 15.8%). Figure 4.5 shows the unadjusted 30-day and 
1-year mortality of patients with UPLMS who received percutaneous coronary 
intervention stratified by arterial access and clinical presentation. 
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Table 4.9: Procedural complications of patients with UPLMS disease who received 
PCI, by clinical presentation. 
 
Variable 
CSA 
n=1900 
STEMI 
n=784 
NSTEACS 
n=2381 
P value * 
Haemorrhage  
Radial access (%) 0/580 (0.0) 3/231 (1.3) 2/791 (0.3) 0.010 
Femoral access (%) 3/1,243 (0.2) 3/526 (0.6) 4/1,497 (0.3) 0.485 
Side branch occlusion (%) 17/1,710 (1.0) 8/714 (1.1) 24/2,129 (1.1) 0.917 
Coronary dissection (%) 106/1,710 (6.2) 50/714 (7.0) 125/2,129 (5.9) 0.553 
Coronary perforation (%) 13/1,710 (0.8) 4/714 (0.6) 20/2,129 (0.9) 0.592 
Direct current cardioversion (%) 6/1,710 (0.4) 24/714 (3.4) 15/2,129 (0.7) <0.001 
No flow/slow flow (%) 11/1,710 (0.6) 38/714 (5.3) 27/2,129 (1.3) <0.001 
Ventilated (%) 4/1,710 (0.2) 29/714 (4.1) 15/2,129 (0.7) <0.001 
Cardiogenic shock induced by 
procedure (%) 11/1,710 (0.6) 44/714 (6.2) 45/2,129 (2.1) <0.001 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance 
(ANOVA) for continues variables. 
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Table 4.10: In-hospital outcomes and mortality rates of patients with UPLMS disease who received PCI, by clinical presentation. 
 
Variable CSA  
n=1900 
STEMI  
n=784 
NSTEACS  
n=2381 
P value * 
Acute myocardial infraction (%) 35/1,767  (2.0) 7/525 (1.3) 22/2,062 (1.1) 
0.067 
Stroke (%) 0/1,767 (0.0) 1/525 (0.2) 1/2,062 (0.1) 
Renal failure/dialysis (%) 4/1,736 (0.2) 7/524 (1.3) 24/2,063 (1.2) 0.002 
Blood transfusion 
Radial access (%) 0/580 (0.0) 5/231 (2.2) 5/791 (0.6) 0.002 
Femoral access (%) 4/1,243 (0.3) 7/526 (1.3) 19/1,497 (1.3) 0.020 
Gastro-intestinal bleeding 
Radial access (%) 0/580 (0.0) 1/231 (0.4) 2/791 (0.3) 0.365 
Femoral access (%) 1/1,243 (0.1) 4/526 (0.8) 2/1,497 (0.1) 0.012 
Revascularisation  Percutaneous coronary intervention (%) 5/1,807 (0.3) 4/789  (0.6) 10/2,240 (0.5) 
0.555 
Coronary artery bypass graft (%) 5/1,807 (0.3) 4/789 (0.6) 12/2,240 (0.5) 
Mean (SD) predicted in-hospital MACCE rates ** 4.1 (3.2) 39.2 (32.1) 14.0 (19.2) <0.001 
Unadjusted in-hospital mortality rate (%)  14/1,830 (0.8) 228/755 (30.2) 139/2,324 (6.0) <0.001 
Unadjusted 7-day mortality rate (%)  19/1,900 (1.0)  193/784 (24.6)  130/2,381 (5.5) <0.001 
Unadjusted 30-day mortality rate (%) 27/1,900 (1.4) 222/784 (28.3)  212/2,381 (8.9) <0.001 
Unadjusted 6-month mortality rate (%) 75/1,900 (4.0) 263/784 (33.6) 373/2,381 (15.7) <0.001 
Unadjusted 1-year mortality rate (%) ** 122/1,736 (7.0) 257/683 (37.6) 414/2,127 (19.5) <0.001 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables. 
** Censored at 10/8/2011, therefore all PCI procedures performed after 10/8/2010 were not included in describing this rate. 
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Figure 4.3: Kaplan-Meier curves for unadjusted survival time to all-cause 
mortality in patients who received PCI to an UPLMS, stratified by STEMI, 
NSTEACS and CSA from time of procedure to 6.6 years.  
 
 
The survival distributions of both strata were significantly different (Mantle-Cox log 
rank test, P<0.001). 
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Figure 4.4: Kaplan-Meier curves for unadjusted survival time to all-cause 
mortality in patients with and without cardiogenic shock who received PCI to an 
UPLMS, stratified by STEMI and NSTEACS from time of procedure to 6.6 years.  
 
 
The survival distributions of both strata were significantly different (Mantle-Cox log 
rank test, P<0.001).  
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Figure 4.5: unadjusted 30-day and 1-year mortality of patients with UPLMS 
disease who received percutaneous coronary intervention, stratified by arterial 
access and clinical presentation. 
 
 
Proportions exclude missing data.  
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4.4.8 Clinical determinants of outcomes 
Multivariate logistic regression modelling was used for this section of the 
analysis. Different covariates were used in the adjustment of the estimates in all the 
types of clinical presentation. More detail was given earlier in this chapter (section 
4.3.6.4 and Table 4.2). 
 
4.4.8.1 Clinical presentations as a determinant of outcomes 
Compared with CSA, STEMI and NSTEACS were at higher risk of early 
MACCE (STEMI: aOR 9.2, 95% CI 7.0-12.1 and NSTEACS: aOR 3.4, 95% CI 2.6-4.4; 
P <0.001). Likewise, both STEMI and NSTEACS were again at higher risk of early 
mortality (STEMI: aOR 19.1, 95% CI 13.7-26.4 and NSTEACS: aOR 8.3, 95% CI 6.0-
11.4; P <0.001). In the same way, risk of 1-year mortality in acute patients was higher 
compared with CSA, more than three folds higher for STEMI (OR 3.6, 95% CI 3.1 to 
4.3) and more than two folds higher for NSTEACS (OR 2.5, 95% CI 2.2 to 2.8; 
P<0.001). 
 
4.4.8.2 Clinical determinants of 30-day mortality 
Figure 4.6 shows the significant clinical determinants (predictors) of 30-day 
mortality by strata of clinical presentation. In all three strata, each one year increase in a 
patient's age was significantly associated with an increased risk of death at 30 days 
(STEMI: aOR 1.03, 95% CI 1.01 to 1.04; NSTEACS: aOR 1.04, 95% CI 1.02 to 1.06 
and CSA: aOR 1.07, 95% CI 1.01 to 1.13).  
For STEMI and NSTEACS, predictors of 30-day mortality were age greater than 
80 years (STEMI: aOR 2.24, 95% CI 1.25 to 4.01 and NSTEACS: aOR 3.26, 95% CI 
1.95 to 5.46), pre-procedural cardiogenic shock (STEMI: aOR 10.11, 95% CI 6.44 to 
15.88 and NSTEACS: aOR 6.13, 95% CI 4.10 to 9.16), poor Left ventricular ejection 
fraction (STEMI: aOR 6.02, 95% CI 1.52 to 23.79 and NSTEACS: aOR 3.21, 95% CI 
1.72 to 6.00), pre-procedural ventilation (STEMI: aOR 3.00, 95% CI 1.72 to 5.24 and 
NSTEACS: aOR 4.62, 95% CI 2.45 to 7.08), peri-procedural shock (STEMI: aOR 3.18, 
95% CI 1.43 to 5.59 and NSTEACS: aOR 7.11, 95% CI 3.28 to 15.43), the use of IVUS 
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(STEMI: aOR 0.27, 95% CI 0.11 to 0.67 and NSTEACS: aOR 0.56, 95% CI 0.34 to 
0.92), and the radial approach over femoral (STEMI: aOR 0.27, 95% CI 0.22 to 0.62 
and NSTEACS: aOR 0.66, 95% CI 0.45 to 0.97). 
After adjustment, the mortality benefit of the radial approach was stronger in 
STEMI patients without cardiogenic shock, and not evident in NSTEACS without 
shock (STEMI: aOR 0.38, 95% CI 0.17 to 0.86 and NSTEACS: aOR 0.75, 95% CI 0.49 
to 1.15). Other significant predictors of poorer 30-day mortality in NSTEACS patients 
were chronic renal failure and peri-procedural AMI. In contrast, significant predictors 
for CSA were age greater than 80 years and peri-procedural coronary dissection. There 
was no difference in risk of 30-day mortality by radial or femoral approach in patients 
with CSA. 
 
4.4.8.3 Clinical determinants of 1-year mortality 
Figure 4.7 shows the significant clinical determinants of 1-year mortality by 
clinical presentation. After adjustment, for each one year increase in a patient's age there 
was a significant increase in the risk of death at one year (STEMI: aOR 1.02, 95% CI 
1.01 to 1.04; NSTEACS: aOR 1.03, 95% CI 1.02 to 1.04 and CSA: aOR 1.02, 95% CI 
1.01 to 1.03).  
For STEMI, predictors of 1-year mortality were age greater than 80 years (aOR 
2.09, 95% CI 1.27 to 3.43), pre-procedural cardiogenic shock (aOR 5.32, 95% CI 3.67 
to 7.71), poor left ventricular ejection fraction (aOR 3.72, 95% CI 1.41 to 9.79), pre-
procedural ventilation (aOR 1.97, 95% CI 1.14 to 3.40), peri-procedural coronary 
dissection (aOR 2.05, 95% CI 1.05 to 4.01), and peri-procedural shock (aOR 2.62, 95% 
CI 1.19 to 5.79). 
For NSTEACS, the predictors were age greater than 80 years (aOR 2.26, 95% 
CI 1.67 to 3.05), pre-procedural cardiogenic shock (aOR 2.86, 95% CI 2.07 to 3.96), 
previous MI (aOR 1.37, 95% CI 1.10 to 1.70), chronic renal failure (aOR 1.94, 95% CI 
1.40 to 2.68), poor left ventricular ejection fraction (aOR 1.59, 95% CI 1.11 to 2.27), 
pre-procedural ventilation (aOR 2.70, 95% CI 1.56 to 4.68), peri-procedural AMI (aOR 
4.67, 95% CI 1.55 to 14.10), peri-procedural shock (aOR 3.32, 95% CI 1.62 to 6.80), 
and the use of Abiximab (aOR 0.55, 95% CI 0.43 to 0.71).  
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For CSA, the significant predictors were age greater than 80 years and the use of 
Abciximab. For STEMI, NSTEACS and CSA, the radial approach was not a statistically 
significant predictor of 1-year mortality. In emergency patients without cardiogenic 
shock, the radial over the femoral approach was not significantly associated with lower 
risk of mortality at 1-year (STEMI: aOR 0.98, 95% CI 0.60 to 1.61 and NSTEACS: 
aOR 1.11, 95% CI 0.88 to 1.41). 
 
 
Figure 4.6: Adjusted risks for 30-day mortality for CSA (complete case & 
imputed). 
 
OR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled 
imputed data. 
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Chronic renal disease*
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Number of stents used
Number of stents used*
Abciximab use
Abciximab use*
Intravascular ultrasound
Intravascular ultrasound*
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Intra-aortic balloon pump*
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Radial vs femoral*
Post-PCI MI
Post-PCI MI*
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Post-PCI side branch occlusion*
Post-PCI coronary dissection
Post-PCI coronary dissection*
ID
Study
1.42 (0.39, 5.11)
1.33 (0.46, 3.81)
12.35 (1.35, 113.09)
3.97 (1.00, 15.80)
1.80 (0.57, 5.66)
1.16 (0.41, 3.29)
0.31 (0.06, 1.67)
0.44 (0.11, 1.70)
3.01 (0.92, 9.88)
2.35 (0.79, 6.95)
1.38 (0.17, 11.28)
0.92 (0.11, 7.51)
2.49 (0.43, 14.47)
1.54 (0.27, 8.81)
0.78 (0.21, 2.84)
0.62 (0.21, 1.82)
0.81 (0.44, 1.50)
1.01 (0.60, 1.71)
0.10 (0.01, 1.23)
0.65 (0.19, 2.24)
0.36 (0.08, 1.64)
0.38 (0.10, 1.39)
4.75 (0.94, 23.92)
2.27 (0.47, 10.93)
1.81 (0.55, 5.95)
1.07 (0.36, 3.16)
0.44 (0.02, 8.05)
3.57 (0.58, 21.87)
6.43 (0.82, 50.42)
9.61 (1.57, 58.71)
4.80 (1.27, 18.18)
4.07 (1.18, 14.06)
OR (95% CI)
  
1.1 10
adjusted odds ratio (aOR) 95% confidence interval (CI)
* Imputed data
MI: myocardial infarction, PCI: percutaneous coronary intervention, LMS: left main stem
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(Continued) Figure 4.6: Adjusted risks for 30-day mortality for STEMI (complete 
case & imputed). 
 
 
OR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled 
imputed data. 
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0.74 (0.45, 1.21)
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0.89 (0.46, 1.71)
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1.15 (0.69, 1.93)
0.60 (0.22, 1.67)
0.92 (0.35, 2.45)
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4.57 (1.78, 11.73)
1.00 (0.61, 1.64)
0.77 (0.51, 1.16)
0.91 (0.73, 1.14)
0.82 (0.68, 0.99)
0.68 (0.42, 1.09)
0.64 (0.42, 0.97)
0.27 (0.11, 0.67)
0.20 (0.08, 0.48)
1.33 (0.83, 2.13)
1.27 (0.85, 1.90)
3.00 (1.72, 5.24)
2.44 (1.51, 3.94)
0.37 (0.22, 0.62)
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2.89 (1.34, 6.25)
2.46 (1.18, 5.11)
3.18 (1.43, 7.06)
2.78 (1.38, 5.59)
OR (95% CI)
  
1.1 10
adjusted odds ratio (aOR) 95% confidence interval (CI)
* Imputed data
MI: myocardial infarction, PCI: percutaneous coronary intervention, LMS: left main stem
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(Continued) Figure 4.6: Adjusted risks for 30-day mortality for NSTEACS 
(complete case & imputed). 
 
 
OR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled 
imputed data. 
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Cardiogenic shock*
Previous MI
Previous MI*
Previous PCI
Previous PCI*
Diabetes mellitus
Diabetes mellitus*
Chronic renal disease
Chronic renal disease*
Ejection fraction <30%
Ejection fraction <30%*
Multi-vessels vs  LMS only
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Abciximab use
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0.76 (0.47, 1.24)
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0.88 (0.58, 1.33)
0.78 (0.52, 1.16)
1.70 (1.06, 2.73)
1.80 (1.16, 2.80)
3.21 (1.72, 6.00)
2.58 (1.44, 4.62)
1.26 (0.82, 1.93)
1.34 (0.93, 1.94)
1.14 (0.94, 1.38)
1.19 (1.00, 1.41)
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1.09 (0.76, 1.56)
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7.11 (3.28, 15.43)
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OR (95% CI)
  
1.1 10
adjusted odds ratio (aOR) 95% confidence interval (CI)
* Imputed data
MI: myocardial infarction, PCI: percutaneous coronary intervention, LMS: left main stem
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Figure 4.7: Adjusted risks for 1-year mortality rate for CSA (complete case & 
imputed). 
 
 
OR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled 
imputed data. 
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1.48 (0.34, 6.44)
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1.1 10
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* Imputed data
MI: myocardial infarction, PCI: percutaneous coronary intervention, LMS: left main stem
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(Continued) Figure 4.7: Adjusted risks for 1-year mortality rate for STEMI 
(complete case & imputed). 
 
 
OR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled 
imputed data. 
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1.91 (0.77, 4.76)
2.50 (1.00, 6.22)
3.72 (1.41, 9.79)
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0.93 (0.60, 1.44)
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0.92 (0.75, 1.13)
0.91 (0.77, 1.08)
0.81 (0.53, 1.23)
0.83 (0.58, 1.18)
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0.91 (0.12, 7.11)
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1.1 10
adjusted odds ratio (aOR) 95% confidence interval (CI)
* Imputed data
MI: myocardial infarction, PCI: percutaneous coronary intervention, LMS: left main stem
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(Continued) Figure 4.7: Adjusted risks for 1-year mortality rate for NSTEACS 
(complete case & imputed). 
 
 
OR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled 
imputed data. 
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* Imputed data
MI: myocardial infarction, PCI: percutaneous coronary intervention, LMS: left main stem
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4.4.9 Sensitivity analyses 
4.4.9.1 Mixed effects modelling at hospital level 
Table 4.11 demonstrates a summary of mixed effects models adjusted odds ratios 
of 1-year mortality for UPLMS patients who underwent PCI. The results of 30-day 
mortality were similar to those of 1-year mortality. Taking into account the hierarchical 
level of cardiac hospitals or centres ‘mixed effects modelling’, the same logistic 
regression models used in the adjusted analysis ‘fixed effects modelling’ were repeated. 
These models were described in detail in this chapter (section 4.3.6.4). In almost all 
mixed effect models for all types of clinical presentation, the likelihood ratio statistics 
were statistically significant (P <0.001) indicating that there was similarities between 
the patients within each hospital and significant difference between hospitals. With the 
evidence for hospital (level 2) effects, the use of mixed effects models did not 
substantially affect the patient (level 1) estimates.  
The adjusted estimates of age of more than 80 years, for example, in the fixed and 
mixed effects models of 1-year mortality were; (STEMI: fixed estimates aOR 2.1, 95% 
CI 1.3 to 3.4, mixed estimates aOR 2.1, 95% CI 1.2 to 3.6, NSTEACS: fixed estimates 
aOR 2.3, 95% CI 1.7 to 3.1, mixed estimates aOR 2.3, 95% CI 1.7 to 3.1 and CSA: 
fixed estimates aOR 1.7, 95% CI 1.1 to 2.6, mixed estimates aOR 1.7, 95% CI 1.1 to 
2.6). Another example was the impact of pre-procedural cardiogenic shock in acute 
UPLS patients on 1-year mortality (STEMI: fixed estimates aOR 5.3, 95% CI 3.7 to 7.7, 
mixed estimates aOR 6.2, 95% CI 4.1 to 9.5 and NSTEACS: fixed estimates aOR 2.9, 
95% CI 2.1 to 4.0, mixed estimates aOR 2.9, 95% CI 2.1 to 4.1) (Figure 4.7 and Table 
4.11). 
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Table 4.11: multi-level (mixed effects) modelling at hospital level adjusted odds ratios of 1-year mortality for UPLMS patients 
underwent PCI. 
Variable 
At hospital level 
CSA STEMI NSTEACS 
aOR 
95% 
confidence 
interval 
likelihood 
ratio 
P value 
aOR 
95% 
confidence 
interval 
likelihood 
ratio 
P value 
aOR 
95% 
confidence 
interval 
likelihood 
ratio 
P value 
Male 0.9 0.6 - 1.3 0.015 1.0 0.9 – 1.5 <0.001 0.9 0.7 – 1.2 <0.001 
Age more than 80 years 1.7 1.1 - 2.6 0.015 2.1 1.2 – 3.6 <0.001 2.3 1.7 – 3.1 <0.001 
Cardiogenic shock --- --- --- 6.2 4.1 – 9.5 <0.001 2.9 2.1 – 4.1 <0.001 
Diabetes mellitus 1.3 0.9 – 1.8 0.015 0.9 0.6 – 1.6 <0.001 1.3 1.0 – 1.7 <0.001 
Chronic renal disease 1.8 0.5 – 2.2 0.015 2.5 0.9 – 6.8 <0.001 2.0 1.4 – 2.8 <0.001 
Previous acute myocardial infarction 1.2 0.8 – 1.7 0.002  0.9 0.5 – 1.4 <0.001 1.4 1.1 – 1.7 <0.001 
Previous PCI 1.1 0.8 – 1.5 0.015 0.9 0.5 - 1.6 <0.001 1.1 0.9 – 1.5 <0.001 
Ejection fraction <30% 0.9 0.4 – 1.7 0.142 9.5 3.5 – 25.7 0.002 1.8 1.3 – 2.6 <0.001 
Number of stents used 0.9 0.8 – 1.1 0.012 0.9 0.8 – 1.1 <0.001 1.0 0.9 – 1.1 <0.001 
Abciximab use 0.3 0.2 – 0.6 0.005 0.9 0.6 – 1.4 <0.001 0.5 0.4 – 0.7 <0.001 
Intravascular ultrasound 1.2 0.9 – 1.8 0.008 0.4 0.2 – 0.7 0.015 1.0 0.7 – 1.3 <0.001 
Intra-aortic balloon pump 1.3 0.6 – 2.8 0.014 2.9 1.9 – 4.3   <0.001 1.6 1.2 – 2.1 <0.001 
Pre-procedure ventilation 3.1 0.5 – 20.1 0.001 3.9 2.2 – 6.7 <0.001 5.1 3.0 – 8.9 <0.001 
Radial vs femoral access 1.5 0.9 – 2.1 0.006 0.5 0.3 – 0.8 0.002 1.0 0.8 – 1.3 <0.001 
Longest stented/treated segment 1.0 0.0 – 1.0 0.008 1.0 0.9 – 1.0 0.002 1.0 0.9 – 1.0 <0.001 
Multi-vessel vs. single vessel 1.2 0.8 – 1.6 0.015 0.7 0.5 – 1.1 <0.001 1.0 0.8 – 1.3 <0.001 
Post-procedure acute myocardial infarction 0.4 0.1 – 1.8 0.018 3.4 0.5 – 22.5 <0.001 5.0 1.6 – 15.9 <0.001 
Procedural 
complication 
Side branch occlusion 1.5 0.3 – 1.6 0.015 1.7 0.3 – 8.9 <0.001 0.5 0.2 – 1.8 <0.001 
Coronary dissection 0.8 0.4 – 1.6 0.015 1.9 0.9 – 3.8 <0.001 0.9 0.6 – 1.5 <0.001 
Shock 0.7 0.3 – 2.0 0.015 2.7 1.1 – 6.3 <0.001 3.5 1.6 – 7.4 <0.001 
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4.4.9.2 Multiple imputation 
The distribution for most variables of the imputed datasets matched those of the 
complete case dataset very closely. Multivariate adjustment of the pooled imputed data 
for the missing data made only small changes to point estimates generated from the 
logistic regression models. Although, due to the increase in the available number of 
patients in the imputed dataset, multiple imputation improved the estimates precision. 
After adjustment, the generated point estimates of regression from the pooled 
imputed data were statistically insignificant. There was no changes observed on the 
significance of the overall association result of the same models from the complete case 
data across the types of clinical presentation. The comparison between the complete 
case data and pooled multiply imputed data are shown in Figures 4.6 and 4.7 which 
shows the adjusted odds ratios for the clinical determinants of the 30-day and 1-year 
mortality for UPLMS patients PCI stratified by the type of clinical presentation. 
For example at 30-day mortality, the adjusted odds ratios for the radial approach 
over femoral were (STEMI: aOR 0.3, 95% CI 0.2 to 0.6 in complete case data compared 
to aOR 0.4, 95% CI 0.3 to 0.7 in imputed data, NSTEACS: aOR 0.7, 95% CI 0.5 to 0.9 
in complete case data compared to aOR 0.7, 95% CI 0.5 to 0.9 in imputed data and 
CSA: aOR 1.8, 95% CI 0.6 to 6.0 in complete case data compared to aOR 1.1, 95% CI 
0.4 to 3.4 in imputed data). The adjusted ratios at 1-year mortality for chronic renal 
failure were (STEMI: aOR 1.9, 95% CI 0.8 to 4.8 in complete case data compared to 
aOR 2.5, 95% CI 1.0 to 6.2 in imputed data, NSTEACS: aOR 1.9, 95% CI 1.4 to 2.7 in 
complete case data compared to aOR 1.9, 95% CI 1.4 to 2.5  in imputed data and CSA: 
aOR 1.1, 95% CI 0.5 to 2.1 in complete case data compared to aOR 1.0, 95% CI 0.5 to 
2.0 in imputed data) (Figures 4.6 and 4.7). 
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4.5 Discussion 
4.5.1 Summary of key findings 
• These national observational data from the BCIS registry showed that over half of 
patients treated with PCI to UPLMS presented acutely.  
• Most of the procedural complications and in hospital outcomes were infrequent 
across the types of clinical presentation. 
• Acute patients were having substantially higher risks of in-hospital MACCE as well 
as 30-day and 1-year mortality when compared with elective patients. 
• Mortality rates at one year for CSA patients approached one in 10. 
• For STEMI and NSTEACS patients, the significant predictors of worse early and 
late mortality were age greater than 80 years, pre-procedural cardiogenic shock, 
poor Left ventricular ejection fraction, pre-procedural ventilation and peri-
procedural shock. 
• The use of Abiximab was associated with lower mortality rate at one year for CSA 
and NSTEACS but not STEMI patients. 
• For CSA patients, age greater than 80 years was a significant predictor of worse 
early and late mortality, while peri-procedural coronary dissection was only a 
predictor of worse early mortality. 
• Cardiogenic shock was common in STEMI and was associated with a nine-fold 
increase in risk of mortality at 30 days and a five-fold increase in risk of mortality at 
one year. 
• The radial approach to access was associated with improved early mortality in acute 
patients, but was not supported by lower mortality in the longer-term.  
• Multiple imputation made slight improvement on the precision of the generated 
adjusted hazard ratios which were statistically insignificant as they did not change 
the overall association result of the same models from the complete case data.  
• Even though there was evidence for hospital effects, the use of mixed effects models 
did not largely affect the adjusted estimates at patient’s level. 
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4.5.2 Findings in the context of literature 
This analysis is the first whole country comparative outcomes study of patients 
with UPLMS who received PCI stratified by the types of clinical presentation. This 
study is more representative of UK patients with UPLMS since most of the reviewed 
population based studies were performed outside the UK [42, 47, 86, 96, 99, 101, 104, 
106]. Non-representative studies are prone to selection bias very easily, caused by the 
expected variations between cardiac centres facilities and the experience of the 
interventionist [76, 117]. 
After consideration of case mix, patients who present with STEMI and 
NSTEACS in the context of UPLMS PCI have substantially higher risks of in-hospital 
MACCE as well as 30-day and 1-year mortality when compared with elective cases. 
Vakili et al. reported that mortality after primary PCI for acute patients was around five-
fold higher than that after elective PCI [76]. Furthermore, over 40% of patients who 
presented with STEMI had evidence of cardiogenic shock and this was associated with 
a nine-fold increase in risk of 30-day mortality rate and a five-fold increase in risk of 1-
year mortality rate. Despite this, rates of 30-day all-cause mortality in patients with 
STEMI and NSTEACS were lower than the suggested benchmark of 55% [34]. These 
findings are of particular clinical relevance at a time when international guidelines 
recommend primary angioplasty in patients with STEMI and as complete 
revascularisation as possible in those with established cardiogenic shock [76, 111]. The 
outcome data that we report in this observational study will be of value when 
considering the early and longer-term risk of outcomes after PCI for patients with 
UPLMS stenosis in an elective setting. 
In terms of adjuvant technologies, this analysis found that the use of an IABP 
was high in both STEMI and NSTEMI. In the light of recent trial data suggesting 
limited or no outcome benefit of IABP in the context of cardiogenic shock [181], it will 
be interesting to see if the use of this device decreases in these subgroups over time. By 
contrast, the use of IVUS was lower than reported in other studies, but when used was 
associated with improved outcomes which is consistent with data previously published 
in the context of left main stem treated by PCI [182-184].  
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This study demonstrated that overall the radial approach to access was 
associated with better outcomes, but only at 30-day mortality rate and only in patients 
with STEMI and NSTEACS. The differences in bleeding rates in radial versus femoral 
were small. This finding may be an important observation, since it adds weight to the 
recently reported finding that the radial access route is safer than the femoral route in 
STEMI patients and suggests that this benefit extends to NSTEACS patients in the real 
world [32-34]. Radial access may, however, reflect a less sick population and/or more 
skilled operators. Benefit of radial access is no longer evident at 1-year, possibly due to 
factors other than the index intervention that are associated with longer-term outcomes. 
For example, mortality at 1-year is more likely to be influenced by non-cardiac factors 
than at 30-days.[185]  Notably, the early mortality effect interacted significantly with 
the presence of cardiogenic shock (a much lower risk of 30-day mortality was evident in 
patients without cardiogenic shock). In this study, limited descriptive analysis on post 
procedure bleeding was presented. This was because detailed modelling analysis is 
beyond the remit of this analysis and is the subject of a separate study of the BCIS data 
which specifically addressed these interesting and complex issues [87].  
Furthermore, this analysis identified a number of additional factors associated 
with outcomes in patients treated by PCI to UPLMS. In keeping with results from other 
cohort studies, STEMI and NSTEACS were significantly associated with higher in-
hospital MACCEs and 30-day and 1-year mortality compared with stable presentations 
[48, 104]. For STEMI and NSTEACS, the significant predictors of 30-day mortality 
were cardiogenic shock, poor left ventricular ejection fraction, pre-procedural 
ventilation, age greater than 80 years and peri-procedural shock: all factors which have 
previously been reported [30, 42, 45, 48, 99]. For CSA, the significant predictors of 
early mortality (age greater than 80 years and peri-procedural coronary dissection) were 
superseded by age greater than 80 years which independently predicted 1-year 
mortality.  
 
Similarly, chronic renal impairment and poor left ventricular ejection fraction 
were not significant predictors of 1-year mortality in elective cases; in this group 
increasing age remained a strong predictor. Notably, the absolute level of 1-year 
mortality in the CSA cohort was higher than expected from previously reported data on 
UPLMS PCI. There is no formal explanation available for this finding, but it is of 
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potential clinical relevance, and indeed requires closer scrutiny, when some cardiac 
interventionists seek to extend the envelope for UPLMS PCI to include some patients 
who are suitable for CABG surgery. 
In keeping with results from other published studies [86, 96, 101], older age 
(more than 80 years) was associated with worse 30-day and 1-year mortality rates 
across the stable and acute patients with UPLMS. This finding, which was well-
matched with other publications such as that by Parma et al. [48], showed that age of 
more than or equal to 75 years was associated with increased 30-day mortality (aOR 
5.9, 95% CI 1.3 to 26.5). Other studies by De Luca et al. [45] and Onuma et al. [94], 
both demonstrated that age was significantly related to overall mortality and one year 
mortality, respectively. Similarly, Buszman et al. [99] presented significant association 
between age of more than 60 and mortality (aOR 2.5, 95% CI 1.0 to 5.9) and Lee et al. 
2014 [95] showed similar association with 30-day mortality (aOR 4.5, 95% CI 1.2 to 
16.3). Most of these studies were executed in a single cardiac centre and/or on a small 
number of UPLMS patients, demonstrating further advantage of this analysis. 
In acute UPLMS patients who were treated with PCI, poor Left ventricular 
ejection fraction was found to be a significant determinant of increased mortality at 30 
days and at one year. Many other studies shared similar findings to this study [86, 96, 
98, 106]. Khattab et al. [104] and Buszman et al. [99] found significant relationship 
between severe poor left ventricular ejection fraction and worse mortality (aOR 3.3, 
95% CI 1.0 to 11.1 and aOR 3.3, 95% CI 1.5 to 7.3, respectively). Being an acute 
patient, of its own accord, was a significant predictor of early and late mortality rates, a 
finding that correlated with the literature. Khattab et al. [104] concluded that being a 
patient with STEMI was significantly associated with increased mortality (aOR 6.4, 
95% CI 1.8 to 21.9). Khattab’s study related to a small number of patients; yet, was to 
some extent representative based on the study design. 
Mortality rates summarised over the 6 years of our national study were lower 
than those reported by others. Parma et al described crude 30-day mortality rates for 
UPLMS PCI patients of 39.7% [48] and Brennan et al reported crude in-hospital 
mortality rates of 2.9% for CSA and 45.1% for emergent cases [42]. A recent meta-
analysis of UPLMS primary PCI outcomes in patients with AMI estimated an average 
30-day all-cause mortality rate of 55% for patients with cardiogenic shock, which 
supports our observed rate of 52% for patients with STEMI [34]. In addition, mortality 
rates at one year for CSA patients approached one in 10, which may have a bearing on 
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the selection of elective patients for UPLMS PCI who were also suitable for CABG 
surgery. 
More discussion on the temporal trends over ten years for UPLMS patients after 
PCI in the UK is given in Chapter 5 (section 5.5). Broader discussions on the 
methodologies used, such as those relating to the importance of multi-level analysis as 
well as multiple imputation, are outlined in the discussion chapter (see Chapter 7) along 
with more detailed discussion on the overall strengths, limitations and implications of 
this thesis. 
 
 
4.5.3 Conclusion 
The study presented comprehensive findings in regard to the clinical 
determinants of the outcomes of patients with UPLMS in the UK who underwent PCI. 
The analysis of this study was divided into three main strata (STEMI, NSTEACS and 
CSA). In this national data from the BCIS registry, more than half of patients treated 
with PCI to the UPLMS presented acutely. For these patients, early and late outcomes 
were significantly worse than that of elective patients. Cardiogenic shock was common 
in STEMI and associated with a 1 in 2 risk of early mortality. The radial approach to 
access was associated with improved early outcomes in acute cases, but was not 
supported by lower mortality in the longer-term. Finally, 1-year mortality rates for CSA 
cases approached 1 in 10, which may have a bearing on the selection of elective cases 
for UPLMS PCI who are also suitable for CABG surgery. 
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5 Chapter 5     Mortality trends after PCI for UPLMS 
 
 
 
 
5.1 Summary 
The previous chapter (Chapter 4) described the clinical outcomes and the clinical 
determinants of early and late mortality according to clinical syndrome at presentation 
over a period of six years as well as the impact of cardiogenic shock and arterial access 
approach on the clinical outcomes. Subsequently, this chapter, using the updated 2014 
BCIS registry, describes the changes over time in the clinical presentation and types of 
treatment offered by biennial years as well as the temporal trends of mortality among 
UK patients with UPLMS who underwent PCI over a period of 9.6 years between 2005 
and 2014. A literature review about ‘the clinical determinants and temporal trends of 
outcomes for PCI in UPLMS disease’ was provided in Chapter 2 (section 2.4). This 
chapter is split into five sections covering: the background, rationale and aims (section 
5.2), methodology including study design, population, stratification, follow-up as well 
as statistical and sensitivity analyses (section 5.3), results including completeness, 
descriptive statistics, multivariate modelling results and sensitivity results (section 5.4) 
followed by a discussion and conclusion (section 5.5).  
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5.2 Introduction 
 
5.2.1 Background and rationale 
With the improvements in stents technology and pharmacology as well as 
evolving practice and experience, PCI has become an alternative strategy of treatment 
for patients with UPLMS; mainly in those at high risk for surgery [44, 117, 176, 186]. 
In addition, the international diffusion of primary percutaneous coronary intervention 
for acute STEMI is likely to have contributed to the case load of ‘de novo’ UPLMS PCI 
[117, 187].  
Nevertheless, up-to-date details regarding the temporal trends in incidence, care 
and outcomes of UPLMS PCI across the full spectrum of acute and elective patients has 
been limited by small, regional and non-consecutive series of patients or inferred from 
randomised controlled trials (RCT) in highly select groups of patients [36-44].  
A 12 year temporal study by Park et al. [43] concluded that the use of PCI for 
the management of UPLMS increased by 17%; while, repeat revascularisation, 
MACCE, all-cause mortality, the composite endpoint of mortality, myocardial 
infarction and stroke decreased significantly (all P <0.001). Another study by 
Naganuma et al. [39] investigated the temporal trend on 262 PCI UPLMS patients over 
four years. Naganuma and his colleagues demonstrated a trend toward higher target 
lesion revascularisation with no significant differences in the trends of MACCE, all-
cause mortality, and the composite endpoint of all-cause mortality, myocardial 
infarction and stroke. 
Notably, there is a shortage of whole country studies of the temporal trends in 
UPLMS PCI and the associated procedural and longer-term outcomes [39, 43]. 
Therefore, further investigation into such an issue using contemporary multi-centre 
population based data such as BCIS data is essential. Knowing what the trends of 
mortality are after PCI in patients with UPLMS in the UK helps contribute to the 
improvement of care provided to those patients. 
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5.2.2 Aims  
The overall rationale and aims of this thesis were mentioned in Chapter 2 (section 
2.6). The primary aim of this chapter was to perform a population-based comparative 
investigation of all UPLMS patients who received PCI in the UK over a period of 9.6 
years (from January 1, 2005 to March 31, 201: 
 
1. To describe the overall completeness of 2014 updated BCIS data for all patients 
with UPLMS and the changes in missing data by biennial years. 
2. To describe demographic and clinical characteristics of patients by biennial 
years, including: 
a. Trends in baseline risk profile (age over 80 years, severe left ventricular 
systolic dysfunction and cardiogenic shock). 
b. To describe the changes in clinical presentation characteristics.  
3. To describe the changes in procedural characteristics and types of treatment 
offered to patients by biennial years, including: 
a. Trends in techniques, medications, types of equipment and types of 
stents. 
b. Trends in the use of radial approach versus femoral approach across all 
clinical presentation types. 
4. To quantify temporal trends in procedural complications and in-hospital 
outcomes including MACCE, by biennial years. 
5. To quantify temporal trends in 30-day and 1-year mortality rates in the cohort 
as a whole, and across all clinical presentation types, by biennial years. 
 
 
5.3 Methodology 
5.3.1 Study setting and design  
The study design was a prospective population based linked cohort study using 
data of patients with UPLMS who received PCI. The data were collected from 113 
interventional cardiology centres and hospitals in England, Scotland, Northern Ireland 
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and Wales. All were part of 117 cardiology centres and hospitals registered with the 
BCIS audit program between 2005 and 2014 (based on BCIS Audit Returns, Adult 
Interventional Procedures, January 2013 to December 2013) [54]. 
 
5.3.2 Patients, procedures and treatments (study population) 
The sampling frame was based on the updated 2014 BCIS dataset and included all 
patients from all countries in the UK (England, Scotland, Northern Ireland and Wales). 
The total number of patients who attended for PCI in all countries in the UK between 
the 1st of January, 2005 and the 31st of March, 2014 was 699,248 (2014 BCIS data). The 
inclusion and exclusion criteria (based on the Delphi group clinical agreement) for the 
derivation of the analytical cohort were: 
• Patients aged less than 18 years were excluded.  
• Patients with multiple admissions, the earliest intervention record was used. 
• Patients who had received PCI to a diseased UPLMS over the 9.6 year period 
(from 2005 to 2014). 
• Patients who had no vessels attempted or missing information about that were 
excluded. In the same way, those who had no lesions attempted or missing 
information about that were also excluded. The remaining number of PCI 
patients was 655,618.   
• Then, 21,566 patients were included as they were drawn from those who had 
the left main stem as the treated vessel. At the same time, 634,052 patients 
who received PCI for disease of other vessels were excluded.  
• Patients with history of previous CABG, missing information on that or had 
any number of grafts present pre-procedure were excluded. The remaining 
number of patients was 11,212. 
• Finally, the same definition of patients with UPLMS from Chapter 4 (section 
4.3.2) was used [20]. Therefore, 10,827 patients with UPLMS who received 
PCI were included. A detailed flow chart of the selected cohort population is 
shown in Figure 5.1. 
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5.3.3 Stratification of cohort population  
According to the year of PCI procedure for patients with UPLMS, the analysis of 
this chapter was stratified into five biennial calendar periods (2005-06, 2007-08, 2009-
10, 2011-12 and 2013-14). This stratification was selected and agreed by the Delphi 
group in order to compare and understand the difference between these five biennial 
years.  
Merging every two years into one biennial period increases patient numbers as a 
group and give more power to the comparison. In addition, the five biennial year groups 
were easier to present and compare. However; data about all procedures performed in 
the year 2014 was not complete (up to 31st of March). Similar to Chapter 4 (section 
4.3.3 and Table 4.1), three strata according to the mode of clinical presentation were 
defined (STEMI, NSTEACS and CSA). 
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Figure 5.1: Flow chart of the selected cohort population. 
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5.3.4 Definitions  
All the key clinical definitions were mentioned in Chapter 4 (section 4.3.4). In 
this analysis, two variables were defined for better exploration of the data, these 
variables were: 
• Cardiac centres participating: simply the frequency of the registered cardiac 
centres or hospitals in the BCIS registry, stratified by biennial years. 
• Standardised number of PCI per centre: in which the standardisation was 
performed by dividing the total number of patients with UPLMS who 
underwent PCI in each biennial year by the number of cardiac centres in that 
biennial year. 
 
5.3.5 Follow up and mortality  
More details concerning patients follow up and mortality can be found in 
Chapter 1 (section 1.4.3 and Figure 1.3). In the 2014 versions of the BCIS database 
received, because of the date of linkage for censored data (31st July 2014), data rgarding 
mortality at 1-year were not available for 119 (1.1%) patients. As a consequence, 
patients with a follow-up period of less than 12 months were excluded from the analysis 
regarding the trends of 1-year mortality rate, still those patients were included in all 
other parts of the analysis. 
 
  
 
148 
 
5.3.6 Statistical analysis 
5.3.6.1 Descriptive data analysis 
Types of tests and methods used for data description were mentioned previously 
in detail in Chapter 3 (section 3.5). As already stated (section 5.3.3), the whole analysis 
was stratified into five biennial calendar periods (2005-06, 2007-08, 2009-10, 2011-12 
and 2013-14). The aim of this stratification was to compare the temporal changes over 
the study period looking first at a detailed description of the extent of missing data in 
the cohort. Exploration of missingness included all the variables in the updated 2014 
BCIS database. Later, missing data patterns were measured and assessed based on the 
percentage of missing data.  
Subsequently, a descriptive analysis for the cohort was performed in order to gain 
more understanding of patients’ characteristics. The described characteristics included: 
baseline demographics, clinical features, pre-procedural, procedural and post-procedural 
characteristics as well as clinical outcomes. The clinical outcomes of intention included: 
procedural complications, in-hospital outcomes, 30-day mortality rate and 1-year 
mortality rate. 
 
5.3.6.2 Multivariate regression modelling 
Multivariate model selection process, interaction assessment and the evaluation of 
goodness of fit were outlined in detail in Chapter 3 (section 3.4.6.5). Clinical outcomes 
(30-day and 1-year mortality rates) were analysed with and without adjustment for 
relevant covariates, while the analyses was focused on the three strata of clinical 
presentation across the five biennial years. Associations with 30-day and 1-year 
mortality were quantified using fixed effects multivariate logistic models and estimates 
were expressed as adjusted odds ratios (aOR) with 95% confidence intervals (CI).  
Each model estimate was adjusted using seven covariates selected following a 
literature review on ‘the clinical determinants and temporal trends of outcomes for PCI 
in UPLMS disease’, see Chapter 2 (section 2.4). Furthermore, based on the clinical 
significance recommended by the Delphi group the estimates of the multivariate logistic 
regression model were adjusted by different covariates. A list of the selected predictors 
and covariates is shown in Table 5.1.  
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Table 5.1: Summary of the multivariate logistic models used including the selected 
covariates, by biennial years and mortality outcomes. 
 
Outcome and method Biennial years Covariates 
30-day mortality and 1-year 
mortality using fixed effects 
multivariate logistic 
regression model in patients 
with UPLMS who underwent 
PCI 
2005-06 
(as a reference) Age groups, sex, cardiogenic shock, history of diabetes 
mellitus, history of renal 
disease, clinical presentation 
and post-procedural 
complications (side branch 
occlusion, coronary dissection 
and shock induced by 
procedure) 
2007-08 
2009-10 
2011-12 
2013-14 
 
 
 
 
 
5.3.7 Sensitivity analyses  
To test for sensitivity, two sensitivity analyses were performed in order to assess 
potential bias from the fixed effect regression methods used. Similar to the previous 
chapter (Chapter 4), the effect of multi-level logistic regression models was evaluated. 
Subsequently, multivariate logistic regression analyses were considered after multiple 
imputation.  
 
5.3.7.1 Multi-level regression modelling 
Multi-level regression or mixed-effects modelling was defined earlier in Chapter 
3 (section 3.5.1.5). Models were fitted with a hierarchy of patients clustered in each 
hospital using random intercepts for hospitals thus permitting for correlations between 
patient outcomes. The mixed-effects models took into account the variance in the 
predictor variables as well as the variance in the hospitals level [133].   
Resembling the fixed effect multivariate logistic regression models, the same 
outcomes (mortality rates at 30 days and one year) and adjustment covariates were fitted 
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in the mixed effect models (Table 5.1). Afterward, estimates were compared with those 
from equivalent fixed effects models. 
 
5.3.7.2 Multiple imputation method 
A total of 21 imputation predictors were selected, that were based on clinical 
consensus and a literature review, Chapter 2 (section 2.4) [36-44]. Table 5.2 displays 
the list of imputation predictor variables of the outcomes of patients with UPLMS who 
had PCI with a summary of missing data and the methods used for imputation. More 
details on multiple imputation general methods were presented in Chapter 3 (sections 
3.5.2 and 3.5.3). 
The frequency of missing values ranged from 0.05% to 35.40% and all missing 
values were assumed to be missing at random. No data were missing for three variables 
‘clinical presentation’, ‘year of operation’ and ‘vessels attempted’. However, these 
variables were still used as auxiliary variables in the imputation for the remaining 18 
variables.   
A predictor matrix was designed based on clinical judgement as well as using 
thresholded P values of less than 0.05 as related and greater than or equal to 0.05 as 
unrelated. The predictor matrix is shown in Table 5.3. For continuous-continuous and 
continuous-categorical associations, linear regression was used. While for categorical-
categorical, Chi-squared test was used. For each of the 18 predictors with missing 
values, 20 datasets were imputed using the chained equation method and the fully 
conditional specification imputation method [141, 153, 180].  
All 18 variables were categorical and all were imputed using either logistic 
regression (if binary) or polytomous regression (if ordinal). For each outcome, 30-day 
mortality and 1-year mortality, 20 separate imputation datasets were created. Lastly, 
imputed datasets for each predictor were pooled together using Rubin's rule and 
followed by the intended regressions. The adjusted estimates from both complete case 
and multiple imputation data were compared to test for the sensitivity of this analyses. 
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Table 5.2: Imputation predictor variables of the outcomes of patients with UPLMS who PCI with a summary of missing data and 
the methods used for imputation. 
Variables Variable type Missing % Imputation method 
1 Age groups Ordinal 0.05 Polytomous regression 
2 Gender Binary 0.59 logistic regression 
3 Clinical presentation Ordinal 0.00 Auxiliary (not imputed) 
4 Pre-procedural cardiogenic shock Binary 3.47 logistic regression 
5 History of Acute myocardial infarction Binary 9.24 logistic regression 
6 History of Percutaneous coronary intervention Binary 1.15 logistic regression 
7 History of diabetes mellitus Binary 4.44 logistic regression 
8 Left ventricular ejection fraction Ordinal 35.40 Polytomous regression 
9 Year of operation Ordinal 0.00 Auxiliary (not imputed) 
10 Major adverse cardiac and cerebrovascular event Binary 2.33 logistic regression 
11 History of renal disease Binary 0.88 logistic regression 
12 Vessels attempted Continuous 0.00 Auxiliary (not imputed) 
13 Procedural complication: Shock induced by procedure Binary 4.79 logistic regression 
14 Number stents used Ordinal 0.43 Polytomous regression 
15 Stent Type Ordinal 2.61 Polytomous regression 
16 Drugs used during procedure Ordinal 5.26 Polytomous regression 
17 Intravascular ultrasound use during procedure Binary 4.96 logistic regression 
18 Use of intra-aortic balloon pump Binary 4.03 logistic regression 
19 Arterial access Ordinal 1.83 Polytomous regression 
20 30-day mortality Binary 11.19 logistic regression 
21 1-year mortality Binary 18.26 logistic regression 
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Table 5.3: Predictor matrix of the outcomes of patients with UPLMS who received PCI using the 2014 BCIS database. 
Variables 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
1 Age                                           
2 Gender 1                                         
3 Clinical presentation 1 1                                       
4 Pre-procedural cardiogenic shock 1 0 1                                     
5 History of acute myocardial infarction 1 0 1 1                                   
6 History of percutaneous coronary intervention 1 0 1 1 1                                 
7 History of diabetes mellitus 1 0 1 1 1 1                               
8 Left ventricular ejection fraction 1 0 1 1 1 1 1                             
9 Year of operation 1 0 0 1 0 1 0 0                           
10 Major adverse cardiac and cerebrovascular event 1 1 1 1 0 1 0 1 0                         
11 History of renal disease 1 1 1 1 1 0 1 1 1 1                       
12 Vessels attempted 1 1 1 0 1 0 1 1 0 1 1                     
13 P-complication: shock induced by procedure 0 0 1 1 0 0 0 1 0 1 0 1                   
14 Number of stents used 1 0 1 1 1 1 0 1 1 1 1 1 0                 
15 Stent type 1 0 1 1 1 1 1 1 1 1 1 1 0 1               
16 Drugs used during procedure 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1             
17 Intravascular ultrasound use during procedure 1 0 1 1 0 1 0 1 1 1 0 0 1 1 1 1           
18 Use of intra-aortic balloon pump 1 0 1 1 0 1 1 1 0 1 1 1 1 1 1 1 1         
19 Arterial access 1 1 1 1 1 1 1 1 1 1 1 0 0 1 1 1 1 1       
20 30-day mortality 1 0 1 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1     
21 1-year mortality 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 0 1   
0: not related, 1: related, P-complication: procedural complication.  
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5.4 Results 
Across 113 hospitals in the UK, and of 21,566 patients who received PCI to a 
diseased left main stem; 10,827 (50.2%) patients had PCI to an UPLMS (Figure 5.1). 
Compared with 2005-06, in 2013-14 the annual numbers of patients increased from 864 
to 2,279. There were 1,914 (17.7%) ST-elevation myocardial infarction (STEMI), 5,114 
(47.2%) non ST-elevation acute coronary syndrome (NSTEACS) and 3,799 (35.1%) 
chronic stable angina (CSA) patients. 
 
5.4.1 Data completeness 
The frequency and percentages of missing values in the variables of the BCIS 
dataset (2014 updated version) are shown in Table 5.4. The mean (SD) level of 
missingness was 22.37 (27.53) and the median percentage of missing values was 
11.18%. In total, 109 variables were used for the analysis of this chapter, out of them 
only 12 (11.0%) variables were 100% complete. These included ‘clinical presentation 
type’, ‘indication for intervention’, ‘procedure urgency’, ‘presenting 
electrocardiography’, ‘date of operation’, ‘previous CABG’, ‘biennial years’, 
‘electrocardiography ischaemia’, ; vessels attempted’, ‘life status at censored date’, 
‘pseudonymised hospital code’ and ‘country hospital in’. In contrast, the remaining 97 
variables had missing information that ranged from 0.04% to 99.56%.  
There were 40 (36.7%) variables that had less than 10% missing information. The 
one with the least missing values was procedure urgency (0.04%) followed by age at 
procedure (0.05%) and censored date and survival time (0.35%). On the other hand, 
only five (4.6%) variables had missing values of more than 90%. The variable with the 
greatest missingness was ‘use of ventilation’ (99.56%) then ‘bleeding up to discharge’ 
(99.18%), ‘PCI for stent thrombosis’ (98.04%), ‘third operator status’ (94.50%) and 
‘time to bypass’ (95.21%).  In total, 40 (36.7%), of the variables had missing values 
between 10 to 50% and only 12 (11.0%) variables had missing values of more than 50% 
to 90%.  
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Overall, from 2005-06 to 2013-14, there was a decrease in the proportion of 
missing data. For example, absence of values for left ventricular ejection fraction 
decreased from 40.9% to 35.5%. Similarly for pre-procedural cardiogenic shock, 
missing values decreased from 12.8% to 2.3%. On the other hand, the proportion of 
missing values for a few other variables did not show too many changes over the study 
period, for example, the missing values for arterial access which was 1.3% in 2005-06 
and 1.6% in 2013-14 (Figure 5.2). 
 
155 
 
Table 5.4: Recoded variables and summary of missing data in the variables of 
UPLMS cohort from the 2014 BCIS data. 
Variable Name Missing Frequency Missing % 
Age At Procedure 5 0.05 
Sex 64 0.59 
Ethnic Group 3,705 34.22 
Patient Status 676 6.24 
Clinical presentation type 0 0.00 
Indication for Intervention 0 0.00 
Procedure Urgency 4 0.04 
Cardiogenic Shock Pre-PCI 376 3.47 
Angina Status Pre-Surgery 3,723 34.39 
Dyspnoea Status Pre-PCI (Stable Only) 406 10.69 
Admission Route (ACS Only) 491 6.99 
Presenting electrocardiography (ACS Only) 1,082 15.40 
Recent Lysis (ACS Only) 768 10.93 
Cardiac Enzymes/Markers Raised 1,797 25.57 
Previous acute myocardial infarction 1,000 9.24 
Previous coronary artery bypass graft (CABG) 0 0.00 
Previous percutaneous coronary intervention (PCI) 124 1.15 
Diabetes 481 4.44 
Height 4,577 42.27 
Weight 4,034 37.26 
Left Ventricular Ejection Fraction Category 3,833 35.40 
Left Ventricular Ejection Fraction 8,371 77.32 
Number of Grafts Present Pre-PCI, CABG Only 3,181 29.38 
Number of Grafts Patent Pre- PCI, CABG Only 3,497 32.30 
Left Main Stem Stenosis Pre-PCI 821 7.58 
Left anterior descending Proximal Stenosis Pre-PCI 1,412 13.04 
Left anterior descending Other Stenosis Pre-PCI 1,778 16.42 
Right coronary artery Stenosis Pre-PCI 1,796 16.59 
Circumflex coronary artery Stenosis Pre-PCI 1,558 14.39 
Flow In infarct related artery Pre-PCI (ACS Only) 5,912 54.60 
Date Of Operation 0 0.00 
Date Of Operation (biennial years) 0 0.00 
Pseudonymised Consultant Responsible 270 2.49 
Pseudonymised First Operator Status 209 1.93 
Primary Operator 515 4.76 
Second Operator Status 3,810 35.19 
Third Operator Status 10,232 94.50 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data) 
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(Continued) Table 5.4: Recoded variables and summary of missing data in the 
variables of UPLMS cohort from the 2014 BCIS data. 
Variable Name Missing Frequency Missing % 
Vessels Attempted 0 0.00 
Number of vessels attempted not Epicardial 
T it i  
0 0.00 
Number Of Lesions Attempted 0 0.00 
Number Of Chronic Occlusions Attempted 540 4.99 
Number Restenosis Attempted 396 3.66 
Number Instant Stenosis Attempted 1,625 15.01 
Number Stents Used 47 0.43 
Number Drug-Eluting Stents Used 254 2.35 
Type of stent used 283 2.61 
Drugs Eluted By Stents 767 7.08 
Drugs Used During Procedure 570 5.26 
Intravascular ultrasound use during procedure 537 4.96 
pressure wire use during procedure 537 4.96 
Use of intra-aortic balloon pump 436 4.03 
Left Main Stem Stenosis Post-PCI 968 8.94 
Left anterior descending Proximal Stenosis Post-PCI 1,631 15.06 
Left anterior descending Other Stenosis Post-PCI 1,981 18.30 
Right coronary artery Stenosis PCI 2,070 19.12 
Circumflex coronary artery Stenosis PCI 1,771 16.36 
Number Lesions Successful 149 1.38 
Number Coronary Grafts Patent PostOp 3,688 34.06 
Flow In infarct related artery PostOp (ACS only) 2,301 32.74 
Device Failure 865 7.99 
PCI Hospital Outcome 252 2.33 
Enzymes Post-PCI 8,328 76.92 
Status At Discharge 254 2.35 
Discharge Date 601 5.55 
Cholesterol 6,977 71.09 
Smoking Status 1,270 11.73 
Family History Of coronary artery disease 1,849 17.08 
Medical History 354 3.27 
History Of Renal Disease 95 0.88 
Ventilated Pre-PCI 1,160 10.71 
Q Wave On electrocardiography 1,449 13.38 
Electrocardiography Ischaemia 1,340 12.38 
Drug Therapy Pre-PCI 457 4.22 
Follow On AdHoc Procedure 492 4.54 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data)  
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(Continued) Table 5.4: Recoded variables and summary of missing data in the 
variables of UPLMS cohort from the 2014 BCIS data.  
Variable Name Missing Frequency Missing % 
Why No IIb/IIIA During Procedure 2,636 24.35 
Indication For Stent 746 6.89 
Surgical Cover 1,222 11.29 
Left Main Stem Protected 0 0.00 
Referral Hospital 7,603 70.22 
Date of electrocardiography Triggering primary PCI 
P th  
1,404 82.25 
Patient Location at Time of STEMI Onset 9,699 89.58 
Creatinine 7,584 70.05 
PCI for stent thrombosis 10,615 98.04 
Training Procedure 735 6.79 
Research Procedure 1,210 11.18 
Arterial Access 198 1.83 
Largest Balloon/Stent Used 1,277 11.79 
Longest Stented/Treated Segment 1,192 11.01 
Procedural Complication 857 7.92 
Arterial Complication 519 4.79 
Time to Bypass 10,308 95.21 
Patient Status During Transfer To Theatre 1,968 18.18 
Bleeding up to discharge 10,738 99.18 
Ventilation 10,779 99.56 
Pseudonymised Hospital Code 0 0.00 
Country Hospital In 0 0.00 
Length of Stay in Hospital (days) 5,927 54.73 
Index of Multiple Deprivation Score 2,570 23.74 
Life Status at 7days 1,210 11.18 
Life Status at 30days 1,211 11.19 
Life Status at 1year 1,977 18.26 
Life Status at 2years 3,368 31.11 
Life Status at 3years 4,472 41.30 
Life Status at 4years 5,426 50.12 
Life Status at 5years 6,150 56.80 
Death after Procedure (days) 7,880 72.78 
Censored date 38 0.35 
Survival time 38 0.35 
Life Status at censored date 0 0.00 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data) 
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Figure 5.2: Proportions of complete and missing values for pre-procedural 
cardiogenic shock, left ventricular ejection fraction and arterial access in biennial 
years from 2005 to 2014. 
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5.4.2 Trends of demographic characteristics 
From 2005-06 to 2013-14, the proportion of STEMI patients increased from 90 
(10.4%) to 441 (19.4%), the proportion of NSTEACS remained similar from 425 
(49.2%) to 1,100 (48.3%) and the proportion of CSA fell slightly from 349 (40.4%) to 
738 (32.4), P <0.001. After standardizing for the expansion in PCI capable centres the 
increase in patients was upheld (Figure 5.3). The method of standardisation was 
outlined earlier (section 5.3.4). 
In all five biennial year groups, there was a preponderance of males (overall: 
7,490 (69.6%) males). The mean (SD) age of the whole cohort was 70.5 (12.1) years, 
which to some extent increased over the years (2005-06: 69.6 (11.8) and 2013-14: 70.6 
(12.2), P =0.004). Patients older than 80 years of age were more frequent over the years 
(2005-06: 179 (20.7%) and 2013-14: 552 (24.2%) patients, P =0.022). The majority of 
patients were of a Caucasian ethnicity in all five biennial years; however, they 
decreased over the years from 90.0% of patients in 2005-06 to 86.7% in 2013-14 (P 
<0.001). 
From 2005-06 through to 2013-14, there were more NHS patients (2005-06: 
(94.4%) and 2013-14: (97.0%) of patients) compared to private patients (2005-06: 
(5.6%) and 2013-14: (3.0%) of patients), P =0.025. For acute patients, in 2005-06 direct 
admission to a cardiac centre was the second route of admission after inter-hospital 
transfer (38.8% and 45.9%, respectively). However, over the years, admission directly 
to hospital became more predominant (36.9% vs 53.0%), P <0.001. Table 5.5 shows the 
distribution of baseline demographic characteristics by biennial year of date of 
procedure.  
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Figure 5.3: Standardized number of patients who received PCI to an UPLMS per 
centre in biennial years from 2005 to 2014, stratified by STEMI, NSTEACS and 
CSA (frequency and percentage). 
 
 
Proportions exclude missing data. 
P-values are for differences between years  
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Table 5.5: Baseline demographic characteristics of patients with UPLMS disease who received PCI, by biennial year of date of 
procedure. 
Variable 2005-06 n=864 
2007-08 
n=1,560 
2009-10 
n=2,494 
2011-12 
n=3.630 
2013-14 
n=2.279 P value * 
Cardiac centres participating 47 67 83 95 98 0.018 
Standardized number of PCI per centre 18.4 23.3 30.0 38.2 23.3 <0.001 
CSA (%) 349 (40.4) 613 (39.3) 879 (35.2) 1,220 (33.6) 738 (32.4) 
<0.001 STEMI (%) 90 (10.4) 212 (13.6) 465 (18.7) 706 (19.5) 441 (16.3) 
NSTEACS (%) 425 (49.2) 735 (47.1) 1,150 (46.1) 1,704 (49.9) 1,100 (48.3) 
Mean (SD) age, years  69.6 (11.8) 69.8 (12.1) 70.5 (12.5) 71.0 (12.0) 70.6 (12.2) 0.004 
Greater than 80 years (%) 179 (20.7) 366 (23.5) 633 (25.4) 906 (25.0) 552 (24.2) 0.022 
Male (%) 577 (70.8) 1,095 (70.3) 1,689 (67.8) 2,513 (69.4) 1,616 (71.0) 0.141 
Ethnic groups 
Caucasian (%) 515 (90.0) 808 (84.1) 1,468 (88.4) 2,226 (88.9) 1,234 (86.7) 
<0.001 
Black (%) 5 (0.9) 6 (0.6) 12 (0.7) 16 (0.6) 10 (0.7) 
Asian (%) 29 (5.1) 46 (4.8) 86 (5.2) 125 (5.0) 78 (5.5) 
Other (%) 23 (4.0) 101 (10.5) 95 (5.7) 137 (5.5) 102 (7.1) 
Patient type 
NHS (%) 756 (94.4) 1,382 (95.4) 2,240 (96.5) 3,273 (96.4) 2,115 (97.0) 
0.025 
Private (%) 45 (5.6) 67 (4.6) 80 (3.5) 124 (3.6) 65 (3.0) 
Admission 
route  
(ACS only) 
Direct to cardiac centre (%) 190 (38.8) 383 (43.6) 785 (46.6) 1,264 (50.9) 827 (53.0) 
<0.001 Inter-hospital transfer (%) 225 (45.9) 363 (41.3) 671 (39.8) 944 (38.0) 577 (36.9) 
Already in cardiac centre (%) 75 (15.3) 133 (15.1) 229 (13.6) 274 (11.1) 157 (10.1) 
Index of multiple deprivation score, mean (SD) 21.9 (14.2) 21.2 (13.7) 20.9 (13.6) 21.1 (13.5) 20.7 (13.2) 0.380 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables. 
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5.4.3 Trends of clinical characteristics  
Table 5.6 shows the distribution of baseline clinical characteristics by biennial 
year of procedure date. For the entire cohort, from 2005-06 through to 2013-14, there 
were fewer patients with a family history of coronary artery disease (46.8% to 40.3%, P 
<0.001). Similarly, from 2005-06 to 2013-14, there were fewer cases of failed 
thrombolysis for STEMI patients (36.7% to 3.1%, P <0.001) and for NSTEACS patients 
(8.4% to 0.9%, P <0.001). In contrast, from 2005-06 to 2013-14, there were more 
patients with a history of previous PCI (18.1% to 25.1%, P <0.001) and diabetes 
mellitus (18.9% to 22.6%, P =0.012).  
In total, 818 (43.1%) STEMI and 466 (9.2%) NSTEACS presented with 
cardiogenic shock, and for the cohort, the proportion of cases with cardiogenic shock 
increased from 9.0% in 2005-06 to 13.3% in 2013-14 (P =0.027). The proportion of 
cardiogenic shock in patients with STEMI decreased (from 49.4% in 2005-06 to 44.6% 
in 2013-14 (P =0.027)) and increased in NSTEACS (from 7.1% in 2005-06 to 9.1% in 
2013-14 (P =0. 450)). Likewise for severe left ventricular systolic dysfunction, the 
percentage of cases in the whole cohort increased from 15.3% to 19.3% (P =0. 327). 
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Table 5.6: Baseline clinical characteristics of patients with UPLMS disease who received PCI, by biennial year of date of 
procedure. 
Variable 2005-06 n=864 
2007-08 
n=1,560 
2009-10 
n=2,494 
2011-12 
n=3.630 
2013-14 
n=2.279 P value * 
Previous acute myocardial infarction (%) 248 (33.7) 434 (34.3) 733 (32.9) 1,148 (33.9) 724 (32.8) 0.824 
Previous PCI (%) 152 (18.1) 318 (20.7) 547 (22.1) 761 (21.2) 567 (25.1) <0.001 
Family history of coronary artery disease (%) 301 (46.8) 548 (47.1) 983 (45.9) 1,268 (41.0) 781 (40.3) <0.001 
Diabetes mellitus (%) 142 (18.9) 293 (19.8) 512 (21.1) 811 (23.3) 497 (22.6) 0.012 
History of renal disease (%) 44 (5.4) 99 (6.9) 172 (6.9) 222 (6.2) 137 (6.1) 0.525 
Smoking status 
Never smoked (%) 245 (36.5) 413 (32.0) 843 (37.5) 1,247 (38.0) 862 (41.6) 
<0.001 Ex-smoker (%) 312 (46.5) 646 (50.1) 1,019 (45.4) 1,440 (44.0) 879 (42.4) 
Current smoker (%) 114 (17.0) 230 (17.9) 385 (17.1) 589 (18.0) 333 (16.1) 
Recent thrombolysis 
Overall (%) 59 (11.6) 82 (9.0) 81 (5.3) 57 (2.5) 22 (1.5) <0.001 
STEMI (%) 29 (36.7) 38 (18.8) 34 (7.8) 22 (3.3) 13 (3.1) <0.001 
NSTEACS (%) 30 (8.4) 44 (7.2) 47 (4.6) 35 (2.3) 9 (0.9) <0.001 
Cardiogenic shock 
Overall (%) 68 (9.0) 172 (11.69) 303 (12.5) 453 (12.8) 297 (13.3) 0.027 
STEMI (%) 40 (49.4) 95 (44.8) 186 (40.1) 302 (43.0) 195 (44.6) 0.450 
NSTEACS (%) 28 (7.1) 77 (10.6) 113 (9.9) 150 (8.9) 98 (9.1) 0.327 
Severe left ventricular 
systolic dysfunction 
Overall (%) 78 (15.3) 211 (20.8) 288 (17.3) 441 (18.9) 283 (19.3) 0.052 
STEMI (%) 15 (41.7) 46 (50.0) 85 (42.7) 107 (35.8) 79 (45.4) 0.088 
NSTEACS (%) 49 (18.9) 107 (21.1) 159 (19.3) 248 (21.3) 165 (21.4) 0.635 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
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5.4.4 Trends of procedural characteristics 
The distribution of procedural characteristics by biennial year of procedure date is 
shown in Table 5.7. From 2005-06 to 2013-14, the proportion of pre-procedural TIMI 3 
increased over the study period (95 (33.0%) patients in 2005-06 versus 577 (52.7%) 
patients in 2013-14, P <0.001). Through all five strata of biennial years of procedure 
date, there was an increase in the proportion of cases that had more than one vessel 
stented (from 614 (71.1%) patients in 2005-06 to 1,681 (73.8) patients in 2013-14, P 
=0.027).  
As would be expected following the development of interventional technologies 
[44, 117, 176, 186], drug eluting stents were used more frequently than bare metal 
stents from 2005-06 to 2013-14 (drug eluting stents in 58.7% of patients in 2005-06 to 
82.8% in 2013-14 while bare metal stents in 22.6% of patients in 2005-06 to 6.5% in 
2013-14). Compared to 2005-06, the stent types that were used more often in 2013-14 
were Promus (Boston Scientific) in 504 (22.9%) patients, followed by Promus Element 
in 316 (14.4%) patients, Xience Prime in 254 (11.6%) patients and Resolute Integrity in 
240 (10.9%) patients (all P <0.001). Conversely, the use of Taxus liberte, Cypher and 
Endeavor stents decreased over the biennial years (from 43.7%, 15.4% and 6.3% in 
2005-06 vs. 0.4%, 0.0% and 1.5% in 2013-14, respectively (both P <0.001)). 
Later in the study period, intravascular ultrasound was performed more frequently 
(17.4% in 2005-06 vs. 40.3% in 2013-14, P <0.001) and pressure wire assessment 
increased (2.8% in 2005-06 vs. 7.1% in 2013-14, P <0.001). An intra-aortic balloon 
pump was inserted less frequently (16.7% in 2005-06 vs. 10.4% in 2013-14, P <0.001), 
especially in STEMI (46.3% vs. 25.8%) and NSTEACS (18.6% vs. 10.2%) (P <0.001). 
For CSA, rotational atherectomy was undertaken more frequently (3.9% in 2005-06 vs. 
7.2% in 2013-14, P <0.001). The glycoprotein IIb IIIa inhibitor, Abciximab, was used 
less frequently for STEMI patients (74.4% in 2005-06 vs. 30.3% in 2013-14), 
NSTEACS patients (54.1% in 2005 vs. 5.5% in 2013-14) and CSA patients (45.1% in 
2005-06 vs. 4.2% in 2013-14) (P <0.001).  
For the cohort, while the practice of femoral PCIs decreased over the years from 
685 (80.3%) in 2005-06 to 863 (38.5%) in 2013-14, radial PCIs increased from 157 
(18.4%) in 2005-06 to 1,375 (61.3%) in 2013-14. Figure 5.4 shows the temporal change 
in access for PCIs for the cohort as a whole and stratified by clinical presentation (all P 
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<0.001). For patients presenting with STEMI associated with cardiogenic shock, 
femoral access was always more frequently used than radial access (in 2005-06 86.8% 
femoral vs. 10.6% radial and in 2013-14 60.6% femoral vs. 39.4% radial, P <0.001), 
similarly for NSTEACS patients with cardiogenic shock (in 2005-06 82.1% femoral vs. 
14.3% radial and in 2013-14 64.2% femoral vs. 33.7% radial, P value =0.004). 
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Table 5.7: Procedural characteristics of patients with UPLMS disease who received PCI, by biennial year of date of procedure. 
Variable 2005-06 n=864 
2007-08 
n=1,560 
2009-10 
n=2,494 
2011-12 
n=3.630 
2013-14 
n=2.279 P value * 
Pre-procedural flow in 
infarct related artery 
TIMI 0 (%) 48 (16.7) 128 (19.8) 245 (20.8) 388 (22.7) 236 (21.5) 
<0.001 
TIMI 1 (%) 14 (4.9) 39 (6.0) 82 (7.0) 119 (7.0) 76 (6.9) 
TIMI 2 (%) 29 (10.0) 83 (12.9) 119 (10.1) 217 (12.7) 123 (11.2) 
TIMI 3 (%) 95 (33.0) 250 (38.7) 583 (49.5) 847 (49.6) 577 (52.7) 
Unknown (%) 102 (35.4) 146 (22.6) 148 (12.6) 137 (8.0) 84 (7.7) 
Vessels attempted  
Left main stem only (%) 250 (28.9) 470 (30.1) 738 (29.6) 995 (27.4) 598 (26.2) 
0.027 
Multi-vessels (%) 614 (71.1) 1,090 (69.9) 1,756 (70.4) 2,635 (72.6) 1,681 (73.8) 
Total number stents 
used 
1 stent (%) 241 (29.0) 457 (32.2) 784 (34.3) 1,181 (34.7) 686 (32.2) 
0.002 2 stents (%) 240 (28.9) 438 (30.9) 731 (32.0) 1,021 (30.0) 682 (32.3) 
≥ 3 stents (%) 350 (42.1) 524 (36.9) 771 (33.7) 1,204 (35.3) 754 (35.2) 
Type of stent used 
Bare metal stent (%) 186 (23.1) 385 (27.5) 480 (21.3) 502 (15.0) 147 (6.5) 
<0.001 Drug eluting stent (%) 484 (60.3) 818 (58.3) 1,581 (70.1) 2,678 (79.7) 1,862 (87.8) 
Both together (%) 133 (16.6) 199 (14.2) 193 (8.6) 179 (5.3) 112 (5.3) 
Type of 
DES used 
Taxus liberte (Boston Scientific)(%) 333 (43.7) 301 (23.1) 225 (9.9) 12 (0.3) 8 (0.4) 
<0.001 
Cypher (Cordis) (%) 117 (15.4) 131 (10.0) 106 (4.7) 11 (0.3) 0 (0.0) 
Endeavor (Medtronic) (%) 48 (6.3) 132 (10.1) 196 (8.6) 110 (3.1) 32 (1.5) 
Xience V (Abbott) (%) 1 (0.1) 87 (6.7) 388 (17.1) 393 (11.2) 97 (4.4) 
Promus (Boston Scientific) (%) 0 (0.0) 16 (1.2) 335 (14.8) 638 (18.1) 504 (22.9) 
BioMatrix (%) 0 (0.0) 0 (0.0) 82 (3.6) 324 (9.2) 205 (9.3) 
Promus Element (%) 0 (0.0) 0 (0.0) 61 (2.7) 481 (13.7) 316 (14.4) 
Xience Prime (%) 0 (0.0) 0 (0.0) 28 (1.2) 448 (12.7) 254 (11.6) 
Resolute Integrity (%) 0 (0.0) 0 (0.0) 9 (0.4) 347 (9.9) 240 (10.9) 
Longest stented/treated segment, mean (SD) mm 24.2 (14.6) 26.7 (16.5) 26.4 (15.9) 27.1 (16.1) 28.9 (19.1) <0.001 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
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(Continued) Table 5.7 Procedural characteristics of patients with UPLMS disease who received PCI, by biennial year of date of 
procedure. 
Variable 2005-06 n=864 
2007-08 
n=1,560 
2009-10 
n=2,494 
2011-12 
n=3.630 
2013-14 
n=2.279 P value * 
Use of ventilation (%) 21 (3.0) 50 (4.0) 131 (5.8) 217 (6.5) 137 (6.4) <0.001 
Drugs used 
None (%) 319 (40.4) 882 (59.0) 1,583 (67.6) 2,577 (74.6) 1,712 (78.4) 
<0.001 Abciximab (%) 
415 (52.6) 490 (32.8) 574 (24.6) 493 (14.3) 215 (9.9) 
Eptifibitide (%) 18 (2.3) 42 (2.8) 65 (2.8) 174 (5.0) 116 (5.3) 
Tirofiban (%) 37 (4.7) 80 (5.4) 116 (5.0) 209 (6.1) 140 (6.4) 
Use of intravascular ultra sound (%) 119 (17.4) 435 (30.2) 870 (36.3) 1,377 (38.9) 898 (40.3) <0.001 
Use of intravascular pressure wire (%) 19 (2.8) 93 (6.4) 195 (8.2) 253 (7.2) 157 (7.1) <0.001 
Use of Intra-aortic balloon pump (%) 130 (16.7) 235 (16.4) 373 (15.6) 458 (12.8) 230 (10.4) <0.001 
Arterial 
access 
Overall 
Femoral artery (%) 685 (80.3) 1,092 (71.6) 1,446 (58.9) 1,555 (43.8) 863 (38.5) 
<0.001 Radial artery (%) 157 (18.4) 428 (28.0) 996 (40.6) 1,981 (55.7) 1,375 (61.3) 
Other arteries (%) 11 (1.3) 6 (0.4) 12 (0.5) 18 (0.5) 4 (0.2) 
STEMI patients 
with cardiogenic 
shock 
Femoral artery (%) 33 (86.8) 77 (82.8) 149 (81.4) 188 (65.3) 117 (60.6) 
<0.001 Radial artery (%) 4 (10.6) 16 17.2) 34 (18.6) 99 (34.4 76 (39.4) 
Other arteries (%) 1 (2.6) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 
NSTEACS 
patients with 
cardiogenic shock 
Femoral artery (%) 23 (82.1) 62 (81.6) 77 (70.6) 85 (58.6) 61 (64.2) 
0.004 Radial artery (%) 4 (14.3) 14 (18.4) 31 (28.4) 60 (41.4) 32 (33.7) 
Other arteries (%) 1 (3.6) 0 (0.0) 1 (0.9) 0 (0.0) 2 (2.1) 
Post-procedure left main 
stem stenosis 
0% stenosis (%) 637 (84.0) 981 (74.4) 1,661 (73.9) 2,600 (76.8) 1,618 (75.4) 
<0.001 1-49% stenosis (%) 100 (13.2) 268 (20.3) 466 (20.7) 620 (18.3) 405 (18.9) 
≥ 50% stenosis (%) 21 (2.8) 70 (5.3) 121 (5.4) 167 (4.9) 124 (5.7) 
Post-procedure flow in 
infarct related artery  
TIMI 0 (%) 9 (2.4) 24 (2.8) 44 (2.9) 75 (3.2) 47 (3.1) 
<0.001 
TIMI 1 (%) 1 (0.3) 9 (1.1) 21 (1.4) 22 (1.0) 14 (0.9) 
TIMI 2 (%) 9.(2.4) 28 (3.3) 62 (4.0) 87 (3.8) 40 (2.7) 
TIMI 3 (%) 247 (66.4) 592 (70.8) 1,228 (80.1) 1,982 (85.5) 1,297 (86.3) 
 Unknown (%) 106 (28.5) 183 (22.0) 179 (11.6) 152 (6.5) 105 (7.0)  
Proportions exclude missing data.  
* P-value was calculated using the Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
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Figure 5.4: Proportion of femoral and radial access in patients who received PCI to an UPLMS in biennial years from 2005 to 
2014, stratified by STEMI, NSTEACS and CSA.  
  
  
Proportions exclude missing data.   
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5.4.5 Trends of procedural complications and in-hospital outcomes 
The rates of side branch occlusion, coronary dissection, coronary perforation, 
direct current cardioversion, no flow/slow flow, ventilation and cardiogenic shock 
occurring during the procedure did not change significantly over the study period. 
During the hospital stay, there were no significant changes in the proportion of patients 
with acute myocardial infarction, stroke, renal failure/dialysis and requiring blood 
transfusion or revascularisation. The distribution of procedural complications and in-
hospital outcomes by biennial year of procedure date is shown respectively in Tables 
5.8 and 5.9. 
 
5.4.6 Trends of Crude mortality 
From 2005-06 to 2013-14, unadjusted in-hospital MACCE rate decreased to some 
extent (10.4% vs. 8.8%, P =0.209) while unadjusted in-hospital mortality rate slightly 
increased (7.8% vs. 8.7%, P =0.404). Overall, there were 2,843 (26.3%) deaths over a 
total follow-up period of 9,329,661 patient years. There were significant interactions 
between biennial year, clinical strata and early and late mortality (all P <0.001). 
Unadjusted 30-day and 1-year mortality rates in UPLMS patients who received PCI in 
biennial years from 2005 to 2014, stratified by clinical presentation are shown 
respectively in Figure 5.5.  
For STEMI patients, 30-day and 1-year crude mortality rates decreased from 
35.3% and 42.4% in 2005-06 to 31.6% and 40.1% in 2013-14, respectively. Similarly 
for NSTEACS patients, 30-day and 1-year mortality rates decreased from 10.6% and 
21.3% in 2005-06 to 8.7% and 17.8% in 2013-14, respectively.  
 
5.4.7 Trends of adjusted mortality 
5.4.7.1 Clinical presentation and mortality 
Compared with 2005-06 and once adjusted for confounders, 30-day mortality in 
2013-14 did not change (STEMI: adjusted odds ratio (aOR) 0.9, 95% confidence 
interval (CI), 0.5 to 1.6; NSTEACS aOR 0.9, 95% CI 0.6 to 1.4; CSA aOR 1.2, 95% CI 
0.2 to 6.4). Figure 5.6 shows the adjusted risk of 30-day mortality for patients who 
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received PCI to UPLMS in biennial years from 2005 to 2014, stratified by clinical 
presentation (complete case data and pooled imputed data). Likewise, 1-year mortality 
remained stable in 2013-14 (STEMI aOR 0.9, 95% CI 0.5 to 1.6; NSTEACS aOR 0.9, 
95% CI 0.6 to 2.3; CSA aOR 1.1, 95% CI 0.5 to 2.4). Adjusted risk of 1-year mortality 
for patients who received PCI to UPLMS in biennial years from 2005 to 2014, stratified 
by clinical presentation (complete case data and pooled imputed data) can be seen in 
Figure 5.7. 
 
5.4.7.2 Cardiogenic shock and mortality 
In STEMI patients with cardiogenic shock, 30-day and 1-year mortality rates 
decreased by 13.3% (95% CI, 10.8% to 15.9%) and 7.0% (95% CI 5.1% to 9.2%), but 
remained high in 2013-14 at 52.5% and 64.0%, respectively. After multivariable 
adjustment, in 2013-14 these temporal improvements were upheld significantly in both 
early and late mortality (30-day mortality: aOR 0.3, 95% CI, 0.1 to 0.7; 1-year 
mortality: aOR 0.3, 95% CI 0.1 to 0.9). Figure 5.8 shows the adjusted risk of 30-day 
and 1-year mortality for patients with cardiogenic shock who received PCI to UPLMS 
in biennial years from 2005 to 2014, stratified by STEMI and NSTEACS. 
 
5.4.7.3 Radial approach and mortality  
At 30-days and 1-year, a decline in mortality for radial PCI cases was only 
evident in those who presented acutely; for STEMI: 9.7% (95% CI 3.9% to 19.6%) at 
30-day and 11.3% (95% CI 4.4% to 22.5%) at 1-year, and for NSTEACS: 3.8%, (95% 
CI 1.7% to 7.7%) at 30-day and 7.5% (95% CI 3.9% to 12.4%) at 1-year. After 
adjustment, the improvements at 30-days and 1-year were not significant except for 
NSTEACS patients at 1-year; for STEMI patients (at 30-days: aOR 0.50, 95% CI 0.14 
to 1.78 and at 1 year: aOR 0.50, 95% CI 0.14 to 1.75) and for NSTEACS patients (at 
30-days: aOR 0.57, 95% CI 0.26 to 1.25 and at 1 year:  aOR 0.42, 95% CI 0.22 to 0.83).  
 
 
 
171 
 
Table 5.8: Procedural complications for patients with UPLMS disease who received PCI, by biennial year of date of procedure. 
Variable 2005-06 n=864 
2007-08 
n=1,560 
2009-10 
n=2,494 
2011-12 
n=3.630 
2013-14 
n=2.279 P value * 
Side branch occlusion (%) 7 (0.9) 18 (1.3) 23 (1.0) 40 (1.2) 24 (1.1) 0.909 
Coronary dissection (%) 35 (4.5) 110 (7.9) 123 (5.5) 185 (5.4) 95 (4.4) <0.001 
Coronary perforation (%) 5 (0.7) 11 (0.8) 19 (0.8) 25 (0.7) 14 (0.7) 0.949 
Direct current cardioversion (%) 6 (0.8) 17 (1.2) 30 (1.3) 39 (1.2) 20 (0.9) 0.622 
No flow/slow flow (%) 17 (2.2) 30 (2.2) 32 (1.4) 45 (1.3) 24 (1.1) 0.045 
Ventilated (%) 11 (1.4) 26 (1.9) 46 (2.0) 64 (1.9) 39 (1.8) 0.866 
Cardiogenic shock induced by procedure (%) 14 (1.8) 24 (1.7) 42 (1.9) 45 (1.3) 34 (1.6) 0.548 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables 
 
 
Table 5.9: In-hospital outcomes for patients with UPLMS disease who received PCI, by biennial year of date of procedure. 
Variable 2005-06 n=864 
2007-08 
n=1,560 
2009-10 
n=2,494 
2011-12 
n=3.630 
2013-14 
n=2.279 P value * 
Acute myocardial infarction (%) 17 (2.1) 18 (1.2) 26 (1.1) 26 (0.7) 19 (0.9) 
0.036 
Stroke (%) 2 (0.3) 2 (0.1) 8 (0.3) 7 (0.2) 3 (0.1) 
Renal failure/dialysis (%) 5 (0.6) 10 (0.7) 18 (0.7) 15 (0.4) 8 (0.4) 0.330 
Blood transfusion (%) 10 (1.2) 13 (0.9) 22 (0.9) 25 (0.7) 15 (0.7) 0.521 
Revascularisation 
Percutaneous coronary intervention (%) 5 (0.6) 5 (0.3) 9 (0.4) 16 (0.5) 7 (0.3) 
0.170 
Coronary artery bypass graft (%) 4 (0.5) 19 (1.3) 12 (0.5) 21 (0.6) 14 (0.6) 
Unadjusted in-hospital MACCE rate (%) 84 (10.4) 120 (7.9) 207 (8.5) 286 (8.1) 198 (8.8) 0.209 
Unadjusted in-hospital mortality rate (%) 61 (7.8) 108 (7.1) 208 (8.5) 305 (8.5) 194 (8.7) 0.404 
Proportions exclude missing data.  
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
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Figure ‎5.5: Unadjusted 30-day and 1-year mortality rates in patients who received PCI to an UPLMS in biennial years from 2005 
to 2014, stratified by STEMI, NSTEACS and CSA. 
 
                            30-day mortality rates                                                                      1-year mortality rates 
 
Proportions exclude missing data.  
** For 1-year mortality: Censored at 31/7/2014, therefore all PCI procedures performed after 31/7/2013 were not included in describing this rate. 
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Figure ‎5.6: Multivariable adjusted risk of 30-day mortality for patients who received PCI to an UPLMS in biennial years from 
2005 to 2014, stratified by STEMI, NSTEACS and CSA (complete case data and imputed data). 
 
 
                              Complete case data                                                                              Imputed data 
 
aOR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled imputed data. 
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Figure ‎5.7: Multivariable adjusted risk of 1-year mortality for patients who received PCI to an UPLMS in biennial years from 2005 
to 2014, stratified by STEMI, NSTEACS and CSA (complete case data and imputed data). 
 
             Complete case data                                                                                   Imputed data 
  
aOR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled imputed data. 
** Censored at 31/7/2014, therefore all PCI procedures performed after 31/7/2013 were not included in describing this rate.  
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Figure 5.8: Multivariable adjusted risk of 30-day and 1-year mortality for patients 
with cardiogenic shock who received PCI to an UPLMS in biennial years from 
2005 to 2014, stratified by STEMI and NSTEACS. 
 
aOR and 95%CI were calculated using multivariate logistic regression for both complete case and pooled 
imputed data. 
** For 1-year mortality only: Censored at 31/7/2014, therefore all PCI procedures performed after 
31/7/2013 were not included in describing this rate.  
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5.4.8 Sensitivity analyses 
5.4.8.1 Mixed effects modelling  
Table 5.10 shows a summary of mixed effects models adjusted odds ratios of 1-
year mortality for UPLMS patients who underwent PCI. Logistic regression models that 
were used in the adjusted ‘fixed effects’ analysis, described in detail earlier in this 
chapter (section 5.3.6.2), were repeated taking into account the hierarchical level of 
hospitals ‘mixed effects’. 
 There was evidence for hospital (level 2) effects indicating that the use of mixed 
effects models did not substantially affect the patient (level 1) estimates. In the mixed 
effect models for the types of clinical presentation (STEMI and NSTEACS), the 
likelihood ratio statistics were statistically significant indicating that there were 
similarities between the patients within each hospital and there was significant 
difference between hospitals 
For example, the adjusted odds ratios at 30-day mortality in 2013-14 for STEMI 
patients were (fixed effects estimates: aOR 0.9, 95% CI 0.5 to 1.6 and mixed effects 
estimates: aOR, 0.9, 95% CI 0.5 to 1.6, the likelihood ratio statistic was significant, P = 
0.004). In the same way, the adjusted odds ratios at 1-year mortality in 2013-14 for 
STEMI patients were (fixed effects estimates: aOR 0.9, 95% CI 0.5 to 1.6 and mixed 
effects estimates: aOR, 0.9, 95% CI 0.5 to 1.6, the likelihood ratio statistic was 
significant, P <0.001) (Figure 5.6, Figure 5.7 and Table 5.10). 
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Table 5.10: multi-level (mixed effects) modelling at hospital level adjusted odds ratios of 30-day and 1-year mortality for UPLMS 
patients who underwent PCI. 
Outcome Variable 
At hospital level 
2007-08 
n=1,560 
2009-10 
n=2,494 
2011-12 
n=3.630 
2013-14 
n=2.279 
likelihood 
ratio 
P value 
aOR 95% CI aOR 95% CI aOR 95% CI aOR 95% CI  
30-day 
mortality 
CSA 3.2 0.7 – 14.2 1.1 0.2 – 5.4 1.9 0.4 – 8.4 1.2 0.2 – 6.4 1.000 
STEMI 0.8 0.4 – 1.5 0.7 0.4 – 1.2 0.8 0.4 – 1.4 0.9 0.5 – 1.6 0.004 
NSTEACS 0.8 0.6 – 1.4 0.9 0.6 – 1.3 0.9 0.6 – 1.4 0.9 0.6 – 1.4 0.002 
STEMI with 
cardiogenic shock 0.4 0.1 – 1.1 0.3 0.1 – 0.7 0.3 0.1 – 0.7 0.3 0.1 – 0.8 0.093 
Radial vs femoral 
access  in STEMI 0.8 0.4 – 1.6 0.9 0.5 – 1.6 0.8 0.4 – 1.4 1.0 0.5 – 1.9 0.203 
1-year 
mortality 
CSA 1.5 0.7 – 2.9 1.3 0.7 – 2.6 1.7 0.9 – 3.2 1.1 0.5 – 2.4 0.200 
STEMI 0.8 0.5 – 1.5 0.7 0.4 – 1.2 0.7 0.4 – 1.2 0.9 0.5 – 1.6 <0.001 
NSTEACS 1.0 0.7 – 1.4 0.9 0.7 – 1.4 0.9 0.7 – 1.3 0.9 0.6 – 1.3 <0.001 
STEMI with 
cardiogenic shock 0.4 0.1 – 1.0 0.3 0.1 – 0.7 0.2 0.1 – 0.6 0.3 0.1 – 0.7 0.078 
Radial vs femoral 
access  in STEMI 0.8 0.4 – 1.5 0.8 0.4 – 1.5 0.7 0.4 – 1.3 1.0 0.5 – 2.1 0.068 
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5.4.8.2 Multiple imputation  
Figures 5.6 and 5.7 show the adjusted odds ratios for 30-day and 1-year mortality in 
patients with UPLMS who received PCI in biennial years from 2005 to 2014, stratified 
by clinical presentation using complete case data and imputed data. In general, the 
multivariate adjustment of the pooled multiple imputation of the missing data made 
only small changes to point estimates generated from the models. However, the 
imputation improved the precision of the estimates (smaller confidence intervals) due to 
the increment in patients’ number in the imputed dataset.  
Compared with 2005-06, 30-day mortality rates in 2013-14 for STEMI patients 
were (adjusted odds ratio (aOR), 95% confidence interval (CI) 0.9, 0.5 to 1.6 in 
complete case data compared to 0.7, 0.4 to 1.2 in imputed data), for NSTEACS patients 
(aOR, 95% CI 0.9, 0.6 to 1.4 in complete case data compared to0.8, 0.5 to 1.2 in 
imputed data) and CSA patients (aOR, 95% CI 1.2, 0.2 to 6.4 in complete case data 
compared to 1.2, 0.3 to 4.6 in imputed data). Similarly, 1-year mortality rates in 2013-
14 for STEMI patients were (aOR, 95% CI 0.9, 0.5 to 1.6 in complete case data 
compared to 0.8, 0.5 to 1.4 in imputed data), for NSTEACS patients (aOR, 95% CI 0.9, 
0.6 to 1.3 in complete case data compared to0.8, 0.6 to 1.1 in imputed data) and CSA 
patients (aOR, 95% CI 1.1, 0.5 to 2.4 in complete case data compared to 1.0, 0.5 to 2.1 
in imputed data).   
After multivariable adjustment of the pooled imputed data, by 2013-14 the 
temporal changes to the generated point estimates were statistically irrelevant as they 
did not change the overall association result of the models and at the same time no 
changes were observed in the significance of these associations at 30-day mortality and 
1-year mortality. A compression between the complete case data and pooled multiply 
imputed data can be seen in Figures 5.6 and 5.7 which shows the adjusted risk of 30-day 
and 1-year mortality rates for patients who received PCI to an UPLMS in biennial years 
from 2005 to 2014, stratified by clinical presentation.  
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5.5 Discussion 
 
5.5.1 Summary of key findings 
• The number of patients with UPLMS who underwent PCI increased by over six-fold 
in cases, particularly patients who presented acutely.  
• Baseline risk profile (reflected in a range of parameters including severe left 
ventricular systolic dysfunction, age over 80 years and cardiogenic shock) increased.  
• Over the study period, several procedural characteristics in UPLMS PCI changed, 
including an increase in drug eluting stents and intravascular ultrasound use and 
considerably less glycoprotein IIbIIIa inhibitor (Abciximab) use. 
• The use of the radial approach across all clinical strata increased by biennial years. 
However, it remained less frequent than the femoral approach in STEMI and 
NSTEACS patients with cardiogenic shock. 
• Mortality rates across the spectrum of clinical presentations following UPLMS PCI 
remained remarkably static despite the significant increase in the number and 
severity of cases.  
• For very high risk cases such as UPLMS PCI for patients with STEMI, complicated 
by cardiogenic shock, 30-day and 1-year mortality rates have declined over the 
study period by about 13% and 7%, respectively. 
• Multiple imputation made a slight improvement on the precision of the generated 
adjusted hazard ratios which were statistically insignificant as they did not change 
the overall association result of the same models from the complete case data.  
• Even though there was evidence for hospital effects, the use of mixed effects models 
did not largely affect the adjusted estimates at patient’s level. 
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5.5.2 Findings in the context of literature 
This whole country observational cohort study of consecutive cases clearly 
demonstrates substantial changes in both the clinical presentation and the treatment of 
patients who received UPLMS PCI between 2005 and 2014. Overall, the number of 
UPLMS cases treated by PCI increased by over six-fold. By contrast to UPLMS PCI, 
the overall number of cases of PCI in the UK has increased, but at a much slower rate 
[20, 54]. 
The increase in patients with UPLMS who underwent PCI in the UK is likely to be 
the result of a combination of factors including: 
1. The improvements in both technology and technique of PCI procedures with the 
augmentation of experience among interventional cardiologists [25, 60].  
2. The relatively recent publication of clinical registry and trial data from a small 
number of PCI centres (in several countries) showing favourable short and long 
term clinical efficacy and mortality rates [126, 188]. 
3. The move from thrombolysis to primary PCI for the treatment of patients with 
STEMI [76, 189]. 
In addition, this study identified that the absolute numbers of UPLMS PCI for 
STEMI with and without cardiogenic shock increased more than for the other clinical 
syndromes. This was probably a consequence of the increase in the provision of primary 
PCI services in the UK during this period [76, 117]. Furthermore, the logistics of 
arranging emergency CABG in the setting of STEMI remains prohibitive, and poor 
outcomes from CABG in this group have led to a reluctance to operate in this clinical 
setting [25, 90, 92].  
When feasible, PCI is therefore the most practical mode of revascularisation for 
UPLMS disease presenting as STEMI in this situation. Whilst observational data 
suggests that there is an outcome benefit for the use of intravascular ultrasound in left 
main stem PCI [190] in this study, even in 2013-2014, it was used in only slightly more 
than one third of cases (40.3%). The lack of high quality randomised trial data 
demonstrating outcome benefit from routine use of intravascular ultrasound represents 
an important unanswered question that will guide clinical practice.  
 
181 
 
 
 
A decline was noted in the proportion of patients who received more than three 
stents and more patients received multi-vessel PCI (from 42.1% in 2005-06 to 35.2% in 
2013-14). There was a change in the deployment of stents with more frequent 
deployment of drug eluting stents and, in particular second generation drug eluting 
stents in the later years of the study. This study showed that there was an increase in the 
proportion of patients with post-procedure left main stem stenosis greater than 50%. On 
the other hand, there was no substantial improvement in the proportion of patients with 
post-procedure TIMI 3 flow in the infarct related artery.  
An increase in the use of the radial approach across all clinical strata was noted. 
However, it remained less frequent than the femoral approach in STEMI and NSTEACS 
patients with cardiogenic shock, in whom the use of intra-aortic balloon pump was 
highest. Across the study population as a whole, the radial approach was associated with 
a lower 30-day, but not 1-year mortality, a finding aligned with other recent 
publications [191, 192]. Nonetheless, for patients with CSA, the radial approach was 
not associated with a significant decline in mortality. However, it is likely that despite 
adjustment for case mix, our results are confounded by indication because higher risk 
patients were more likely to be selected for a femoral approach. 
The results of the temporal investigation suggested that early and late mortality 
rates across the spectrum of clinical presentations did not change, except for STEMI 
patients with cardiogenic shock which demonstrated a significant decline in the risk of 
death (30-day mortality: aOR 0.3, 95% CI, 0.1 to 0.7; 1-year mortality: aOR 0.3, 95% 
CI 0.1 to 0.9). However, the mortality rate in this group of patients was very high 
(52.5% and 64.0%, respectively), calling for research into interventions which may 
address these potentially avoidable deaths. Park et al. [43] reported a decline by 40% in 
all-cause mortality over 12 years (aHR 0.6 95% CI 0.4 to 0.9). Although, Park’s 
findings were similar to the findings in this analysis; the size of the cohort of Park’s 
study was small and less representative since it was performed outside the UK. 
Of note was the lack of decline in mortality rates when on the whole 
cardiovascular outcomes have improved substantially over the last few years [76, 78, 
193]. There was an increase in the baseline risk of patients with UPLMS who received 
PCI and it is possible that this may have attenuated any decline in mortality associated 
with advances in interventional technologies, adjunctive pharmacology as well as the 
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quality of care provided. Data from the Swedish Coronary Angiography and 
Angioplasty Registry (SCAAR) registry [194] over the same period of study included 
144,039 PCI procedures from 1990 to 2010. An investigation that also revealed stable 
1-year adjusted mortality rates after PCI to any vessel. It is possible that PCI has 
reached a plateau phase where patient characteristics (co-morbidities) as well as mode 
of presentation rather than procedural factors now dominate outcomes. Whilst this is 
possible, we found no change in the crude or adjusted rates, suggesting that other 
factors come into play, or that our adjustment regression model was not sufficient to 
comprehensively incorporate cardiovascular risk.  
Broader discussions on the methodologies used, such as those relating to the 
importance of multi-level analysis as well as multiple imputation, are outlined in the 
discussion chapter. Moreover, more detailed discussion on the overall strengths, 
limitations and implications of this thesis will be debated in the discussion chapter (see 
Chapter 7). The next chapter investigates the determinants of survival in patients with 
STEMI after primary PCI. 
 
 
 
5.5.3 Conclusion 
Over the study period, these contemporary multicentre observational data show 
considerable changes in the presentation and treatment but not mortality of patients with 
UPLMS who underwent PCI. Substantial increase in the number of UPLMS PCI 
patients was noted, predominantly in acute patients. Early and late mortality rates were 
stable across all clinical presentation groups. Early and late mortality rates for STEMI 
with cardiogenic shock declined; however, both mortality rates persisted to be high. The 
use of the radial approach increased by biennial years. Nevertheless, the radial approach 
in STEMI and NSTEACS patients with cardiogenic shock was used less frequently than 
the femoralapproach. 
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6 Chapter 6   Determinants of survival after primary PCI 
 
 
 
 
6.1 Summary 
In the previous two chapters (Chapters 4 and 5), the determinants and temporal 
trends of outcomes after PCI in UPLMS patients were evaluated. For more 
understanding to the quality of care for the patients who received PCI in the UK, this 
chapter concerns an investigation using the BCIS data into the clinical determinants of 
primary PCI survival in patients with STEMI. Brief definitions of the types of PCIs 
(facilitated, rescue and primary) in the management of patients with STEMI as well as a 
full introduction to primary PCI were described in Chapter 1 (sections 1.3.3 and 1.3.4). 
A literature review about ‘the clinical determinants of the survival for patients with 
STEMI who underwent primary PCI’ was provided in Chapter 2 (section 2.5). This 
chapter is split into four sections covering: the background, rationale and aims (section 
6.2); methodology including study design, population, stratification, definitions, follow-
up as well as statistical and sensitivity analyses (section 6.3); results including 
completeness, descriptive statistics, survival time, multivariate modelling results and 
sensitivity results (section 6.4); and discussion and conclusion (section 6.5). 
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6.2 Introduction 
6.2.1 Background and rationale 
Worldwide, the recommended first line treatment in the management of acute 
STEMI with or without cardiogenic shock is primary PCI [4, 74]. Survival following 
acute myocardial infarction patients, particularly among those with STEMI, is 
profoundly affected by the timing (i.e. urgency) of the medical or interventional 
treatment provided [4, 7]. Delays to the treatment of patients with STEMI can lead to 
undesirable complications and potentially avoidable adverse outcomes [71-73]. The 
practice of primary PCI is increasing globally and particularly in the UK [70-73, 195]. 
In England and Wales, the frequency of primary PCIs increased by 15.0% from 2004 to 
2007 [70, 71, 195].  
Evidence from the medical literature supports the fact that primary PCI is 
associated with better outcomes and survival for patients with STEMI than rescue or 
facilitated PCI [70]. However, some studies in the literature contradicted these findings 
and concluded that the impact of primary PCI on survival was worse than the facilitated 
and rescue PCI [118, 196]. Furthermore, there is a gap of knowledge regarding the 
predictors of survival after primary PCI. These predictors subsequently have influence 
on the outcomes and survival of primary PCI [71, 75, 76]. The influence of admission 
route and hospital differences on primary PCI survival rates is not well defined [78, 79]. 
Therefore, clinical determinants of survival have a variety of incongruity that need 
additional exploration and analysis. 
In addition, the majority of the existing literature about primary PCI has arisen 
from randomised controlled trials and is typically conducted outside the UK. Thus they 
may not be generalisable to the UK. Likewise, there are few prospective studies of the 
survival in the UK STEMI patients who underwent primary PCI [78, 79, 87]. The 
results of most of the reviewed studies were not representative of the general population 
as the majority of these studies were implemented at a local, hospital level and only 
three studies were performed using population-based datasets; thus, further 
representative studies using national registries are essential. 
Using contemporary primary PCI data available in an observational national-
based dataset such as BCIS database allows us to infer all primary PCI survival to the 
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UK population. Consequently, significant results are worth reporting to patients, 
cardiology professionals and healthcare managers in the UK on the benefits of existing 
interventional care of such patients as well as to highlight to stakeholders all areas 
where care and/or organisational changes and improvements are required. 
 
6.2.2 Aims 
The overall rationale and aims of the thesis were mentioned in Chapter 2 
(section 2.6). The primary aim of this chapter was to perform a population-based 
comparative investigation of all patients with STEMI who received facilitated, rescue 
and primary PCI in the UK over a period of ten years (from January 1 2005 to March 31 
2014) in order to: 
1. Describe the overall completeness of the 2014 updated BCIS data for all patients 
with STEMI. 
2. Describe demographic and clinical characteristics of patients stratified by the 
type of PCI (‘facilitated or rescue’ versus primary). 
3. Describe the procedural characteristics of patients stratified by the type of PCI, 
including: 
a. Techniques, medications, types of equipment and types of stents used. 
b. The use of radial approach versus the femoral approach. 
4. Evaluate the outcomes including survival of primary PCI for patients with 
STEMI compared to facilitated and rescue PCI. 
5. Identify the clinical determinants of primary PCI survival in patients with 
STEMI and to measure their level of association compared to facilitated and 
rescue PCI. 
6. Measure the impact of admission route (using multi-level analysis) on the effect 
of the clinical determinants of survival in patients with STEMI after primary 
PCI procedures.  
7. Measure the influence of hospitals’ dissimilarities (using multi-level analysis) on 
the survival in patients with STEMI stratified by the type of PCI 
8. Generate imputed BCIS datasets ‘fit for purpose’ using multiple imputation in 
order to test for the analysis sensitivity. 
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6.3 Methodology 
6.3.1 Study setting and design  
The study design was a prospective population-based linked cohort study using 
data of patients with STEMI who receive any one of facilitated, rescue and primary PCI. 
The data were collected from 111 interventional cardiology centres and hospitals in 
England, Scotland, Northern Ireland and Wales. All were part of 117 cardiology centres 
and hospitals registered with the BCIS audit program between 2005 and 2014 (based on 
BCIS Audit Returns, Adult Interventional Procedures, January 2013 to December 2013) 
[54]. 
 
6.3.2 Patients, procedures and treatments (Study population) 
The sampling frame was based on the updated BCIS dataset and included all 
patients from all countries in the UK (England, Scotland, Northern Ireland and Wales). 
The total number of patients who attended for PCI in all countries in the UK between 
the 1st of January, 2005 and the 31st of March, 2014 was 699,248 patients (2014 BCIS 
data). The inclusion and exclusion criteria (based on the Delphi group clinical 
agreement) for the derivation of the analytical cohort were: 
• Patients who were age less than 18 years were excluded.  
• The earliest intervention record was used for patients with multiple 
admissions.  
• Chronic stable angina patients (279,894) and NSTEACS patients (256,815) 
were excluded. In the same way, patients who had received PCI for ‘other 
reasons’, ‘unlisted reasons’ or ‘with missing information’ were also 
excluded (31,140 patients).  
• The remaining number of PCI records (134,710) were all patients with 
STEMI who had received PCI in the UK over a period of ten years (from 
January 1 2005 to March 31 2014). 
• Out of these, 36,073 patients who did not meet electrocardiography criteria 
for STEMI were excluded.  
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• Therefore, the final population used for the analysis in this chapter was 
98,637 patients with STEMI undergoing PCI. A detailed flow chart of the 
selected cohort population is shown in Figure 6.1.  
 
6.3.3 Stratification of cohort population  
The designated strata of the cohort population are shown in the flow chart, 
Figure 6.1. Based on the type of PCI provided to treat patients with STEMI, the whole 
analysis of this chapter was conducted across two main strata: 
1. Patients with STEMI who had received primary PCI (91,359 patients). 
2. Patients with STEMI who had received ‘facilitated or rescue’ PCI (7,278 
patients): 
• Facilitated PCI (1,549 patients) 
• Rescue PCI (5,729 patients) 
Assuming both types have similar patterns of risk factors, the patients of both 
facilitated and rescue PCI were joined together in one group for statistical and analytical 
reasons. Due to the low number of patients in both types compared to primary PCI, 
combining facilitated and rescue PCI increases the patients number as a group and gives 
more power to the comparison. The clinical definition of each stratum was described 
previously in Chapter 1 (section 1.3.3 and Figure 1.2) and in Chapter 4 (Table 4.1).  
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Figure 6.1: Flow chart of the selected cohort population. 
 
 
 
 
  
 
  
36,073 patients did not meet 
ECG criteria for STEMI 
699,248 consecutive patients who attended for PCI in England and Wales 
between January 1, 2005 and March 31, 2014 
134,710 STEMI 
patients received 
PCI 
256,518 NSTEACS 
patients received PCI 
276,894 CSA 
patients received PCI 
31,140 patients 
received other 
PCI or unlisted 
5,729 STEMI patients 
received Rescue PCI 
 
1,201  direct to 
cardiac centre 
4,226  In-hospital 
transfer* 
147 already in 
cardiac centre 
155 missing** 
 
1,549 STEMI patients 
received Facilitated PCI 
 
545 direct to cardiac 
centre 
872 In-hospital 
transfer* 
53 already in cardiac 
centre 
79  missing** 
 
 * Only STEMI patients who had their symptoms before or after admission to the referring 
hospital were added to this group by comparing symptom onset date to Door 1date. 
** Missing records + STEMI patients who had mismatch in their symptom onset date (by 
comparing symptom onset date to Door 1 date). 
 
91,359 STEMI patients 
received Primary PCI 
 
66,252  direct to cardiac 
centre 
20,725  In-hospital 
transfer* 
2,814  already in 
cardiac centre 
1,568  missing** 
 
98,637 STEMI 
patients 
received PCI 
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6.3.4 Other definitions  
Please refer to Chapter 4 (section 4.3.4) for the definitions of acute myocardial 
infarction, patients with STEMI, PCI, cardiogenic shock and MACCE. The categories 
of the routes of admission were defined in the BCIS database spreadsheet version 5.6.x 
as follows: 
• Direct admission to a cardiac centre: is simply when any patient admitted from the 
community where he/she developed his/her symptoms. 
• Inter-hospital transfer: a patient whose admission was because of ACS and was then 
transferred to another hospital for PCI.  
• Already in a cardiac centre: a patient who developed new symptoms of chest pain 
after being admitted to a hospital for a different reason. For example, the patient was 
admitted with a chest infection and then developed chest pain and ECG changes 
while still in hospital. 
However, some patients in the ‘already in a cardiac centre’ category had 
mismatched symptom onset and admission dates. Therefore, further data cleaning was 
performed and any patient with such an issue was considered to have missing 
information about his/her admission, a process that led to the drop out of more records 
in the complete case analysis of that variable. More details can be seen in Figure 6.1.  
 
6.3.5 Follow-up and mortality  
More details concerning patients’ follow-up and mortality can be found in 
Chapter 1 (section 1.4.3 and Figure 1.3). In summary, the analysis of all-cause mortality 
was produced by the MRIS by linkage with the ONS using each patient’s unique NHS 
number. Afterwards, using each patient’s geographical residence and IMD score, a 
linkage was made by the CCAD to their corresponding BCIS record.  
In the received 2014 versions of the BCIS database, patients, interventionists 
and hospital identifiers were secondary anonymised. Due to the date of linkage for 
censored data (31st July 2014), mortality at 1-year and survival data were not available 
for 519 (10.2%) patients. Thus, patients with a follow-up period of less than 12 months 
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were excluded from the analysis of patients’ survival and 1-year mortality rate; 
however, those patients were included in all other parts of the analysis. 
 
6.3.6 Statistical analysis 
6.3.6.1 Descriptive data analysis 
With the intention of obtaining more understanding of patients’ characteristics, 
an initial overall description of the cohort was executed, followed by an exploration of 
missing data for all the variables in the selected cohort (from the 2014 BCIS database). 
Missing data patterns were measured and assessed based on the percentage of 
missingness. Later, a few examples were described on the extent of missing data in both 
strata, ‘facilitated or rescue’ and primary PCI. 
As mentioned earlier, the whole analysis was stratified by the type of PCI 
performed for patients with STEMI (‘facilitated or rescue’ and primary). The purpose of 
this stratification was to compare the differences between the patients in both 
intervention groups. It is well understood that primary PCI in patients with STEMI 
produces better outcomes compared to rescue or facilitated PCI [70]. Later in the 
analysis, this stratification gave the opportunity to identify and compare the clinical 
determinants of survival in both intervention groups. Types of tests and methods used 
for data description are mentioned before in detail in Chapter 3 (section 3.5). 
The described includes: baseline demographics, clinical features and procedural 
characteristics (including pre-procedural and post-procedural). Clinical outcomes were 
also described (including procedural complications, in-hospital outcomes, 30-day 
mortality rate and 1-year mortality rate). The frequency of 30-day and 1-year mortality 
rates were measured further, stratified by the type of arterial approach used.  
 
6.3.6.2 Survival curves 
Cumulative unadjusted survival estimates of patients with STEMI who received 
facilitated, rescue and primary PCI were illustrated using the Kaplan-Meier method 
from the time of the procedure to 9.6 years. The differences across strata were compared 
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using the Mantel-Cox log-rank test. The same analysis was repeated to compare the 
differences between the unadjusted survival times in both ‘facilitated or rescue’ and 
primary PCI groups stratified by three routes of admission (direct admission to a cardiac 
centre, inter-hospital transfer and already in a cardiac centre).  
 
6.3.6.3 Survival modelling 
The general principle of survival modelling was described earlier in Chapter 3 
(section 3.4.6.3). A survival modelling strategy with adjustment was executed to 
identify the clinical determinants of the survival of patients with STEMI in both 
intervention groups. The associations with survival at 9.6 years were quantified using 
fixed effects multivariate Cox proportional hazards models, and estimates were 
expressed as adjusted hazard ratios (aHR) with 95% confidence intervals (CI). For all 
tests, a P value less than 5% was considered a cut-off point for statistical significance. 
All analyses were conducted using Stata IC version 13.0 (StataCorp LP, Texas, USA). 
The chosen clinical determinants (predictors) are listed in Table 6.1. The 
predictors and model covariates were selected based on a literature review on ‘the 
clinical determinants of survival for primary percutaneous coronary intervention’; see 
Chapter 2 (section 2.5). In addition, they were selected in light of the clinical 
importance recommended by the Delphi group. Multivariate model selection process, 
interaction assessment and the evaluation of goodness of fit were mentioned in detail in 
Chapter 3 (section 3.4.6.5). In brief, variables with significant predictive value of a P 
value < 0.05 after univariable modelling were added to the multivariate model. The 
likelihood ratio test was used to assess for interactions and to evaluate the model 
goodness of fit. 
For each predictor, the estimates of the multivariate Cox hazards regression 
model in both intervention groups were adjusted by eight different covariates. These 
selected covariates included ‘age groups’, ‘sex’, ‘pre-procedural cardiogenic shock’, 
‘history of diabetes mellitus’, ‘history of renal disease’ and ‘post-procedural 
complications (side branch occlusion, coronary dissection and shock induced by 
procedure)’ (Table 6.1).   
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Table 6.1: Summary of the multivariate Cox hazards models used including the selected predictor variables and covariates. 
Outcome and method Predictors Covariates 
Survival at 9.6 years using fixed 
effects multivariate Cox proportional 
hazards model in patients with 
STEMI who underwent ‘facilitated 
or rescue’ and primary PCI 
Age groups 
Age groups, sex, cardiogenic shock, 
history of diabetes mellitus, history of 
renal disease and post-procedural 
complications (side branch occlusion, 
coronary dissection and shock induced 
by procedure) 
Sex 
Routes of admission 
Pre-procedural cardiogenic shock 
History of Acute myocardial infarction 
History of PCI 
History of hypertension 
History of Diabetes mellitus 
History of Renal disease 
Left ventricular ejection fraction 
Vessels attempted 
Longest Stented/Treated Segment 
Number stents used 
Drugs used during procedure 
Intravascular ultrasound use during procedure 
Use of intra-aortic balloon pump 
Arterial Access 
Time from start of the first symptom to the intervention 
In-hospital acute myocardial infarction & stroke 
Procedural complication: Side branch occlusion 
Procedural complication:  Coronary dissection 
Procedural complication: Shock induced by procedure 
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6.3.7 Sensitivity analyses  
Three sensitivity analyses were performed to evaluate potential bias from using 
fixed effect regression methods. Like the previous chapters, the influence of mixed 
effects Cox hazards models at hospital level was evaluated. Then, the multivariate Cox 
hazards regression analyses were considered after multiple imputation of missing data. 
 
6.3.7.1 Multi-level regression modelling 
The general concept of multi-level regression or mixed effects modelling was 
defined previously in Chapter 3 (section 3.5.1.5). Models were fitted with a hierarchy of 
patients clustered in each hospital using random intercepts for hospitals, therefore, 
allowing for correlations between patient outcomes. Consequently, the mixed effects 
models accounted for the variance in the predictor variables as well as the variance at 
the hospital level [133].  
This method was performed separately for the ‘facilitated or rescue’ PCI group 
and for the primary PCI group. Like fixed effect multivariate Cox hazards regression 
models, the same predictor variables and covariates (Table 6.1) were fitted in the 
mixed-effect models. Afterward, the adjusted hazard ratio estimates were compared 
with those from the equivalent fixed effects model.  
 
6.3.7.2 Multiple imputation method 
A detailed explanation of multiple imputation method was mentioned earlier in 
Chapter 3 (sections 3.4.7 and 3.4.8). Table 6.2 show the list of imputation predictor 
variables of the survival of patients with STEMI who received ‘facilitated or rescue’ 
and primary PCI with a summary of missing data and the methods used for imputation. 
In total, 22 imputation predictors were selected, which were based on clinical consensus 
and a literature review; see Chapter 2 (section 2.5). The frequency of missing values 
ranged from 0.10% to 65.43%, and all missing values were assumed to be missing at 
random.  
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No data were missing for four of these variables: ‘routes of admission’, ‘type of 
PCI’, ‘year of operation’ and ‘life status at censoring time’. Though, these factors were 
still used in the imputation as auxiliary variables. As mentioned before in Chapter 3 
(section 3.4.8), imputation is not recommended for variables with more than 40% 
missingness [174]. Therefore, the variable ‘left ventricular ejection fraction’ was not 
imputed as the missing values were (65.43%). Yet again, the variable was used in the 
imputation model as an auxiliary variable.  
A predictor matrix of 22 variables was designed based on clinical agreement as 
well as using thresholded P values of less than 0.05 as related and greater than or equal 
to 0.05 as unrelated (Table 6.3). Chi-squared tests were used for categorical-categorical 
associations while linear regression was used for continuous-continuous and 
continuous-categorical associations. From the beginning, the variable ‘time from start of 
the first symptom to the intervention’ was not included in the predictors list due to 
collinearity with the ‘routes of admission’ variable.  
For each of the remaining 16 predictors with missing values, 20 datasets were 
imputed using the chained equation method [141, 180]. The fully conditional 
specification imputation method was used. Separate, individual conditional models for 
each incomplete predictor were specified and imputed in another ward [153]. The 
categorical variables were 15 in total. All were imputed using either logistic regression 
or polytomous regression methods. Only one variable, ‘survival time’, was a normally 
distributed continuous variable. The method used to impute this variable was the 
predictive mean matching. The outcome variables ‘survival time’ and ‘life status at 
censoring time’ were included in the imputation model in order to decrease the pooled 
estimates bias [166]. 
For each type/group of PCI (‘facilitated or rescue’ and primary), 20 separate 
imputation datasets were created. Using the likelihood ratio test to evaluate the 
goodness of fit, the imputation models diagnostics did not give any cause for concern. 
Lastly, the 20 imputed datasets for each predictor were pooled together using Rubin's 
rule and followed by the intended regression model. A comparison between the adjusted 
hazard ratios from both complete case and imputed data was used to test for the 
sensitivity of this analysis. 
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Table 6.2: Imputation predictor variables of the survival of patients with STEMI who received ‘facilitated or rescue’ and primary 
PCI with a summary of missing data and the methods used for imputation. 
Variables Variable type Missing % Imputation method 
1 Age groups Ordinal 0.10 Polytomous regression 
2 Sex Binary 0.36 logistic regression 
3 Routes of admission Ordinal 0.00 Auxiliary (not imputed) 
4 Type of PCI Ordinal 0.00 Auxiliary (not imputed) 
5 Pre-procedural cardiogenic shock Binary 0.81 logistic regression 
6 History of acute myocardial infarction Binary 4.20 logistic regression 
7 History of PCI Binary 2.08 logistic regression 
8 History of diabetes mellitus Binary 4.31 logistic regression 
9 Left ventricular ejection fraction Ordinal 65.43 Auxiliary (not imputed) 
10 Year of operation Continuous 0.00 Auxiliary (not imputed) 
11 History of renal disease Binary 0.41 logistic regression 
12 Longest stented/treated segment Continuous 9.46 Collinearity (not imputed) 
13 Number stents used Ordinal 0.83 Polytomous regression 
14 Drugs used during procedure Ordinal 6.38 Polytomous regression 
15 Intravascular ultrasound during procedure Binary 3.64 logistic regression 
16 Use of intra-aortic balloon pump Binary 2.95 logistic regression 
17 Arterial access Ordinal 1.68 Polytomous regression 
18 Procedural complication: side branch occlusion Binary 3.06 logistic regression 
19 Procedural complication:  coronary dissection Binary 3.06 logistic regression 
20 Procedural complication: shock induced by procedure Binary 3.06 logistic regression 
21 Survival time Continuous 0.28 Predictive mean matching 
22 Life status at censoring time Binary 0.00 Auxiliary (not imputed) 
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Table 6.3: Predictor matrix of the survival of patients with STEMI who received ‘facilitated or rescue’ and primary PCI using the 
2014 BCIS database. 
Variables 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
1 Age                       
2 Sex 1                      
3 Routes of admission 1 1                     
4 Type of PCI 1 1 1 1                   
5 Pre-procedural cardiogenic shock 1 1 1 1                   
6 History of Acute myocardial infarction 1 1 1 1 1                  
7 History of PCI 1 1 1 1 1 1                 
8 History of diabetes mellitus 1 1 1 1 1 1 1                
9 Left ventricular ejection fraction 1 0 1 1 1 1 1 1               
10 Year of operation 1 1 1 1 1 1 1 1 1              
11 History of renal disease 1 1 1 0 1 1 0 1 1 1             
12 P-complication: side branch occlusion 1 0 0 0 0 0 0 0 1 1 0            
13 P-complication: coronary dissection 1 1 0 1 1 0 0 0 1 1 0 1           
14 P-complication: shock induced by procedure 1 1 0 0 1 0 0 1 1 1 1 1 1 1         
15 Longest stented/treated segment 1 1 0 0 1 0 0 1 1 1 1 1 1 1         
16 Number of stents used 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1        
17 Drugs used during procedure 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1       
18 Intravascular ultrasound use during procedure 1 0 0 1 1 0 1 0 1 1 0 0 1 0 0 1 1      
19 Use of intra-aortic balloon pump 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1     
20 Arterial access 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1    
21 Survival time 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1   
22 Life status at censoring time 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  
0: not related, 1: related, P-complication: procedural complication. 
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6.4 Results 
Between 2005 and 2014, the overall cohort of patients with STEMI who received 
PCI was 98,637. Out of which 91,359 (92.6%) patients were treated by primary PCI, 
1,549 (1.6%) patients were treated by facilitated intervention and 5,729 (5.8%) patients 
were treated by rescue PCI. Over the study period, the frequency of primary 
interventions increased (from 887 (57.2%) in 2005 to 19,744 (98.1%) in 2013). While, 
the facilitated or rescue interventions declined (from 663 (42.8%) in 2005 to 400 (2.0%) 
in 2013). In 2014, the data were collected up to the 21st of March (1,456 (99.0%) 
primary interventions and 14 (1.0%) facilitated or rescue interventions (Figure 6.2). 
 
 
 
 
Figure 6.2: Frequency of patients with STEMI who received ‘facilitated or rescue’ 
and primary PCI by years of procedure. 
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6.4.1 Data completeness 
The mean (SD) level of missingness was 19.92% (27.74%) and the median 
percentage of missing values was 7.36%. Out of the total 109 variables used for the 
analysis of this chapter, only 10 (9.2%) variables were 100% complete. These variables 
were ‘clinical presentation type’, ‘indication for intervention’, ‘procedure urgency’, 
‘presenting electrocardiography’, ‘date of operation’, ‘biennial years’, 
‘electrocardiography ischaemia’, ‘life status at censored date’, ‘pseudonymised hospital 
code’ and ‘country hospital in’. However, the remaining 100 variables had missing 
information that ranged from 0.10% to 99.63%.  
Overall, 82 (75.2%) of the variables had missing values of 50% or less, while 
only 17 (15.6%) variables had missing values of more than 50%. There were 55 
(50.5%) variables that had less than 10% missing values. The one with the least missing 
values was ‘age at procedure’ (0.10%) followed by ‘number of lesions attempted’ 
(0.17%) and ‘censored date and survival time’ (0.28%). Conversely, only five (3.7%) 
variables had more than 90% missing information. These included ‘use of ventilation’ 
(99.63%), ‘bleeding up to discharge’ (99.08%), ‘PCI for stent thrombosis’ (98.52%), 
‘third operator status’ (97.49%) and ‘time to bypass’ (92.57%). The frequency and 
percentages of missing values in the variables of this cohort from the BCIS dataset 
(2014 version) are shown in Table 6.4. 
Furthermore, few examples of the missing values proportions stratified by 
‘facilitated or rescue’ and primary PCI are shown in Figure 6.3. One of the variables 
with high missing values was ‘left ventricular ejection fraction’, which was 63.79% in 
the facilitated or rescue group and 65.61% in the primary intervention group. The 
missing values in ‘pre-procedural cardiogenic shock’ were far less in both groups 
(facilitated or rescue: (1.12%) and primary (0.82%)). The proportion of missing values 
in few other variables were slightly higher in the facilitated or rescue intervention 
group, such as ‘life status at discharge’ (facilitated or rescue: (3.48%) and primary 
(1.91%)). Another example was ‘major adverse cardiac and cerebrovascular event 
(MACCE)’ (facilitated or rescue: (4.23%) and primary (2.81%)). 
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Figure 6.3: Examples of the missing values proportions for some variables 
stratified by ‘facilitated or rescue’ and primary PCI. 
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Table 6.4: Recoded variables and summary of missing data in the variables of 
STEMI cohort from the 2014 BCIS data. 
Variable Name Missing Frequency Missing % 
Age At Procedure 96 0.10 
Sex 353 0.36 
Ethnic Group 22,041 22.35 
Patient Status 8,851 8.97 
Clinical presentation type 0 0.00 
Indication for Intervention 0 0.00 
Procedure Urgency 0 0.00 
Cardiogenic Shock Pre-PCI 802 0.81 
Angina Status Pre-Surgery 55,546 56.31 
Dyspnoea Status Pre-PCI (Stable Only) 57,332 58.12 
Admission Route (ACS Only) 1,097 1.11 
Presenting electrocardiography (ACS Only) 0 0.00 
Recent Lysis (ACS Only) 1,845 1.87 
Cardiac Enzymes/Markers Raised 45,586 46.22 
Previous acute myocardial infarction 4,146 4.20 
Previous coronary artery bypass graft (CABG) 2,398 2.43 
Previous percutaneous coronary intervention (PCI) 2,054 2.08 
Diabetes 4,249 4.31 
Height 48,162 48.83 
Weight 36,997 37.51 
Left Ventricular Ejection Fraction Category 66,068 66.98 
Left Ventricular Ejection Fraction 64,535 65.43 
Number of Grafts Present Pre-PCI, CABG Only 24,032 24.36 
Number of Grafts Patent Pre- PCI, CABG Only 27,917 28.30 
Left Main Stem Stenosis Pre-PCI 14,432 14.63 
Left anterior descending Proximal Stenosis Pre-PCI 9,244 9.37 
Left anterior descending Other Stenosis Pre-PCI 11,296 11.45 
Right coronary artery Stenosis Pre-PCI 7,853 7.96 
Circumflex coronary artery Stenosis Pre-PCI 10,772 10.92 
Flow In infarct related artery Pre-PCI (ACS Only) 7,255 7.36 
Date Of Operation 0 0.00 
Date Of Operation (biennial years) 0 0.00 
Pseudonymised Consultant Responsible 3,159 3.20 
Pseudonymised First Operator Status 1,894 1.92 
Primary Operator 4,129 4.19 
Second Operator Status 34,551 35.03 
Third Operator Status 96,165 97.49 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data) 
 
 
201 
 
(Continued) Table 6.4: Recoded variables and summary of missing data in the 
variables of STEMI cohort from the 2014 BCIS data 
Variable Name Missing Frequency Missing % 
Vessels Attempted 718 0.73 
Number of vessels attempted not Epicardial 
T it i  
683 0.69 
Number Of Lesions Attempted 164 0.17 
Number Of Chronic Occlusions Attempted 3,967 4.02 
Number Restenosis Attempted 1,921 1.95 
Number Instant Stenosis Attempted 8,448 8.56 
Number Stents Used 815 0.83 
Number Drug-Eluting Stents Used 1,228 1.24 
Type of stent used 989 1.00 
Drugs Eluted By Stents 3,557 3.61 
Drugs Used During Procedure 6,296 6.38 
Intravascular ultrasound use during procedure 3,591 3.64 
pressure wire use during procedure 3,591 3.64 
Use of intra-aortic balloon pump 2,914 2.95 
Left Main Stem Stenosis Post-PCI 13,978 14.17 
Left anterior descending Proximal Stenosis Post-PCI 10,869 11.02 
Left anterior descending Other Stenosis Post-PCI 12,948 13.13 
Right coronary artery Stenosis PCI 9,705 9.84 
Circumflex coronary artery Stenosis PCI 13,530 13.72 
Number Lesions Successful 723 0.73 
Number Coronary Grafts Patent PostOp 28,742 29.14 
Flow In infarct related artery PostOp (ACS only) 7,844 7.95 
Device Failure 3,280 3.33 
PCI Hospital Outcome 2,856 2.90 
Enzymes Post-PCI 75,836 76.88 
Status At Discharge 2,022 2.05 
Discharge Date 2,801 2.84 
Cholesterol 66,579 67.50 
Smoking Status 9,524 9.66 
Family History Of coronary artery disease 14,023 14.22 
Medical History 2,684 2.72 
History Of Renal Disease 400 0.41 
Ventilated Pre-PCI 3,587 3.64 
Q Wave On electrocardiography 5,273 5.35 
Electrocardiography Ischaemia 0 0.00 
Drug Therapy Pre-PCI 4,697 4.76 
Follow On AdHoc Procedure 6,057 6.14 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data)  
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 (Continued) Table 6.4: Recoded variables and summary of missing data in the 
variables of STEMI cohort from the 2014 BCIS data  
Variable Name Missing Frequency Missing % 
Why No IIb/IIIA During Procedure 26,794 27.16 
Indication For Stent 5,531 5.61 
Surgical Cover 3,762 3.81 
Left Main Stem Protected 24,592 24.93 
Referral Hospital 67,591 68.52 
Date of electrocardiography Triggering primary PCI 
P th  
81,360 82.48 
Patient Location at Time of STEMI Onset 47,629 48.29 
Creatinine 66,521 67.44 
PCI for stent thrombosis 97,174 98.52 
Training Procedure 5,112 5.18 
Research Procedure 7,268 7.37 
Arterial Access 1,573 1.59 
Largest Balloon/Stent Used 10,664 10.81 
Longest Stented/Treated Segment 9,335 9.46 
Procedural Complication 3,017 3.06 
Arterial Complication 3,837 3.89 
Time to Bypass 91,306 92.57 
Patient Status During Transfer To Theatre 14,376 14.57 
Bleeding up to discharge 97,734 99.08 
Ventilation 98,270 99.63 
Pseudonymised Hospital Code 0 0.00 
Country Hospital In 0 0.00 
Length of Stay in Hospital (days) 20,026 20.30 
Index of Multiple Deprivation Score 19,725 20.00 
Life Status at 7days 8,569 8.69 
Life Status at 30days 8,574 8.69 
Life Status at 1year 16,480 16.71 
Life Status at 2years 32,076 32.52 
Life Status at 3years 46,675 47.32 
Life Status at 4years 59,460 60.28 
Life Status at 5years 69,197 70.15 
Death after Procedure (days) 84,962 86.14 
Censored date 275 0.28 
Survival time 275 0.28 
Life Status at censored date 0 0.00 
Red (no missing data), Green (less than 10% missing data), Blue (More than 90% missing data) 
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6.4.2 Baseline demographic characteristics 
In the UK, patients with STEMI who received PCI were treated in 111 different 
hospitals or centres.  As mentioned earlier, the analysis in this chapter was split into two 
groups of patients: 91,359 (92.6%) who received primary PCI and 7,278 (7.4%) patients 
who were treated by either facilitated or rescue intervention. The mean (SD) age of the 
overall cohort was 63.2 (13.0) years, which was 61.0 (11.8) years for those who 
received facilitated or rescue intervention and 63.4 (13.1) years for those who received 
primary intervention (P<0.001). Patients older than 80 years of age were more frequent 
in the primary intervention group at 10,458 (11.5%) patients compared to 384 (5.3%) 
patients in facilitated or rescue intervention group (P <0.001). 
In total, there were more males than females who were recorded as having 
STEMI and PCI 73,332 (74.4%) males versus 24,952 (25.3%) females (males in 
facilitated or rescue: 5,806 (80.2%) and primary: 67,526 (74.2%) patients, P <0.001). 
Caucasian patients were the most common ethnic group in the cohort (facilitated or 
rescue: 4,080 (87.9%) and primary: 62,853 (87.4%) patients, P<0.001). The majority of 
the patients were treated in NHS hospitals or centres, (98.8%) in facilitated or rescue 
intervention group and (98.1%) in the primary intervention group (P<0.001). 
Predominantly, most of the patients with STEMI were treated in English hospitals or 
centres (facilitated or rescue: 5,897 (81.0%) and primary: 83,509 (91.4%) patients, P 
<0.001). 
Direct to cardiac centre was the commonest route of admission in patients with 
STEMI who were treated by primary PCI at 66,252 (73.8%) which was much higher 
than the proportion of inpatients admitted and treated by facilitated or rescue 
intervention compared to 1,746 (24.8%). On the other hand, inter-hospital transfer was 
the most frequent route of admission in patients who were treated by facilitated or 
rescue intervention (facilitated or rescue: 5,098 (72.4%) and primary: 20,725 (23.1%) 
patients, P <0.001). Table 6.5 shows the distribution of baseline demographic 
characteristics stratified by ‘facilitated or rescue’ and primary PCI. 
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Table 6.5: Baseline demographic characteristics of patients with STEMI who received ‘facilitated or rescue’ and primary PCI. 
Variable Facilitated or Rescue PCI n=7,278 Primary PCI n=91,359 P value * 
Mean (SD) age, years  61.0 (11.8) 63.4 (13.1) < 0.001 
Age 
Less than 65 years (%) 4,548/7,273 (62.5) 49,525/91,268  (54.2) 
< 0.001 65 - 80 years (%) 2,341/7,273 (32.2) 31,285/91,268  (34.3) 
More than 80 years (%) 384/7,273 (5.3) 10,458/91,268 (11.5) 
Gender 
Female (%) 1,435/7,241 (19.8) 23,517/91.043 (25.8) 
< 0.001 Male (%) 5,806/7,241 (80.2) 67,526/91.043 (74.2) 
Ethnic groups 
Caucasian (%) 4,080/4,640 (87.9) 62,853/71,956 (87.4) 
Black (%) 11/4,640 (0.2) 635/71,956 (0.9) 
< 0.001 Asian (%) 141/4,640 (3.0) 5,100/71,956 (7.1) 
Other (%) 408/4,640 (8.9) 3,368/71,956 (4.6) 
Patient type 
NHS hospital or centre (%) 6,561/6,689 (98.1) 82,073/83,097 (98.8) 
< 0.001 
Private hospital or centre (%) 128/6,689 (1.9) 1,024/83,097 (1.2) 
Country 
England (%) 5,897/7,278 (81.0) 83,509/91,359 (91.4) 
< 0.001 
North Ireland (%) 491/7,278 (6.8) 1,333/91,359 (1.5) 
Scotland (%) 334/7,278 (4.6) 3,623/91,359 (4.0) 
Wales (%) 556/7,278 (7.6) 2,894/91,359 (3.1) 
Admission route 
Direct to cardiac centre (%) 1,746/7,044 (24.8) 66,252/89,791 (73.8) 
< 0.001 Inter-hospital transfer (%) 5,098/7,044 (72.4) 20,725/89,791 (23.1) 
Already in cardiac centre (%) 200/7,044 (2.8) 2,814/89,791 (3.1) 
Index of multiple deprivation score, mean (SD) 19.7 (12.8) 22.6 (14.2) < 0.001 
Proportions exclude missing data. 
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
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6.4.3 Clinical characteristics  
History of previous acute myocardial infarction was slightly higher in facilitated 
or rescue intervention patients (17.4%) compared to the primary intervention patients 
(13.1%) (P <0.001). History of previous PCI was, to some extent, more frequent in the 
primary intervention patients, 8,028 (9.0%) compared to 448 (6.3%) in facilitated or 
rescue intervention patients (P <0.001). The frequency of family history of coronary 
artery disease was more in facilitated or rescue intervention patients (facilitated or 
rescue: 2,769 (45.5%) and primary: 29,423 (37.5%) patients, P <0.001). 
The proportions of patients with a history of diabetes mellitus, renal disease or 
hypertension were higher in the primary PCI group (all P <0.001), whereas the presence 
of hypercholesterolemia, current smoking, pre-procedural cardiogenic shock and severe 
left ventricular systolic dysfunction showed the opposite distribution, as the proportions 
were slightly higher in the facilitated or rescue intervention group of patients (all P 
<0.001). The distribution of the clinical characteristics stratified by ‘facilitated or 
rescue’ and primary PCI can be seen in more detail in Table 6.6.  
 
 
206 
 
Table 6.6: Baseline clinical characteristics of patients with STEMI who received ‘facilitated or rescue’ and primary PCI. 
Proportions exclude missing data. 
* P-value was calculated using Chi-square test for categorical variables and analysis of variance (ANOVA) for continues variables.  
Variable Facilitated or Rescue PCI n=7,278 Primary PCI n=91,359 P value * 
Previous acute myocardial infarction (%) 1,218/7,007 (17.4) 11,425/87,484 (13.1) <0.001 
Previous percutaneous coronary intervention (%) 448/7,086 (6.3) 8,028/89,497 (9.0) <0.001 
History of previous coronary artery bypass graft (%) 149/7,125 (2.1) 2,483/89,114 (2.8) 0.001 
Family history of coronary artery disease (%) 2,769/6,086 (45.5) 29,423/78,528 (37.5) <0.001 
History of diabetes mellitus (%) 875/6,953 (12.6) 12,290/87,435 (14.1) 0.001 
History of renal disease (%) 104/7,253 (1.4) 1,448/90,984 (1.6) 0.300 
Hypercholesterolemia (%) 2,817/7,033 (40.1) 34,939/88,920 (39.3) 0.208 
Hypertension (%) 2,673/7,033 (38.0) 35,838/88,920 (40.3) <0.001 
Smoking status 
Never smoked (%) 1,762/6,493 (27.1) 26,967/82,620 (32.6) 
<0.001 Ex-smoker (%) 1,922/6,493 (29.6) 21,707/82,620 (26.3) 
Current smoker (%) 2,809/6,493 (43.3) 33,946/82,620 (41.1) 
Recent thrombolysis (%) 6,525/7,166 (91.1) 0/89,626 (0.0) <0.001 
Cardiogenic shock (%) 529/7,196 (8.2) 6,772/90,639 (7.5) 0.019 
Severe left ventricular systolic dysfunction - <30% (%) 392/2,634 (14.9) 4,309/31,468 (13.7) <0.001 
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6.4.4 Procedural characteristics 
With regard to the use of pre-procedural medications, aspirin was the most 
prevalent medication in both groups (facilitated or rescue: 6,127 (88.5%) and primary: 
74,475 (85.6%) patients, P <0.001). The second frequently used medication was 
clopidogrel (facilitated or rescue: 5,923 (85.6%) and primary: 50,465 (58.0%) patients, 
P <0.001). The proportion of pre-procedural TIMI 3 was higher in the facilitated or 
rescue intervention group while TIMI 0 was higher in the primary intervention patients 
(P <0.001). More details on the distribution of pre-procedural characteristics stratified 
by ‘facilitated or rescue’ and primary PCI can be seen in Table 6.7. 
The majority of patients in both groups had their procedures more than two 
hours from the onset of symptoms (facilitated or rescue: 7,146 (99.1%) and primary: 
75,618 (83.4%) patients, P <0.001). In both groups, patients who had only one vessel 
stented were more common than those who had stents in more than one vessel (one 
vessel stented in facilitated or rescue: 6,218 (86.2%) patients and primary: 80,979 
(89.2%), P <0.001). One stent was the most frequent number of stents used in both 
groups (facilitated or rescue: 4,193 (58.6%) and primary: 53,463 (59.0%) patients, P 
<0.001). The most prevalent type of the utilised drug eluted stents in the primary 
intervention group were Promus (13.0%), Xience V (8.2%) and Resolute Integrity 
(7.0%). For the facilitated or rescue intervention group, Taxus liberte were used in 
(9.2%) of patients and Promus in (7.5%) of patients. 
The mean (SD) of the longest stented segment was 24.4 (11.9) mm for the 
patients who received facilitated or rescue intervention and 24.8 (12.6) mm for those 
who received primary intervention, (P =0.017). Femoral access was used more 
frequently than radial access in the facilitated or rescue intervention group (femoral: 
3,831 (53.7%) and radial: 3,291 (46.1%), P <0.001). In contrast, the radial artery was 
accessed more frequently in the primary intervention patients (femoral: 38,095 (42.4%) 
and radial: 51,554 (47.4%), P <0.001). Predominantly, femoral access was used more 
frequently in female patients (facilitated or rescue: 811 (57.5%) and primary: 10,670 
(46.2%) patients, both P <0.001). 
The use of intravascular ultrasound was not that prevalent; however, to some 
extent, it was performed more in the primary intervention patients (facilitated or rescue: 
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127 (1.8%) patients and primary: 2,033 (2.3%), P =0.007). At the same time, intra-
aortic balloon pump was inserted less frequently in the primary intervention group 
(facilitated or rescue: 417 (6.0%) patients and primary: 4,601 (5.2%), P =0.006).  
The glycoprotein IIb IIIa inhibitor, Abciximab, was the commonest medication 
used during procedures. However, Abciximab was used less frequently for the 
facilitated or rescue intervention patients (facilitated or rescue: 2,399 (34.4%) and 
primary: 35,438 (41.5%) patients, P <0.001). In both intervention groups, post-
procedural TIMI 3 flow was the commonest type of flow (P <0.001). The distribution of 
procedural characteristics stratified by ‘facilitated or rescue’ and primary PCI can be 
seen in more detail in Table 6.8. 
 
 
 
Table 6.7: Pre-procedural characteristics of patients with STEMI who received 
‘facilitated or rescue’ and primary PCI. 
Proportions exclude missing data.   
* P-value was calculated using Chi-square test for categorical variables and analysis of variance 
(ANOVA) for continues variables.  
Variable Facilitated or Rescue PCI n=7,278 
Primary PCI 
n=91,359 
P value 
* 
Pre-procedural 
medications 
Aspirin (%) 6,127/6,923 (88.5) 74,475/87,017 (85.6) 
<0.001 
Clopidogrel (%) 5,923/6,923 (85.6) 50,465/87,017 (58.0) 
Heparin (%) 2,653 /6,923 (38.3) 20,656 /87,017 (23.7) 
Bivalirudin (%) 144/6,923 (2.1) 11,698 /87,017 (13.4) 
Nitrates (%) 858/6,923 (12.4) 5,205/87,017 (6.0) 
Prasugrel (%) 108/6,923 (1.6) 13,882/87,017 (16.0) 
Ticagrelor (%) 68/6,923 (1.0) 5,808/87,017 (6.7) 
Pre-procedure 
flow in IRA 
TIMI 0 (%) 2,484/6,823 (36.4) 58,650/84,559 (69.4) 
<0.001 
TIMI 1 (%) 740/6,823 (10.8) 6,730/84,559 (8.0) 
TIMI 2 (%) 1,117/6,823 (16.4) 7,888/84,559 (9.3) 
TIMI 3 (%) 1,881/6,823 (27.6) 9,160/84,559 (10.8) 
Unknown (%) 601/6,823 (8.8) 2,131/84,559 (2.5) 
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Table 6.8: Procedural characteristics of patients with STEMI who received 
‘facilitated or rescue’ and primary PCI. 
Variable 
Facilitated or 
Rescue PCI 
n=7,278 
Primary PCI 
n=91,359 P value * 
Time from the onset 
of symptoms to PCI 
2 hours or less (%) 61/7,207 (0.9) 15,100/90,718 (16.6) 
<0.001 
More than 2 hours (%) 7,146/7,207 (99.1) 75,618/90,718 (83.4) 
Vessels attempted  
None (%) 59/7,212 (0.8) 426/90,742 (0.5) 
<0.001 Single vessel (%) 6,218/7,212 (86.2) 80,979/90,742 (89.2) 
Multi-vessels (%) 935/7,212 (13.0) 9,337/90,742 (10.3) 
Total number stents 
used 
0 (%) 369/7,154 (5.2) 6,963/90,668 (7.7) 
<0.001 
1 (%) 4,193/7,154 (58.6) 53,463/90,668 (59.0) 
2 (%) 1,815/7,154 (25.4) 21,761/90,668 (24.0) 
≥ 3 (%) 777/7,154 (10.8) 8,481/90,668 (9.3) 
Type of 
drug 
eluted 
stents 
used 
Taxus liberte (Boston Scientific) (%) 652/7,089 (9.2) 2,081/87,991 (2.4) 
<0.001 
Cypher (Cordis) (%) 362/7,089 (5.1) 1,963/87,991 (2.2) 
Endeavor (Medtronic) (%) 430/7,089 (6.1) 3,451/87,991 (3.9) 
Xience V (Abbott) (%) 424/7,089 (6.0) 7,216/87,991 (8.2) 
Promus (Boston Scientific) (%) 529/7,089 (7.5) 11,445/87,991 (13.0) 
BioMatrix (%) 115/7,089 (1.6) 3,393/87,991 (3.9) 
Promus Element (%) 284/7,089 (4.0) 5,844/87,991 (6.6) 
Xience Prime (%) 125/7,089 (1.8) 5,808/87,991 (6.6) 
Resolute Integrity (%) 108/7,089 (1.5) 6,133/87,991 (7.0) 
Longest stented/treated segment/mm, mean (SD) 24.4 (11.9) 24.8 (12.6) 0.017 
Arterial access 
Femoral (%) 3,831/7,137 (53.7) 38,095/89,776 (42.4) 
<0.001 Radial (%) 3,291/7,137 (46.1) 51,554/89,776 (57.4) 
Others (%) 15/7,137 (0.2) 127/89,776 (0.2) 
Intravascular ultrasound (%) 127/7,007 (1.8) 2,033/88,039 (2.3) 0.007 
Pressure wire (%) 22/7,007 (0.3) 356/88,039 (0.4) 0.247 
Intra-aortic balloon pump (%) 417/7,008 (6.0) 4,601/88,715 (5.2) 0.006 
Use of ventilation (%) 292/7,071 (4.1) 3,479/87,979 (4.0) 0.468 
Medications used 
during procedure 
None (%) 3,793/6,970 (54.4) 39,027/85,371 (45.7) 
<0.001 
Abciximab (%) 2,399/6,970 (34.4) 35,438/85,371 (41.5) 
Eptifibitide (%) 211/6,970 (3.0) 5,558/85,371 (6.5) 
Tirofiban (%) 567/6,970 (8.2) 5,348/85,371 (6.3) 
Post-procedure flow 
in IRA 
TIMI 0 (%) 273/6,683(4.1) 4,687/84,110 (5.6) 
<0.001 
TIMI 1 (%) 121/6,683(1.8) 1,097/84,110 (1.3) 
TIMI 2 (%) 506/6,683(7.6) 4,195/84,110 (5.0) 
TIMI 3 (%) 5,221/6,683(78.1) 72,232/84,110 (85.9) 
Unknown (%) 562/6,683(8.4) 1,899/84,110 (2.3) 
Proportions exclude missing data.   
* P-value was calculated using Chi-square test for categorical variables and analysis of variance 
(ANOVA) for continues variables.  
 
 
210 
 
6.4.5 Clinical outcomes 
The distribution of the procedural complications of patients with STEMI 
stratified by ‘facilitated or rescue’ and primary PCI can be seen in Table 6.9. The 
proportions of side branch occlusion, coronary dissection, coronary perforation, heart 
block requiring pacing, need for direct current cardioversion, ventilation and 
cardiogenic shock occurring during the procedure were very rare and comparable in 
both groups. However, no flow/slow flow occurred slightly more during the procedures 
of facilitated or rescue intervention patients (facilitated or rescue 240 (3.4%) and 
primary 2,195 (2.5%) patients, P <0.001).   
Most of the in-hospital outcomes were infrequent in both groups of intervention. 
They were comparable, although they were more to some extent in facilitated or rescue 
intervention patients. Gastro-intestinal bleeding and the need for blood transfusion were 
less frequent in both groups of intervention when approached through the radial artery. 
The prevalence of the unadjusted MACCE complications was slightly higher in the 
facilitated or rescue intervention group (facilitated or rescue 367 (5.3%) and primary 
4,260 (4.8%) patients, P =0.080). More details on in-hospital outcomes of patients 
stratified by ‘facilitated or rescue’ and primary PCI are shown in Table 6.10. 
 
 
Table 6.9: Procedural complications of patients with STEMI who received 
‘facilitated or rescue’ and primary PCI. 
Variable 
Facilitated or 
Rescue PCI 
n=7,278 
Primary PCI 
n=91,359 P value * 
Side branch occlusion (%) 40/7,121 (0.6) 472/88,499 (0.5) 0.752 
Coronary dissection (%) 70/7,121 (1.0) 1,208/88,499 (1.4) 0.007 
Coronary perforation (%) 15/7,121 (0.2) 207/88,499 (0.2) 0.695 
Heart block requiring pacing (%) 54/7,121 (0.8) 662/88,499 (0.8) 0.923 
Direct current cardioversion (%) 76/7,121 (1.1) 1,327/88,499 (1.5) 0.004 
No flow/slow flow (%) 240/7,121 (3.4) 2,195/88,499 (2.5) <0.001 
Ventilated (%) 43/7,121 (0.6) 532/88,499 (0.6) 0.977 
Cardiogenic shock induced by procedure (%) 39/7,121 (0.6) 486/88,499 (0.5) 0.987 
Proportions exclude missing data. 
* P-value was calculated using Chi-square test for categorical variables and analysis of variance 
(ANOVA) for continues variables.  
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Table 6.10: In-hospital outcomes and mortality rates of patients with STEMI who 
received ‘facilitated or rescue’ and primary PCI. 
Variable 
Facilitated or 
Rescue PCI 
n=7,278 
Primary PCI 
n=91,359 P value * 
Acute myocardial infarction (%) 59/6,972 (0.9) 355/88,809 (0.4) 
<0.001 
Stroke (%) 35/6,972 (0.5) 257/88,809 (0.3) 
Renal failure/dialysis (%) 27/6,972 (0.4) 237/88,809 (0.3) 0.065 
Blood transfusion 
Radial access (%) 13/3,165 (0.4) 133/50,125 (0.3) 0.129 
Femoral access (%) 33/3,659 (0.9) 286/37,001 (0.8) 0.399 
Gastro-intestinal 
bleeding 
Radial access (%) 14/3,165 (0.4) 114/50,125 (0.2) 0.017 
Femoral access (%) 18/3,659 (0.5) 142/37,001 (0.4) 0.319 
Revascularisation 
Percutaneous coronary 
intervention (%) 40/6,972 (0.6) 592/88,809 (0.7) 
0.267 
Coronary artery bypass 
graft (%) 24/6,972 (0.3) 404/88,809 (0.5) 
Unadjusted in-hospital MACCE rate (%) 367/6,972 (5.3) 4,260/88,809 (4.8) 0.080 
Unadjusted in-hospital mortality rate (%) 336/7,020 (4.8) 4,330/89,595 (4.8) 0.861 
Unadjusted 
30-day 
mortality 
rate  
Overall mortality (%) 409/6,282 (6.5) 5,058/83,781(6.0) 0.130 
Arterial 
access 
Radial access (%) 123/2,546 (4.8) 1,832/46,130 (4.0) <0.001 Femoral access (%) 283/3,626 (7.8) 3,135/36,397 (8.6) 
Routes of 
admission 
Direct admission (%) 108/1,587 (6.8) 3,441/61,380 (5.6) 
<0.001 Interhospital transfere (%) 274/4,357 (6.3) 1,295/19,014 (6.8) 
Already in hospital (%) 17/185 (9.2) 264/2,507 (10.5) 
Unadjusted 
1-year 
mortality 
rate ** 
Overall mortality (%) 531/6,198 (8.6) 7,168/75,220 (9.5) 0.013 
Arterial 
access 
Radial access (%) 187/2,507 (7.5) 3,188/40,246 (7.9) 
<0.001 Femoral access (%) 354/3,608 (9.8) 4,561/34,583 (13.2) 
Routes of 
admission 
Direct admission (%) 144/1,555 (9.3) 5,412/55,372 (9.8) 
<0.001 Interhospital transfere (%) 367/4,329 (8.5) 1,992/17,469 (11.4) 
Already in hospital (%) 22/182 (12.1) 405/2,308 (17.6) 
MACCE:  major adverse cardiac and cerebrovascular event 
Proportions exclude missing data. 
* P-value was calculated using Chi-square test for categorical variables and analysis of variance 
(ANOVA) for continues variables.  
** Censored at 31/7/2014, therefore all PCI procedures performed after 31/7/2013were not 
included in describing this rate. 
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6.4.6 Crude mortality 
The median follow-up period of the cohort was 910 days (range: 1 day to 3,435 
days). In total, there were 13,476 (13.6%) deaths over a total follow-up period of 
90,709,415 patient years. For the facilitated or rescue intervention patients, there were 
975 (13.4%) deaths over a total follow-up period of 10,062,299 patient years. For the 
primary PCI patients, 12,501 (13.7%) deaths over a total follow-up period of 
80,647,116 patient years. The unadjusted crude mortality rate at 30 days was similar in 
both intervention groups (facilitated or rescue: 409 (6.5%) and primary: 5,058 (6.0%) 
patients, P =0.130). On the other hand, the unadjusted crude mortality rate at one year 
was more in the primary intervention patients (facilitated or rescue: 531 (8.6%) and 
primary: 7,168 (9.5%) patients, P =0.013) (Table 6.10). 
 
6.4.7 Clinical variables and crude mortality 
Compared with the femoral artery access, the radial artery access was associated 
with lower crude 30-day and 1-year mortality rates in both intervention groups (all P 
<0.001). In the facilitated or rescue intervention patients, the rate of 30-day mortality 
was 123 (4.8%) in radial access versus 283 (7.8%) in femoral, while the rate of 1-year 
mortality was 187 (7.5%) in radial versus 354 (9.8%) in femoral. Likewise, for the 
primary intervention patients, the rate of 30-day mortality was 1,832 (4.0%) in radial 
access versus 3,135 (8.6%) in femoral, while the rate of 1-year mortality was 3,188 
(7.9%) in radial versus 4,561 (13.2%) in femoral access (Table 6.10). 
Compared to the other routes of admission, direct admission to a cardiac hospital 
or centre was associated with lower crude 30-day and 1-year mortality rates in the 
primary intervention patients (all P <0.001). In the facilitated or rescue intervention 
patients, inter-hospital transfer as a route of admission was associated with the lowest 
crude 30-day and 1-year mortality rates (Table 6.10). 
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6.4.8 Survival time  
Figure 6.4 illustrates the Kaplan–Meier curves for unadjusted survival estimates 
to all-cause mortality in patients with STEMI who received facilitated, rescue and 
primary PCI from time of procedure to 9.6 years. The survival distributions of all strata 
were significantly different, showing that the survival of patients with STEMI who were 
treated by primary intervention was significantly less than the facilitated and/or rescue 
intervention patients (P <0.001).  
The Kaplan–Meier curves in Figure 6.5 demonstrates the unadjusted survival 
time (from time of procedure to 9.6 years) to all-cause mortality in patients who 
received ‘facilitated or rescue’ and primary PCI, stratified by time from symptoms onset 
to the procedure. Patients who received primary PCI before or at two hours from the 
onset of symptoms had better survival over the first five years of the study period. For 
procedures performed after two hours, primary PCI patients had worse survival 
compared to the ‘facilitated or rescue’ group P <0.001). 
Further stratified by age groups, Figure 6.6 shows the Kaplan–Meier curves for 
unadjusted survival time (from time of procedure to 9.6 years) to all-cause mortality in 
patients who received ‘facilitated or rescue’ and primary PCI. The survival of elderly 
(more than 80 years) patients with STEMI in both PCI groups was significantly worse 
than younger patients (‘60 to 80 years’ then ‘less than 60 years’) (P <0.001). 
Figure 6.7 shows the Kaplan–Meier curves for unadjusted survival time (from 
time of procedure to 9.6 years) to all-cause mortality in patients who received 
‘facilitated or rescue’ and primary PCI, further stratified by three routes of admission. 
Once more, the survival distributions of all routes of admission in both groups of 
intervention were significantly different (P <0.001). In both intervention groups, the 
survival of patients who received their PCI while they were already in a cardiac centre 
was significantly less than those who were treated after a direct admission or an inter-
hospital transfer. 
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Figure ‎6.4: Kaplan-Meier curves for unadjusted survival time to all-cause mortality in patients who received facilitated, rescue and 
primary PCI from time of procedure to 9.6 years.   
 
   ‘Facilitated‎or‎Rescue’‎and‎Primary PCI                                     Primary, Facilitated and Rescue PCI 
 
  
The survival distributions of all strata were significantly different (Mantle-Cox log rank test, P<0.001). 
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Figure ‎6.5: Kaplan-Meier curves for unadjusted survival time to all-cause mortality in patients‎who‎received‎‘facilitated‎or‎rescue’‎
and primary PCI, stratified by time from symptoms onset to procedure, from time of procedure to 9.6 years. 
 
                      Two hours or less                                                                           More than two hours 
  
The survival distributions of all strata were significantly different (Mantle-Cox log rank test, P<0.001). 
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Figure ‎6.6: Kaplan-Meier curves for unadjusted survival time to all-cause‎mortality‎in‎patients‎who‎received‎‘facilitated‎or‎rescue’‎
and primary PCI, further stratified by age groups, from time of procedure to 9.6 years. 
 
       Facilitated or Rescue PCI                                                                              Primary PCI 
 
  
The survival distributions of all strata were significantly different (Mantle-Cox log rank test, P<0.001). 
PCI: percutaneous coronary intervention 
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Figure ‎6.7: Kaplan-Meier curves for unadjusted survival time to all-cause‎mortality‎in‎patients‎who‎received‎‘facilitated‎or‎rescue’‎
and primary PCI, further stratified by admission route, from time of procedure to 9.6 years .  
 
         Facilitated or Rescue PCI                                                                                  Primary PCI 
 
   
The survival distributions of all strata were significantly different (Mantle-Cox log rank test, P<0.001). 
PCI: percutaneous coronary intervention 
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6.4.9 Clinical determinants of survival  
Multivariate Cox regression modelling was used for this section of the analysis. 
Eight different covariates were used in the adjustment of the estimates in both 
intervention groups. More details were described earlier in this Chapter (section 6.3.6.3 
and Table 6.1). After adjustment, patients with STEMI who were treated by primary 
PCI remained at a significantly elevated risk of death compared to the ‘facilitated or 
rescue’ intervention group, adjusted hazard ratio (aHR) 1.1, 95% confidence interval 
(CI) 1.0 to 1.2. This association was significantly upheld for primary PCI that were 
performed after two hours from the onset of symptoms (two hours or less: aHR 0.8, 
95% CI 0.4 to 1.5 and more than two hours: aHR 1.2, 95% CI 1.1 to 1.3).  
 
6.4.9.1 Age and sex 
In both intervention groups, each one year increase in a patient's age was 
significantly associated with an increased risk of death (facilitated or rescue: aHR 1.1, 
95% CI 1.0 to 1.2 and primary: aHR 1.1, 95% CI 1.0 to 1.2). Similarly, 80 years of age 
and over was a significant determinant of worse survival in both intervention groups 
(facilitated or rescue: aHR 5.9, 95% CI 1.7 to 20.0 and primary: aHR 7.8, 95% CI 5.2 to 
11.8). After adjustment, male patients with STEMI had better survival than females. An 
association that was statistically significant in the primary intervention patients only 
(facilitated or rescue: aHR 0.90, 95% CI 0.78 to 1.03 and primary: aHR 0.91, 95% CI 
0.88 to 0.95) (Figures 6.8 and 6.9). 
 
6.4.9.2 Clinical determinants of survival (‘facilitated or rescue’ intervention)  
Figure 6.8 demonstrates the adjusted hazard ratios for the independent predictors 
of survival in the facilitated or rescue PCI group. The only significant independent 
predictor of better survival in the facilitated or rescue intervention patients was the use 
of radial artery approach (aHR 0.8, 95% CI 0.7 to 0.9). However, the significant 
independent predictors of worse survival were age greater than 80 years, pre-procedural 
cardiogenic shock, diabetes mellitus, chronic renal disease, history of a previous acute 
myocardial infarction, poor ventricular ejection fraction, pre-procedural ventilation and 
the use of intra-aortic balloon pump (all P <0.001). 
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6.4.9.3 Clinical determinants of survival (primary intervention)  
Figure 6.9 displays the adjusted hazard ratios for the independent predictors of 
survival in the primary PCI group. The significant independent predictors of better 
survival in the primary intervention patients were male sex, the used number of stents 
(aHR 0.93, 95% CI 0.92 to 0.95), the use of Abciximab (aHR 0.80, 95% CI, 0.77 to 
0.82), and the use of radial artery approach (aHR 0.80, 95% CI 0.77 to 0.82). In 
contrast, the significant independent predictors of worse survival in this group of 
patients were age greater than 80 years, pre-procedural cardiogenic shock, diabetes 
mellitus, chronic renal disease, history of a previous acute myocardial infarction, history 
of a previous PCI, poor ventricular ejection fraction, pre-procedural ventilation, the use 
of intra-aortic balloon pump, post-procedural acute myocardial infarction and post-
procedural acute stroke (all P <0.001). 
 
6.4.9.4 Hypertension and thrombolysis in myocardial infarction flow  
A medical history of hypertension was a significant determinant of worse 
survival in the primary PCI patients (facilitated or rescue: aHR 1.1, 95% CI 0.9 to 1.3 
and primary: aHR 1.1, 95% CI 1.0 to 1.2). In both intervention groups, pre-procedural 
thrombolysis in myocardial infarction flow 0 (TIMI0) was significantly associated with 
worse survival in patients with STEMI (facilitated or rescue: aHR 1.3, 95% CI 1.0 to 
1.5 and primary: aHR 1.1, 95% CI 1.0 to 1.1) (Figure 6.10). 
 
6.4.9.5 Time from symptoms to intervention 
Compared to ‘two hours or less’, the length of time ‘more than two hours’, from 
the start of the first symptom to the intervention, was a significant determinant of worse 
survival in patients with STEMI who underwent primary PCI (facilitated or rescue: aHR 
1.2, 95% CI 0.7 to 1.9 and primary: aHR 1.2, 95% CI 1.1 to 1.2). 
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6.4.9.6 Routes of admission 
The relationship between the routes of admission and survival was adjusted and 
measured by using the direct admission route as a baseline for comparison. In the 
facilitated or rescue intervention group, inter-hospital transfer route, and already in a 
cardiac hospital or centre route, were not significantly associated with the patients’ 
survival. However, for the primary intervention patients, the survival was worse in both 
routes of admission (inter-hospital transfer: aHR 1.1, 95% CI 1.0 to 1.2 and already in 
cardiac centre aHR 1.4, 95% CI 1.2 to 1.5) (Figure 6.11). 
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Figure ‎6.8:‎Adjusted‎hazard‎ratios‎for‎the‎clinical‎determinants‎of‎the‎survival‎of‎STEMI‎patients‎underwent‎‘facilitated‎or‎rescue’‎
PCI (Complete case vs Imputed). 
 
                  Complete case data                                                                                Imputed data 
  
HR and 95%CI were calculated using multivariate Cox hazards regression for both complete case and pooled imputed data. 
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Figure ‎6.9: Adjusted hazard ratios for the clinical determinants of the survival of STEMI patients underwent primary PCI 
(Complete case vs Imputed). 
 
             Complete case data                                                                      Imputed data 
 
 
HR and 95%CI were calculated using multivariate Cox hazards regression for both complete case and pooled imputed data. 
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Figure 6.10: Adjusted hazard ratios for pre-procedural TIMI 0 as determinants of 
the survival of STEMI patients underwent ‘facilitated or rescue’ and primary PCI 
(Complete case vs Imputed). 
 
 
 
HR and 95%CI were calculated using multivariate Cox hazards regression for both complete 
case and pooled imputed data. 
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Figure ‎6.11: Adjusted hazard ratios for the routes of admission as determinants of the survival of STEMI patients underwent 
‘facilitated‎or‎rescue’‎and‎primary‎PCI‎(Complete case vs Imputed). 
 
                Complete case data                                                                             Imputed data 
 
HR and 95%CI were calculated using multivariate Cox hazards regression for both complete case and pooled imputed data. 
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6.4.10  Sensitivity analyses 
6.4.10.1 Mixed effects modelling at hospitals level  
The same Cox proportional hazards models that were used in the adjusted analysis 
‘fixed effects modelling’ of this chapter (described in section 6.3.6.3) were repeated, 
taking into account the hierarchical level of cardiac hospitals or centres ‘mixed effects 
modelling’. In almost all mixed effect models for both intervention groups, the 
likelihood ratio statistics were statistically significant (P <0.001). Indicating that there 
were similarities between the patients within each hospital and there was significant 
difference between hospitals. See Table 6.11 for full summary of mixed effects models 
adjusted hazard ratios at hospital level for patients underwent ‘facilitated or rescue’ and 
primary PCI. 
Whilst there was evidence for hospital (level 2) effects, the use of mixed effects 
models did not substantially affect the patient (level 1) estimates. For example, in the 
fixed effects model, the adjusted hazard ratio (aHR), 95% confidence interval (CI) of 
pre-procedural cardiogenic shock for the facilitated or rescue intervention patients was 
5.1, 2.2 to 11.2, while in the mixed effects model, aHR, 95% CI of pre-procedural 
cardiogenic shock for the same patients was 5.1, 2.2 to 11.5. Another example for the 
facilitated or rescue intervention patients was the presence of a history of diabetes 
mellitus (fixed effects estimates: aHR, 95% CI 1.7, 1.3 to 2.3 and mixed effects 
estimates: aHR, 95% CI 1.7, 1.3 to 2.3) (Figure 6.8 and Table 6.11). 
Examples for the primary intervention patients were age more than 80 years 
(fixed effects estimates: aHR, 95% CI 7.8, 5.2 to 11.8 and mixed effects estimates: 
aHR, 95% CI  7.8, 5.2 to 11.7), left ventricular ejection fraction of less than 30% (fixed 
effects estimates: aHR, 95% CI 3.3, 2.5 to 4.4 and mixed effects estimates: aHR, 95% 
CI 3.6, 2.6 to 5.0) and the use of pre-procedural ventilation (fixed effects estimates: 
aHR, 95% CI 3.3, 2.7 to 4.1 and mixed effects estimates: aHR, 95% CI 3.3, 2.7 to 4.2) 
(Figure 6.9 and Table 6.11). 
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Table 6.11: Shared-frailty (mixed effects modelling) at hospital level adjusted hazard ratios for patients underwent ‘facilitated or rescue’ 
and primary PCI. 
Variable 
At hospital level 
Facilitated and Rescue  
PCI 
Primary  
PCI 
aHR 95% confidence interval 
likelihood ratio 
P value aHR 
95% confidence 
interval 
likelihood ratio 
P value 
Male 0.9 0.8 - 1.0 <0.001 0.91 0.87 – 0.94 <0.001 
Age more than 80 years 6.1 1.7 - 22.0 <0.001 7.8 5.2 – 11.7 <0.001 
Cardiogenic shock 5.1 2.2 - 11.5 <0.001 5.2 4.1 – 6.6 <0.001 
Diabetes mellitus 1.7 1.3 – 2.3 <0.001 1.5 1.4 – 1.6 <0.001 
Chronic renal disease 1.8 1.0 – 3.2 <0.001 2.5 2.0 – 3.1 <0.001 
Previous acute myocardial infarction 1.4 1.1 – 1.7 <0.001 1.4 1.3 – 1.5 <0.001 
Previous PCI 1.4 1.0 – 2.0 <0.001 1.1 1.0 – 1.2 <0.001 
Ejection fraction <30% 4.9 0.9 – 25.9 0.211 3.6 2.6 – 5.0 <0.001 
Number of stents used 1.1 1.0 – 1.2 <0.001 0.93 0.91 – 0.95 <0.001 
Abciximab use 0.9 0.8 – 1.1 <0.001 0.77 0.75 – 0.80 <0.001 
Intravascular ultrasound 0.9 0.6 – 1.6 <0.001 1.0 0.9 – 1.2 <0.001 
Intra-aortic balloon pump 2.5 1.4 – 4.5 <0.001 1.9 1.7 – 2.2 <0.001 
Pre-procedure ventilation 3.3 1.5 – 7.2 <0.001 3.3 2.7 – 4.2 <0.001 
Radial vs femoral access 0.9 0.7 – 1.0 <0.001 0.78 0.75 – 0.80 <0.001 
Longest stented/treated segment 1.01 1.00 – 1.02 <0.001 0.97 0.96 – 0.99 <0.001 
Post-procedure acute myocardial infarction 2.2 0.6 – 8.5 <0.001 1.9 1.3 – 2.7 <0.001 
Post- procedure stroke 4.7 0.5 – 42.1 <0.001 2.3 1.5 – 3.7 <0.001 
Procedural complication 
Side branch occlusion --- --- --- 0.6 0.4 – 0.9 <0.001 
Coronary dissection 1.0 0.2 – 4.5 <0.001 1.4 0.5 – 3.8 <0.001 
Shock --- --- --- 2.2 0.7 – 6.8 <0.001 
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6.4.10.2 Multiple imputation  
The overall distribution for most variables of the imputed datasets matched those 
of the complete case dataset very closely. Multivariate adjustment of the pooled 
imputed data for the missing data made only small changes to point estimates generated 
from the Cox proportional hazards models. Although, due to the increase in patients’ 
number available in the imputed dataset, multiple imputation improved the estimates 
precision (smaller confidence intervals).  
After adjustment, the generated point estimates of survival from the pooled 
imputed data were statistically insignificant as they did not change the overall 
association result of the same models from the complete case data. More accurately, no 
changes were noticed on the significance of these associations for both ‘facilitated and 
rescue’ and primary PCI. A comparison between the complete case data and pooled 
multiply imputed data can be seen in Figures 6.8 to 6.11, which shows the adjusted 
hazard ratios for the clinical determinants of the survival of STEMI patients who 
underwent PCI stratified by the type of intervention. 
For example, the adjusted hazard ratios for left ventricular ejection fraction of 
less than 30% were (facilitated and rescue: aHR, 95% CI 4.8, 1.0 to 22.5 in complete 
case data compared to aHR, 95% CI 4.0, 1.2 to 12.8 in imputed data and primary: aHR, 
95% CI 3.3, 2.7 to 4.1 in complete case data compared to aHR, 95% CI 3.1, 2.4 to 3.9 in 
imputed data). The adjusted ratios for post-procedural acute myocardial infarction were 
(facilitated and rescue: aHR, 95% CI 1.9, 0.6 to 5.8 in complete case data compared to 
aHR, 95% CI 1.8, 0.6 to 5.3 in imputed data and primary: aHR, 95% CI 1.8, 1.3 to 2.6 
in complete case data compared to aHR, 95% CI 1.8, 1.3 to 2.5 in imputed data) 
(Figures 6.8 and 6.9). 
Compared with direct admission to cardiac hospital or centre, the adjusted hazard 
ratios for inter-hospital transfer were (facilitated and rescue: aHR, 95% CI 0.9, 0.8 to 
1.0 in complete case data compared to aHR, 95% CI 0.9, 0.8 to 1.1 in imputed data and 
primary: aHR, 95% CI 1.1, 1.1 to 1.2 in complete case data compared to aHR, 95% CI 
1.2, 1.1 to 1.2 in imputed data). The adjusted estimates for already in a cardiac centre 
route were (facilitated and rescue: aHR, 95% CI 1.4, 0.8 to 2.5 in complete case data 
compared to aHR, 95% CI 1.5, 0.9 to 2.4 in imputed data and primary: aHR, 95% CI 
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1.4, 1.2 to 1.5 in complete case data compared to aHR, 95% CI 1.4, 1.2 to 1.5 in 
imputed data) (Figure 6.11). 
 
 
6.5 Discussion 
6.5.1 Summary of key findings 
• The majority of the STEMI cohort were treated by primary PCI. From 2005 to 2014, 
the frequency of primary interventions increased and ‘facilitated or rescue’ 
interventions decreased. 
• Majority of the procedural complications and in-hospital outcomes (including 
MACCE) were infrequent in both intervention groups. 
• Crude late mortality rate was higher in the primary intervention patients compared 
with patients who received facilitated and/or rescue PCI. After adjustment, the 
association between primary PCIs ‘two hours from symptom onset’ and long-term 
survival was significantly upheld. 
• Overall, the survival rate of primary intervention patients was significantly less than 
that of facilitated and/or rescue intervention patients.  
• In both intervention groups, elderly patients had worse survival rates. 
• More than two hours’ delay from the time of symptoms onset to the intervention 
was a significant predictor of worse survival in primary intervention patients. 
• In primary intervention patients, worse survival was associated significantly with 
both routes of admission ‘inter-hospital transfer’ and ‘already in a cardiac centre’. 
• Radial access was used more frequently than femoral in primary interventions. In 
both intervention groups, radial access was associated with lower crude early and 
late mortality rates. After adjustment, the association with long-term survival was 
significantly maintained. 
• Other clinical determinants of better survival in primary PCIs were male gender, the 
number of used stents and the use of Abciximab. 
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• Clinical determinants of worse survival in primary intervention group were old age, 
pre-procedural cardiogenic shock, hypertension, diabetes mellitus, renal disease, 
previous myocardial infarction, previous PCI, poor ventricular ejection fraction, pre-
procedural ventilation, pre-procedural TIMI 0 and the use of intra-aortic balloon 
pump. 
• One-tenth of the variables had no missingness, three quarters had 50% or less 
missing values and only five variables had missing values of more than 90%. 
• Multiple imputation made slight improvement on the precision of the generated 
adjusted hazard ratios, which were statistically insignificant as they did not change 
the overall association result of the same models from the complete case data.  
• Even though there was evidence for hospital effects, the use of mixed effects models 
did not largely affect the adjusted estimates at patient’s level. 
 
6.5.2 Findings in the context of literature 
Compared to the other studies from literature, this study is more representative 
of the UK patients with STEMI, simply because most of those other studies were 
international and executed outside the UK. In addition, only few other multi-centre 
studies have prospectively evaluated the clinical determinants of survival of patients 
with STEMI after primary PCI using a population-based national cohort [113, 115, 
118]. Majority of the reviewed studies were not representative of the general population 
as they were implemented at hospital-based level [79, 112, 114, 119-123]. Such studies 
produce selection bias very easily due to the expected variations between cardiac 
centres facilities and the experience of interventionists [76, 117]. 
This prospective analysis of consecutive patients with STEMI in the UK 
between 2005 and 2014 shows important differences between both types of PCIs. More 
importantly, it demonstrates many significant clinical determinants of survival over a 
fairly long period (9.6 years). Over that period, the number of patients with STEMI who 
were treated by primary PCI increased. This increment over the years was comparable 
to the overall number of patients who underwent primary PCI in the UK [54, 71]. 
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The increase in primary PCI in the UK is likely to be the result of a combination 
of factors including: 
1. The shifting from treating patients with STEMI by thrombolysis medications 
to primary PCI [76, 117, 189]. 
2. The enhancements in technology by means of highly equipped intervention 
laboratories and emergency rooms, along with the improvements in 
techniques as well as the availability of more well trained and experienced 
interventional cardiologists and departments [60]. 
3. The progress in pre- and post-procedural care provided by well-equipped 
high dependency intensive care units [60].  
4. The initiation of a plan by the NHS in England and Wales which aimed to 
provide a national primary PCI service for all patients with STEMI by 2012 
[189, 195]. 
Overall, crude late mortality rates and survival time were worse after primary 
PCI when compared to ‘facilitated or rescue’ interventions. These findings were aligned 
with other recent publications [118, 196]. As a matter of fact, this study matched the 
findings of two previous studies by Danchin et al. [118] and Westerhout et al. [196] that 
primary interventions is a significant predictor of worse survival. In this study, the 
association of primary interventions with patients’ survival was aHR, 95% CI 1.1, 1.0 to 
1.2 compared to ‘facilitated and rescue’ interventions. Compared to primary PCI, the 
association of fibrinolysis with patients’ five-year survival in Danchin’s study was aHR, 
95% CI 0.6, 0.4 to 0.9. Likewise, the combined CAPTIM and WEST trials by 
Westerhout reported that within the first two hours after symptoms, the association of 
pre-hospital fibrinolysis with patients’ survival at one year was aHR, 95% CI 0.4 0.2 to 
0.9.  
Similar to this study, Danchin’s study was on a large number of STEMI patients 
and was representative of the general population since the study was a multi-centre 
observational in design. The findings in Danchin’s study were comparable to this study 
findings as 84% of the fibrinolysis patients received PCI afterward. However, the 
plausibility of reporting bias was a limitation in this study as well as in Danchin’s study, 
since the cause of mortality was not available. The main weakness of the CAPTIM and 
WEST trials was the lack of generalizability as well as comparability to this study, 
based on the fact that rescue PCI was performed in around 25% of the pre-hospital 
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fibrinolysis patients. Data about the timing of PCIs from fibrinolysis was measured and 
presented in CAPTIM and WEST trials; yet, this kind of data was not available in the 
BCIS database. Primary PCI as a determinant of worse survival in this study can be 
explained by the fact that more than 83% of the primary PCI were after two hours from 
the onset of symptoms. Delayed primary PCIs lead to unwanted complications and 
outcomes [71-73]. Besides, in early interventions (two hours or less) there was no 
difference between ‘facilitated and rescue’ and primary PCI. However, the lack of 
power due to the small number in ‘facilitated and rescue’ (61 PCIs) may be the reason 
behind this non-significant association [118]. Another explanation might be that these 
findings were biased by the effect of confounding by indication, since the type of 
procedure is the treatment variable which might be an intermediate phase in the 
causation pathway [197].  
Across the study population and primary intervention patients, in particular, 
older age was associated with worse survival (aHR 7.8, 95% CI 5.2 to 11.8). A finding 
that was well matched with other recent publications: McCormick et al. [112] (adjusted 
odds ratio (aOR) 1.1, 95% CI 1.0 to 1.1), De Luca et al. [115] (aHR 7.5, 95% CI 3.7 to 
15.1) and Brodie et al. [121] (younger age: aHR 0.6, 95% CI 0.4 to 0.9). De Luca’s 
results were the closest to this study’s results. The best possible explanation might be 
because both share a similar and more reprehensive study design (population-based) 
with large number of STEMI patients. Older age and survival association can elucidate 
the possible causes behind the worse survival in the primary intervention patients as 
they tended to be older than those who underwent ‘facilitated and rescue’ interventions 
which may also reflect the type of patients referred or accepted for PCI following 
fibrinolysis. 
Compared with females, males in the primary intervention group had a better 
survival (aHR 0.9, 95% CI 0.8 to 0.9), Patel et al. [86] demonstrated similar finding 
(aHR 0.4, 95% CI 0.3 to 0.7). The results of this study showed that femoral access was 
used more frequently in female patients with STEMI; therefore, this may explain to 
some extent why females had worse survival. It has been shown in this study that 
femoral access was associated with worse survival in patients with STEMI who 
underwent primary intervention (radial vs. femoral approach: aHR, 95% CI 0.8, 0.7 to 
0.8). This result is similar to other published findings in the literature on radial access as 
a safer access route than femoral in patients with STEMI [32, 33, 87, 191, 192]. In this 
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study, radial access was used for more than half the primary intervention patients and 
small differences in bleeding rates were noticed compared to femoral. Furthermore, 
crude early and late mortality rates were far less compared with femoral access. These 
observations were in parallel with the conversion of UK interventionists to the radial 
access rather than the femoral (from 32% in 2005 to 71.5% in 2013) [54]. 
International guidelines recommended that primary PCI is the best treatment in 
STEMI patients with cardiogenic shock; primary PCI is associated with a 37% relative 
risk reduction compared with fibrinolysis [4, 74, 76, 111]. However, and as expected, 
pre-procedural cardiogenic shock was another significant determinant of worse survival 
in the primary intervention group, a result that matched those of other reviewed studies 
[71, 75, 76, 112, 113]. The results of Chapter 4 of this thesis, specifically (Figures 4.3 
and 4.4), showed a worse survival time and a significant impact of cardiogenic shock on 
mortality in patients with STEMI after PCI. This study confirms these findings further 
and over a longer period of time. Such findings were of specific clinical relevance, 
calling for the need for advanced longer-term risk management for patients with STEMI 
with established cardiogenic shock [198].  
Histories of previous acute myocardial infarction or previous PCI were 
associated with worse survival in patients with STEMI after primary PCI (aHR 1.4, 
95% CI 1.3 to 1.5 and aHR 1.1, 95% CI 1.0 to 1.2, respectively). De Luca et al. [115] 
reported a similar finding in regard to previous myocardial infarction (aHR 3.0, 95% CI 
1.1 to 8.6). Probably such history may reflect the existence of a more complicated 
coronary artery disease or a pre-existent multi-vessel involvement, which have negative 
influence on patients’ survival [199, 200]. 
In keeping with results from other published studies [45, 48, 115, 181], 
additional numbers of clinical determinants were identified to be associated with worse 
survival in patients with STEMI treated by primary PCI. These included hypertension, 
pre-existing diabetes mellitus, chronic renal disease, poor ventricular ejection fraction, 
pre-procedural ventilation, the use of intra-aortic balloon pump, post-procedural acute 
myocardial infarction and post-procedural acute stroke. Pre-procedural TIMI 0 was 
another predictor of worse survival after primary interventions (aHR 1.1, 95% CI 1.0 to 
1.1). De Luca et al. [115] demonstrated a similar result (TIMI 3 with 30-day mortality: 
aHR 0.5, 95% CI 0.2 to 0.9). However, contradicting findings were presented by 
Taniguchi et al. [113] (TIMI 0 with 5-year survival: aHR 0.6, 95% CI 0.4 to 0.9). The 
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explanation for such contradiction was not entirely clear and possibly in need for further 
confirming studies. 
In this study, the time from the symptoms onset to the intervention ‘more than 
two hours’ was found to be a significant determinant of worse survival after primary 
PCI (aHR 1.2, 95% CI 1.1 to 1.2). A study by McCormick et al. [112] presented 
opposing findings (aOR 1.0, 95% CI 0.9 to 1.0). Nevertheless, many other studies 
shared similar findings to this study [113, 120-123]. These studies illustrated that the 
shorter the time of primary intervention from onset of symptoms, the better the short- 
and long-term survival of STEMI patients. In general, it is well established that more 
than two-hour delays after symptoms onset to primary PCI procedures can lead to 
unfavourable complications and outcomes compared to earlier primary PCI [71-73].  
In alignment with results from other reviewed studies [79, 119, 123, 201], the 
admission routes ‘inter-hospital transfer’ and ‘already in a cardiac centre’ predicted 
worse survival in the primary intervention patients (aHR, 95% CI 1.1, 1.0 to 1.2 and 
aHR, 95% CI 1.4, 1.2 to 1.5, respectively). This might be best explained by the fact that 
some routes of admission are directly correlated with the time from symptoms to 
intervention. Patients who were admitted directly to a cardiac centre were treated earlier 
than those who required inter-hospital transfer or needed to be observed further in the 
cardiac hospital or centre. Lastly, despite near ‘saturation’ of primary PCI for STEMI 
throughout the cardiac centres and hospitals in the UK, there was evidence of between 
hospital variations in rates of primary PCI utilisation, which were only in part 
determined by patient-level factors [195]. 
Broader discussions on the used methodologies, such as those about the 
importance of multi-level analysis as well as multiple imputation, will be in the 
discussion chapter. Moreover, more detailed discussion on the overall strengths, 
limitations and implications of this thesis will be in the discussion chapter (see Chapter 
7). 
 
 
  
 
234 
 
6.5.3 Conclusion  
The study presented comprehensive findings in regard to the determinants of 
long-term survival (9.6 years) of patients with STEMI in the UK who underwent 
facilitated, rescue and primary PCIs. The analysis of this study was stratified into two 
main strata (‘facilitated or rescue’ and primary). In this UK whole-country study, 
survival of primary intervention patients was significantly less than that of facilitated 
and rescue intervention patients, particularly when performed after two hours from the 
onset of symptoms. Therefore, earlier primary PCI (two hours or less) is advocated for 
better survival. In primary intervention patients, worse survival was associated with old 
age, pre-procedural cardiogenic shock, hypertension, diabetes mellitus, renal disease, 
previous myocardial infarction, previous PCI, poor ventricular ejection fraction, pre-
procedural ventilation, pre-procedural TIMI 0 and the use of intra-aortic balloon pump. 
More than two-hour delays of intervention, inter-hospital transfer and being already in a 
cardiac centre were independent predictors of worse survival in primary interventions. 
Significant predictors of better survival in the primary intervention patients were male 
sex, the used number of stents, the use of Abciximab and the use of radial artery 
approach. 
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7 Chapter 7              Discussion  
 
 
7.1 Summary 
The two literature reviews outlined in Chapter 2 (sections 2.4 and 2.5) 
demonstrated the lack of current publications relating to the objectives of this thesis. 
The reviews revealed many gaps in knowledge about the care of patients undergoing 
PCI. Furthermore, there was paucity in population based studies on the long-term 
outcomes of PCI, particularly in the UK. The UK population has a large burden of 
cardiovascular disease and its outcomes, in terms of morbidity and mortality [11]. 
Together, most of contemporary research were conducted outside the UK. Therefore, 
understanding the clinical determinants of treatment outcomes is crucial as health 
services in the UK differ to that in other countries, such as the United States. 
Consequently, important risk factors or determinants may be different across countries 
and need quantifying. Furthermore, several major risk factors already known or 
postulated needed to be explored in more detail in the BCIS data. The aim of this thesis 
was to fill some of these gaps in knowledge by presenting the first population based 
study in the UK evaluating the care provided to coronary artery disease patients who 
underwent PCI.  
This chapter brings together the main findings and key discussion points of the 
previous three results Chapters 4, 5, and 6 presented in this thesis. First “a summary of 
the research is presented (section 7.2)”, followed by “a statement of the key findings of 
each study (section 7.3)”, “a critical evaluation of the main findings in the context of 
other research (section 7.40)”, “the overall strengths and limitations of the thesis 
(section 7.5)” then “study implications and future considerations (sections 7.6 and 7.7)” 
and lastly “thesis conclusions (section 7.8)”. 
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7.2 Summary of research undertaken 
In this thesis, different literature reviews were performed to build up the 
research questions, the reviews were:  
• What are the clinical determinants and temporal trends of outcomes for PCI in 
patients with UPLMS in the UK? 
• What are the clinical determinants of long-term survival after primary PCI in 
patients with STEMI in the UK? 
Subsequently, in order to answer the research questions, several retrospective 
analyses of prospectively collected data were undertaken: 
• To describe the overall population included in the 2010 and 2014 versions of the 
BCIS data. 
• To identify the clinical determinants of outcomes for UPLMS patients who 
underwent PCI in England and Wales as well as to compare these determinants 
between STEMI, NSTEACS and stable patients. 
• To quantify the temporal trends in the complications, in-hospital outcomes and 
mortality of UPLMS patients after PCI in the UK. 
• To identify the clinical determinants of primary PCI survival in patients with 
STEMI in the UK. 
 
7.3 Key findings 
7.3.1 The clinical determinants of PCI outcomes in UPLMS patients in the 
UK, from 2005 to 2010 (Chapter 4) 
• Compared to elective patients, the risks of in-hospital MACCE, 30-day mortality 
and 1-year mortality were higher in STEMI and NSTEACS patients. 
• The clinical determinants of worse 30-day and 1-year mortality in acute patients 
were ‘old age’, ‘pre-procedural cardiogenic shock’, ‘poor ventricular ejection 
fraction’, ‘pre-procedural ventilation’ and ‘peri-procedural shock’. In elective 
patients, ‘old age’ was a significant determinant of worse 30-day and 1-year 
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mortality and ‘peri-procedural coronary dissection’ was a predictor only of worse 
30-day mortality. 
• The use of radial approach was associated with lower 30-day mortality in STEMI 
and NSTEACS patients, but was not supported by lower mortality in the longer-
term. The use of Abciximab was associated with improved 1-year mortality rate for 
elective and NSTEACS patients but not STEMI patients. 
• Over 40% of patients with STEMI presented with cardiogenic shock which was 
associated with a nine-fold increase in risk of 30-day mortality and a five-fold 
increase in risk of 1-year mortality. 
 
 
7.3.2 Mortality trends after unprotected left main stem PCI in the UK, 
from 2005 to 2014 (Chapter 5) 
• Over the study period, there was a substantial rise in the number of PCIs recorded 
in UPLMS, particularly acute patients. At the same time, the baseline risk profile 
increased which was reflected in a series of parameters including increasing 
numbers of patients with ‘poor left ventricular systolic function’, ‘old age’ and 
‘cardiogenic shock’.  
• The use of the radial approach increased across biennial years. Yet, the femoral 
approach continued to be the most common approach in STEMI and NSTEACS 
patients with cardiogenic shock. Over the study period, the use of drug eluting 
stents and intravascular ultrasound increased while Abciximab was used less 
frequently. 
• For patients with STEMI with the complication of cardiogenic shock, 30-day and 1-
year mortality rates have declined over the study period by about 13% and 7%, 
respectively. After adjustment for patient-related covariates, these temporal 
improvements remained significant. 
• Despite the significant increase in the number and severity of UPLMS patients who 
underwent PCI, 30-day and 1-year mortality rates remained remarkably stable. 
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7.3.3 The clinical determinants of primary PCI survival in STEMI patients 
in the UK, from 2005 to 2014 (Chapter 6) 
• In comparison with ‘facilitated or rescue’ interventions, the survival of primary 
intervention patients was significantly worse and overall elderly patients had the 
worst survival. 
• Radial access was used more frequently than femoral in primary interventions. In 
both intervention groups, radial access was associated with lower crude early and 
late mortality rates. After adjustment, the significant association with long-term 
survival was maintained. 
• Clinical determinants of better survival in primary PCIs were ‘male gender’, ’the 
use of radial approach’, ‘the number of stents used’ and ‘the use of Abciximab’. 
• Clinical determinants of worse survival in primary intervention patients were ‘old 
age’, ‘pre-procedural cardiogenic shock’, ‘hypertension’, ‘diabetes mellitus’, ‘renal 
disease’, ‘previous myocardial infarction’, ‘previous PCI’, ‘poor ventricular 
ejection fraction’, ‘pre-procedural ventilation’, ‘the use of intra-aortic balloon 
pump’, ‘pre-procedural TIMI 0’, ‘more than two hours delay to intervention’, 
‘inter-hospital transfer’ and ‘already being in a cardiac centre’. 
 
 
7.4 The main findings in context with other research 
Most of the presented results in this thesis were consistent with those from the 
studies identified in the literature. However, the findings of this thesis added more 
consistency and generalisability to the literature because it used large population based 
data from the UK. In addition, efforts were made to minimise any plausible bias 
including data management, as well as choosing the best possible type of methodologies 
during the analyses. The findings of each study in this thesis were discussed in detail in 
Chapters 4, 5 and 6 (sections 4.5, 5.5 and 6.5).  However, this section summarises the 
main findings and places them in the wider clinical context. 
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7.4.1 Survival time and mortality rates 
For patients with UPLMS disease, the survival among those who presented to 
hospital with STEMI was the worst compared to NSTEACS and stable patients. 
Similarly, survival time was worse after primary PCI when compared to ‘facilitated or 
rescue’ interventions. After adjustment, long-term survival was significantly worse after 
a primary PCI. These findings were consistent with other recent publications [118, 196]. 
Previous authors have suggested that this could be due to the delay in performing 
primary PCI for more than 90 to 120 minutes from the onset of symptoms [118]. 
Furthermore, this thesis demonstrated that early mortality rates were lower than those 
reported by others in the literature [34, 42, 48] possibly due to the different sets of 
covariates used for adjusting the analyses in each study. Parma et al. [48] presented 
higher mortality rates; however, this was a hospital based study on a small group of 
acute  patients (58 patients with STEMI). Therefore, Parma’s findings cannot be 
compared with the findings of this thesis.  
Other than the decline in mortality for STEMI patients with cardiogenic shock, 
no temporal changes were observed on mortality rates across the types of clinical 
presentations even though patient volume and patients from populations known to have 
a higher risk of poorer outcomes were increasing. The crude early and late mortality 
rates in STEMI patients with cardiogenic shock were very high (52.5% at 30 days and 
64.0% at one year, in 2013-14,), particularly in those who underwent primary 
percutaneous coronary intervention. Thus, further research is worthy in order to 
understand whether these are potentially preventable deaths. For example the long-term 
use of clopidogrel (an antiplatelet agent) after PCI. Mehta et al. [202] demonstrated an 
association between clopidogrel and less cardiovascular mortality (RR 0·7, 95% CI 0·5 
to 0·9, P =0·030). 
 
7.4.2 Old age 
Old age, greater than 80 years, was a significant determinant of worse short and 
long-term outcomes in stable and acute patients who underwent PCI; a finding that 
matched those of other reviewed studies [86, 92, 93, 95, 96]. Aging by itself and 
alongside other associated medical conditions may be the underlying cause of these 
relationships. That is to say, late mortality after PCI is more liable to be influenced by 
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other non-cardiac risk factors [185]. However, since the data were secondary, further 
information on such possible confounders were out of reach. For that reason, linkage 
with other databases that have more information on all-cause real world mortality is 
essential for any future research on the same relationship. For example, the linkage to 
hospitalisation and procedure data from Hospital Episode Statistics database on 
previous admissions, prescription data or GP data [203].  
With an aging population there will be a greater number of those treated who 
will be older, possibly over 90 years old. In elderly patients, more complications and 
unfavourable outcomes are expected after myocardial infarction and PCI procedures. 
There is also the argument of whether these patient groups are not always offered all 
treatment options because of their old age [204]. Therefore, the need for more research 
on this population is necessary to identify whether alternative treatment options are 
needed, particularly after PCI treatment, for example, antiplatelet medications or cardiac 
rehabilitation (like physical activity) [202, 204]. 
 
7.4.3 Cardiogenic shock  
In alignment with findings from literature [30, 42, 45, 48, 71, 75, 76, 99, 112, 
113], pre-procedural cardiogenic shock was an alarming determinant of worse outcomes 
in PCI patients. Cardiogenic shock in UPLMS patients who presented acutely (STEMI 
and NSTEACS) was associated with an increased risk of early and late mortality. 
Similarly, long-term survival was worse in STEMI patients with cardiogenic shock. 
Therefore, more room for improvement is required for advanced longer term risk 
management and care in PCI patients with such a condition [198]. Cardiac rehabilitation 
is an alternative post-procedural treatment that minimise the impact of cardiogenic 
shock on the outcomes [205]. 
 
7.4.4 Radial approach  
In acute STEMI patients, several studies in the literature have reported an 
association between the use of radial approach and lower rates of bleeding and short-
term mortality as well as better long-term survival [32-34, 191, 192]; a result that was 
repeated in the findings of this thesis. Radial access was demonstrated to be safer than 
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femoral in STEMI and NSTEACS patients with UPLMS. Better bleeding rates with less 
hospital stay as well as lower early mortality rates make the use of radial access a cost-
effective approach [206]. Nevertheless, there was lack of association between radial 
access and mortality at one year. Again, this might be due to the greater effect of non-
cardiac risk factors on late mortality, or the fact that radial access may reflect more 
skilled operators and/or a less sick population (different case-mix).  
Whether the associations described in the literature were artefacts of poorly 
conducted analysis with unmeasured confounders, or whether the sample of patients in 
this thesis was biased, is unclear. This is unlikely because it is a whole population study 
and therefore all patients should be included. Overall, the trends of radial access used in 
this thesis were increasing gradually. A finding that was similar to the trends of current 
practice which is calling for further research with the inclusion of more confounding 
risk factors. 
  
7.4.5 Delayed interventions  
After primary PCIs, ‘more than two hours delay after symptoms onset to the 
intervention’, ‘being transferred between hospitals’ and ‘already being in a cardiac 
centre’ were associated with worse long-term survival. Results that matched those of 
other reviewed studies [71-73, 79, 113, 119-123], and re-emphasise the need for prompt 
treatment as seen in the increased risk of unfavourable outcomes with more than two 
hours delay to primary PCI. 
 
7.4.6 Other determinants 
The use of Abciximab (a platelet aggregation inhibitor) was associated with 
improved late mortality rate for stable and NSTEACS but not STEMI in patients with 
UPLMS. Still, better survival in all patients with STEMI after primary, facilitated or 
rescue PCIs was significantly associated with Abciximab use. Poor left ventricular 
ejection fraction and pre-procedural ventilation were associated with worse early and 
late mortality rates in UPLMS patients, as well as worse long-term survival in STEMI 
patients after primary, facilitated or rescue PCIs. These were consistent with other 
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findings from the literature and reflects patients who are more likely to be unstable [45, 
48, 115, 181]. 
 
 
7.5 Strengths and limitations 
Throughout the analyses of this thesis, every effort has been made to enhance 
strengths and decrease limitations. The main strengths and weaknesses of the BCIS 
database were described in Chapter 1 (sections 1.4.9 and 1.4.10). The following section 
summarises the overall strengths and limitations of the thesis. 
 
7.5.1 Strengths  
• The patients included in all three studies are likely to be representative of all patients 
who underwent PCI in the UK during the data collection period. The BCIS database 
is one of the largest population based whole country (multi-centre) registries in the 
world. It is designed for the detailed evaluation of quality of care and outcomes of 
unselected patients who receive PCI. The participating cardiac centres represent all 
four countries of the UK and reflect real practices and outcomes. Representing the 
general population of such patients in the UK make the scope of this thesis a unique 
and significant strength. The BCIS database is up-to-date and covers the collection 
of PCIs over a reasonably long time period which adds more strengths to the data. 
• The BCIS data undergoes regular checks of validity and consistency to ensure data 
quality [55]. The depth of detail of data as well as the robust tracking of mortality by 
linkage through NHS number were major strengths of the BCIS database. The 
quality of the linked ONS mortality data was another strength of this study that 
allowed accurate tracking of all-cause mortality. The compulsion of mortality 
registration in the UK makes the ONS data almost complete. 
• Comparative stratification was performed in all three analyses (by clinical 
presentation in Chapter 4, by biennial years in Chapter 5 and by type of intervention 
in Chapter 6). This allowed for better understanding of the compared group’s 
characteristics, outcomes and clinical determinants. Stratification strategies before 
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complex analyses (e.g. multivariate regression modelling) were used as a method to 
deal with the possible confounding effect of the stratification variables (i.e. clinical 
presentation, biennial years and type of intervention) [207]. 
• Other strengths of this study were the tests implemented for the sensitivity of the 
analysis (multiple imputation of missing data and mixed effect analysis at the level 
of hospitals and routes of admission).  
 
7.5.2 Limitations 
• During the stages of data cleaning and recording, some variables required cross-
matching between two or more variables in order to categorise them. This process 
was performed to minimise any possible entry errors and missingness from such 
variables. For example, the type of clinical presentation variable was categorised 
into CSA, STEMI and NSTEACS using three different variables from the row BCIS 
data (‘clinical syndrome’, ‘indication for intervention’ and ‘presenting ECG’). 
Although unlikely, this could however lead to some misclassification in the 
variables that have attenuated the described associations. 
• Like many prospective observational data, the utilised 2010 and 2014 BCIS 
databases were dependent and reliant on the accuracy of the ascertainment of all 
eligible cases and the quality of the data recorded from each operator and hospital; 
case ascertainment was high at 92.6% by the end of 2010 and 97.6% by September 
2014 [20, 54].  
• No sufficient data fields were available to calculate the EuroSCORE [39] or other 
clinical, established risk scores. For instance, extra cardiac arteriopathy, chronic 
lung disease and mobility status were not available in the BCIS database, indicating 
that case-mix adjustment using a calculated score was not plausible. This could 
mean that some of the findings are not fully adjusted for the underlying case-mix.  
• Information bias due to selective reporting was a possibility in some of the main 
variables (such as procedural complications and in-hospital outcomes like 
MACCE). The validation of such information was not possible which may have had 
an impact on the presented results. In addition, as mentioned earlier, the lack of 
complete information regarding the all-cause mortality may have caused 
information bias. 
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• Lastly, the analyses of this thesis have disclosed many important associations; but as 
an observational study, cannot provide evidence for causation but may be suggested 
[208].  
 
7.5.3 Evaluation of the methodologies used 
All three analyses in this thesis have potential pitfalls. The strengths and 
limitations of the cohort study methodologies in relation to other methodologies and in 
relation to the minimisation of bias are discussed in this section.  
 
7.5.3.1 Population and design 
Careful identification and definition of each study population was an essential 
part of these analyses. Several steps were taken in order to minimise bias during the 
selection procedure, this included using a clear inclusion and exclusion criteria based 
upon advice and agreements from the Delphi group (Section 3.4.2) and using several 
variables in the BCIS database to define clinical group rather than relying on only one 
to gain full information. This ensured the findings in this thesis were generalisable to 
patients across the UK. 
All the three analyses in this thesis were based on prospectively collected, 
secondary observational data. The majority of the reviewed studies from literature were 
also observational studies. Thus, all may be subject to some level of residual 
confounding from poorly measured or unmeasured confounding variables, but they are 
the most comprehensive datasets currently available and where several studies agree on 
the effect of a particular variable and background evidence indicates plausibility it can 
suggest a likely effect [209]. Therefore, the evidence for causation in these studies 
cannot be confirmed but may be suggested. One of the emerging methods that could 
help to allow for the suggesting causation in any future analysis is the use of directed 
acyclic graphs [208].  
One of the important limitations in all secondary data, such as the BCIS 
database, is the inability to have input on the type of data collected and any information 
biases in measurement that may be produced [210]. The BCIS data was collected by 
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many different cardiac interventionists and clerks in multiple cardiac hospitals and 
centres all over the UK. This will influence both the accuracy and completeness of the 
data, creating selection bias. A bias of this kind in a large sample of secondary data may 
lead to underestimation or overestimation of associations [211]. To limit such errors, all 
data entry staff should receive proper training [212]. In order to further compensate for 
some of the collection and selection bias in the analyses of this thesis, data cleaning and 
multiple imputation were utilised. 
 
7.5.3.2 Descriptive analyses 
In the descriptive analyses of this thesis, many differences were highly 
statistically significant. A possible reason behind this was the large cohorts of patients 
analysed, particularly that of patients with STEMI in Chapter 6. Future analytical work 
might be needed by using more strict cut-offs for significant P values or other statistical 
methods. For instance, by comparing effects sizes (the magnitude of the difference 
between the size of the groups) to see what variables are clinically significant [213].   
 
7.5.3.3 Multivariate regression modelling 
Both logistic and Cox hazards regression modelling were used in the analyses of 
this thesis. Directed acyclic graphs, a method for describing causal relationships 
between variables [214], was considered as a way to understand the relationships 
between confounders, but due to the size and the number of the variables of the BCIS 
database, it was not feasible to generate them in this data-set. However, comprehensive 
sets of confounders were adjusted for in the multivariable regression analyses based on 
literature reviews in addition to clinical input from the Delphi group. The regression 
analyses were based on the complete case data as the generated model estimates did not 
considerably change after multiple imputation.  
All attempts for model adjustment were made in order to avoid problems such as 
collinearity [133].  In such a large and complex database, collinearity was still plausible 
and could have arisen during the analyses in this thesis. These limitations were 
minimised by removal or categorisation of offending predictor variables.  
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Other methods that have been used and increased the appropriateness of 
regression modelling, were stratification (such as the types of clinical presentation and 
the types of PCI) or recoding continuous covariates to categorical covariates. The 
variables ‘age’ and ‘time from onset to intervention’ were recorded into categories. The 
limitation of categorisation of the continuous variables is when the categorised variables 
are then used in Cox hazards regression and modelled on survival. This approach might 
have an impact on the significance of the association between the predictors and 
survival [133].  
 
7.5.3.4 Multi-level regression modelling 
Multi-level regression models account for the variance in the independent 
variables and in the clusters level e.g. cardiac hospitals. The effect of each cluster is 
measured using shared collective data not only from the cluster in question but also 
from the other clusters [133]. This method was used as a sensitivity test in all the studies 
of this thesis. 
The multivariate regression models were repeated taking into account the 
‘random effects’ of cardiac hospitals or centres. The random effects terms were 
statistically significant and indicated that there was similarities between the patients 
within each hospital and there was significant difference between hospitals (i.e. 
clustering). Similar results were demonstrated at the level of the routes of admission for 
primary percutaneous coronary interventions. However, the use of multi-level 
regression models did not markedly change the adjusted estimates at patient level. 
Therefore, the adjusted estimates from the fixed effects models were used in the 
analyses of this thesis. 
 
7.5.3.5 Multiple imputation 
A full justification and description of the methodology of multiple imputation 
was reviewed earlier in Chapter 3 (sections 3.4.7 and 3.4.8, respectively). In the 
analyses of this thesis, missing data was noted and it was assumed to be missing at 
random which permitted for multiple imputation. In all three studies, no considerable 
changes were observed on the generated adjusted estimates. Therefore, multiple 
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imputation was employed as a sensitivity test for the complete case analyses. In some 
cases, complete case analysis can create biased estimates, loss of statistical power and 
loss of precision [164]. But in this thesis estimates did not change significantly after 
multiple imputation inferring that the overall association result of the same models from 
both complete case and imputed data were comparable.  
One of the limitations was the existence of high rates of missingness (more than 
40%) in some important predictor variables (for example ‘left ventricular ejection 
fraction’ variable in the STEMI cohort, the missing values were 65.43%). The 
imputation of such variables introduces selection bias to the estimates and limits the 
statistical power of regression modelling [174]. To avoid that, predictors with more than 
40% missing values were excluded from the imputation models. 
Variables of different types were present in the data-set (binary e.g. ‘sex’, 
categorical e.g. ‘clinical presentation type’ or continuous e.g. ‘survival time’). Such 
differences create bias by generating unrealistic assumptions and/or incorrect 
combinations in the imputed variables [153, 155]. Therefore, the fully conditional 
specification imputation method was the imputation method of choice in all three 
studies. A method in which separate individual conditional models for each incomplete 
predictor variable are specified for the imputation [153].  
The accuracy of the employed multiple imputation was increased by the number 
of variables (predictors and auxiliary) in the imputation model. The recommended 
number of variables to be included from the literature was between 15 and 25 [154]. 
The number of variables used in each imputation model in all three studies were within 
this range. In the same way, the number of all imputations datasets produced in the 
analyses of this thesis was 20 datasets for each predictor variable with missingness. 
Increasing the number of imputation datasets decreases the variability between 
important statistics such as standard errors and P values [162-164]. Overall, there was 
slight improvement in the level of completeness over the 9.6 years study period for all 
PCI patients in the BCIS data. Yet, the absence of important information in most of the 
variables is still a concern and a key gap in the BCIS database.  
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7.5.4 Using the BCIS for audit and research – practicalities and data 
quality arrangements 
Monthly, quarterly and annual feedback reports are provided by NICOR to all PCI 
centres and consultants across the UK. Therefore, operators are able to monitor, 
appraise and revalidate their activities and outcomes [20, 52, 81]. In order to expand and 
promote the interventional research potentials of the BCIS database, the data are 
distributed to researchers. More than 50 papers have been published using the BCIS 
data. Currently, 25 research projects are being conducted following approval from the 
research and development group [84]. 
As previously stated, as in other secondary databases, missing data in most of the 
variables in the BCIS database is a main concern to BCIS, NICOR, cardiologists and 
researchers. Unrecorded data and entry errors are the best possible explanations behind 
missing information in the BCIS database [55]. Consequently, both the accuracy and 
completeness of the entered data may be compromised, creating selection bias [212]. 
The studies in this thesis exposed plenty of high rate missing data in some variables 
(such as ‘use of ventilation’ variable (99.63%)) and data entry errors (such as that in 
‘the routes of admission’ variable). To minimise the bias produced by entry errors, data 
cleaning and recoding as well as multiple imputation were employed.  
Details on data cleaning and recoding were mentioned in Chapter 3 (section 3.4.4). 
Consuming a significant amount of efforts and time, data cleaning and recoding were 
performed twice, for the 2010 and 2014 versions of the BCIS database. However, both 
were critical steps in the course of this thesis. They improved the data quality and 
enhanced the research potential of the BCIS database in this thesis and for future 
researchers. 
With multiple imputation being limited to the variables with less than 40% 
missingness, improvement of the completeness and quality of the BCIS data is crucial. 
Most researchers use the complete case method to overcome the dilemma of missing 
data. Others prefer to default impute (i.e. use ‘9’ as the number meaning missing data) 
to allow more patients to be included in regression models [215]. However, additional 
imputation techniques that deal with missing data, such as multiple imputation are 
becoming more of a practical consideration as computing power increases. The use of 
multiple imputation can be as the main method of analysis or a sensitivity analysis as in 
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this thesis. Using such methods gives reassurance if the results of the same models 
using complete case and imputed data are comparable. 
The underlying problems of missing data can only be properly corrected at sources 
(i.e. better data entry). Several recommendations for the improvement of data entry are 
suggested based on findings made throughout the data management process and the 
analyses of this thesis. The suggested changes (improvements) are mainly to the BCIS 
local entry system to increase the accuracy and completeness of the data entered: 
• The entry of date variables should be connected and sequenced to prevent missing 
and/or mismatched information. In this thesis, for example, situations were 
observed during the analyses in which ‘the discharge date’ of the patient was earlier 
than ‘the date for the intervention’. Simply, a system rejection of mismatched or 
empty dates would prevent such errors. 
• Limits should be added to the open-ended continuous variables such as ‘the number 
of stents used’, ‘the number of attempted vessels’ and ‘the longest stented/treated 
segment’. Clinically implausible numbers (outliers) were noticed and cleaned for 
most of the continuous variables.  
• Mandatory entry is another suggestion particularly for all important variables. 
Again to avoid too much absent information, entry personnel must complete all the 
information required for a variable to move on to the next one. 
• Adding jumps to the entry system will help in saving time during data entry as well 
as avoiding unnecessary or wrong entries. For example, if the choice in ‘the 
intervention type’ was primary percutaneous coronary intervention, answering the 
variable ‘recent thrombolysis’ is not required and should be skipped. Such errors 
were noticed during data cleaning and recoding. 
Of course, the feasibility and accessibility of all the above recommendations needs 
to be assessed. At the same time, continued training and awareness of the importance of 
data accuracy and completeness is required to ensure the enhancement of clinical 
practice and future research. 
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7.5.5 Data ethical measures 
Throughout this thesis, careful attention has been paid to ethical aspects at all 
stages of the analyses: 
• Data was kept securely in accordance with the University of Leeds regulations. 
• Patients’ privacy, anonymity and confidentiality were upheld at all times. The data 
were pseudo-anonymised. Therefore, the identification of patients, operators and 
cardiac hospitals is not possible.  
 
7.6 Vision for percutaneous coronary intervention 
In this thesis, comparison tables and figures for each study were presented and 
discussed. At the same time, future considerations for improved practice were 
suggested. Such comparative analyses relating to PCI for coronary artery disease in the 
UK have rarely been described in such detail. The output of this thesis is expected to 
have an impact on the improvement of knowledge on how PCI procedures are delivered 
nationally. This thesis had provided an evidence base on which stakeholders and 
interventional cardiologists can change future practice to improve hospital care for those 
who receive PCI. 
This thesis comes at an important time as there is a need to continue to improve 
quality of care in the NHS, aiming to build on the improvement of short and long-term 
survival and quality of life [216]. There is a need for more comprehensive determinants 
of the quality of care related to the outcomes after PCI [25, 26, 71, 75, 76]. The studies 
in this thesis demonstrated some important characteristics in relation to the clinical 
determinants of UPLMS patients’ outcomes after PCI and STEMI patients’ survival 
after primary PCI. Accordingly, the findings of these studies may have important 
implications for policy makers in order to improve patient care and to establish more 
evidence based management choices and policies.  
For reasonably equal PCI delivery across the NHS trusts, the national 
implementation of PCI, particularly primary PCI, should continue to be 24 hour/all 
week service with adequate numbers of interventionist and other supporting staff to 
deliver this. Strict compliance with policies and clinical guidelines is mandatory for the 
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improvement of PCI patients care. For example, delayed primary PCIs should be 
avoided as much as possible. In such situations, early fibrinolysis followed by PCI may 
have better outcomes. 
Using a representative data, reporting the benefits and inherent risks of PCI to 
inform patients and other healthcare professionals have many implications and help to 
quantify the relative effect of different risk factors and clinical characteristics on long 
and short-term outcomes. Communicating such results will highlight areas where novel 
interventions aimed at improving outcomes may be targeted. For example, the need for 
increased implementation of the radial approach as this research has confirmed previous 
studies and demonstrated it to be safer (less bleeding complications and better survival) 
than femoral access [35]. Establishing ways in which pre and post-procedural care for 
acute patients with established cardiogenic shock can be improved is another important 
example.  
 
7.7 Future considerations  
The investigative nature of this thesis has uncovered further questions of interest 
in relation to the care of patients after percutaneous coronary intervention. The results 
have illustrated complex associations and have led to recognition of the value of further 
validation and exploration of large multi-centre datasets, such as the BCIS data. Further 
validation of the reliability and reproducibility of the findings is needed for both the 
descriptive statistics and the regression models.  
The possibility of confounding by indication in patients receiving facilitated, 
rescue and primary percutaneous coronary interventions cannot be unravelled using 
observational data [197]. Therefore, randomised clinical trials should be considered, 
although the utilisation of multiple imputation to deal with missing data in this thesis 
showed clear advantage as a sensitivity test. Yet, its use in medical research remains 
uncommon and the use of multiple imputation techniques should be more frequent. 
More fundamentally, the accuracy and completeness of the BCIS data needs to improve 
from the early stages of data entry. One of the possible future considerations might be 
the utilisation of data mining as potential alternatives to the data management methods 
used. 
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Calculating and measuring the scoring mechanisms such as EuroSCORE and 
SYNTAX score in such data will be a challenge for any research. The main advantage 
of using these clinical scores is that they allow for underlying differences in case-mix. 
The addition of more variables related to these scores is one feasible way to distinguish 
them. Further linkages to other electronic databases (such as the MINAP database) is 
another way. In addition, linkage to other database with more information on cardiac 
surgical procedures (e.g. CABG) or medical treatments (e.g. thrombolysis) will allow 
for additional comparative research opportunity with percutaneous coronary 
intervention. Such linkages will permit more investigation into the differences in 
characteristics, determinants and outcomes between these lines of management. Linkage 
to primary care databases should be sought to evaluate the early (preventive) and late 
(clinical or rehabilitative) determinants of outcomes for the patients who received 
percutaneous coronary intervention. 
What are the geographical differences in the temporal trends of early and late 
mortality across the clinical presentation groups or the type of intervention? What is the 
impact of geographical differences on the survival of the same groups? Both are other 
important research questions that may need further exploration. Further exploration into 
how patients’ socio-economic status or IMD may affects the relationship between some 
clinical determinants (such as old age or diabetes mellitus) and PCI outcomes or 
survival. This could be achieved by using a hierarchical multi-level modelling with 
socio-economic status as an upper level.  
Assessment of the relative survival of both cohorts (UPLMS patients and 
primary PCI patients) and international comparisons with the UK data are other 
motivating scope. Future research on patient outcomes across other after-effects of 
interest such as quality of life, other health outcomes and costs as an outcome will help 
the evaluation of the quality of care for PCI patients.  
 
7.7.1 Future planned publications 
In addition the published papers and abstracts arising from this thesis, two more 
papers based on the results from Chapters 5 and 6 will be submitted to peer-reviewed 
journals. The first entitled:’ Mortality trends after unprotected left main stem PCI in the 
UK, 2005-2014: Analysis of 10,825 cases from the British Cardiovascular Intervention 
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Society (BCIS) national registry’, the manuscript is written and ready for submission to 
Euro Intervention journal. The second entitled: ‘Clinical determinants of long-term 
survival for STEMI after primary PCI in the UK, 2005-2014: the British Cardiovascular 
Intervention Society (BCIS) national registry’, aiming for submission to Euro 
Intervention. 
 
 
7.8 Thesis conclusions 
Currently in the UK, there is an increasing need for more detailed clinical 
determinants of outcome in patients who receive percutaneous coronary intervention as 
the patient population increases in volume and complexity due to an aging population 
and increasing co-morbidities. This comes with the existence of a prospect to define the 
quality of care plan for such patients. The work in this thesis has utilised population 
based data in the UK which provided a unique opportunity to study the quality of care 
provided to patients who underwent percutaneous coronary intervention. 
In examining the determinant and temporal trends of the outcomes in UPLMS 
patients, the studies of consecutive patients clearly demonstrates significantly associated 
clinical determinants of early and late mortalities. Furthermore, they illustrated 
substantial changes in the clinical presentation, the treatment and the outcomes of 
patients who received UPLMS PCI over a period of ten years.  In the final analysis, the 
study presented comprehensive and original results with regard to the clinical 
determinants of survival in primary percutaneous coronary intervention patients over a 
reasonably long period (9.6 years). These findings were compared to facilitated and 
rescue interventions as a group, most of these findings were consistent with those in the 
literature. 
Together, these findings provided a unique insight into gaining more knowledge 
and understanding of these intervention procedures. These results represent a step 
forward in assessing the quality of care for patients after percutaneous coronary 
intervention.  
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9 Appendices 
9.1 Appendix I: The 2010 BCIS data description 
 
9.1.1 Demographic characteristics 
In total, 411,324 PCI patients were recorded in the 2010 BCIS database in 
England and Wales between 2005 and 2010. Over the study period, the number of PCIs 
performed per year was steadily increasing (from 41,023 procedures in 2005 to 84,608 
in 2010) (Figure 9.1). The mean age (SD) for all patients was 64.4 (11.4) years and the 
age range was from 18.6 years to 100.0 years. Patients older than 80 years of age were 
the least frequent (8.1%) patient to undergo the PCI procedure.  
Males were dominant out of all patients at 301,765 (73.4%). The mean age (SD) 
was 63.2 (11.3) years for male patients and 67.8 (11.2) years for females. Figure 9.2 
shows the difference in the frequency and age distribution between males and females. 
The majority of patients (82.8%) were treated in NHS hospitals/centres and most 
(62.5%) were of Caucasian ethnicity. Table 9.1 demonstrates the distribution of baseline 
demographic characteristics of all patients’ records in the 2010 BCIS database. 
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Figure 9.1: Number of PCIs performed per year, from 2005 to 2010. 
 
 
 
 
 
 
 
Figure 9.2: Age distribution by gender of all PCI patients in England and Wales 
from 2005 to 2010 
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Table 9.1: Baseline demographic characteristics of all PCI patients in England and 
Wales from 2005 to 2010 
Variable Total    n= 411,324 Missing values (%) 
Mean (SD) age, years   63.1 (12.6) 
471 (0.1) 
Age 
Less than 65 years (%) 208,717 (50.7) 
65 – 80 years (%) 168,930 (41.1) 
Greater than 80 years (%) 33,206 (8.1) 
Gender 
Female (%) 106,988 (26.0)  
2,571 (0.6) 
Male (%) 301,765 (73.4) 
Ethnic groups 
Caucasian (%) 257,160 (62.5) 
115,378 (28.1) 
Black (%) 2,157 (0.5) 
Asian (%) 18,994 (4.6) 
Other (%) 17,635 (4.3) 
Patient type 
NHS (%) 340,592 (82.8) 
53,884 (13.1) 
Private (%) 16,848 (4.1) 
Admission 
route  
(ACS only) * 
Direct to cardiac centre (%) 68,445 (33.5) 
47,258 (23.2) Inter-hospital transfer (%) 73,309 (35.9) 
Already in cardiac centre (%) 15,048 (7.4) 
Index of multiple deprivation score, mean (SD) 21.6 (13.9) 167,934 (40.8) 
* ACS n= 204,070. 
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9.1.2 Clinical characteristics 
Clinical characteristics of PCI between 2005 and 2010 are listed in Table 9.2. 
Around half (50.3%) of the patients recorded were chronic stable angina patients, while 
STEMI patients were 18.2% and NSTEACS were 31.5%. Over the study period, 
patients with chronic stable angina gradually decreased (from 56.7% in 2005 to 45.4% 
in 2010) and the number of STEMI patients steadily increased (13.1% in 2005 to 24.6% 
in 2010) (Figure 9.3). Primary PCI was performed for 50,445 (67.8%) acute patients 
(12.3% of all patients); in addition, only 6,155 (1.5%) of all patients had pre-procedural 
cardiogenic shock. Severe left ventricular systolic dysfunction (less than 30%) was in 
23,752 (5.8%) patients. 
 
 
Figure 9.3: Distribution of all PCI patients in England and Wales from 2005 to 
2010, by clinical syndrome 
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Table 9.2: Baseline clinical characteristics of all PCI patients in England and 
Wales from 2005 to 2010 
Variable Total    n= 411,334 Missing values (%) 
Clinical syndrome  
CSA (%) 207,254 (50.3) 
0 (0.0) STEMI (%) 74,369 (18.2) 
NSTEACS (%) 129,701 (31.5) 
PCI type  
(STEMI only) * 
Primary (%) 50,445 (67.8) 
12,633 (17.0) Facilitated (%) 2,591 (3.5) 
Rescue (%) 8,690 (11.7) 
Previous acute myocardial infarction (%) 105,221 (25.6) 56,985 (13.9) 
Previous PCI (%) 77,600 (18.9) 32,640 (7.5) 
Family history of coronary artery disease (%) 161,337 (39.2) 77,363 (18.8) 
Diabetes mellitus (%) 68,718 (16.7) 31,244 (7.6) 
History of renal disease (%) 9,420 (2.3) 45,764 (11.1) 
Smoking status 
Never smoked (%) 120,628 (29.3) 
68,172 (16.6) Ex-smoker (%) 138,465 (33.7) 
Current smoker (%) 84,059 (20.4) 
Recent thrombolysis (%) 24,174 (5.9) 190,095 (46.2) 
Cardiogenic shock (%) 6,155 (1.5) 38,985 (9.5) 
LVEF (%) 
Good, LVEF ≥ 50%  147,761 (35.9) 
189,742 (46.1) Fair, LVEF = 30 – 49% 50,074 (12.2) 
Poor (sever), LVEF < 30%  23,752 (5.8) 
* STEMI n= 74,369. 
 
 
9.1.3 Procedural characteristics 
Pre-procedural thrombolysis in myocardial infarction type 3 (TIMI 3) was in 
30,350 (14.9%) ACS patients (7.4% of all patients), and subsequently post-procedure 
increased to be in 89,950 (44.1%) ACS patients (21.9% of all patients). One stent was 
used in 200,680 (48.8%) of the patients; at the same time, drug eluted stents were 
deployed more frequently than bare metal stents. Overall, the use of the femoral artery 
as an access route was one fold higher than the use of radial artery (62.4% compared to 
32.8%). More details about the procedural characteristics are shown in Table 9.3.  
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Table 9.3: Baseline procedural characteristics of all PCI patients in England and 
Wales from 2005 to 2010 
Variable Total    n= 411,334 Missing values (%) 
Pre-procedural flow in 
infarct related artery 
(ACS only) * 
TIMI 0 (%) 36,981 (18.1) 
103,077 (50.5) 
TIMI 1 (%) 7,893 (3.9) 
TIMI 2 (%) 11,339 (5.6) 
TIMI 3 (%) 30,350 (14.8) 
Unknown (%) 14,420 (7.1) 
Arterial access 
Femoral artery (%) 256,671 (62.4) 
18,619 (4.5) Radial artery (%) 134,986 (32.8) 
Other arteries (%) 1.048 (0.3) 
Total number stents 
used 
1 stent (%) 200,680 (48.8) 
51,704 (12.6) 2 stents (%) 99,632 (24.2) 
≥ 3 stents (%) 59,308 (14.4) 
Longest stented/treated segment, mean (SD) mm 23.5 (11.8) 110,958 (27.0) 
Largest balloon/stent used, mean (SD) mm 3.2 (0.6) 117,448 (28.6) 
Type of stent used 
Bare metal stent (%) 119,244 (29.0) 
50,488 (12.3) Drug eluting stent (%) 218,986 (53.2) 
Both together (%) 22,606 (5.5) 
Type of 
drug 
eluting 
stent used  
Taxus liberte (Boston Scientific) (%) 21,415 (5.2) 
53,522 (13.0) 
Cypher (Cordis) (%) 35,147 (8.5) 
Endeavor (Medtronic) (%) 30,886 (7.5) 
Xience V (Abbott) (%) 33,450 (8.1) 
Promus (Boston Scientific) (%) 23,148 (5.6) 
BioMatrix (%) 3,029 (0.7) 
Promus Element (%) 3,716 (0.9) 
Xience Prime (%) 1,481 (0.4) 
Drugs used 
None (%) 256,095 (62.3) 
44,028 (10.7) Abciximab (%) 
87,600 (21.3) 
Eptifibitide (%) 6,577 (1.6) 
Tirofiban (%) 17,024 (4.1) 
Use of intravascular ultra sound (%) 11,809 (2.9) 88,176 (21.4) 
Use of intravascular pressure wire (%) 21,291 (5.2) 88,176 (21.4) 
Use of Intra-aortic balloon pump (%) 5,893 (1.4) 51,693(12.6) 
Post-procedural flow 
in infarct related 
artery (ACS only) *  
TIMI 0 (%) 6,983 (3.4) 
101,807 (49.9) 
TIMI 1 (%) 1,156 (0.6) 
TIMI 2 (%) 4,164 (2.0) 
TIMI 3 (%) 89,950 (44.1) 
* ACS n= 204,070.  
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9.1.4 Clinical outcomes  
Coronary dissection was the most frequent procedural complication (1.7%) and 
the need for ventilation was the least 0.1%. During the hospital stay, MACCE occurred 
in 7,403 (1.8%) patients, while acute myocardial infarction occurred in 2,412 (0.6%) 
patients. PCI revascularisation was performed for 1,173 (0.3%) of patients. In-hospital 
mortality was in 1.1% of patients, which increased to 1.6% after 30 days post the 
procedure, and increased further to 4.7% after one year post the procedure. Procedural 
complications, in-hospital outcomes and mortality rates are shown in Table 9.4. 
 
Table 9.4: Clinical outcomes of all PCI patients in England and Wales from 2005 
to 2010 
Variable Total     n= 411,334 
Missing values 
(%) 
Procedural 
complications 
Side branch occlusion (%) 2,696 (0.7) 
65,482 (15.9) 
Coronary dissection (%) 7,153 (1.7) 
Coronary perforation (%) 1,078 (0.3) 
Direct current cardioversion (%) 1,188 (0.3) 
No flow/slow flow (%) 3,608 (0.9) 
Ventilated (%) 367 (0.1) 
Cardiogenic shock induced by procedure (%) 866 (0.2) 
In-hospital 
outcomes 
Acute myocardial infarction (%) 2,412 (0.6) 
24,193 (5.9) 
Stroke (%) 56 (0.1) 
Renal failure/dialysis (%) 399 (0.1) 
Blood transfusion (%) 836 (0.2) 
Revascularisation 
PCI (%) 1,173 (0.3) 
CABG (%) 451 (0.1) 
Unadjusted MACCE rate (%) 7,403 (1.8) 
Unadjusted in-hospital mortality rate (%) 4,373 (1.1) 14,155 (3.4) 
Unadjusted mortality rate at 30 days  (%) 6,505 (1.6) 259 (0.1) 
Unadjusted mortality rate at 1 year *  (%) 17,895 (4.7) 259 (0.1) 
MACCE: major adverse cardiovascular and cerebrovascular event. 
* Censored at 10/8/2011, therefore all PCI procedures performed after 10/8/2010 were not included in 
describing this rate. 
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9.1.5 Data completeness  
A total of 113 variables are in the 2010 BCIS database (after cleaning). Of them, 
only two (1.8%) variables were 100% complete, which were clinical presentation type 
and date/time of operation. Furthermore, the remaining 111 variables had missing 
information that ranged between 0.1% (such as age at procedure) and 96.0% (creatinine 
level). Tables 9.1 to 9.4 list the missing values of most of the 2010 BCIS database. 
Overall, between 2005 and 2010, there was a decrease in the proportion of missing data. 
Some examples of changes over the period were pre-procedural cardiogenic shock 
(missing values decreased from 13.0% to 5.2%), left ventricular ejection fraction 
(missing values decreased from 48.9% to 45.3%) and arterial access (missing values 
decreased from 9.2% to 2.2%) (Figure 9.4).  
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Figure 9.4: Proportions of complete and missing values for pre-procedural 
cardiogenic shock, left ventricular ejection fraction and arterial access in England 
and Wales stratified by years from 2005 to 2010 
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9.2 Appendix II: NICOR Data Application Form  
Ref number:   
(Office use) 
 
1.PROJECT TITLE 
An investigation into primary PCI diffusion and provider effects on survival.  
 
2.PRINCIPAL INVESTIGATOR  
 
Title, forename, surname: Dr Chris Gale 
Employing organisation: Division of Epidemiology and Biostatistics, University of Leeds.     
Position in organisation: Associate Professor     
Address of organisation: Division of Epidemiology and Biostatistics 
Faculty of Medicine and Health 
Level 8, Worsley Building, 
University of Leeds 
Clarendon Way, Leeds, LS2 9JT 
 
Telephone: 
0044 (0) 113 343 8816 
0044 (0) 7985 442297 
Email: c.p.gale@leeds.ac.uk    
Please attach the Principal Investigator’s Curriculum Vitae. 
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3.RESEARCH PROJECT  
 
3.1 SUMMARY 
Evidence continues to support the fact that primary PCI is associated with better 
outcomes for STEMI patients. However, the majority of studies have been randomised 
controlled trials and conducted outside England and Wales, thus cannot be fully 
generalisable to England and Wales. On the other hand, there is local variation at both 
levels of operators and hospitals, in the implementation of, outcomes and survival from 
this service which require further investigation. Using primary PCI data available in an 
observational national dataset such as the BCIS database will allow us to characterise all 
primary PCI survival estimates and the impact of provider (at hospital level and 
operator level) on these estimates in England and Wales population. This research 
proposal, therefore aims to quantify, on a national scale, the survival estimates as well 
as hospital level and operator level effects on survival after primary PCI and measure 
the impact of changes over time. Our application will not cover what is to be undertaken 
at NICOR. We will undertake a shared frailty survival analysis to report variance 
components, a spatial diffusion analysis, and a relative survival analysis. We also wish 
to improve the data using statistical techniques such as multiple imputation for missing 
data to try to overcome some of the expected biases. This will permit the evaluation of 
the effect of missing data on research outcomes and offer the potential to enhance the 
research strengths of the BCIS database. 
 
 
3.2 CONTEXT 
This will form part of a larger 5 year programme of research funded by the National 
Institute for 
Health Research (Dr CP Gale, PI), studying variation in cardiovascular care and 
outcomes in England and Wales. 
 
3.3 PROJECT DESCRIPTION 
Background 
For patients presenting with acute STEMI, primary PCI is now considered the favoured 
line of management especially when performed within the first 90 to 120 minutes of 
medical attention.[60, 217, 218] This is because, when compared with thrombolysis, 
primary PCI is associated with better outcomes.[219, 220] and is cost effective.[77] 
Consequently, a national primary PCI strategy has been adopted in England and Wales. 
However, the evidence uptake and its implementation has been prolonged and varied,[4] 
and may have prevented avoidable deaths if undertaken earlier and more uniformly 
across  the country.   
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t is well established that patient level (case-mix) and hospital level (volume) are 
associated with early outcomes after primary PCI.[1,5-8] For example, many 
observational cohorts have reported significant centre volume outcome effects, 
suggesting a need for dedicated heart attack centres, whereby high throughput high 
volume centres are able to provide optimal care and outcomes.[9] Operator level factors 
may also impact on outcomes, for which there are only limited data in the literature. The 
invstigation of transparent reporting of operator level adjusted outcomes provides an 
ideal opportunity to quantify nationally if this impacts on survival after primary PCI 
after accounting for patient level and hospital level influences.  
 
Providing a local primary PCI service for acute STEMI has been an immense challenge 
for many centres and resultantly there are a range of services provided. Indeed, there has 
been geographical inequity in primary PCI diffusion (and format of its uptake, for 
example, 24 hours service versus non 24 hour service) such that variation in potentially 
avoidable outcomes may have resulted over time and be present to this day. Yet, there 
are no independently published analyses to support or refute this notion.  
 
 
Scientific hypothesis 
We hypothesise that there have been significant temporal improvements in survival 
after primary PCI, but that are significant residual hospital level and operator level 
effects.  
 
 
 
 
Objectives 
1.To report crude and adjusted survival estimates after primary PCI. 
2. To quantify the hospital level and operator level effects on survival after 
primary PCI. 
3.To describe the national diffusion of primary PCI, and quantify associated 
avoidable death. 
4.To investigate the temporal trends in survival after primary PCI.  
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Methodology and planned statistical analyses 
Data: 
BCIS database 
 
Sampling frame: 
Patients over 18 years of age who revived primary PCI for acute STEMI 
 
 
Methods 
1)Missing data: Multiple imputation of missing data specific for survival 
analyses 
2)Survival analysis: a) Shared frailty using accelerated failure, b) relative 
survival, c) crude and adjusted estimates with 95% confidence intervals, d) 
hospital and operator variance components will be quantified and compared with 
fixed effects coefficients 
3)Diffusion: a) rates of primary PCI per population estimates, b) linear models 
to quantify associations with regional level ecological data where available 
4)Avoidable deaths: derived from SMRs and numbers of centre procedures 
 
 
 
Please refer to our published manuscripts which detail the above methods for use in the 
NICOR national cardiovascular registries.  
We are aware that a centre volume outcome analysis is to be undertaken through 
NICOR UCL. We do not plan to duplicate this project.   
We, therefore, request a further download of the psuedoanonymised BCIS dataset to 
include contemporary cases from 2005 to 2013, linked to status and date of death / time 
to death. 
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Research team 
members / Co-
applicants   
Employing 
organisation 
Position in 
organisation 
Contact details                        
(Email address/ Telephone 
no) 
Dr Chris Gale 
Division of 
Epidemiology and 
Biostatistics,  
University of 
Leeds, 
LS2 9JT 
NIHR Clinician 
Scientist Award 
Associate Professor 
of Cardiovascular 
Health Sciences 
and Honorary 
Consultant 
Cardiologist 
c.p.gale@leeds.ac.uk 
 
0113 343 8916 
07985 442297 
Dr Paul 
Baxter 
Division of 
Epidemiology and 
Biostatistics,  
University of 
Leeds, 
LS2 9JT 
Associate Professor 
in Biostatistics 
p.d.baxter@leeds.ac.uk 
 
0113 343 9078 
Dr Sarah 
Fleming 
Division of 
Epidemiology and 
Biostatistics,  
University of 
Leeds, 
LS2 9JT 
Senior Research 
Fellow in 
Epidemiology and 
Biostatistics 
s.j.fleming@leeds.ac.uk 
 
0113 343 4878 
Dr Sami 
Almudarra 
Division of 
Epidemiology and 
Biostatistics,  
University of 
Leeds, 
LS2 9JT 
PhD student, 
Epidemiology and 
Biostatistics 
umssal@leeds.ac.uk 
 
0113 343 8874 
Dr Oras 
Alabas 
Division of 
Epidemiology and 
Research Fellow in 
Epidemiology and 
o.alabas@leeds.ac.uk 
 
285 
 
Biostatistics,  
University of 
Leeds,  
LS2 9JT 
Biostatistics  
0113 343 8874 
Dr K Laut 
Department of 
Clinical Medicine 
Aarhus University, 
8000 Aarhus C, 
Denmark 
Research Fellow kristina@laut.dk 
 
00 45 29 72 32 15 
Dr Peter 
Ludman 
Cardiology 
Department 
University Hosp 
Birmingham 
B15 2TH 
Consultant 
Cardiologist 
Peter.Ludman@uhb.nhs.uk 
0121 627 2921 
07767425818 
Dr Mark 
deBelder 
James Cook 
University 
Hospital 
Middlesbrough 
TS4 3BW 
Consultant 
Cardiologist 
mark.debelder@stees.nhs.u
k 
0164 285 4620 
 
 
 
 
286 
 
5. PUBLICATIONS OF THE RESEARCH TEAM MEMBERS 
 
List of the main publications of each Research team member involved in the 
project. 
 
 
Gale CP 
 
An assessment of composite measures of hospital performance and associated mortality for patients 
with acute myocardial infarction. Analysis of individual hospital performance and outcome for the 
National Institute for Cardiovascular Outcomes Research (NICOR).  
Simms AD, Baxter PD, Cattle BA, Batin PD, Wilson JI, West RM, Hall AS, Weston CF, Deanfield JE, 
Fox KA, Gale CP.  
Europ Heart J Acute Cardiovasc Care. 2013 Mar;2(1):9-18.  
 
Persistent geographical disparities in the use of primary percutaneous coronary intervention in 120 
European regions: exploring the variation. 
Laut KG, Gale CP, Pedersen AB, Fox KA, Lash TL, Kristensen SD.  
EuroIntervention. 2013 Aug 22;9(4):469-76. 
 
Determinants and patterns of utilization of primary percutaneous coronary intervention across 12 
European countries: 2003-2008.  
Laut KG, Gale CP, Lash TL, Kristensen SD.  
Int J Cardiol. 2013 Oct 3;168(3):2745-53.  
 
Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis.  
Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C, Cade JE, Gale 
CP, Burley VJ.  
Stroke. 2013 May;44(5):1360-8.  
 
The use of anticoagulants in the management of atrial fibrillation among general practices in England. 
Cowan C, Healicon R, Robson I, Long WR, Barrett J, Fay M, Tyndall K, Gale CP.  
Heart. 2013 Aug;99(16):1166-72.  
 
Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-
ischaemic aetiology.  
Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, Gale CP, Batin PD, Ajjan R, 
Kearney L, Wheatcroft SB, Sapsford RJ, Witte KK, Kearney MT. 
Diab Vasc Dis Res. 2013 Jul;10(4):330-6.  
 
Statistical profiling of hospital performance using acute coronary syndrome mortality. 
 Manda SO, Gale CP, Hall AS, Gilthorpe MS.  
Cardiovasc J Afr. 2012 Nov;23(10):546-51.  
 
The effect of referral for cardiac rehabilitation on survival following acute myocardial infarction: a 
comparison survival in two cohorts collected in 1995 and 2003. 
Lewinter C, Bland JM, Crouch S, Doherty P, Lewin RJ, Køber L, Hall AS, Gale CP.  
Eur J Prev Cardiol. 2012 Nov 22. [Epub ahead of print] 
 
Age-dependent inequalities in improvements in mortality occur early after acute myocardial infarction 
in 478,242 patients in the Myocardial Ischaemia National Audit Project (MINAP) registry.  
Gale CP, Cattle BA, Baxter PD, Greenwood DC, Simms AD, Deanfield J, Fox KA, Hall AS, West RM.  
Int J Cardiol. 2013 Sep 30;168(2):881-7.  
 
 
 
 
287 
 
Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial 
Ischaemia National Audit Project (MINAP) 2003-2009: National Institute for Cardiovascular Outcomes 
Research (NICOR).  
Simms AD, Reynolds S, Pieper K, Baxter PD, Cattle BA, Batin PD, Wilson JI, Deanfield JE, West RM, 
Fox KA, Hall AS, Gale CP.  
Heart. 2013 Jan;99(1):35-40.  
 
Acute coronary syndromes: an old age problem. 
Simms AD, Batin PD, Kurian J, Durham N, Gale CP.  
J Geriatr Cardiol. 2012 Jun;9(2):192-6.  
 
Engaging with the clinical data transparency initiative: a view from the National Institute for 
Cardiovascular Outcomes Research (NICOR).Gale CP, Weston C, Denaxas S, Cunningham D, de 
Belder MA, Gray HH, Boyle R, Deanfield JE; NICOR Executive.  
Heart. 2012 Jul;98(14):1040-3.  
 
Evaluation of Methods and Management of Acute Coronary Events (EMMACE) Investigators. 
Association of frontal QRS-T angle--age risk score on admission electrocardiogram with mortality in 
patients admitted with an acute coronary syndrome. 
Lown MT, Munyombwe T, Harrison W, West RM, Hall CA, Morrell C, Jackson BM, Sapsford RJ, 
Kilcullen N, Pepper CB, Batin PD, Hall AS, Gale CP;  
Am J Cardiol. 2012 Feb 1;109(3):307-13.  
 
Is cardiac rehabilitation still relevant in the new millennium? 
Dobson LE, Lewin RJ, Doherty P, Batin PD, Megarry S, Gale CP.  
J Cardiovasc Med (Hagerstown). 2012 Jan;13(1):32-7.  
 
Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The 
Myocardial Ischaemia National Audit Project 2003-2010. 
Gale CP, Cattle BA, Woolston A, Baxter PD, West TH, Simms AD, Blaxill J, Greenwood DC, Fox KA, 
West RM.  
Eur Heart J. 2012 Mar;33(5):630-9.  
 
An assessment of the concentration-related prognostic value of cardiac troponin I following acute 
coronary syndrome.  
Gale CP, Metcalfe E, West RM, Das R, Kilcullen N, Morrell C, Crook R, Batin PD, Hall AS, Barth JH.  
Am J Cardiol. 2011 Nov 1;108(9):1259-65.  
 
Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical 
and echocardiographic assessment.  
Gale CP, White JE, Hunter A, Owen J, Allen J, Watson J, Holbrook I, Durham NP, Pye MP.  
J Cardiovasc Med (Hagerstown). 2011 Sep;12(9):613-8.  
 
Multiple imputation for completion of a national clinical audit dataset. 
Cattle BA, Baxter PD, Greenwood DC, Gale CP, West RM.  
Stat Med. 2011 Sep 30;30(22):2736-53.  
 
Changing characteristics and mode of death associated with chronic heart failure  caused by left 
ventricular systolic dysfunction: a study across therapeutic eras. 
Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, Fox KA, Rajwani A, Baig 
W, Groves D, Barlow P, Fisher AC, Batin PD, Kahn MB, Zaman AG, Shah AM, Byrne JA, Lindsay SJ, 
Sapsford RJ, Wheatcroft SB, Witte KK, Kearney MT.  
Circ Heart Fail. 2011 Jul;4(4):396-403.  
 
Impact of diabetes on long-term mortality after presentation with acute myocardial infarction.  
Gale CP, Thow J, Batin PD, Hall AS.  
J Cardiovasc Med (Hagerstown). 2011 Jun;12(6):387-9.  
 
 
 
 
 
288 
 
Impact of missing data on standardised mortality ratios for acute myocardial infarction: evidence 
from the Myocardial Ischaemia National Audit Project (MINAP) 2004-7.  
Gale CP, Cattle BA, Moore J, Dawe H, Greenwood DC, West RM.  
Heart. 2011 Dec;97(23):1926-31. 
 
Impact of hospital proportion and volume on primary percutaneous coronary intervention performance 
in England and Wales. 
West RM, Cattle BA, Bouyssie M, Squire I, de Belder M, Fox KA, Boyle R, McLenachan JM, Batin PD, 
Greenwood DC, Gale CP.  
Eur Heart J. 2011 Mar;32(6):706-11.  
 
Development and validation of a clinical index to predict  survival after cardiac resynchronisation 
therapy.  
Artis NJ, Gale CP.  
Heart. 2010 Mar;96(5):388. 
 
Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes.  
Gale CP, Cattle BA, Simms AD, Greenwood DC, West RM.  
Heart. 2009 Aug;95(16):1355. 
 
Ups and downs of balloon times. 
Cattle BA, Greenwood DC, Gale CP, West RM.  
BMJ. 2009 Jun 15;338:b2424. 
 
Point of care testing in acute coronary syndromes: when and how? 
Gale CP, Simms AD, Cattle BA, Greenwood D, West RM.  
Heart. 2009 Jul;95(14):1128-9.  
 
An unusual presentation of pulmonary artery dissection. 
Hoye SL, Gale CP, Tolan DJ, Pepper CB.  
Thorax. 2009 Apr;64(4):368.  
 
Letter by Gale et al regarding article, "which hospitals have significantly better or worse than expected 
mortality rates for acute myocardial infarction patients? Improved risk adjustment with present-at-
admission diagnoses".  
Gale CP, Birkhead JS, Manda SO.  
Circulation. 2008 Jul 1;118(1):e9.  
 
Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction 
National Audit Project (MINAP) database.  
Gale CP, Manda SO, Weston CF, Birkhead JS, Batin PD, Hall AS.  
Heart. 2009 Mar;95(3):221-7.  
 
Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: a real-
world study using the Myocardial Infarction National Audit Project (MINAP) database. 
Gale CP, Manda SO, Batin PD, Weston CF, Birkhead JS, Hall AS.  
Heart. 2008 Nov;94(11):1407-12.  
 
Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. 
Cubbon RM, Gale CP, Rajwani A, Abbas A, Morrell C, Das R, Barth JH, Grant PJ, Kearney MT, Hall 
AS.  
Diabetes Care. 2008 Feb;31(2):363-5.  
 
Hyperglycaemia, in relation to sex, and mortality after acute coronary syndrome.  
Cubbon RM, Rajwani A, Abbas A, Gale CP, Grant PJ, Wheatcroft SB, Barth JH, Kearney MT, Hall AS.  
Eur J Cardiovasc Prev Rehabil. 2007 Oct;14(5):666-71. 
 
Lower rates of heart failure and death in acute coronary syndromes.  
Cubbon RM, Gale CP, Grant PJ, Hall AS, Kearney MT.  
JAMA. 2007 Sep 5;298(9):969. 
 
 
289 
 
Are acute coronary syndromes risk models too complex? 
Gale CP, Manda SO, Hall AS.  
Eur Heart J. 2007 Sep;28(17):2175-6. 
 
Evaluation of Methods and Management of Acute Coronary Events Investigators. Temporal trends in 
mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 
3000 patients between 1995 and 2003.  
Cubbon RM, Wheatcroft SB, Grant PJ, Gale CP, Barth JH, Sapsford RJ, Ajjan R, Kearney MT, Hall 
AS 
Eur Heart J. 2007 Mar;28(5):540-5. 
 
The association between hyperglycaemia and elevated troponin levels on mortality in acute coronary 
syndromes.  
Gale CP, Kashinath C, Brooksby P.  
Diab Vasc Dis Res. 2006 Sep;3(2):80-3. 
 
Funnel plots, performance variation and the Myocardial Infarction National Audit Project 2003-2004.  
Gale CP, Roberts AP, Batin PD, Hall AS.  
BMC Cardiovasc Disord. 2006 Aug 2;6:34.  
 
Is bedside teaching in cardiology necessary for the undergraduate education of medical students? 
Gale CP, Gale RP.  
Med Educ. 2006 Jan;40(1):11-3. 
 
Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors.  
Gale CP, Futers TS, Summers LK.  
Diab Vasc Dis Res. 2004 May;1(1):34-9. 
 
Detection of coins ingested by children using a handheld metal detector: a systematic review.  
Lee JB, Ahmad S, Gale CP.  
Emerg Med J. 2005 Dec;22(12):839-44.  
 
A migrating pacemaker.  
Gale CP, Mulley GP.  
Postgrad Med J. 2005 Mar;81(953):198-9.  
 
The characterisation and functional analysis of the human glyoxalase-1 gene using methods of 
bioinformatics.  
Gale CP, Grant PJ.  
Gene. 2004 Oct 13;340(2):251-60.  
 
Depiction of elderly and disabled people on road traffic signs: international comparison.  
Gale RP, Gale CP, Roper TA, Mulley GP.  
BMJ. 2003 Dec 20;327(7429):1456-7.  
 
Atherothrombotic disease and factor XIII: lucky for some?  
Gale CP, Grant PJ. 
Eur J Clin Invest. 2002 Sep;32(9):637-9.  
 
Pacemaker explosions in crematoria: problems and possible solutions. 
Gale CP, Mulley GP.  
J R Soc Med. 2002 Jul;95(7):353-5.  
 
 
Baxter PD 
 
Simms AD, Baxter PD, Cattle BA, Batin PD, Wilson JI, West RM, Hall AS,  Weston CF, Deanfield JE, 
Fox KA, Fox KA, Gale CP (2013) An assessment of composite measures of hospital performance and 
associated mortality for patients with acute myocardial infarction. Analysis of individual  hospital 
performance and outcome for the National Institute for Cardiovascular Outcomes Research (NICOR). 
Europ Heart J Acute Cardiovasc Care 2(1): 9-18. 
 
290 
 
Harrison WJ, Gilthorpe MS, Downing A, and Baxter PD. (2013) Multilevel Latent Class Modelling of 
Colorectal Cancer Survival Status at Three Years and Socioeconomic Background Whilst 
Incorporating Stage of Disease. International Journal of Statistics and Probability, 2(3). 
 
Gierula J, Cubbon RM, Jamil HA, Byrom R, Baxter PD, Pavitt S, Gilthorpe MS, Hewison J, Kearney 
MT, Witte KK, (2013), Cardiac resynchronization therapy in pacemaker-dependent patients with left  
ventricular dysfunction, Europace 04 Jun 2013 
 
Bailey, MA, Griffin, KJ, Sohrabi, S, Whalley DJ, Johnson, AB, Baxter, PD, Ariëns, RA, Scott, DJA, 
Plasma thrombin-antithrombin complex, prothrombin fragments 1 and 2, and D-dimer levels are 
elevated after endovascular but not open repair of infrarenal abdominal aortic aneurysm, Journal of 
Vascular Surgery, doi: http://dx.doi.org/10.1016/j.jvs.2012.12.030, Mar 2013 
 
Griffin KJ, Fleming SJ, Bailey MA, Czoski-Murray C, Baxter PD, Target setting for elective infra-renal 
AAA surgery: A single mortality figure? Surgeon 02 Jan 2013 
 
Gale CP, Cattle BA, Baxter PD, Greenwood DC, Simms AD, Deanfield J, Fox KA, Hall AS, West RM 
Age-dependent inequalities in improvements in mortality occur early after acute myocardial infarction 
in 478,242 patients in the Myocardial Ischaemia National Audit Project (MINAP)  
registry. Int J Cardiol 20 Nov 2012 
 
Bailey MA, Baxter PD, Scott DJA, (2012), Essential statistics for the clinician, Surgery (United 
Kingdom) 30(9):442-446. 
 
Cattle, B. A., Baxter, PD, Flemming, T. J., Gale, C. P., Mitchell, D. C., Gilthorpe, M. S., Scott, D. J. A., 
Czoski-Murray, C. J., & McCabe, C. (2012). Data Quality Improvement, Data Linkage and Multiple 
Imputation in the UK National Vascular Database. International Journal of Probability and Statistics, 
1(2). 
 
Simms AD, Reynolds S, Pieper K, Baxter PD, Cattle BA, Batin PD, Wilson JI, Deanfield JE, West RM, 
Fox KA, et al., (2012), Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction 
using the Myocardial Ischaemia National Audit Project (MINAP) 2003-2009: National Institute for 
Cardiovascular Outcomes Research (NICOR). Heart 22. 
 
Alzahrani SH, Hess K, Price JF, Strachan M, Baxter PD, Cubbon R, Phoenix F, Gamlen T, Ariëns RA, 
Grant PJ, et al., (2012), Gender-Specific Alterations in Fibrin Structure Function in Type 2  
Diabetes: Associations with Cardiometabolic and Vascular Markers. J Clin Endocrinol Metab. 
 
Ghosh D, Jamson SL, Baxter PD, Elliott MW (2012). Continuous measures of driving performance on 
an advanced office-based driving simulator can be used to predict simulator task failure in patients 
with obstructive sleep apnoea syndrome. Thorax. May 5. [Epub ahead of print] 
 
Bailey MA, Sohrabi S, Flood K, Griffin KJ, Rashid ST, Johnson AB, Baxter PD, Patel JV, Scott DJA 
(2012) Calcium channel blockers enhance sac shrinkage after endovascular aneurysm repair. J Vasc 
Surg. 
 
Woolston A, Tu YK, Baxter PD, Gilthorpe MS, (2012), A Comparison of Different Approaches to 
Unravel the Latent Structure within Metabolic Syndrome. PLoS One 7(4):e34410 2012 
 
Bailey, MA, Charnell, AM, Griffin, KJ, Czoski-Murray, CJ, Sohrabi, S, Rashid, ST, Baxter, PD and 
Scott, DJA (2011), A systematic review of the methodology employed to calculate abdominal aortic 
aneurysm growth rate, Ultrasound. 
 
Gale, CP, Cattle, BA, Woolston, A, Baxter, PD, West, TH, Simms, AD, Blaxill, J, Greenwood, DC, 
Fox, KAA, West, RM, (2011), Resolving inequalities in care? Reduced mortality in the elderly after 
acute  
coronary syndromes. The Myocardial Ischaemia National Audit Project  2003 – 2010, European Heart 
Journal. 
 
Cattle, BA, Greenwood, DC, Gale, CP, Baxter, PD, West, RM, (2011), Multiple Imputation of a Large 
Clinical Audit Dataset, Statistics in Medicine, 30(22), 2736-2753. 
 
291 
 
 
 McKibbin, M, Ali, M, Bansal, S, Baxter, PD, West, K, Williams, G, Cassidy, F, and Inglehearn, CF, 
(2011), HTRA1 promoter genotype may influence the initial response to intra-vitreal ranibizumab 
therapy for neovascular age-related macular degeneration, British Journal of Opthalmology, May 10. 
[Epub ahead of print]. 
 
Tu Y-K, Woolston A, Baxter PD, Gilthorpe MS, (2010), On Separating the Effects of Body Size and 
Growth on Later Blood Pressure, Epidemiology, 21(4):452-453. 
 
Tu, Y-K, Woolston, A, Baxter, PD, and Gilthorpe, MS, (2010), Assessing the Impact of Body Sizes 
Throughout the Lifecourse on Blood Pressure in Later Life Using Partial Least Squares Regression, 
Epidemiology, 21(4), 440-448. 
 
Baxter, PD, and Marchant, PR, (2010), The cross product ratio in bivariate log normal and gamma 
distributions, with an application to non-randomised trials, Journal of Applied Statistics, 37(4), 529-536. 
 
 
Fleming SJ 
Pedersen M, Schoket B, Godschalk RW, Wright J, von Stedingk H, Törnqvist M, Sunyer J, 
Nielsen JK, Merlo DF, Mendez MA, Meltzer HM, Lukács V, Landström A, Kyrtopoulos SA, 
Kovács K, Knudsen LE, Haugen M, Hardie LJ, Gützkow KB, Fleming S, Fthenou E, Farmer 
PB, Espinosa A, Chatzi L, Brunborg G, Brady NJ, Botsivali M, Arab K, Anna L, Alexander J, 
Agramunt S, Kleinjans JC, Segerbäck D, Kogevinas M.  
 
Bulky DNA Adducts in Cord Blood, Maternal Fruit-and-Vegetable Consumption, and Birth 
Weight in a European Mother-Child Study (NewGeneris).  
Environ Health Perspect. 2013;121(10):1200-6. 
 
Bannon FJ, O'Rorke MA, Murray LJ, Hughes CM, Gavin AT, Fleming SJ, Cardwell CR.  
Non-steroidal anti-inflammatory drug use and brain tumour risk: a case-control study within 
the Clinical Practice Research Datalink.  
Cancer Causes Control. 2013; 24(11):2027-34. 
 
Griffin KJ, Fleming SJ, Bailey MA, Czoski-Murray C, Baxter PD.  
Target setting for elective infra-renal AAA surgery: A single mortality figure?  
Surgeon. 2013 Jan 2. [Epub ahead of print] 
 
Pedersen M, von Stedingk H, Botsivali M, Agramunt S, Alexander J, Brunborg G, Chatzi L, 
Fleming S, Fthenou E, Granum B, Gutzkow KB, Hardie LJ, Knudsen LE, Kyrtopoulos SA, 
Mendez MA, Merlo DF, Nielsen JK, Rydberg P, Segerbäck D, Sunyer J, Wright J, Törnqvist 
M, Kleinjans JC, Kogevinas M; NewGeneris Consortium.  
Birth weight, head circumference, and prenatal exposure to acrylamide from maternal diet: the 
European prospective mother-child study (NewGeneris).  
Environ Health Perspect. 2012 Sep 24. [Epub ahead of print] 
 
J Laubenthal, O Zlobinskaya, K Poterlowicz, A Baumgartner, MR Gdula, E Fthenou, M 
Keramarou, SJ Hepworth, JC Kleinjans, FJ van Schooten, G Brunborg, RW Godschalk, TE 
Schmid, D Anderson.  
Cigarette smoke-induced transgenerational alterations in genome stability in cord blood of 
human F1 offspring. FASEB J, 2012 Jun 22. [Epub ahead of print] 
 
 
 
 
292 
 
Lacourt A, Cardis E, Pintos J, Richardson L, Kincl L, Benke G, Fleming S, Hours M, 
Krewski D, McLean D, Parent ME, Sadetzki S, Schlaefer K, Schlehofer B, Lavoue J, van 
Tongeren M, Siemiatycki J. INTEROCC case-control study: lack of association between 
glioma tumors and occupational exposure to selected combustion products, dusts and other 
chemical agents.  
BMC Public Health. 2013; 13(1):340. 
 
Enciso-Mora V, Hosking FJ, Di Stefano AL, Zelenika D, Shete S, Broderick P, Idbaih A, 
Delattre JY, Hoang-Xuan K, Marie Y, Labussière M, Alentorn A, Ciccarino P, Rossetto M, 
Armstrong G, Liu Y, Gousias K, Schramm J, Lau C, Hepworth SJ, Schoemaker M, Strauch 
K, Müller-Nurasyid M, Schreiber S, Franke A, Moebus S, Eisele L, Swerdlow A, Simon M, 
Bondy M, Lathrop M, Sanson M, Houlston RS. Low penetrance susceptibility to glioma is 
caused by the TP53 variant rs78378222.  
Br J Cancer. 2013; 108(10):2178-85. 
 
 
Almudarra SA 
 
Comparative outcomes after unprotected left main stem percutaneous coronary intervention: 
A national linked cohort study of 6,339 acute and elective cases from the British 
Cardiovascular Intervention Society (BCIS) database.  
Almudarra SA, Gale CP, Baxter PD, Fleming S, Brogan R, Ludman P, de Belder M, Curzen 
N. 
JACC Cardiovasc Interv 2013 (in press) 
 
 
Mortality and MACCE after unprotected left main stem percutaneous coronary intervention 
2005-2010: Temporal comparisons using a national linked cohort of 6,339 acute and elective 
cases from the British Cardiovascular Intervention Society (BCIS) registry. 
Almudarra SA, Curzen N, Baxter PD, Fleming S, Pearson I, Ludman P, de Belder M, Gale 
CP 
JAMA 2013 (to be submitted) 
 
 
 
Alabas OA 
 
Alabas OA, Allan V, McLenachan JM,  Feltbower R, Gale CP. Age-dependent improvement 
in survival after hospitalization with acute myocardial infarction. An analysis of the 
Myocardial Ischemia National Audit Project (MINAP). Age and Aging 2013 (under review). 
 
Alabas OA, Tashani OA, Johnson MI. Effects of ethnicity and gender role 
expectations of pain on experimental pain: a cross-cultural study. Eur J Pain. 
2013 May;17(5):776-86. 
 
Alabas OA, Tashani OA, Tabasam G, Johnson MI. Gender role affects experimental pain responses: 
a systematic review with meta-analysis. Eur J Pain. 2012 Oct;16(9):1211-23.  
 
Alabas OA, Tashani OA, Johnson MI. Gender role expectations of pain mediate sex differences in 
cold pain responses in healthy Libyans. Eur J Pain. 2012 Feb;16(2):300-11.  
 
Alabas OA, Tashani OA, Johnson MI. Gender role expectations of pain mediate sex differences in 
cold pain responses in healthy Libyans. Eur J Pain. 2011 Jun 24.  
 
293 
 
 
Tashani OA, Alabas OA, Johnson MI. Cold pressor pain responses in healthy Libyans: effect of 
sex/gender, anxiety, and body size. Gend Med. 2010 Aug;7(4):309-19.  
 
 
 
Laut KG 
 
Persitent geographical disparaties in use of primary percutaneous coronary intervention in 120 
European regions: Exploring the variation. Laut KG, Gale CP, Pedersen AB, Fox KAA, Lash 
TL, Kristensen SD. EuroIntervention 2013; 9(4):469-76 
 
Determinants and patterns of utilization of primary percutaneous coronary intervention across 
12 European countries: 2003-2008. Laut KG, Gale CP, Lash TL, Kristensen SD 
Int J Cardiol. 2013 Apr 19. doi:pii: S0167-5273(13)00516-0. 10.1016/j.ijcard.2013.03.085. 
[Epub ahead of print] 
 
Implementation of primary angioplasty in Europe: stent for life initiative progress report. 
Kristensen SD, Fajadet J, Di Mario C, Kaifoszova Z, Laut KG, Deleanu D et. Al. 
EuroIntervention 2012;15(8):35-42. 
 
International variation in readmission after myocardial infarction.  
Laut KG, Kristensen SD, Terkelsen CJ.  
JAMA, Vol. 307, Nr. 16, 2012, s. 1690-1; author reply 1691. 
 
The effects on length of stay of introducing a fast track patient pathway for myocardial 
infarction: a before and after evaluation. Laut KG, Foldspang A. Health Serv. Manage Res 
2012;25:31-34. 
 
Status of Stent for Life Initiative across Europe. Laut KG, Kaifoszova Z, Kristensen SD. J 
Cardiovasc Med. 2011;12(12):856-9. 
 
Barriers to Implementation of Primary Percutaneous Coronary intervention in Europe, Laut 
KG, Pedersen AB, Lash TL, Kristensen SD. European Cardiology, 2011;7(2):108-12. 
 
 
 
Ludman PF 
 
Moat NE, Ludman PF, de Belder MA, Bridgewater B, Cunningham AD, Young CP, Thomas 
M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D, Davies SW, Trivedi U, 
Blackman DJ, Levy RD, Brecker SJD, Baumbach A, Daniel T, Gray H, Mullen MJ. Long-
Term Outcomes After Transcatheter Aortic Valve Implantation in High-Risk Patients With 
Severe Aortic Stenosis.  The U.K. TAVI (United Kingdom Transcatheter Aortic Valve 
Implantation) Registry. 
Journal of the American College of Cardiology 2011;58:2130 
 
Ratib K, Mamas A, Routledge HC, Ludman PF, Fraser D, Nolan J. Influence of access site 
choice on incidence of neurologic complications after percutaneous coronary intervention. 
American Heart Journal 2013;165:317-324 
 
 
294 
 
Moody WE, Chue CD, Ludman PF, Chan YK, Narayan G, Millington JM, Townend JN, 
Doshi SN.  Bleeding outcomes after routine trans-radial primary angioplasty for acute 
myocardial infarction using eptifibatide and unfractionated heparin: A single-center 
experience following the HORIZONS-AMI trial. 
Catheter and Cardiovascular Interventions 2012 Oct doi: 10.1002/ccd.24703 
 
Di Mario C, Eltchaninoff H, Moat N, Goicolea J; Ussia GP, MD; Kala P,Wenaweser P, 
Zembala M; Nickenig G, Barrero EA, Snow T; Iung B, Zamorano P; Schuler G; Corti R, 
Alfieri O; Prendergast B; Ludman P; Windecker S; Sabate M, Gilard M, Witkowski A, 
Danenberg H, Schroeder E, Romeo F, Macaya C, Derumeaux G, Maggioni A, Tavazzi L: on 
behalf of the Transcatheter Valve Treatment Sentinel Registry (TCVT) Investigators of the 
EURObservational Research Programme (EORP) of the European Society of Cardiology 
The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-
hospital results in 4,571 patients. 
Eurointervention 2013;8:1362 
 
Influence of arterial access site selection on outcomes in primary percutaneous coronary 
intervention; are the results of randomized trials achievable in clinical practice? Mammas m, 
Karim Ratib , Helen Routledge , Ludwig Neyses , Douglas Fraser , Mark de Belder , Peter 
Ludman , James Nolan 
J Am Coll Cardiol Intv 2013;6:698–706 
 
 
de Belder MA 
 
Rajwani A, Richardson JD, Kaabneh A, Kendall S, de Belder MA.  
Intra-cardiac erosion of a pectus bar.  
Eur Heart J Cardiovasc Imaging. 2013 Sep 20. [Epub ahead of print]  
 
Close H, Hancock H, Mason JM, Murphy JJ, Fuat A, de Belder M, Hungin AP.  
"It's Somebody else's responsibility" - perceptions of general practitioners, heart failure nurses, care 
home staff, and residents towards heart failure diagnosis and management for older people in long-
term care: a qualitative interview study. 
BMC Geriatr. 2013 Jul 5;13:69. 
 
Mamas MA, Ratib K, Routledge H, Neyses L, Fraser DG, de Belder M, Ludman PF, Nolan J; British 
Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research.  
Influence of arterial access site selection on outcomes in primary percutaneous coronary intervention: 
are the results of randomized trials achievable in clinical practice? 
 JACC Cardiovasc Interv. 2013 Jul;6(7):698-706.  
 
Eldabe S, Raphael J, Thomson S, Manca A, de Belder M, Aggarwal R, Banks M, Brookes M, Merotra 
S, Adeniba R, Davies E, Taylor RS.  
The effectiveness and cost-effectiveness of spinal cord stimulation for refractory angina (RASCAL 
study): study protocol for a pilot randomized controlled trial.  
Trials. 2013 Feb 22;14:57.  
 
Mason JM, Hancock HC, Close H, Murphy JJ, Fuat A, de Belder M, Singh R, Teggert A, Wood E, 
Brennan G, Hussain N, Kumar N, Manshani N, Hodges D, Wilson D, Hungin AP.  
Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart 
failure in care homes (HFinCH) diagnostic accuracy study. PLoS One. 2013;8(1):e53560. 
 
Hancock HC, Close H, Mason JM, Murphy JJ, Fuat A, de Belder M, Hunt T, Baker A, Wilson D, 
Hungin AP.  
Feasibility of evidence-based diagnosis and management of heart failure in older people in care: a 
pilot randomised controlled trial.  
BMC Geriatr. 2012 Nov 14;12:70.  
 
295 
 
 
Hancock HC, Close H, Mason JM, Murphy JJ, Fuat A, Singh R, Wood E, de Belder M, Brennan G, 
Hussain N, Kumar N, Wilson D, Hungin AP.  
High prevalence of undetected heart failure in long-term care residents: findings from the Heart 
Failure in Care Homes (HFinCH) study.  
Eur J Heart Fail. 2013 Feb;15(2):158-65. 
 
de Belder MA.  
Interventional management of acute coronary syndromes: applying  the lessons of ST-elevation 
services to non-ST-elevation myocardial infarction. 
Heart. 2012 Oct;98(19):1407-11.  
 
Gale CP, Weston C, Denaxas S, Cunningham D, de Belder MA, Gray HH, Boyle R, Deanfield JE; 
NICOR Executive.  
Engaging with the clinical data transparency initiative: a view from the National Institute for 
Cardiovascular Outcomes Research (NICOR).  
Heart. 2012 Jul;98(14):1040-3.  
 
 
 
6. PREVIOUS APPLICATIONS  
 
Have you or any of the Research team members/co-applicants applied for NICOR 
data in the past?  
Yes. 
 
If Yes, please give details: 
Main 
Applicant   
Application 
Date 
Project Title Scientific Outputs 
Dr Chris 
Gale 
December 
2010 
Primary PCI in 
England and Wales: 
defining a framework 
for excellence 
Project application accepted 
Dr Chris 
Gale 
June 2011 Multiple imputation 
for completion of the 
British Cardiovascular 
Intervention Society 
(BCIS) database 
Project application accepted 
 
296 
 
 
7. FUNDING  
Do you already have funding to carry out this project?    
N/A. 
 
If you are planning to seek funding to carry out this project and the grant application is 
to be partially or totally based in the use of NICOR data, please give details about the 
funding application. 
 
Name of funding body 
Dr Chris Gale is funded by the NIHR. The project will be undertaken by members of staff 
from the 
University of Leeds. 
 
 
 
 
8. DATA REQUESTED 
8.1 Patient identifiable data NO 
8.2 Proposed linkage: NO 
      List datasets BCIS dataset 
      TTP (if used)  
8.3 Please refer to the audit dataset:  
      Dataset items required A cleaned BCIS dataset with: 
1.Mortality tracking (date of censor, 
date of response, and status) 
2.Unique BCIS patient code, which 
will then allow data tracking to the 
 
297 
 
original BCIS dataset for the purposes 
of third party linkage and / data 
updating (if necessary) for 
identification of index procedure 
3.Hospital-level identifiers 
4.Hospital-specific information – eg 
number of PCIs, no of Drs etc 
5.Anonymised operator id. 
      Time period From 1st of January 2005 to 2013 (or the 
latest possible) 
      Geographical location Data for England and Wales  
Data for Northings and Eastings for each 
patient 
      Annual updates required Yes 
 
 
 
 
9. PROPOSED PROJECT COMPLETION DATE  
2014 
 
MEETING DATE (Office use):    
  
 
 
298 
 
9.3 Appendix III: Ethical requirements 
 
9.3.1 Research/audit/service evaluation queries 
Information about the person undertaking the project 
Who: 
Dr Sami Almudarra, a PhD research postgraduate, Centre for Epidemiology and 
Biostatistics, School of Medicine, Faculty of Medicine & Health, University of Leeds. 
Why the study is being conducted: 
To use anonymised (secondary) data from the British Cardiovascular Intervention 
Society (BCIS) to evaluate the care of patients who have undergone percutaneous 
coronary interventions (PCI). 
 
Why I am seeking an opinion: 
As part of my Ph.D in Cardiovascular Epidemiology, I would like to undertake 
statistical work using anonymised BCIS data which aims to evaluate the care of patients 
who have undergone PCI and I would like to know whether this requires ethical 
approval or audit / service evaluation. Dr Chris Gale, my supervisor, works with this 
and a similar anonymised database – the Myocardial Ischaemic National Audit Project 
(MINAP), and after similar enquiry to you, it has been suggested that this type of work 
does not require formal application for ethical review.  
Purpose/aims of the study 
Project (thesis) title: 
Evaluating the care of patients who have undergone PCI using the BCIS database. 
Summary of proposed work: 
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The proposed work aims to utilise contemporary data from BCIS. BCIS data arise from 
a retrospective multi-centre observational study. The data that we will access from the 
BCIS is anonymised – we cannot trace it back to and therefore cannot identify 
individual patients, physicians or hospitals. We wish to improve the data using 
statistical techniques such as multiple imputation for missing data, and also evaluate 
quality of care by analysing the data.  
Context: 
This work is under the auspice of the National Institute for Health Research Clinician 
Scientist Award (held by Dr Chris Gale). 
 
Project description: 
Background 
There are clinical and statistical concerns about the use of routine clinical data for the 
purposes of research which create biases when the datasets have missing and/or 
implausible values. So, as part of my PhD, I will consider a variety of statistical 
techniques such as multiple imputation to try to overcome some of the biases. This will 
permit the evaluation of the effect of missing data on research outcomes and offer the 
potential to enhance the research strengths of the BCIS database. Afterwards, we aim to 
utilise BCIS data to study PCI quality of care so that a framework for excellence may be 
defined that will promote improvements in care for all patients admitted to hospital with 
acute coronary syndrome regardless of where they live in England and Wales. We will, 
for example, consider studying the impact of primary PCI, outcomes from PCI to the 
left main stem coronary artery. 
 
Scientific uncertainty 
1) This is a retrospective observational study and not a randomised controlled trial; 
substantial biases will challenge the analyses – many of which difficult to overcome. 
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2) Modelling will never adjust for all potential confounders. 
3) New statistical techniques will be applied and evaluated. 
4) An imputed BCIS dataset ‘fit for purpose’ will be an outcome of this research. 
Expected value of results 
We feel that this project will help answer several important questions regarding the 
level of care provided to patients who have undergone PCI in England and Wales. 
Scientific hypothesis 
What is the level of care provided to patients who have undergone PCI in England and 
Wales based on the national BCIS database? 
Objectives 
1)To use BCIS data to evaluate the care of patients who have undergone PCI in 
England and Wales. 
2)To enhance the research potential of BCIS database through multiple imputation. 
Competing interests  
None 
 
Eligibility criteria    
Permission for the use of the data to undertake this work has been granted from the 
BCIS Academic Committee. 
Sample size  There are over 650,000 acute coronary syndrome events recorded in the 
BCIS database 2005-2010, of which 411,324 underwent PCI.  
Recruitment  We will not be recruiting patients – rather we will use secondary 
anonymised data from a national audit database. 
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Population   Anonymised data relating to patients who have undergone PCI, entered 
into the BCIS database between 2005 and 2010. We will not be recruiting patients. We 
cannot identify patients, hospital or physicians.  
If patients or their records/material are to be part of the study the following information 
should be provided: 
•Whether there will be any direct patient contact.       No 
•Details on whether the person undertaking the project will be part of the 
clinical team.        No 
•If they are not part of the clinical team, who will access the medical records 
and will all data passed on to them be fully anonymised. 
Only secondary (anonymised) data will be used that has been collected locally 
and sent to BCIS via the Central Cardiac Audit Database (CCAD). 
Information should be provided on whether any vulnerable groups, such as children, the 
elderly or those with a mental illness, will be included in the study 
All submission to BCIS who present to hospital with acute coronary syndrome and have 
undergone PCI. 
Procedure    If the study involves clinical interventions, details should be provided on 
whether these are part of routine clinical practice or new interventions. 
It does not involves clinical interventions 
Data collection     If data collection is via questionnaires, information should be given 
on how many will be used and whether they are validated. If subject are to be 
interviewed, brief details of the interview themes should be given. 
Data is collected by CCAD and sent to BCIS, whereby upon successful application 
anonymised data is released to academics. 
Methodology and planned statistical analyses 
Multi-centre retrospective observational study. Contemporary BCIS data (+/- imputed 
data). Statistical modelling.  
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9.3.2 Copy of the reply e-mail received from FREC 
 
----- Message from FMHUniEthics@leeds.ac.uk --------- 
     Date: Wed, 8 Feb 2012 14:33:37 +0000 
     From: Medicine and Health Univ Ethics Review 
<FMHUniEthics@leeds.ac.uk> 
Reply-To: Medicine and Health Univ Ethics Review 
<FMHUniEthics@leeds.ac.uk> 
  Subject: RE: Requirements for review of queries 
       To: 'Sami Almudarra' <umssal@leeds.ac.uk> 
 
Dear Sami, 
 
Apologies for the delay in getting back to you about this.  I have re-
contacted the FREC Chair would has agreed that we do not need to 
require ethics review for research utilising anonymised datasets such 
as this. 
 
Best wishes, 
 
Georgina 
 
 
 
